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Abstract
Part I: The axially chiral biaryl motif is found in many natural products as well as in ligands for catalysis such as
1,1’-binaphthol. Formation of axially chiral compounds was accomplished by means of the asymmetric
oxidative coupling, which has proven to be both an efficient and environmentally benign synthetic method.
Interests toward an effective asymmetric oxidative coupling of simple phenols, which are challenging
substrates because of relatively high oxidation potential and regioselectivity issues, have arisen due to a lack of
corresponding methods. After many efforts to design and modify the catalyst scaffold, we found that a
monomeric vanadium(V) catalyst together with LiCl or HOAc as an additive accomplished C-C bond
formation to afford the bisphenol moiety in good yield and good enantioselectivity. The carbazole moiety is
another good candidate to apply our oxidative coupling method because of its electron-rich nature. Using
various 3-substituted-2-hydroxycarbazole derivatives, oxidative coupling afforded products containing diverse
functional groups, including ketone, ester, trifluoromethyl, halides, allyl, etc.
Part II: The azaphilone alkaloid, chaetoglobin A, has drawn attention due to its intriguing dimeric structure.
The molecule features a 2H-isoquinoline-6,8-dione moiety containing quaternary centers and a chiral axis
that connects two identical motifs. Although a variety of monomeric azaphilone alkaloids have been
synthesized, a dimeric class of azaphilone has not been synthesized to date. Installing axial chirality by means
of the asymmetric oxidative phenol coupling is the key step in making the natural product. Afterwards,
bisformylation and oxidative dearomatization were carried out smoothly to afford highly oxygenated bicyclic
cores. Thorough optimization of the selective acetyl deprotection and final amination afforded access to the
synthetic chaetoglobin A in 12 linear steps.
Part III: These days, the ligand plays an important role in versatile chemical reactions. Understanding the
ligand effect provided critical information to tackle challenging issues. Taking advantage of High Throughput
Experimentation (HTE) allowed access to a variety of ligands in a rapid and efficient manner. Due to easy
synthesis of a series of different alkynylphosphine oxides and azides, our efforts were focused on generating
the diverse triazole-based phosphine ligands. The ligand was prepared by [3+2]-cycloaddition with the
alkynylphosphine oxide and azide, followed by the corresponding phosphine oxide reduction. Ultimately, a
one-pot protocol reinforced the efficient ligand synthesis and accomplished the synthesis of a number of
ligands by HTE parallel synthesis. Currently, with the ClickPhos ligands, the ligand effect was explored under
the challenging chemical reaction conditions.
Part IV: 2,2-Disubstituted indolin-3-one is not only a core structure for many natural products but also serves
as a useful synthetic intermediate. To construct the C-2 quaternary center via the oxidative coupling between
3-oxindole and various aryl substrates, including indoles, pyrroles, and electron-rich aryl compounds, was
achieved in the presence of a copper catalyst incorporated with a salan ligand. This milder catalytic protocol
efficiently generated the quaternary center with various functional groups tolerance, such as halide, ester,
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CHAPTER 1: VANADIUM–CATALYZED ASYMMETRIC OXIDATIVE COUPLING OF 
PHENOLS AND HYDROXYCARBAZOLES AND ITS MECHANISTIC STUDY1 
1.1. Background 
 Asymmetric oxidative catalysis offers a simple and atom-economic method to 
generate an enantioenriched biaryl motif, which is widely found in natural products and 
catalysts (Figure 1.1).2,3 Naturally occurring dimeric scaffolds, connected through a chiral 
axis, feature intriguing structures as well as biological activities, such as agonism of 
neuritic streaming2a or inhibition of cancer cell lines.2f Furthermore, these axial chiral 
backbones have been widely utilized in asymmetric catalysts. BINOL has been proven to 
                                                     
1 Adapted from Kang, H.; Lee, Y. E.; Reddy, P. V. G.; Dey, S.; Allen, S. E.; Niederer, K. A.; Sung, 
P.; Hewitt, K.; Torruellas, C.; Herling, M. R.; Kozlowski, M. C. Asymmetric Oxidative Coupling of 
Phenols and Hydroxycarbazoles. Org. Lett. 2017, 19, 5505–5508. Copyright 2017 American 
Chemical Society. 
2 (a) Fukuyama, Y.; Asakawa, Y. Novel Neurotrophic Isocuparane-Type Sesquiterpene Dimers, 
Mastigophorenes A, B, C and D, Isolated from the Liverwort Mastigophora Diclados. J. Chem. Soc. 
[Perkin 1] 1991, 0 (11), 2737–2741. (b) Degnan, A. P.; Meyers, A. I. Total Syntheses of (−)-
Herbertenediol, (−)-Mastigophorene A, and (−)-Mastigophorene B. Combined Utility of Chiral 
Bicyclic Lactams and Chiral Aryl Oxazolines. J. Am. Chem. Soc. 1999, 121, 2762–2769. (c) 
Narayan, S.; Roush, W. R. Studies Toward the Total Synthesis of Angelmicin B (Hibarimicin B):  
Synthesis of a Model CD−D‘ Arylnaphthoquinone. Org. Lett. 2004, 6, 3789–3792. (d) Kenar, J. A. 
Reaction Chemistry of Gossypol and Its Derivatives. J. Am. Oil Chem. Soc. 2006, 83, 269–302. (e) 
Buter, J.; Heijnen, D.; Vila, C.; Hornillos, V.; Otten, E.; Giannerini, M.; Minnaard, A. J.; Feringa, B. 
L. Palladium‐Catalyzed, Tert‐Butyllithium‐Mediated Dimerization of Aryl Halides and Its Application 
in the Atropselective Total Synthesis of Mastigophorene A. Angew. Chem. Int. Ed. 2016, 55, 3620–
3624. (f) Ming Ge, H.; Yun Zhang, W.; Ding, G.; Saparpakorn, P.; Chun Song, Y.; Hannongbua, S.; 
Xiang Tan, R. Chaetoglobins A and B, Two Unusual Alkaloids from Endophytic Chaetomium 
Globosum Culture. Chem. Commun. 2008, 5978-5980. (g) Nutan, M. T.; Hasan, C.; Rashid, M. 
Bismurrayafoline E: A New Dimeric Carbazole Alkaloid from Murraya Koenigii. Fitoterapia 1999, 
70, 130–133. (h) Tachibana, Y.; Kikuzaki, H.; Lajis, N. H.; Nakatani, N. Comparison of Antioxidative 
Properties of Carbazole Alkaloids from Murraya Koenigii Leaves. J. Agric. Food Chem. 2003, 51, 
6461–6467. 
3 (a) Brunel, J. M. BINOL: A Versatile Chiral Reagent. Chem. Rev. 2005, 105, 857–898. (b) Qiu, L.; 
Kwong, F. Y.; Wu, J.; Lam, W. H.; Chan, S.; Yu, W.-Y.; Li, Y.-M.; Guo, R.; Zhou, Z.; Chan, A. S. C. 
A New Class of Versatile Chiral-Bridged Atropisomeric Diphosphine Ligands: Remarkably Efficient 
Ligand Syntheses and Their Applications in Highly Enantioselective Hydrogenation Reactions. J. 
Am. Chem. Soc. 2006, 128, 5955–5965. (c) Melhado, A. D.; Luparia, M.; Toste, F. D. Au(I)-
Catalyzed Enantioselective 1,3-Dipolar Cycloadditions of Münchnones with Electron-Deficient 
Alkenes. J. Am. Chem. Soc. 2007, 129, 12638–12639. (d) Heiser, B.; Broger, E. A.; Crameri, Y. 
New Efficient Methods for the Synthesis and In-Situ Preparation of Ruthenium(II) Complexes of 
Atropisomeric Diphosphines and Their Application in Asymmetric Catalytic Hydrogenations. 
Tetrahedron Asymmetry 1991, 2, 51–62. 
2 
 
be effective in reduction, oxidation, and diverse asymmetric C-C bond–forming reactions, 
which include the ene, Diels-Alder, aldol, allylation, alkynylation, cycloaddition, and 
Friedel-Crafts reactions, etc.3a In addition, axial chiral bisphosphine ligands have been 
used in numerous reactions, including asymmetric hydrogenation and cycloaddition 
reactions.3b-d  
 
Figure 1.1. Example of a Chiral Axis in Natural Products and Catalysis1 
 
 In the last three decades, a variety of transition metals have been proven to effect 
such transformations. In 1999, Nakajima and coworkers reported that copper complexes 
3 
 
with proline derivatives as ligands allowed access to BINOL analogs.4 The Kozlowski 
group discovered that the 1,5-diaza-cis-decalin ligand afforded further improvement on 
both reactivity and enantioselectivity.5  The unsymmetrical H8–BINAM ligand has been 
utilized to construct a chiral axis by the Ha group in 2004.6 It was necessary, however, to 
have an additional coordination group next to phenol to generate the complex, which was 
needed to produce facial selectivity by blocking one side (Scheme 1.1). 
 
Scheme 1.1. Cu-catalyzed Asymmetric BINOL Derivative Syntheses 
 
 Vanadium also has been widely used as an asymmetric catalyst to synthesize 
BINOL derivatives. Monomeric vanadium complexes, by the Uang7 and Chen groups,8 or 
dimeric vanadium complexes, by the Gong9 and Sasai groups,10 afforded highly selective 
                                                     
4 Nakajima, M.; Miyoshi, I.; Kanayama, K.; Hashimoto, S.; Noji, M.; Koga, K. Enantioselective 
Synthesis of Binaphthol Derivatives by Oxidative Coupling of Naphthol Derivatives Catalyzed by 
Chiral Diamine·Copper Complexes. J. Org. Chem. 1999, 64, 2264–2271. 
5 Li, X.; Yang, J.; Kozlowski, M. C. Enantioselective Oxidative Biaryl Coupling Reactions Catalyzed 
by 1,5-Diazadecalin Metal Complexes. Org. Lett. 2001, 3, 1137–1140. 
6 Kim, K. H.; Lee, D.-W.; Lee, Y.-S.; Ko, D.-H.; Ha, D.-C. Enantioselective Oxidative Coupling of 
Methyl 3-Hydroxy-2-Naphthoate Using Mono-N-Alkylated Octahydrobinaphthyl-2,2′-Diamine 
Ligand. Tetrahedron 2004, 60, 9037–9042. 
7 Chu, C.-Y.; Uang, B.-J. Catalytic Enantioselective Coupling of 2-Naphthols by New Chiral 
Oxovanadium Complexes Bearing a Self Accelerating Functional Group. Tetrahedron Asymmetry 
2003, 14, 53–55. 
8 Barhate, N. B.; Chen, C.-T. Catalytic Asymmetric Oxidative Couplings of 2-Naphthols by 
Tridentate N-Ketopinidene-Based Vanadyl Dicarboxylates. Org. Lett. 2002, 4, 2529–2532. 
9 Guo, Q.-X.; Wu, Z.-J.; Luo, Z.-B.; Liu, Q.-Z.; Ye, J.-L.; Luo, S.-W.; Cun, L.-F.; Gong, L.-Z. Highly 
Enantioselective Oxidative Couplings of 2-Naphthols Catalyzed by Chiral Bimetallic Oxovanadium 
Complexes with Either Oxygen or Air as Oxidant. J. Am. Chem. Soc. 2007, 129, 13927–13938. 
10 Takizawa, S.; Katayama, T.; Somei, H.; Asano, Y.; Yoshida, T.; Kameyama, C.; Rajesh, D.; 
Onitsuka, K.; Suzuki, T.; Mikami, M.; Yamataka, H.; Jayaprakash, D.; Sasai, H. Dual Activation in 
4 
 
BINOL analogs (Scheme 1.2). 
 
Scheme 1.2. V-catalyzed Asymmetric BINOL Derivative Syntheses 
 
 Later, Katsuki and coworkers disclosed that a Schiff base-iron complex was able 
to construct bisnaphthols efficiently, which are connected through a chiral axis.11 Using an 
asymmetric phosphoric acid coordinated to iron, Toste and Pappo introduced the axial 
chiral bond in BINOL analogs in 2016 (Scheme 1.3).12 
                                                     
Oxidative Coupling of 2-Naphthols Catalyzed by Chiral Dinuclear Vanadium Complexes. 
Tetrahedron 2008, 64, 3361–3371. 
11 Egami, H.; Katsuki, T. Iron-Catalyzed Asymmetric Aerobic Oxidation: Oxidative Coupling of 2-
Naphthols. J. Am. Chem. Soc. 2009, 131, 6082–6083. 
12 Narute, S.; Parnes, R.; Toste, F. D.; Pappo, D. Enantioselective Oxidative Homocoupling and 
Cross-Coupling of 2-Naphthols Catalyzed by Chiral Iron Phosphate Complexes. J. Am. Chem. Soc. 
2016, 138, 16553–16560. 
5 
 
 
Scheme 1.3. Ru or Fe-catalyzed Asymmetric BINOL Derivative Syntheses 
 
 Compared to 2-naphthols, phenol couplings have been limited and less explored 
(Scheme 1.4). Furthermore, no highly selective oxidative phenol homocoupling is known 
to date. In 1999, Uang and coworkers (Scheme 1.4.A) reported oxidative phenol 
dimerization by means of a vanadium catalyst.13 Recently, Kozlowski and Pappo 
highlighted that Cr14 or Fe-catalyzed15 oxidative phenol coupling allowed access to cross-
coupled bisphenols (Scheme 1.4.C). Notably, the Liu and Kurti groups have reported 
highly enantioselective phenol couplings by utilizing preoxidized compounds, which 
                                                     
13 Hwang, D.-R.; Chen, C.-P.; Uang, B.-J. Aerobic Catalytic Oxidative Coupling of 2-Naphthols and 
Phenols by VO(Acac)2. Chem. Commun. 1999, 1207–1208. 
14 Lee, Y. E.; Cao, T.; Torruellas, C.; Kozlowski, M. C. Selective Oxidative Homo- and Cross-
Coupling of Phenols with Aerobic Catalysts. J. Am. Chem. Soc. 2014, 136, 6782–6785. 
15 Libman, A.; Shalit, H.; Vainer, Y.; Narute, S.; Kozuch, S.; Pappo, D. Synthetic and Predictive 
Approach to Unsymmetrical Biphenols by Iron-Catalyzed Chelated Radical–Anion Oxidative 
Coupling. J. Am. Chem. Soc. 2015, 137, 11453–11460. 
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impose constraints on the product types that can be formed (Scheme 1.4.D).16,17 
 
Scheme 1.4. Previous Oxidative Phenol Couplings 
 
 Hydroxycarbazoles have been found to be effective in oxidative coupling due to 
their electron-rich nature (Scheme 1.5). A variety of different oxidants have enabled the 
formation of the central bond. Benzoyl peroxide was utilized by Moody and coworkers to 
                                                     
16 Chen, Y.-H.; Cheng, D.-J.; Zhang, J.; Wang, Y.; Liu, X.-Y.; Tan, B. Atroposelective Synthesis of 
Axially Chiral Biaryldiols via Organocatalytic Arylation of 2-Naphthols. J. Am. Chem. Soc. 2015, 
137, 15062–15065. 
17 Wang, J.-Z.; Zhou, J.; Xu, C.; Sun, H.; Kürti, L.; Xu, Q.-L. Symmetry in Cascade Chirality-Transfer 
Processes: A Catalytic Atroposelective Direct Arylation Approach to BINOL Derivatives. J. Am. 
Chem. Soc. 2016, 138, 5202–5205. 
7 
 
make biscarbazole in 1989.18 Bringmann and other groups used tert-butyl peroxide to 
introduce the C-C bond oxidatively from 1-hydroxycarbazoles.19 Later, Knӧlker reported 
that tetrachloro-para-benzoquinone produced an axial bond ortho to the hydroxyl group.20 
In 2015, the Kozlowski group revealed that the vanadium-catalyzed oxidative coupling 
with N-protected 2-hydroxycarbazole generated the ortho-ortho’ adduct as the major 
product.21 
                                                     
18 Moody, C. J.; Shah, P. Diels-Alder Reactivity of Pyrano[3,4-b]Indol-3-Ones. Part 4. Synthesis of 
the Carbazole Alkaloids Carbazomycin A and B and Hyellazole. J. Chem. Soc. [Perkin 1] 1989, 
2463–2471. 
19 (a) Bringmann, G.; Ledermann, A.; Stahl, M.; Gulden, K. Bismurrayaquinone A: Synthesis, 
Chromatographic Enantiomer Resolution, and Stereoanalysis by Computational and Experimental 
CD Investigations. Tetrahedron 1995, 51, 9353–9360. (b) Lin, G.; Zhang, A. Synthesis of Optically 
Pure Clausenamine-A and Its Demethoxylated Analogs. Tetrahedron 2000, 56, 7163–7171. (c) 
Fillion, H.; Bouaziz, Z.; Nebois, P.; Poumaroux, A. Carbazole-1,4-Diones: Syntheses and 
Properties. HETEROCYCLES 2000, 52, 977–1000. 
20 Knölker, H.-J.; Goesmann, H.; Hofmann, C. Transition Metal Complexes in Organic Synthesis, 
Part 31.1 A Novel Molybdenum-Mediated Synthesis of Carbazole Derivatives: Application to the 
Total Synthesis of Mukonal and 1,1’-Bis(2-Hydroxy-3-Methylcarbazole). Synlett 1996, 1996, 737–
740. 
21 Liu, L.; Carroll, P. J.; Kozlowski, M. C. Vanadium-Catalyzed Regioselective Oxidative Coupling 
of 2-Hydroxycarbazoles. Org. Lett. 2015, 17, 508–511. 
8 
 
 
Scheme 1.5. Oxidative Hydroxycarbazole Couplings with Various Oxidants 
 
1.2. Catalyst Optimization 
 Inspired by an effective oxidative coupling with VO(acac)2,13 2,3,5-trimethylphenol 
(1.1a) was examined as the substrate in initial studies (Scheme 1.6). Its success in 
asymmetric BINOL derivative syntheses indicates that vanadium catalysts are highly 
efficient at introducing a chiral axis. Encouragingly, our initial attempts coupling 1.1a with 
dimeric vanadium catalyst V0 provided only ortho-ortho 1.2a and para-para 1.3a products 
among the many potential outcomes. 
9 
 
 
Scheme 1.6. Preliminary Oxidative Phenol Coupling with V0 Catalyst1 
 
 However, the outcome from trial to trial was found to vary considerably. Part of the 
irreproducibility was attributed to the exact preparation of the catalyst, for which several 
protocols have been reported using different vanadium sources including VO(SO4)9,22a-d 
and VO(Cl)3.22e-h A base is sometimes used for ligand deprotonation prior to complexation, 
and removal of inorganic salts is effected with an aqueous wash.  For the phenol 
couplings, we discovered that the hydration state of the catalyst had a great influence on 
reactivity.  For example, an inactive catalyst was produced when the complex was placed 
under high vacuum. We attributed this reduced reactivity to formation of a less potent, 
oxo-bridged species. Fortunately, using VO(OEt)3 as previously described for asymmetric 
                                                     
22 (a) Chu, C.-Y.; Hwang, D.-R.; Wang, S.-K.; Uang, B.-J. Chiral Oxovanadium Complex Catalyzed 
Enantioselective Oxidative Coupling of 2-Naphthols. Chem. Commun. 2001, 0 (11), 980–981. (b) 
Hon, S.-W.; Li, C.-H.; Kuo, J.-H.; Barhate, N. B.; Liu, Y.-H.; Wang, Y.; Chen, C.-T. Catalytic 
Asymmetric Coupling of 2-Naphthols by Chiral Tridentate Oxovanadium(IV) Complexes. Org. Lett. 
2001, 3, 869–872. (c) Luo, Z.; Liu, Q.; Gong, L.; Cui, X.; Mi, A.; Jiang, Y. The Rational Design of 
Novel Chiral Oxovanadium(IV) Complexes for Highly Enantioselective Oxidative Coupling of 2-
Naphthols. Chem. Commun. 2002, 0 (8), 914–915. (d) Somei, H.; Asano, Y.; Yoshida, T.; Takizawa, 
S.; Yamataka, H.; Sasai, H. Dual Activation in a Homolytic Coupling Reaction Promoted by an 
Enantioselective Dinuclear Vanadium(IV) Catalyst. Tetrahedron Lett. 2004, 45, 1841–1844. (e) 
Takizawa, S.; Katayama, T.; Kameyama, C.; Onitsuka, K.; Suzuki, T.; Yanagida, T.; Kawai, T.; 
Sasai, H. Chiral Dinuclear Vanadium(V) Catalysts for Oxidative Coupling of 2-Naphthols. Chem. 
Commun. 2008, 0 (15), 1810–1812. (f) Takizawa, S.; Katayama, T.; Sasai, H. Dinuclear Chiral 
Vanadium Catalysts for Oxidative Coupling of 2-Naphtholsvia a Dual Activation Mechanism. Chem. 
Commun. 2008, 0 (35), 4113–4122. (g) Takizawa, S.; Kodera, J.; Yoshida, Y.; Sako, M.; Breukers, 
S.; Enders, D.; Sasai, H. Enantioselective Oxidative-Coupling of Polycyclic Phenols. Tetrahedron 
2014, 70, 1786–1793. (h) Sako, M.; Takeuchi, Y.; Tsujihara, T.; Kodera, J.; Kawano, T.; Takizawa, 
S.; Sasai, H. Efficient Enantioselective Synthesis of Oxahelicenes Using Redox/Acid Cooperative 
Catalysts. J. Am. Chem. Soc. 2016, 138, 11481–11484. 
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homoallylic oxidation,23 some catalysts provided reproducible results. The dimeric V1 
catalyst afforded a 37% ee for 1.2a, although low conversion (49%) and the mixture of 
products were observed (28:21 1.2a:1.3a, Figure 1.2). 
 
Figure 1.2. Catalyst Evolution in the Asymmetric Phenol Coupling1,24 
 
 To improve conversion and regioselectivity, it was necessary to modify the reaction 
conditions. We speculated that the phenoxide substrate accelerates the reaction rate. 
Using Et3N as an additive, however, led to no product formation. Conversely, a protic acid 
additive, which was capable of catalyst activation by means of protonation, afforded both 
enhanced reactivity (91% conv, 75% isolated yield) and selectivity (60% ee) to produce 
ortho-ortho (1.2a) product (Figure 1.2). 
 Additional improvement was achieved by manipulating the catalyst backbone. The 
use of a scaffold with a greater dihedral angle between the upper and lower portions (V2, 
Figure 1.2) improved yields to 83% and enantioselectivity to 77%.  No further readily 
optimized parameters were available within this scaffold, so an alternate linker was 
explored.  The free acid positions were not found to be crucial since similar results were 
obtained with the methyl ester derived ligands. However, linking via the carboxylic acids 
                                                     
23 Hartung, J.; Drees, S.; Greb, M.; Schmidt, P.; Svoboda, I.; Fuess, H.; Murso, A.; Stalke, D. (Schiff-
Base)Vanadium(V) Complex-Catalyzed Oxidations of Substituted Bis(Homoallylic) Alcohols − 
Stereoselective Synthesis of Functionalized Tetrahydrofurans. Eur. J. Org. Chem. 2003, 2003 (13), 
2388–2408. 
24 These catalysts engineering work had done by Dr. Scott E. Allen, Dr. Young Eun Lee and Gina 
Kim. 
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was not effective with the original tetrahydronaphthol backbone using a variety of tether 
lengths (V3, 34% 1.2a, 0% ee). We hypothesized that a large group is needed where the 
chiral axis had seen to offer selective coupling. Thus, a tert-butyl–substituted phenol was 
employed. With a linker length of six carbons being optimal (V4), a larger improvement in 
selectivity was seen (67% ee). To interrogate whether a dimeric catalyst was really 
necessary, a trial with monomer V5 was undertaken, which revealed results similar to 
those of the dimer. 
 
Entry R1 R2 Conversion (%)a ee (%)b 
1 t-Bu t-Bu 40 66 
2 t-Bu 2-tolyl 78 49 
3 t-Bu 2,6-xylyl 92 50 
4 t-Bu 1-naphthyl 85 38 
5 t-Bu 2-methoxy-1-naphthyl 81 57 
6 t-Bu SiMe3 70 73 
7 t-Bu SiEt3 58 75 
8 t-Bu SiiPr3 35 76 
9 t-Bu SiPh2
tBu 13 60 
10 t-Bu adamantyl 24 66 
11 t-Bu CPh3 15 56 
12 t-Bu CMe2Ph 37 76 
13 OMe t-Bu 47 65 
14 OAc t-Bu 43 62 
15 NO2 t-Bu 86 75 
12 
 
16 NO2 SiEt3 100 75 
aDetermined from 1H NMR; isolated yield in parentheses. bDetermined using CSP HPLC. 
Table 1.1. SAR of Monomeric Vanadium Catalyst31 
 
 In line with the previous results, bulky groups, such as tert-butyl (Table 1.1, entry 
1), SiR3 (entry 6–8), or adamantyl (entry 10), at the R2 position tend to provide better 
selectivity. A sterically more congested substituent, 1,1-dimethylbenzyl, gave higher 
selectivity (entry 12, 76% ee). However, the reactivity declined as R2 became larger than 
TMS (entry 6–8). To tackle the low conversion issue, we modulated the electronics by 
substituting at R1. Our objective was to achieve a more powerful oxidizing catalyst by 
destabilizing the higher oxidation state of the vanadium catalyst. An electron-withdrawing 
substituent (R1 = NO2, entry 15) facilitated the reaction in accordance with our hypothesis 
(entry 13 vs 15). With the modified monomeric catalyst (V6), in the presence of HOAc, the 
ortho-ortho coupled product (1.2a) was obtained in 80% isolated yield as the only product 
with 83% ee. 
1.3. Phenol Scope 
 A variety of phenols were examined with the optimized conditions (Table 1.4). The 
substituent ortho to the phenol possessed an important role in obtaining enantioselectivity, 
with methyl being optimal. Smaller groups, such as a hydrogen, showed drastically 
decreased selectivity (entries 2, 5). The larger tert-butyl group gave no selectivity (entry 
3). 2,3,5-Trisubstituted phenols generally provided better results. 
 
13 
 
Entry Temperature (C) Conversion (%)
a ee (%) 
1 23 72  50 
2 0 53 63 
3 –20 30 75 
4 –40 15 85 
 
Table 1.2. Oxdative Coupling of Dihydroxyarene 1.1g at Various Temperatures 
 
 Dioxygenated substrates such as 1.1g were examined next, with the expectation 
that the more electron-rich systems would undergo oxidative coupling more readily. In line 
with this hypothesis, reaction of 1.1g occurred quickly at room temperature (Table 1.2, 
entry 1), and the selectivity could be increased by lowering the temperature (entries 2-4).  
However, below 0 °C reaction rates were compromised. 
 As a result, additional additive screening was undertaken with this class of 
substrates (Table 1.3). Most additives resulted in lesser reactivity although cationic lithium 
species resulted in significantly higher reactivity (entries 10, 12, 17). LiCl (entry 5) afforded 
the highest enantioselectivity (entry 5, 85% ee), which did not appear to devolve solely 
from the chloride (c.f., entries 6-8).  Using the LiCl additive with substrate 1.1f gave a 
similar boost in selectivity (Table 1.4, entry 6, 82% ee). Unfortunately, LiCl did not provide 
equal levels of improvement for all of these substrates. 
Entry Additives Conversion (%)b ee (%) 
1 - 70 52 
2 Sn(OTf)2 33 43 
3 Sc(OTf)3 43 67 
4 Yb(OTf)3 48 69 
5 LiCl 46 85 
6 NaCl 52 47 
7 KCl 59 45 
8 MgCl2 28 78 
9 LiF 46 46 
10 LiBr 100 63 
11 LiI 12 57 
12 LiClO4 94 73 
14 
 
13 LiOAc 43 18 
14 Li2CO3 53 27 
15 4Å MS - 68 
16 MgSO4 50 70 
17 LiCl + 12-crown-4 100 60 
aReaction conditions: 20 mol % V6, 40 mol % additive, PhCH3, O2, 0 °C, 6 h. bConversion was determined 
by 1H NMR. 
Table 1.3. Additive Screening with Dihydroxyarene 1.1g31 
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Entry Substrate Additiveb Temp Yield (%)c ee (%)d Entry Substrate Additiveb Temp Yield (%)c ee (%)d 
1 
 
HOAc rt 89(72)e 85(95)e 9 
 
LiCl 0 C 66 89 
2 
 
HOAc rt 100f 10 10 
 
HOAc rt 56(99)g 77 
3 
 
HOAc rt 100f 0 11 
 
HOAc rt 80(98)g 72 
4 
 
HOAc rt ND 60 12 
 
HOAc rt 44f 34 
5 
 
HOAc rt 38f 38 13 
 
HOAc rt 100f 10 
6 
 
HOAc rt 100f 50 
14 
 
HOAc 0 C 78 40 
LiCl 0 C 80(76)e 82(95)e 
7 
 
HOAc rt 89 63 
15 
 
HOAc rt 24f 20 
LiCl 0 C 81 86 
8 
 
HOAc 0 C 65 50 16 
 
HOAc rt 12f 47 
aReaction conditions: 20 mol% catalyst, x equiv additives, O2, 0.5 M PhCH3.  b6.25 equiv HOAc, 0.4 equiv LiCl.  
cIsolated yield. d ee determined by chiral HPLC. eAfter trituration in parentheses. fConversion. gIsolated yield based on 
recovered substrate  
Table 1.4. Scope of Phenol Couplinga,1 
 
 Other substituents, such as allyl or propyl, ortho to the phenol, resulted in 
16 
 
comparable selectivity (Table 1.4, entry 10, 11). However, the allyl or propyl groups were 
no longer tolerated with either 3-methoxy or 5-methoxy substrates (entry 12–14) in 
contrast to 3-methoxy with 2-methyl substituent (entry 6). To examine the effects of 
substituents at the 5-position, experiments were conducted with a phenyl (entry 8), alkynyl 
chain (entry 9), and electron-withdrawing groups (entries 15, 16). Notably, oxidative 
coupling of the phenol bearing an alkynyl chain afforded good selectivity (entry 9, 89% ee) 
in the presence of LiCl. As we expected, 5-bromo analogs caused slower oxidation with 
only 24% (1.1o) and 12% (1.1p) conversion after 48 h. Racemic biaryl products have 
much poorer solubility than enantiopure biaryls in hexane. Exploiting this difference, one 
trituration was found to increase the enantiomeric excess of the filtrate. For example, 
substrates 1.1a and 1.1f were enhanced to 95% ee following trituration. 
1.4. Hydroxycarbazole Scope 
 The electron rich nature of hydroxycarbazoles allows access to dimeric 
compounds via oxidative coupling (Scheme 1.5). Accordingly, hydroxycarbazole 1.4 was 
examined in our asymmetric oxidative coupling.20 Our previous report demonstrated that 
the N-protecing group was essential for selective oxidation ortho to the hydroxyl group by 
excluding reaction with the amine.21  
 
Entry R Catalyst Solvent Yield (%) ee (%) 
1 Bn (1.4b) V6 (R = OMe) PhMe 78 70 
17 
 
2 Bn (1.4b) V7 (R = F) PhMe 40 70 
3 Bn (1.4b) V8 (R = Oi-Pr) PhMe 71 78 
4 Bn (1.4b) V9 (R = Ot-Bu) PhMe 44 74 
5 Bn (1.4b) V8 (R = Oi-Pr) PhCl 91 87 
6 Me (1.4c) V8 (R = Oi-Pr) PhCl 82  71 
7 allyl (1.4d) V8 (R = Oi-Pr) PhCl 71 76 
8 i-Pr (1.4e) V8 (R = Oi-Pr) PhCl 58 42 
9 2,4,6-Me3Bn (1.4f) V8 (R = Oi-Pr) PhCl 27 37 
aReaction Conditions: 20 mol% catalyst, 6.5 equiv AcOH, O2, 0.5 M solvent, 0 °C, 48 h. 
Table 1.5. Oxidative Coupling of 2-Hydroxycarbazole Optimization31 
 
 With the nitrogen position protected with a benzyl substituent, promising levels of 
selectivity (70% ee) were observed (Table 1.5, entry 1). Examining related vanadium 
catalysts V7 (R = F, entry 2) and V8 (R = Oi-Pr, entry 3) revealed that a larger ligand on 
the vanadium center gave rise to higher selectivity (78% ee). However, even larger 
substituents on vanadium (R = Ot-Bu, entry 4) did not afford further improvement. Finally, 
optimization of solvent (CH2Cl2, DCE, CHCl3, toluene, dichlorobenzene) revealed that 
chlorobenzene (entry 5) provided the best result (91% yield, 87% ee). With the optimal 
catalyst (V8), examination of the nitrogen substituent showed that either smaller (Me, entry 
6, 71% ee) or larger groups (i-Pr; 2,4,6-trimethylbenzyl, entries 8-9) were detrimental. 
Moderate–sized groups such as allyl (entry 7, 76% ee) and benzyl (entry 5, 87% ee) were 
superior. 
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Scheme 1.7. 2-Hydroxy-3-methylcarbazole Analog Synthesis1 
 
 Various 2-hydroxycarbazole analog syntheses are outlined in Scheme 1.7–10. 
Most of the substituted carbazoles were prepared from commercially available aniline 1.6 
(Scheme 1.7). Carboxylic acid was reduced to methyl with BH3•SMe2, followed by a 
Buchwald–Hartwig amination using a wide range of aryl bromides, which allowed access 
to a variety of substituted precursors (1.7).25 Cyclization was achieved in the presence of 
Pd(OAc)2 and monodentate trialkyl phosphine ligand to generate carbazole 1.9.25 To 
obtain nitrogen protected hydroxycarbazoles, BBr3 demethylation,21 followed by selective 
                                                     
25 Bedford, R. B.; Betham, M. N-H Carbazole Synthesis from 2-Chloroanilines via Consecutive 
Amination and C−H Activation. J. Org. Chem. 2006, 71, 9403–9410. 
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benzylation afforded 2-hydroxy-3-methylcarbazoles (1.4) or vice versa.26  
 
Scheme 1.8. 3-Substituted-2-hydroxycarbazole Syntheses1 
 
 Substrates that contained a different moiety ortho to the phenol were prepared 
form the commercially available hydroxycarbazole 1.12 by Kyle Niederer, 3rd year 
graduate student in our laboratory (Scheme 1.8). A one-pot benzylation of the oxygen and 
nitrogen was followed by a bromination, using NBS, to obtain 1.13. Suzuki and Negishi27 
couplings, respectively, introduced a phenyl and allyl group to the C-3 position. Thereafter, 
deprotection of the phenol was achieved in the presence of AlCl3 to afford 1.4q, 1.4r, and 
1.4s.28 
                                                     
26 Albanese, D.; Landini, D.; Penso, M.; Spanò, G.; Trebicka, A. Chemoselective N-Alkylation of 
2-Hydroxycarbazole as a Model for the Synthesis of N-Substituted Pyrrole Derivatives Containing 
Acidic Functions. Tetrahedron 1995, 51, 5681–5688. 
27 Duggan, K. A. Preparation of biphenyl propanamide compounds for the treatment of 
hypertension and/or fibrosis. PCT Int. Appl. WO 2015039172 A1, Mar. 26, 2015. 
28 Akiyama, T.; Hirofuji, H.; Ozaki, S. AlCl3-N,N-Dimethylaniline: A New Benzyl and Allyl Ether 
Cleavage Reagent. Tetrahedron Lett. 1991, 32, 1321–1324. 
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Scheme 1.9. 6-Methoxy-2-hydroxycarbazole (1.4o) Synthesis1 
 
 To investigate how introducing an electron donating group to the carbazole 
affected enantioselectivity, a substrate with a methoxy group at the C-6 position was also 
synthesized by Kyle Niederer (Scheme 1.9).  For substrates containing two methoxy 
substituents, selective deprotection of the oxygen at the C-2 position proved untenable. 
To synthesize the desired substrate, the carboxylic acid 1.6 was reduced to methyl with 
borane to provide 1.7. A demethylation with BBr3 was followed by a selective benzylation 
of the phenol to yield the aniline 1.14. Thereafter, a Buchwald Hartwig amination with aryl 
bromide 1.15 was followed by cyclization in the presence of Pd(OAc)2 and a monodentate 
trialkyl phosphine ligand to generate carbazole 1.17. Finally, N-benzylation followed by 
selective O-debenzylation with AlCl3 afforded 1.4o. 
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Scheme 1.10. Synthesis of 6-Carboalkoxy-2-hydroxycarbazole 1.4l1 
 
 To prepare the ester-functionalized hydroxycarbazole, we conducted the C-N 
coupling with 4-bromobenzonitrile, followed by intramolecular cyclization reaction to obtain 
carbazole 1.9l (Scheme 1.10). After benzyl protection, the nitrile was converted to the 
benzoic acid (1.19) by treatment with sodium hydroxide in EtOH and water.29 Subsequent 
demethylation with boron tribromide followed by esterification afforded 1.4l. 
 
Entry Substrate Yield (%)b ee (%)c Entry Substrate Yield (%)b ee (%)c 
1 
 
91 87 9 
 
62 37 
                                                     
29 Baba, K.; Tobisu, M.; Chatani, N. Palladium-Catalyzed Synthesis of Six-Membered Benzofuzed 
Phosphacycles via Carbon–Phosphorus Bond Cleavage. Org. Lett. 2015, 17, 70–73. 
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2 
 
87 92 10 
 
90(45)f 60(76)f 
3 
 
73 92 11g 
 
82 74 
4 
 
80 91 12 
 
70 82 
5 
 
70 93 13 
 
17(30)e 72 
6 
 
60 94 14 
 
75 83 
7d 
 
53(76)e 85 15 
 
26(43)e 60 
8 
 
46(67)e 96     
aReaction Conditions: 20 mol% V8 catalyst, 6.5 equiv HOAc, O2, 0.5 M chlorobenzene, 48 h. bIsolated 
yield. cee determined by chiral HPLC. dHFIP/PhCl as a solvent. eIsolatted yield based on recovered 
substrate. fReaction was conducted at 15 C. gReaction time was 26 h.  
Table 1.6. Scope of 2-Hydroxycarbazole Couplinga,1 
 
 Thereafter, we investigated the scope of a variety of 2-hydroxycarbazoles (Table 
6). Electron-withdrawing substituents gave good to excellent selectivity (85–96% ee) along 
with moderate to good conversions (46–87% yield). Highly enantioenriched 
bishydroxycarbazoles were obtained with the fluoride substituent regardless of their 
position (entries 2–4, 91–92% ee). More electron-deficient hydroxycarbazoles, 6-CF3 
(entry 5) and 7-CF3 (entry 6), offered excellent selectivities (93% and 94% ee) with good 
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yields. Incorporating another electron–withdrawing substituent, a carbonyl group (entry 7), 
gave rise to solubility issues. A mixed solvent system, which included 
hexafluoroisopropanol as a co-solvent, was needed. Accordingly, compromised 
conversion was observed along with slightly lower selectivity (85% ee). The ester–
substituted compound provided the most selective coupling result (entry 8, 96% ee). The 
diphenylamino group was an outlier, with drastically lower selectivity (entry 9, 37% ee). 
Faster oxidative coupling reactions were observed with electron-donating substituents. 
For example, the 6-methoxyhydroxycarbazole coupling reaction was completed in 26 
hours with moderate selectivity (entry 11, 74% ee). With a methyl or allyl group adjacent 
to the phenol, good enantioselectivites were observed (entry 1, 13). On the other hand, 
an electron-withdrawing bromide (entry 14) or an aryl group (entry 15) at this site 
compromised reactivity while retaining moderate levels of selectivity. 
1.5. Mechanistic Study 
 
entry catalyst conditiona conversion 
1 20 mol% V6 control 100% 
2 20 mol% V6 0.2 equiv TEMPO 35% 
3 20 mol% V6 N2 atmosphere 9% (3 days) 
4 50 mol% V6 N2 atmosphere 26% (3 days) 
aReaction Conditions: 6.25 equiv HOAc, toluene, O2, rt, 2 d.  
Table 1.7. Control Experiments1 
 
 With 20 mol% of V6, the oxidative coupling of 2,3,5-trimethylphenol was completed 
within 2 days at ambient temperature under oxygen (Table 1.7, entry 1). However, the 
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addition of an equimolar amount of the radical inhibitor TEMPO relative to catalyst led to 
low conversion (35%, entry 2), which suggested a radical process. Under an inert 
atmosphere, 9% and 26% conversions were detected in the presence of 20 and 50 mol% 
of V6 catalyst (entry 3–4). Accordingly, vanadium(V) species were implicated as the active 
oxidants. Further, the stoichiometry is consistent with each vanadium(V) abstracting one 
electron. 
 
Figure 1.3. Proposed Mechanism1 
 
 Based on the control experiments, our proposed mechanism is described in Figure 
1.3. Initially, we speculated that catalyst activation would be achieved through protonation 
by excess acetic acid to produce A. We excluded the possibility of H• abstraction due to 
the absence of an isotope effect between HOAc and acetic acid-D4 (Figure 1.4.b).30 
Ligand exchange with phenol 1.1a would generate intermediate B, which was observed 
by LCMS analysis. Subsequent single electron transfer to oxidize the phenol, would be 
                                                     
30 Wiberg, K. B. The Deuterium Isotope Effect. Chem. Rev. 1955, 55, 713–743. 
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followed by coupling (C). The control experiment in Table 1.7 (entry 2) supports such a 
radical coupling. To test this theory further, we performed the cross-coupling experiment 
with 1.1a and 1.1g (Scheme 1.11). The major product was 1.2g, which is derived from 
more readily oxidizable phenol 1.1g. The overall product distribution is consistent with a 
radical-radical mechanism where oxidizability dictates the rate of radical formation and a 
statistical distribution is observed.9 Bond formation via dimeric cluster D was supported by 
positive non-linear effect (Figure 1.4.a), which was determined by Kirsten Hewitt. Oxygen 
as the terminal oxidant enabled regeneration of vanadium (V) and product 1.2a was 
produced after tautomerization. 
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Figure 1.4. (a) Theoretical vs Measured Nonlinear Effect (b) CH3COOH vs CD3COOD1 
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Scheme 1.11. Cross-coupling Experiment with 1.1a and 1.1g 
 
1.6. DFT Calculations 
 To understand the origin of regio- and enantioselectivity further, we initiated a DFT 
study of the catalytic cycle using a simplified catalyst structure. Calculations by Madison 
Herling, a 2nd year graduate student, suggest a stepwise radical coupling (Figure 1.5).  
Formation of the acetate-bridged aggregate Int B1 was predicted to be exergonic by 7.5 
kcal/mol. Singlet-triplet transition of the aggregate was speculated to lead to stable 
diradical intermediate Int B2. Coupling was shown to be rate-limiting with ∆G‡ of 16.6 
kcal/mol and proceed through transition state TS A to form intermediate Int C.  Additional 
calculations demonstrated both that the µ2-acetate bridge was essential for a reasonable 
activation energy and that the singlet-triplet transition was not rate-determining.  Finally, 
our computations suggest that dissociation of product 1.2a from the aggregate and 
oxidation to regenerate the catalyst may occur sequentially rather than in tandem.  The 
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transition state leading to ortho–para coupled product was predicted to be disfavored by 
5.5 kcal/mol, which explains why the ortho–para product is not observed and suggests 
that the coupling step is regiodetermining.  To model the enantioselectivity, we computed 
two diastereomeric transition structures incorporating the complete Schiff base ligand, 
which lead to formation of the S and R product enantiomers, respectively. Our model 
predicts an enantiomeric excess of 84% in favor of the S-enantiomer, which agrees with 
the experimentally obtained value of 86% ee and supports the notion that the coupling 
step is enantiodetermining. 
 
Figure 1.5. Reaction Energy Diagram Representing Alternative Calculated Pathway 
 
1.7. Absolute Stereochemistry Determination 
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Figure 1.6. X-ray Crystallographic Analysis of 1.2a31 
 
 X-Ray crystallographic analysis of 1.2a indicated the (S) absolute axial 
configuration was present (Figure 1.6). On this basis, a preliminary stereochemical model 
can be proposed as illustrated in intermediate C of Figure 1.6.  The phenol coordinates 
to minimize steric interactions; namely, the less hindered lone pair of the phenol 
coordinates to the vanadium and the less substituted ortho-position orients closest to the 
catalyst, placing the larger ortho-substituent into unoccupied space.  Approach of the 
second phenol from the face opposite the tert-butyl group then gives rise to the observed 
stereochemistry. 
1.8. Conclusions 
 In summary, the first enantioselective oxidative coupling of phenols and 2-
hydroxycarbazoles has been accomplished and gives rise to adducts not available with 
alternate approaches. A much more active vanadium oxidative catalyst was developed 
capable of acting on these less reactive substrates to form the axial chiral dimers 
efficiently.  Less electron-rich ligands were employed, which stabilize the low valent 
vanadium(IV) and destabilize the high valent vanadium(V), giving rise to a more potent 
                                                     
31 Reprinted with permission from Kang, H.; Lee, Y. E.; Reddy, P. V. G.; Dey, S.; Allen, S. E.; 
Niederer, K. A.; Sung, P.; Hewitt, K.; Torruellas, C.; Herling, M. R.; Kozlowski, M. C. Asymmetric 
Oxidative Coupling of Phenols and Hydroxycarbazoles. Org. Lett. 2017, 19, 5505–5508. Copyright 
2017 American Chemical Society. 
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oxidizing species.  Counterintuitively, the addition of a Brønsted or Lewis acid was found 
to accelerate the process, indicating that ligand exchange of the substrate is not driven by 
deprotonation of the phenol. Rather, the Brønsted acid likely activates the vanadium 
catalyst, enhancing both its oxidizing properties and its ability to coordinate a neutral 
phenol.  Together, these features should prove useful in the design of other asymmetric 
oxidants.  
1.9. Experimental Section 
General Considerations 
 Unless otherwise noted, all non-aqueous reactions were carried out under an 
atmosphere of dry N2 in dried glassware. When necessary, solvents and reagents were 
dried prior to use. THF was distilled from sodium benzophenone ketyl. CH2Cl2, 
ClCH2CH2Cl, and toluene were distilled from CaH2. High throughput experiments were 
performed at the Penn/Merck High Throughput Experimentation Laboratory at the 
University of Pennsylvania. The screens were analyzed by HPLC by addition of an internal 
standard. 
Analytical thin layer chromatography (TLC) was performed on EM Reagents 0.25 mm 
silica-gel 254-F plates. Visualization was accomplished with UV light. Chromatography 
was performed using a forced flow of the indicated solvent system on EM Reagents Silica 
Gel 60 (230-400 mesh). When necessary, the column was pre-washed with 1% Et3N in 
the eluent system. 1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical 
shifts are reported in ppm from tetramethylsilane (0 ppm) or from the solvent resonance 
(CDCl3 7.26 ppm, DMSO-d6 3.58 ppm, acetone-d6 2.05 ppm, DMF-d7 2.50 ppm, CD3CN 
1.94 ppm, CD2Cl2 5.32 ppm). Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, 
and number of protons. Decoupled 13C NMR spectra were recorded at 125 MHz. IR 
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spectra were taken on an FT-IR spectrometer using a thin film on NaCl plate. Accurate 
mass measurement analyses were conducted via time-of-flight mass analyzer GCMS with 
electron ionization (EI) or via time-of-flight mass analyzer LCMS with electrospray 
ionization (ESI). The signals were measured against an internal reference of 
perfluorotributylamine for EI-GCMS and leucine enkephalin for ESI-LCMS. The instrument 
was calibrated and measurements were made using neutral atomic masses; the mass of 
the electron removed or added to create the charged species is not taken into account. 
Low resolution LCMS data were obtained by use of a UPLC system with a SQD mass 
analyzer equipped with electrospray ionization. Circular dichroism and UV-vis 
spectroscopy measurements carried out at ambient temperature (23 C). Solution spectra 
in methanol recorded in 10-mm quartz cuvettes and corrected by subtracting the spectrum 
of the pure solvent at the same temperature. A scan rate of 100 nm/min with a response 
time of 1 s and a bandwidth of 1 nm was used to measure the CD spectra, which were 
recorded in low sensitivity mode with 4 accumulations. Melting points are corrected. 
Enantiomeric excesses were determined using analytical HPLC with UV detection at 254 
nm. Analytical Chiralpak columns (4.6 mm x 250 mm, 5 µm) from Daicel were used. 
Optical rotations were measured on a polarimeter with a sodium lamp. 
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Table 1.S1. CD Spectrum of Compound 1.2a in MeOH 
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Table 1.S2. CD Spectrum of Compound 1.4l in MeOH 
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(S)-Vanadium Catalyst V6. All glassware was flame dried. A mixture of L-tert-leucine (45 
mg, 0.34 mmol) and 3-tert-butyl-5-nitro-2-hydroxybenzaldehyde (76 mg, 0.34 mmol) in 
MeOH:CH2Cl2 (2 mL, 1:1) was heated at reflux and monitored by TLC. The reaction 
mixture was cooled to room temperature and VO(OEt)3 (69 mg, 0.34 mmol) was added 
followed by stirring for 3 h under Ar. Removal of solvent afforded the catalyst (147 mg, 
99%) as a deep blue solid: HRMS (ESI-TOF) m/z = 433.1180 calcd for C18H26N2O7V 
[M+H]+, found 433.1179. 
 
(S)-Vanadium Catalyst V8. 3-tert-Butyl-5-nitro-2-hydroxybenzaldehyde (300 mg, 1.34 
mmol) and L-tert-leucine (176 mg, 1.34 mmol) in MeOH:CH2Cl2 (7.6 mL, 1:1) were added 
to an oven-dried round-bottom flask. The resultant mixture was heated at reflux for 3 h. 
After evaporation of organic solvents, the residual solid was redissolved in CH2Cl2 (6.7 
mL). VO(Oi-Pr)3 (0.32 mL, 1.34 mmol) was introduced to the mixture followed by stirring 
for 3 h under Ar. Removal of solvent afforded the catalyst (590 mg, 99%) as a deep blue 
solid: HRMS (ESI-TOF) m/z = 461.1493 calcd for C20H30N2O7V [M+H]+, found 461.1476.  
 
2-Chloro-5-methoxy-4-methylaniline (1.7) 4-Amino-5-chloro-2-methoxybenzoic acid 
(5.00 g, 24.8 mmol) was suspended in chlorobenzene (50 mL) and cooled to 0 °C. Neat 
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BH3•SMe2 (7.1 mL, 74.4 mmol) was added with vigorous stirring. When effervescence 
ceased, the mixture was heated for 3 h at 80 °C and then for 18 h at 130 °C. The reaction 
was quenched by addition of aqueous Na2CO3 (aq) (1 M, 82 mL). The mixture was 
extracted with CH2Cl2 (50 mL X 3), dried (MgSO4), filtered, and the solvent was removed 
under reduced pressure to give a yellow solid. Chromatography (9:1 = hexane/EtOAc) 
afforded the product as a white powder (2.76 g 65%): 1H NMR (360 MHz, CDCl3)  6.90 
(s, 1H), 6.40 (s, 1H), 5.05 (s, 2H), 3.68 (s, 3H), 1.96 (s, 3H). Spectra are in accord with 
those previously reported.25  
General procedure A: Buchwald-Hartwig C-N coupling. A mixture of NaOt-Bu (2.8 g, 
29.1 mmol), Pd(OAc)2 (52 mg, 0.23 mmol), and [HP(t-Bu)3][BF4] (85 mg, 0.29 mmol) was 
suspended in toluene (0.17 M). 2-Chloro-5-methoxy-4-methylaniline (1.0 g, 5.83 mmol) 
and an aryl bromide (5.94 mmol) were added. The reaction mixture was heated at reflux 
for 18 h. After the resultant mixture was cooled to ambient temperature, the mixture was 
quenched by addition of 2 M HCl (aq) (35 mL). The mixture was extracted with CH2Cl2 (30 
mL X 3), dried over Na2SO4, filtered, and the solvent was removed under reduced 
pressure. Chromatography afforded the product. 
General procedure B: palladium catalyzed cyclization. Chlorobiphenylaniline (1.89 
mmol), K2CO3 (783 mg, 5.67 mmol), Pd(OAc)2 (21 mg, 0.09 mmol), and [HP(t-Bu)3][BF4] 
(55 mg, 0.19 mmol) were combined with DMA (7.6 mL) under an Ar atmosphere. After 
stirring at 130 oC for 18 h, the mixture was cooled and then quenched by addition of 2 M 
HCl (aq) (7 mL). The mixture was poured into excess amount of water and extracted with 
EtOAc (30 mL X 3). The combined organic layers were washed thoroughly with H2O (2 
mL X 5) and brine followed by drying over Na2SO4. After  filtration and removal of solvent, 
the compounds was chromatographed.  
General procedure C: demethylation. The 2-methoxycarbazole (1.62 mmol) was 
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dissolved in CH2Cl2 (23 mL). After cooling to –78 ºC, a solution of BBr3 (1 M in 
dichloromethane, 3.24 mmol) was added dropwise. The resultant mixture was allowed to 
warm to room temperature and stirred until completion as judged by TLC (30 min – 18 h). 
The mixture was subsequently quenched with water (15 mL) under ice bath. The solution 
was then extracted with EtOAc (30 mL X 3), washed with brine and the combined organic 
layers were dried over Na2SO4. Removal of solvent was followed by chromatography. 
General procedure D: protection of carbazole nitrogen. To a stirring solution of DMF 
(1.4 mL) and NaH (85 mg, 3.55 mmol) was added a solution of 2-hydroxycarbazole (1.42 
mmol) in THF (14 mL) at 0 °C. After stirring for 30 minutes at room temperature, BnCl (1.6 
mL, 1.56 mmol, 1.0 M in THF) was added to the solution. After stirring for 18 h at 10 oC, 
the solution was quenched with ice-water (15 mL), extracted with EtOAc (30 mL X 3). After 
washing the combined organic layers with water (2 mL X 5) and brine, the organic phase 
was dried with Na2SO4. Removal of solvent was followed by chromatography. 
General procedure E: asymmetric oxidative 2-hydroxycarbazole coupling. To a 
microwave vial was added N-protected 2-hydroxycarbazole (0.42 mmol), catalyst V8 (38 
mg, 0.08 mmol) and AcOH (0.16 mL, 2.71 mmol). The vial was sealed with a septum and 
the chlorobenzene (0.84 mL) was added. After degassing and purging with O2 three times, 
the vial was sealed with a microwave vial cap and was stirred at 0 oC for 48 h. Upon 
completion, the reaction mixture was then directly chromatographed using silica gel. 
 
2-Chloro-5-methoxy-4-methyl-N-phenylaniline (1.8a). Following General Procedure A 
for 23 h, the product was obtained as brown oil (1.26 g) in 87% yield. Rf  = 0.6 
(EtOAc/Hexanes = 1/4): 1H NMR (500 MHz, acetone-d6)  7.30 (t, J = 6.3 Hz, 2H), 7.13-
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7.10 (m, 3H), 6.99 (s, 1H), 6.8 (s, 1H), 5.94 (s, 1H), 3.71 (s, 3H), 2.13 (s, 3H); 13C NMR 
(125 MHz, acetone-d6)  157.1, 143.3, 138.8, 130.7, 129.2, 120.9, 120.0, 118.2, 113.8, 
101.3, 55.0, 14.5; IR (neat) 3400, 2925, 2850, 1512, 1200, 605 cm-1; HRMS (ESI-TOF) 
calcd for C14H15ClNO [M+H]+ 248.0842, found 248.0842. 
 
2-Methoxy-3-methyl-9H-carbazole (1.9a). Following General Procedure B for 20 h, the 
product was obtained as a white solid (342 mg) in 86% yield. Spectral data were in 
agreement with those reported.32 
 
3-Methyl-9H-carbazol-2-ol (1.10a). Following General Procedure C for 23 h, the product 
was obtained as a white solid (342 mg) in 86% yield. Spectral data were in agreement 
with those reported.32 
 
9-Benzyl-3-methyl-9H-carbazol-2-ol (1.4a). Following General Procedure D for 24 h, 
the product was obtained as an off-white powder (72 mg) in 52% yield. Spectral data were 
in agreement with those reported.32 
                                                     
32 Dai, J.; Ma, D.; Fu, C.; Ma, S. Gram Scale Total Synthesis of 2-Hydroxy-3-Methylcarbazole, 
Pyrano[3,2-a]Carbazole and Prenylcarbazole Alkaloids. Eur. J. Org. Chem. 2015, 2015 (25), 
5655–5662. 
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3,9-Dimethyl-9H-carbazol-2-ol (1.4b). Following General Procedure D using a 1.0 M 
solution of MeI in THF (0.067 mL) for 2 h, the product was obtained as a brown solid (10 
mg) in 23% yield. Rf  = 0.4 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.29 
(s, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.80 (s, 1H) 7.39 (d, J = 8.0 Hz, 1H), 7.30 (dt, J = 7.5, 1.0 
Hz, 1H), 7.10 (dt,  J = 8.0, 0.5 Hz, 1H), 6.89 (s, 1H), 3.76 (s, 3H), 2.35 (s, 3H); 13C NMR 
(125 MHz, acetone-d6)  155.9, 142.1, 141.8, 124.6, 124.0, 122.4, 119.7, 119.3, 117.6, 
116.4, 109.1, 95.2, 29.2, 16.6; IR (neat) 3391, 2922, 2853, 1634, 1604, 815, 740, 719, 
621 cm-1; HRMS (ESI-TOF) calcd for C14H12NO [M-H]– 212.1075, Found 212.1083. 
 
9-Allyl-3-methyl-9H-carbazol-2-ol (1.4c). Following General Procedure D, the product 
was obtained as a colorless solid (71 mg) in 43% yield. Rf  = 0.47 (EtOAc:Hexanes = 1:4): 
1H NMR (500 MHz, CDCl3)  7.98 (d, J = 7.7 Hz, 1H), 7.82 (s, 1H), 7.37 (td, J = 8.2, 1.1 
Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 7.20 (td, J = 7.8, 0.9 Hz, 1H),  6.79 (s, 1H), 6.00-5.93 
(m, 1H), 5.16 (dd, J = 10.3, 1.3 Hz, 1H), 5.04 (dd, J = 17.1, 1.2 Hz, 1H), 4.85 (s, 1H), 4.81-
4.80 (m, 2H), 2.42 (s, 3H); 13C NMR (125 MHz, CDCl3)  153.3, 140.6, 132.4, 124.4, 123.2, 
122.0, 119.5, 119.1, 117.0, 116.9, 115.9, 108.6, 95.1, 45.5, 16.2; IR (neat) 3350, 2918, 
1633, 1604, 1495, 1461, 1326, 1251, 1183, 1141, 1120, 1022, 923, 808, 744, 721 cm-1; 
HRMS (EI-TOF) calcd for C16H15NO [M]+ m/z = 237.1154; found 237.1152. 
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9-Isopropyl-3-methyl-9H-carbazol-2-ol (1.4d). Following General Procedure D, the 
product was obtained as a white solid (65 mg) in 39% yield. Rf  = 0.43 (EtOAc:Hexanes = 
1:4): 1H NMR (500 MHz, CDCl3)  7.97 (d, J = 7.7 Hz, 1H), 7.81 (s, 1H), 7.45 (d, J = 8.3 
Hz, 1H), 7.35 (td, J = 8.2, 1.2 Hz, 1H), 7.17 (td, J = 7.8, 0.8 Hz, 1H),  6.95 (s, 1H), 4.91-
4.84 (m, 1H), 4.82 (s, 1H), 2.42 (s, 3H), 1.67 (d, J = 7.0 Hz, 6H); 13C NMR (125 MHz, 
CDCl3)  152.8, 139.7, 139.4, 124.0, 123.5, 121.9, 119.5, 118.6, 117.5, 115.4, 109.7, 96.4,  
46.8, 20.8, 16.1; IR (neat) 3383, 2972, 2917, 2849, 1635, 1602, 1459, 1350,  1223, 1101, 
996, 1879, 721 cm-1; HRMS (EI-TOF) calcd for C16H17NO [M]+ m/z = 239.1310; found 
239.1321. 
 
3-Methyl-9-(2,4,6-trimethylbenzyl)-9H-carbazol-2-ol (1.4e). Following General 
Procedure D using 2,4,6-trimethylbenzylchloride (0.117 g, 0.70 mmol), the product was 
obtained as a white solid (92 mg) in 40% yield. Rf  = 0.4 (EtOAc:Hexanes = 1:4): 1H NMR 
(500 MHz, CDCl3)  7.95 (d, J = 7.7 Hz, 1H), 7.79 (s, 1H), 7.25 (td, J = 8.3, 1.2 Hz, 1H), 
7.15 (td, J = 7.9, 0.8 Hz, 1H), 7.09 (d, J = 8.2 Hz, 1H), 6.89 (s, 2H), 6.50 (s, 1H), 5.34 (s, 
2H), 4.69 (s, 1H), 2.38 (s, 3H), 2.30 (s, 3H), 2.18 (s, 6H); 13C NMR (125 MHz, CDCl3)  
153.0, 140.9, 140.8, 137.7, 137.6, 129.9, 129.6, 124.3, 123.3, 121.8, 119.3, 118.9, 117.1, 
115.8, 109.2, 95.7, 43.3, 21.1, 20.5, 16.2; IR (neat) 3241, 2954, 1604, 1460, 1300, 1188, 
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742 cm-1; HRMS (EI-TOF) calcd for C23H23NO [M]+ m/z = 329.1780; found 329.1798. 
 
2-Chloro-N-(4-fluorophenyl)-5-methoxy-4-methylaniline (1.8f). Following General 
Procedure A, the product was obtained as brown oil (1.55 g) in 99% yield. Rf  = 0.65 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.20-7.17 (m, 2H), 7.12 (s, 1H), 
7.07-7.04 (m, 2H), 6.83 (s, 1H), 6.78 (s, 1H), 3.72 (s, 3H), 2.09 (s, 3H); 13C NMR (125 
MHz, acetone-d6)  158.0 (d, J = 238 Hz), 157.2, 139.54 (d, J = 2.1 Hz), 139.5, 130.9 (d, 
J = 1.8 Hz), 121.0 (d, J = 8.2 Hz), 119.6, 115.7 (d, J = 22.0 Hz), 113.2, 100.5 (d J = 3.9 
Hz), 55.1, 14.6; IR (neat) 3420, 2925, 1609, 1200, 602, cm-1; HRMS (ESI-TOF) calcd for 
C14H14ClFNO [M+H]+ 266.0748, found 266.0743. 
 
6-Fluoro-2-methoxy-3-methyl-9H-carbazole (1.9f). Following General Procedure B, 
the product was obtained as a yellow solid (104 mg) in 72% yield. Rf  = 0.20 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  10.08 (s, 1H), 7.81 (s, 1H), 7.69 
(dd, J = 9.3, 2.5 Hz, 1H), 7.40 (dd, J = 8.8, 4.4 Hz, 1H), 7.04 (td, J = 9.4, 2.4 Hz, 1H), 7.01 
(s, 1H), 3.89 (s, 3H), 2.30 (3H); 13C NMR (125 MHz, acetone-d6)  157.9, 157.3 (d, J = 
233 Hz), 141.2, 136.3, 123.9 (d, J = 10.1 Hz), 121.4, 118.5, 115.7 (d, J = 3.8 Hz), 111.1, 
111.0 (d, J = 15.1 Hz), 104.4 (d, J = 23.9 Hz), 92.6, 54.9, 16.0; IR (neat) 3395, 2910, 1486, 
847, 822, 803, 783, cm-1; HRMS (ESI-TOF) calcd for C14H13FNO [M+H]+ 230.0981, Found 
230.0986. 
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6-Fluoro-3-methyl-9H-carbazol-2-ol (1.10f). Following General Procedure C, the 
product was obtained as a brown solid (166 mg) in 90% yield. Rf  = 0.20 (EtOAc:Hexanes 
= 1:2): 1H NMR (500 MHz, acetone-d6)  9.94 (s, 1H), 8.34 (s, 1H), 7.78 (s, 1H), 7.66 (dd, 
J = 9.5, 2.6 Hz, 1H), 7.35 (dd, J = 8.8, 4.5 Hz, 1H), 7.01 (td, J = 9.0, 2.5 Hz, 1H), 6.97 (s, 
1H), 2.35 (s, 3H); 13C NMR (125 MHz, acetone-d6)  157.0 (d, J = 233 Hz), 155.3, 141.3, 
136.3, 124.2 (d, J = 10.1 Hz), 121.6, 117.2, 115.8 (d, J = 3.8 Hz), 110.9, 110.7 (d, J = 14.8 
Hz), 104.4 (d, J = 23.9 Hz), 96.2, 15.8; IR (neat) 3406, 2919, 1485, 1406, 1257, 1146, 
1013, 600 cm-1; HRMS (ESI-TOF) calcd for C13H9NOF [M-H]+ 214.0668, Found 214.0672. 
 
9-Benzyl-6-fluoro-3-methyl-9H-carbazol-2-ol (1.4f). Following General Procedure D, 
the product was obtained as a yellow solid (193 mg) in 81% yield. Rf = 0.35 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.40 (s, 1H), 7.85 (s, 1H), 7.73 
(dd, J = 9.0, 5.0 Hz, 1H), 7.41 (dd, J = 10.0, 5.0 Hz, 1H), 7.28-7.19 (m, 3H), 7.15-7.13 (m, 
2H), 7.05 (td, J = 10.0, 1.0 Hz, 1H), 6.89 (s, 1H), 5.50 (s, 2H), 2.34 (s, 3H); 13C NMR (125 
MHz, acetone-d6)  157.4 (d, J = 233 Hz), 155.6, 141.7, 137.9, 137.0, 128.6, 127.2, 126.5, 
123.9, (d, J = 10.6 Hz), 122.0, 117.5, 115.3, 110.9 (d, J = 25.6 Hz), 109.3 (d, J = 9.3 Hz), 
104.6 (d, J = 24.3 Hz), 94.9, 46.1, 15.7; IR (neat) 3301, 2922, 2851, 1633, 862, 828, 791, 
729, 696, 626 cm-1; HRMS (ESI-TOF) calcd for C20H17FNO [M+H]+ 306.1494 Found: 
306.1497 
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2-Chloro-N-(3-fluorophenyl)-5-methoxy-4-methylaniline (1.8g). Following General 
Procedure A, the product was obtained as brown oil (826 mg) in 65% yield. Rf  = 0.78 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.24 (dd, J = 15.0, 8.0 Hz, 1H), 
7.18 (s, 1H), 7.11 (br s, 1H), 6.95 (s, 1H), 6.90 (dd, J = 8.0, 2.0 Hz, 1H), 6.80 (dt, J = 11.5, 
2.5 Hz, 1H), 6.58 (td, J = 8.0, 2.5 Hz, 1H), 3.79 (s, 3H), 2.13 (s, 3H); 13C NMR (125 MHz, 
acetone-d6)  163.8 (d, J = 243 Hz), 156.9, 144.6 (d, J = 10.0 Hz), 137.1, 131.0, 130.6 (d, 
J = 10.0 Hz), 121.3, 114.2, 113.6 (d, J = 2.5 Hz), 108.0 (d, J = 21.3 Hz), 104.7 (d, J = 25.0 
Hz), 101.3, 55.7, 15.4; IR (neat) 3405, 2920, 2851, 1604, 1582, 1518, 834, 815, 776, 767, 
678, 615 cm-1; HRMS (ESI-TOF) calcd for C14H14FClNO [M+H]+ 266.0748, found 
266.0740. 
 
 
7-Fluoro-2-methoxy-3-methyl-9H-carbazole (1.9g). Following General Procedure B, 
the product was obtained as a yellow solid (60 mg) in 5% yield. Rf  = 0.10 (EtOAc:Hexanes 
= 1:4): 1H NMR (500 MHz, acetone-d6)  10.18 (s, 1H), 7.92 (dd, J = 8.6, 5.5 Hz, 1H), 7.78 
(s, 1H), 7.15 (dd, J = 10.0, 2.4 Hz, 1H), 7.03 (s, 1H), 6.90-6.86 (m, 1H), 3.89 (s, 3H), 2.30 
(s, 3H); 13C NMR (125 MHz, acetone-d6)  158.7 (d, J = 245 Hz), 158.5, 143.2 (d, J = 11.0 
Hz), 140.6, 125.4 (d, J = 8.2 Hz), 124.0 (d, J = 2.9 Hz), 120.0, 114.0, 112.3, 107.6 (d, J = 
3.5 Hz), 105.0 (d, J = 19.1 Hz), 93.5, 55.8, 16.8; IR (neat) 3396, 2921, 1611,  841, 808, 
742 cm-1; HRMS (ESI-TOF) calcd for C14H11FNO [M-H]– 228.0825, Found 228.0822. 
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7-Fluoro-3-methyl-9H-carbazol-2-ol (1.10g). Following General Procedure C, the 
product was obtained as a brown solid (69 mg) in 99% yield. Rf  = 0.20 (EtOAc:Hexanes 
= 1:2): 1H NMR (500 MHz, acetone-d6)  10.06 (s, 1H), 8.26, (s, 1H), 7.89 (dd, J = 8.5, 5.5 
Hz, 1H), 7.74 (s, 1H), 7.11 (dd, J = 10.5, 2.5 Hz, 1H), 6.96 (s, 1H), 6.88-6.84 (m, 1H) 2.33 
(s, 3H); 13C NMR (125 MHz, acetone-d6)  161.0 (d, J = 235 Hz), 154.6, 140.6 (d, J = 14.8 
Hz), 140.6, 121.2, 120.3, 119.7 (d, J = 10.5 Hz), 117.4, 115.7, 106.2 (d, J = 24.1 Hz), 97.0 
(d, J = 26.3 Hz), 96.5, 15.9; IR (neat) 3406, 2920, 1486, 1293, 834, 820, 810, 781, 600, 
cm-1; HRMS (ESI-TOF) calcd for C13H9FNO [M-H]
– 214.0668, Found: 214.0669. 
 
9-Benzyl-7-fluoro-3-methyl-9H-carbazol-2-ol (1.4g). Following General Procedure D, 
the product was obtained as a yellow solid (57 mg) in 83% yield. Rf = 0.17 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.38 (s, 1H), 7.84 (s, 1H), 7.28-
7.19 (m, 5H), 7.14 (d, J = 7.0 Hz, 2H), 6.91 (s, 1H), 6.84 (ddd, J = 8.5, 7.0, 1.5 Hz, 1H), 
5.50 (s, 2H), 2.33 (s, 3H); 13C NMR (125 MHz, acetone-d6)  157.6 (d, J = 245 Hz), 155.0, 
143.0, 140.3, 137.5, 128.5, 127.2, 126.4, 124.5 (d, J = 8.3 Hz), 123.7 (d, J = 3.0 Hz), 
117.9, 112.8, 111.0, (d, J = 21.0 Hz), 104.9, 104.4 (d, J = 19.3 Hz), 94.3, 46.2, 15.5; IR 
(neat) 3456, 3370, 2918, 1470, 883, 776, 741, 715, 702, 693 cm-1; HRMS (ESI-TOF) calcd 
for C20H15FNO [M-H]
– 304.0876 Found: 304.0875 
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2-Chloro-N-(2-fluorophenyl)-5-methoxy-4-methylaniline (1.8h). Following General 
Procedure A for 20 h, the product was obtained as brown oil (398 mg) in 64% yield. 
Spectral data were in agreement with those reported.33 
 
1-Fluoro-7-methoxy-6-methyl-9H-carbazole (1.9h). Following General Procedure B 
for 20 h, the product was obtained as a light brown solid (313 mg) in 91% yield. Spectral 
data were in agreement with those reported.33 
 
8-Fluoro-3-methyl-9H-carbazol-2-ol (1.10h). Following General Procedure C, the 
product was obtained as a brown solid (200 mg) in 69% yield. Rf  = 0.38 (EtOAc:Hexanes 
= 1:2): 1H NMR (500 MHz, acetone-d6)  10.28 (br s, 1H), 8.43 (s, 1H), 7.80 (s, 1H), 7.75-
7.74 (m, 1H), 7.06-7.03 (m, 3H), 2.37 (s, 3H); 13C NMR (125 MHz, acetone-d6)  156.3, 
149.8 (d, J = 240.5 Hz), 141.2, 128.3 (d, J = 6.0  Hz), 128.1, 122.4 (d, J = 4.0 Hz), 119.6 
(d, J = 5.9 Hz), 118.6, 116.8 (d, J = 2.6 Hz), 115.6, 109.6 (d, J = 16.6 Hz), 97.4, 16.7; IR 
(neat) 3540, 3404, 2911, 1623, 1576, 1475, 1450, 1429, 1299, 1290, 1262, 1237, 1219, 
1200, 1174, 1157, 1137, 1057, 1050, 833 cm-1; HRMS (EI-TOF) calcd for C13H10FNO [M]+ 
m/z = 215.0746, found 215.0758. 
                                                     
33 Bedford, R. B.; Betham, M.; Charmant, J. P. H.; Weeks, A. L. Intramolecular Direct Arylation in 
the Synthesis of Fluorinated Carbazoles. Tetrahedron 2008, 64, 6038–6050. 
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9-Benzyl-8-fluoro-3-methyl-9H-carbazol-2-ol (1.4h). Following General Procedure D, 
the product was obtained as a yellow solid (55 mg) in 28% yield. Rf = 0.65 
(EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6)  8.49 (br s, 1H), 7.86 (s, 1H), 
7.81 (d, J = 7.5 Hz, 1H), 7.27 (t, J = 7.0 Hz, 2H), 7.22 (t, J = 7.2 Hz, 1H), 7.15 (d, J = 7.2 
Hz, 2H), 7.11-7.02 (m, 2H), 6.93 (s, 1H), 5.65 (s, 2H), 2.34 (s, 3H); 13C NMR (125 MHz, 
acetone-d6)  156.5, 150.2 (d, J = 241.5 Hz), 142.1, 139.4, 129.5, 129.4, 128.3 (d, J = 5.0 
Hz), 128.0, 127.1, 122.6, 120.1 (d, J = 6.3 Hz), 119.0, 116.6, 115.9 (d, J = 3.8 Hz), 110.8 
(d, J = 18.9 Hz), 95.9, 49.0, 16.6; IR (neat) 3310, 2918, 1577, 1472, 1454, 1423, 1347, 
1296, 1235, 1219, 1186, 1137, 1105, 1058, 1000, 819 cm-1; HRMS (ESI-TOF) calcd for 
C20H17FNO [M+H]+ m/z = 306.1294, found 306.1314. 
 
2-Chloro-5-methoxy-4-methyl-N-(4-(trifluoromethyl)phenyl)aniline (1.8i). Following 
General Procedure A using Pd2(dba)3 as the catalyst at room temperature for 10 min, the 
product was obtained as a white solid (252 mg) in 45% yield. Rf = 0.57 (EtOAc:Hexanes 
= 1:4): 1H NMR (500 MHz, CDCl3)  7.54 (d, J = 8.5 Hz, 2H), 7.18 (s, 1H), 7.10 (d, J = 8.5 
Hz, 2H), 6.89 (s, 1H), 6.08 (br s, 1H), 3.78 (s, 3H), 2.21 (s, 3H); 13C NMR (125 MHz, 
CDCl3)  157.0, 146.3, 136.4, 131.2, 126.9, 124.6 (q, J = 271 Hz), 122.6 (q, J = 32.7 Hz), 
122.5, 116.4, 115.5, 102.6, 55.7, 15.5; IR (neat) 3400, 2925, 1604, 1525, 1509, 1481, 
1450, 1395, 1323, 1289, 1244, 1201, 1186, 1159, 1103, 1066, 990, 946, 873 cm-1; HRMS 
(ESI-TOF) calcd for C15H14ClF3NO [M+H]+ m/z = 316.0716, found 316.0742. 
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2-methoxy-3-methyl-6-(trifluoromethyl)-9H-carbazole (1.9i) Following General 
Procedure B for 48 h, the product was obtained as a light brown solid (94 mg) in 84% 
yield. Rf = 0.44 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.21 (s, 1H), 7.87 
(br s, 1H), 7.81 (s, 1H),  7.55 (d, J = 8.5 Hz, 1H), 7.30 (d, J = 8.5 Hz, 1H), 6.72 (s, 1H), 
3.87 (s, 3H), 2.39 (s, 3H); 13C NMR (125 MHz, CDCl3)  158.2, 140.7, 139.8, 125.5 (q, J 
= 271 Hz), 123.2, 121.8, 121.7 (q, J = 31.8 Hz), 121.0, 120.5, 116.8, 115.6, 110.3, 92.5, 
55.6, 16.8; IR (neat) 3360, 2915, 1614, 1458, 1334, 1297, 1261, 1230, 1197, 1164, 1145, 
1112, 1095, 1051, 1039, 1015, 978, 880, 819 cm-1; HRMS (EI-TOF) calcd for C15H13F3NO 
[M+H]+ m/z = 279.0871, found 279.0877. 
 
3-Methyl-6-(trifluoromethyl)-9H-carbazol-2-ol (1.10i). Following General Procedure C, 
the product was obtained as a light tan solid (98 mg) in 71% yield. Rf = 0.29 
(EtOAc:Hexanes = 1:1): 1H NMR (500 MHz, acetone-d6)  10.36 (br s, 1H), 8.44 (s, 1H), 
8.31 (s, 1H), 7.95 (s, 1H), 7.57-7.53 (m, 2H), 7.04 (s, 1H), 2.37 (s, 3H); 13C NMR (125 
MHz, acetone-d6)  156.5, 142.5, 141.7, 126.7 (q, J = 270  Hz), 124.2, 122.7, 121.1 (q, J 
= 3.8 Hz), 121.0 (q, J = 31.4 Hz), 119.0, 117.1 (q, J = 3.8 Hz), 116.3, 111.4, 97.3, 16.7; IR 
(neat) 3412, 3270, 2925, 1641, 1616, 1414, 1330, 1298, 1255, 1225, 1210, 1194, 1169, 
1156, 1137, 1108, 1052, 1015, 883 cm-1; HRMS (EI-TOF) calcd for C14H10F3NO [M]+ m/z 
= 265.0714, found 265.0714. 
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9-Benzyl-3-methyl-6-(trifluoromethyl)-9H-carbazol-2-ol (1.4i). Following General 
Procedure D, the product was obtained as a white powder (24 mg) in 29% yield. Rf = 0.50 
(EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6)  8.52 (s, 1H), 8.37 (s, 1H), 8.01 
(s, 1H), 7.64-7.58 (m, 2H), 7.30-7.24 (m, 3H), 7.17 (d, J = 7.0 Hz, 2H), 6.97 (s, 1H), 5.58 
(s, 2H), 2.37 (s, 3H); 13C NMR (125 MHz, acetone-d6)  156.7, 143.0, 142.4, 138.3, 129.5, 
128.2, 127.4, 126.6 (q, J = 270 Hz), 124.0, 123.0, 121.4 (q, J = 3.6 Hz), 121.3 (q, J = 31.7 
Hz), 119.4, 117.2 (q, J = 4.3 Hz), 116.0, 109.8, 96.1, 47.0, 16.6; IR (neat) 3350, 2923, 
1613, 1453, 1371, 1330, 1301, 1260, 1213, 1175, 1158, 1141, 1103, 1068, 1044, 1013, 
963, 882 cm-1; HRMS (EI-TOF) calcd for C21H16F3NO [M]+ m/z = 355.1184, found 
355.1175. 
 
2-Chloro-5-methoxy-4-methyl-N-(3-(trifluoromethyl)phenyl)aniline (1.8j). Following 
General Procedure A using Pd2(dba)3 as the catalyst at room temperature for 10 min, the 
product was obtained as a yellow oil (677 mg) in 92% yield. Rf = 0.69 (EtOAc:Hexanes = 
1:5): 1H NMR (500 MHz, CDCl3)  7.40-7.36 (m, 2H), 7.23-7.19 (m, 2 H), 7.15 (s, 1H), 6.81 
(s, 1H), 6.03 (s, 1H), 3.74 (s, 3H), 2.16 (s, 3H); IR (neat) 3405, 2940, 1607, 1598, 1518, 
1496, 1466, 1447, 1434, 1398, 1332, 1320, 1236, 1200, 1162, 1120, 1098, 1069, 1000, 
875, 789, 697 cm-1; HRMS (ESI-TOF) m/z = 315.0638 calcd for C15H13ClF3NO [M]+, found 
315.0627. 
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2-Methoxy-3-methyl-7-(trifluoromethyl)-9H-carbazole (1.9j). Following General 
Procedure B for 24 h, the product was obtained as a light tan solid (295 mg) in 67% yield. 
Rf = 0.10 (EtOAc:Hexanes = 1:6): 1H NMR (500 MHz, acetone-d6)  10.43 (br s, 1H), 8.13 
(d, J = 8.2 Hz, 1H), 7.91 (s, 1H), 7.77 (s, 1H),  7.41 (d, J = 8.1 Hz, 1H), 7.10 (s, 1H), 3.93 
(s, 3H), 2.33 (s, 3H); 13C NMR (125 MHz, acetone-d6)  159.6, 142.3, 139.9, 127.2, 126.5 
(q, J = 269 Hz), 125.8 (q, J = 31.0 Hz), 122.7, 120.5, 120.4, 116.1 (q, J = 4.0 Hz), 116.0, 
108.6, (q, J = 4.0 Hz), 93.7, 56.0, 17.0; IR (neat) 3395, 2935, 1630, 1478, 1448, 1332, 
1323, 1293, 1217, 1197, 1163, 1146, 1114, 1070, 1057, 1035, 1002, 920, 874, 821, 791, 
666 cm-1; HRMS (ESI-TOF) m/z = 279.0871 calcd for C15H12F3NO [M]+, found 279.0866. 
 
3-Methyl-7-(trifluoromethyl)-9H-carbazol-2-ol (1.10j). Following General Procedure C, 
the product was obtained as a tan solid (144 mg) in 68% yield. Rf = 0.15 (EtOAc:Hexanes 
= 1:5): 1H NMR (500 MHz, acetone-d6)  10.31 (br s, 1H), 8.52 (s, 1H), 8.11 (d, J = 8.1 
Hz), 7.89 (s, 1H), 7.73 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.03, (s, 1H), 2.36 (s, 3H); IR 
(neat)  3505, 3380, 2920, 1635, 1620, 1473, 1451, 1433, 1351, 1322, 1302, 1285, 1217, 
1161, 1115, 1056, 1010 917, 873, 843, 822, 727, 669 cm-1; HRMS (ESI-TOF) m/z = 
265.0714 calcd for C14H10F3NO [M]+, found 265.0726.  
 
9-Benzyl-3-methyl-7-(trifluoromethyl)-9H-carbazol-2-ol (1.4j). Following General 
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Procedure D, the product was obtained as a white solid (77 mg) in 58% yield. Rf = 0.28 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.60 (s, 1H), 8.18 (d, J = 8.2 
Hz, 1H), 7.96 (s, 1H), 7.83 (s, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.30-7.24 (m, 3H), 7.16 (d, J 
= 7.1 Hz, 2H), 6.96 (s, 1H), 5.63 (s, 2H), 2.36 (s, 3H); 13C NMR (125 MHz, acetone-d6)  
156.3, 142.0, 139.8, 137.5, 128.7, 127.3, 126.5, 126.2, 125.5 (q, J = 269 Hz), 125.1 (q, J 
= 31.0 Hz), 122.4, 119.4, 118.5, 115.3 (q, J = 4.0 Hz), 114.7, 105.8 (q, J = 4.0 Hz), 95.1, 
46.1, 15.7; IR (neat) 3345(w), 2915, 1640, 1453, 1370, 1317, 1296, 1262, 1248, 1214, 
1168, 1142, 1132, 1116, 1063, 1042, 1011, 887, 858, 821, 702, 665, 653 cm-1; HRMS 
(ESI-TOF) m/z = 356.1262 calcd for C21H16F3NO [M]+, found 356.1247. 
 
(4-((2-Chloro-5-methoxy-4-methylphenyl)amino)phenyl)(phenyl)methanone (1.8k). 
Following General Procedure A using Pd2(dba)3 (4 mol %) as a catalyst at room 
temperature for 20 min, the product was obtained as a brown solid (497 mg) in 81% yield. 
Rf = 0.44 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  7.81 (d, J = 8.5 Hz, 2H), 
7.77 (d, J = 7.0 Hz, 2H), 7.55 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 8.0 Hz, 2H), 7.16 (s, 1H), 7.05 
(d, J = 6.5 Hz, 2H), 6.92 (s, 1H), 6.31 (s, 1H), 3.76 (s, 3H), 2.18 (s, 3H); 13C NMR (125 
MHz, CDCl3)  195.2, 156.8, 147.5, 138.5, 135.7, 132.6, 131.7, 131.1, 129.6, 129.3, 128.2, 
122.9, 116.0, 115.1, 103.3, 55.7, 15.6; IR (neat) 3360, 3000, 2949, 1584, 1574, 1516, 
1500, 1480, 1465, 1443, 1394, 1309, 1282, 1249, 1201, 1174, 1165, 1143, 837 cm-1; 
HRMS (ESI-TOF) calcd for C21H19ClNO2 [M+H]+ m/z = 352.1104, found 352.1100. 
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(7-Methoxy-6-methyl-9H-carbazol-3-yl)(phenyl)methanone (1.9k). Following General 
Procedure B for 23 h, the product was obtained as a brown solid (288 mg) in 65% yield. 
Rf = 0.19 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, DMF-d7)  11.55 (br s, 1H), 8.53 (s, 
1H), 7.99 (s, 1H),  7.84 (d, J = 8.4 Hz, 3H), 7.70 (t, J = 7.4 Hz, 1H), 7.63-7.60 (m, 3H), 
7.15 (s, 1H), 3.96 (s, 3H), 2.33 (s, 3H); 13C NMR (125 MHz, DMF-d7)  196.0, 158.2, 143.1, 
141.2,  139.6, 131.9, 129.8, 128.6, 128.5, 126.6, 123.1, 122.7, 121.9, 119.4, 116.1, 110.6, 
93.4, 55.5, 16.3; IR (neat) 3300, 2910, 1629, 1599, 1565, 1473, 1332, 1312, 1282, 1247, 
1195, 1147, 1131, 1036, 1001, 876, 825 cm-1; HRMS (ESI-TOF) calcd for C21H18NO2 
[M+H]+ m/z = 316.1338, found 316.1347. 
 
(9-Benzyl-7-methoxy-6-methyl-9H-carbazol-3-yl)(phenyl)methanone (1.11k). 
Following General Procedure D at room temperature for 22 h, the product was obtained 
as a pale yellow solid (206 mg) in 80% yield. Rf = 0.80 (EtOAc:Hexanes = 1:1): 1H NMR 
(500 MHz, acetone-d6)  8.51 (s, 1H), 7.97 (s, 1H), 7.84 (dd, J = 8.6, 1.6 Hz, 1H), 7.81 
(dd, J = 8.1, 1.5 Hz, 2H), 7.64-7.54 (m, 4H), 7.31-7.24 (m, 6H), 5.72 (s, 2H), 3.91 (s, 3H), 
2.32 (s, 3H); 13C NMR (125 MHz, acetone-d6)  196.2, 159.1, 143.7, 142.4, 140.1, 138.4, 
132.3, 130.4, 129.6, 129.5, 129.0, 128.2, 127.6, 127.3, 123.6, 123.1, 122.6, 120.6, 116.5, 
109.6, 92.6, 56.0, 47.0, 16.8; IR (neat) 2925, 1649, 1630, 1600, 1452, 1356, 1310, 1283, 
1254, 1194, 1174, 1161, 1140, 877 cm-1; HRMS (ESI-TOF) calcd for C28H24NO2 [M+H]+ 
m/z = 406.1807, found 406.1792. 
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(9-Benzyl-7-hydroxy-6-methyl-9H-carbazol-3-yl)(phenyl)methanone (1.4k). Following 
General Procedure C at room temperature for 45 min, the product was obtained as an 
off-white powder (97 mg) in quantitative yield. Rf = 0.34 (EtOAc:Hexanes = 1:2): 1H NMR 
(500 MHz, acetone-d6)  8.48 (d, J = 3.9 Hz, 2H), 7.94 (s, 1H), 7.84 (dd, J = 8.5, 1.6 Hz, 
1H), 7.81 (d, J = 7.0 Hz, 2H), 7.65 (t, J = 7.5 Hz, 1H), 7.61-7.55 (m, 3H), 7.32-7.25 (m, 
3H), 7.21 (d, J = 7.0 Hz, 2 H), 6.98 (s, 1H), 5.61 (s, 2H), 2.35 (s, 3H); 13C NMR (125 MHz, 
acetone-d6)  196.2, 156.5, 144.0, 142.3, 140.2, 138.3, 132.3, 130.4, 129.6, 129.5, 129.1, 
128.3, 127.5, 127.4, 123.8, 122.98, 122.97, 119.3, 116.6, 109.2, 96.3, 47.1, 16.6; IR (neat) 
3381, 2924, 2854, 1649, 1597, 1449, 1414, 1318, 1281, 1251, 1183, 1136, 1072, 1028, 
1002, 948 cm-1; HRMS (ESI-TOF) calcd for C27H22NO2 [M+H]+ m/z = 392.1651, found 
392.1664. 
 
4-((2-Chloro-5-methoxy-4-methylphenyl)amino)benzonitrile (1.8l). Following General 
Procedure A using Pd2(dba)3 as a catalyst at room temperature for 10 min, the product 
was obtained as a yellow powder (412 mg) in 86% yield. Rf = 0.41 (EtOAc:Hexanes = 
1:4): 1H NMR (500 MHz, CDCl3)  7.51 (d, J = 8.5 Hz, 2H), 7.17 (s, 1H), 6.99 (d, J = 8.5 
Hz, 2H), 6.83 (s, 1H), 6.11 (br s, 1H), 3.77 (s, 3H), 2.17 (s, 3H); 13C NMR (125 MHz, 
CDCl3)  157.0, 147.5, 135.1, 133.9, 131.3, 124.0, 119.7, 116.9, 115.8, 104.1, 102.6, 55.8, 
15.7; IR (neat) 3402, 2925, 2217, 1599, 1506, 1469, 1455, 1441, 1396, 1372, 1333, 1299, 
1283, 1251, 1202, 1169, 985, 868, 815 cm-1; HRMS (ESI-TOF) calcd for C15H13ClN2O [M]+ 
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m/z = 272.0716, found 272.0706. 
 
7-Methoxy-6-methyl-9H-carbazole-3-carbonitrile (1.9l). Following General Procedure 
B for 48 h, the product was obtained as a light brown powder (249 mg) in 78% yield. Rf = 
0.33 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6)  10.62 (br s, 1H), 8.38 (s, 
1H), 7.93 (s, 1H),  7.57 (s, 2H), 7.09 (s, 1H), 3.92 (s, 3H), 2.32 (s, 3H); 13C NMR (125 
MHz, acetone-d6)  159.3, 142.5, 141.4, 127.8, 124.6, 124.4, 122.4, 121.2, 120.8, 115.7, 
112.2, 102.2, 93.7, 55.8, 16.8; IR (neat) 3311, 2910, 2217, 1609, 1466, 1444, 1323, 1297, 
1272, 1234, 1200, 1160, 1136, 1118, 1039, 1003, 862, 806 cm-1; HRMS (EI-TOF) calcd 
for C15H12N2O [M]+ m/z = 236.0950, found 236.0964. 
 
9-Benzyl-7-methoxy-6-methyl-9H-carbazole-3-carbonitrile (1.11l). Following General 
Procedure D at room temperature for 22 h, the product was obtained as a yellow solid 
(249 mg) in 90% yield. Rf = 0.63 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6) 
 8.46 (s, 1H), 8.02 (s, 1H), 7.64-7.60 (m, 2H), 7.30-7.20 (m, 6H), 5.72 (s, 2H), 3.92 (s, 
3H), 2.34 (s, 3H); 13C NMR (125 MHz, acetone-d6)  159.6, 142.9, 142.4, 138.1, 129.6, 
128.3, 128.0, 127.6, 124.7, 124.3, 122.8, 121.1, 121.0, 115.5, 110.8, 102.5, 92.7, 56.1, 
47.0, 16.8; IR (neat) 2923, 2852, 2211, 1632, 1602, 1487, 1469, 1455, 1352, 1326, 1255, 
1198, 1171, 1141, 1051, 1039, 873 cm-1; HRMS (EI-TOF) calcd for C22H18N2O [M]+ m/z = 
326.1419, found 326.1436. 
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9-Benzyl-7-methoxy-6-methyl-9H-carbazole-3-carboxylic acid (1.19). To a solution of 
S-5t (90 mg, 0.28 mmol) in EtOH (1.0 mL) and H2O (0.5 mL) was added NaOH (276 mg, 
6.89 mmol). The reaction mixture was refluxed overnight and then cooled to room 
temperature. EtOH was removed under reduced pressure, and the resultant aqueous 
mixture was acidified at 0 oC with 2 M HCl (3.5 mL). The resultant insoluble solid was 
filtered, washed with water (20 mL X 2), and dried to give the product as a white solid (95 
mg) in quantitative yield. Rf = 0.20 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, DMSO-d6) 
 12.50 (br s, 1H), 8.64 (d, J = 1.0 Hz, 1H), 8.01 (s, 1H), 7.92 (dd, J = 8.5, 1.5 Hz, 1H), 
7.56 (d, J = 9.0 Hz, 1H), 7.29-7.18 (m, 6H), 5.69 (s, 2H), 3.87 (s, 3H), 2.30 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6)  168.0, 157.5, 142.3, 140.9, 137.4, 128.5, 127.2, 126.7, 
125.4, 122.2, 121.6, 121.3, 121.2, 118.9, 114.8, 108.8, 92.1, 55.6, 45.7, 16.4; IR (neat) 
3350, 2924, 1605, 1556, 1495, 1446, 1391, 1351, 1324, 1254, 1192, 1161, 1133, 1054, 
1037, 884 cm-1; HRMS (ESI-TOF) calcd for C22H20NO3 [M+H]+ m/z = 346.1443, found 
346.1460. 
 
Butyl 9-benzyl-7-hydroxy-6-methyl-9H-carbazole-3-carboxylate (1.4l). To a solution of 
S-5t (267 mg, 0.77 mmol) in CH2Cl2 (11 mL) at –78 ºC, a solution of BBr3 (1 M in CH2Cl2, 
1.5 mL, 1.54 mmol) was added dropwise. The resultant mixture was allowed to warm to 
room temperature and stirred for 40 min. The mixture was subsequently quenched with 
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water (15 mL) with cooling in an ice bath. The solution was extracted with EtOAc (30 mL 
X 3), washed with brine, and the combined organic layers were dried over Na2SO4. 
Removal of solvent yielded the product (234 mg). No further purification was necessary. 
A microwave vial was charged with above product (103 mg, 0.31 mmol), n-BuOH (3.9 
mL), and two drops of concentrated H2SO4.  After stirring at at 100 oC for 22 h, the solvent 
was removed and the resultant residue was basified with satd NaHCO3 (aq) to a pH of 8. 
The mixture was extracted with EtOAc (10 mL X 3) and the combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated. Chromatography 
(hexane:ethyl acetate = 10:1) afforded the product as a tan amorphous solid (59 mg) in 
49% yield. Rf = 0.47 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6)  8.70 (d, J 
= 1.4 Hz, 1H), 8.44 (s, 1H), 8.01 (dd, J = 8.6, 1.7 Hz, 1H), 7.96 (s, 1H), 7.52 (d, J = 8.5 
Hz, 1H), 7.29-7.23 (m, 3H), 7.17 (d, J = 7.1 Hz, 2H), 6.95 (s, 1H), 5.56 (s, 2H), 4.34 (t, J = 
6.5 Hz, 2H), 2.38 (s, 3H), 1.81-1.76 (m, 2H), 1.56-1.48 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H); 
13C NMR (125 MHz, acetone-d6)  167.5, 156.4, 144.1, 142.2, 138.3, 129.5, 128.2, 127.4, 
126.3, 124.0, 122.8, 122.1, 121.8, 119.2, 116.5, 109.1, 96.2, 64.7, 47.0, 31.8, 20.0, 16.6, 
14.1; IR (neat) 3351, 2955, 2930, 1674, 1633, 1602, 1450, 1388, 1353, 1297, 1281, 1241, 
1178, 1134, 1100, 1020, 997, 972, 768 cm-1; HRMS (ESI-TOF) calcd for C25H26NO3 
[M+H]+ m/z = 388.1913, found 388.1911. 
 
N1-(2-Chloro-5-methoxy-4-methylphenyl)-N4,N4-diphenylbenzene-1,4-diamine 
(1.8m). Following General Procedure A for 18 h, the product was obtained as a pale 
brown solid (720 mg) in 87% yield. Rf = 0.40 (EtOAc:Hexanes = 1:9): 1H NMR (500 MHz, 
acetone-d6)  7.26 (t, J = 7.4 Hz, 4H), 7.16 (d, J = 8.7 Hz, 2H), 7.13 (s, 1H), 7.03 (d, J = 
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7.7 Hz, 6H), 6.98 (t, J = 7.4 Hz, 2H), 6.90 (s, 1H), 6.83 (br s, 1H), 3.75 (s, 3H), 2.10 (s, 
3H); 13C NMR (125 MHz, acetone-d6)  157.9, 149.0, 142.1, 140.1, 139.8, 131.6, 130.0, 
127.4, 126.7, 124.1, 123.9, 123.3, 123.2, 123.0, 120.52, 120.49, 114.2, 101.8, 55.9, 15.4; 
IR (neat) 3401, 3036, 2926, 1586, 1506, 1463, 1395, 1313, 1246, 1200, 1186, 995, 876, 
819 cm-1; HRMS (EI-TOF) calcd for C26H23ClN2O [M]+ m/z = 414.1499; found 414.1508.     
 
7-Methoxy-6-methyl-N, N´-diphenyl-9H-carbazol-3-amine (1.9m). Following General 
Procedure B for 24 h, the product was obtained as a colorless solid (529 mg) in 70% 
yield. Rf = 0.25 (EtOAc:Hexanes = 3:7): 1H NMR (500 MHz, acetone-d6)  10.11 (br s, 1H), 
7.75 (d, J = 1.9 Hz, 1H), 7.73 (s,1H), 7.43 (d, J = 8.5 Hz, 1H), 7.23 (t, J = 8.0 Hz, 4H), 7.07 
(dd, J = 8.5, 2.0 Hz, 1H), 7.04 (d, J = 8.7 Hz, 5H), 6.93 (t, J = 7.3 Hz, 2H), 3.90 (s, 3H), 
2.27 (s, 3H); 13C NMR (125 MHz, acetone-d6)  158.5, 149.8, 141.6, 141.4, 140.1, 138.3, 
138.1, 129.9, 125.4, 125.3, 124.7, 123.2, 122.2, 119.3, 118.7, 116.7, 112.4, 112.3, 93.50, 
93.45, 55.8, 16.8; IR (neat) 3403, 3042, 2908, 1584, 1484, 1433, 1310, 1275, 1228, 1200, 
1037 cm-1; HRMS (EI-TOF) calcd for C26H22N2O [M]+ m/z = 378.1732; found 378.1732.   
 
9-Benzyl-7-methoxy-6-methyl-N,N´-diphenyl-9H-carbazol-3-amine (1.11m). Following 
General Procedure D at room temperature for 2 h, the product was obtained as a 
colorless solid (222 mg) in 95% yield. Rf = 0.46 (EtOAc:Hexanes = 1:4): 1H NMR (500 
MHz, acetone-d6)  7.79 (dd, J = 7.8, 2.1 Hz, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.31-7.20 (m, 
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9H), 7.15 (s, 1H), 7.10 (dd, J = 8.6, 2.1 Hz, 1H), 7.03 (dd, J = 8.7, 1.0 Hz, 4H), 6.93 (t, J = 
7.4 Hz, 2H), 5.62 (s, 2H), 3.89 (s, 3H), 2.28 (s, 3H); 13C NMR (125 MHz, acetone-d6)  
158.8, 149.7, 142.3, 140.5, 138.9, 138.7, 129.9, 129.5, 128.2, 127.7, 125.1, 124.6, 123.3, 
122.5, 122.3, 119.5, 118.7, 116.2, 110.8, 92.2, 56.0, 47.0, 16.7; IR (neat) 3021, 2912, 
1632, 1585, 1490, 1470, 1423, 1354, 1317, 1254, 1193, 1037, 805, 736 cm-1; HRMS (EI-
TOF) calcd for C33H28N2O [M]+ m/z = 468.2202; found 468.2215.     
 
9-Benzyl-6-(diphenylamino)-3-methyl-9H-carbazol-2-ol (1.4m). Following General 
Procedure C at room temperature for 1.5 h, the product was obtained as a white solid 
(105 mg) in 93% yield. Rf = 0.30 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  
7.77 (br s, 1H),  7.67 (s, 1H), 7.29-7.07 (m, 15H), 6.92 (s, 2H), 6.71 (s, 1H), 5.36 (s, 2H), 
4.76 (s, 1H), 2.34 (s, 3H); 13C NMR (125 MHz, acetone-d6)  155.2, 148.8, 141.2, 139.4, 
137.93, 137.90, 128.9, 128.5, 127.1, 126.6, 124.3, 123.6, 122.3, 121.8, 121.3, 117.6, 
117.3, 115.4, 109.5, 94.8, 46.1, 15.6; IR (neat) 3421, 2923, 1632, 1585, 1490, 1393, 1367, 
1355, 1310, 648 cm-1; HRMS (EI-TOF) calcd for C32H26N2O [M]+ m/z 454.2045; found 
454.2072.     
 
2-Chloro-5-methoxy-4-methyl-N-(p-tolyl)aniline (1.8n). Following General Procedure 
A for 20 h, the product was obtained as yellow oil (443 mg) in 73% yield. Rf = 0.75 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.12 (d, J = 8.0, 2H), 7.08 (s, 
1H), 7.04 (d, J = 8.5, 2H), 6.72 (s, 1H), 6.72 (s, 1H), 5.88 (br s, 1H), 3.96 (s, 3H), 2.32 (s, 
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3H), 2.12 (s, 3H); 13C NMR (125 MHz, acetone-d6)  2 rotamers; IR (neat) 3420, 2921, 
1589, 606 cm-1; HRMS (ESI-TOF) calcd for C15H17ClNO [M+H]+ 262.0999, found 
262.1003.  
 
2-Methoxy-3,6-dimethyl-9H-carbazole (1.9n). Following General Procedure B, the 
product was obtained as a brown solid (1.39 g) in 83% yield. Rf = 0.30 (EtOAc:Hexanes = 
1:4): 1H NMR (500 MHz, acetone-d6)  7.79 (s, 1H), 7.74 (s, 2H), 7.25 (d, J = 8.0 Hz, 1H), 
7.12 (d, J = 7.0 Hz, 1H), 6.84 (s, 1H), 3.91 (s, 3H), 2.56 (s, 3H), 2.35 (s, 3H); 13C NMR 
(125 MHz, acetone-d6)  157.3, 140.3, 138.2, 127.5, 125.0, 123.5, 121.0, 118.9, 117.9, 
115.8, 110.1, 92.6, 54.8, 20.6, 15.0; IR (neat) 3390, 2920, 1634, 1615, 818, 746 cm-1; 
HRMS (ESI-TOF) calcd for C15H16NO [M+H]+ 226.1232, found 226.1229. 
 
3,6-Dimethyl-9H-carbazol-2-ol (1.10n). Following General Procedure C, the product 
was obtained as a brown solid (510 mg) in 94% yield. Rf = 0.24 (EtOAc:Hexanes = 1:2): 
1H NMR (500 MHz, acetone-d6)  9.75 (s, 1H), 8.15 (s, 1H), 7.74 (s, 1H), 7.72 (d, J = 0.6 
Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 7.06 (dd, J = 8.2, 1.3 Hz, 1H), 6.93 (s, 1H), 2.44 (s, 3H), 
2.34 (s, 3H); 13C NMR (125 MHz, acetone-d6)  155.5, 141.3, 139.1, 128.2, 125.8, 124.6, 
122.1, 119.7, 117.4, 116.9, 110.9, 97.1, 21.5, 16.8; IR (neat) 3398, 2921, 1603, 826, 744, 
719, 640 cm-1; HRMS (ESI-TOF) calcd for C14H14NO [M+H]+ 212.1075, Found 212.1080. 
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9-Benzyl-3,6-dimethyl-9H-carbazol-2-ol (1.4n). Following General Procedure D, the 
product was obtained as a yellow solid (81 mg) in 53% yield. Rf = 0.40 (EtOAc:Hexanes 
= 1:4): 1H NMR (500 MHz, acetone-d6)  8.22 (s, 1H), 7.80 (s, 1H), 7.79 (s, 1H), 7.30 (d, J 
= 8.3 Hz, 1H), 7.27-7.21 (m, 3H), 7.14 (d, J = 7.0 Hz, 2H), 7.10 (dd, J = 8.3, 1.1 Hz, 1H), 
6.86 (s, 1H), 5.46 (s, 2H), 2.46 (s, 3H), 2.35 (s, 3H); 13C NMR (125 MHz, acetone-d6)  
154.8, 140.9, 138.9, 138.2, 128.5, 127.8, 127.1, 126.5, 125.1, 123.5, 121.5, 119.0, 116.8, 
115.6, 108.3, 94.8, 45.9, 20.5, 15.7. IR (neat) 3421, 2919, 2852, 1494, 863, 796, 735, 697 
cm-1; HRMS (ESI-TOF) calcd for C21H20NO [M+H]+ 302.1545, Found: 302.1545.     
 
5-Amino-4-chloro-2-methylphenol. Following General Procedure C, the product was 
obtained as a light tan solid (244 mg) in 49% yield. Rf = 0.22 (EtOAc:Hexanes = 1:5): 1H 
NMR (500 MHz, CD3CN)  6.97 (s, 1H), 6.25 (s, 1H), 4.50 (s, 1H), 3.82 (br s, 2H), 2.12 (s, 
3H); 13C NMR (125 MHz, CD3CN)  155.4, 143.5, 131.4, 115.8, 110.0, 103.3, 15.2; IR 
(neat) 3405, 3416, 3195 (w), 2923, 1618, 1515, 1413, 1378, 1311, 1274, 1197, 1164, 988, 
847, 723, 630, 460 cm-1; HRMS (ESI-TOF) m/z = 158.0373 calcd for C7H9ClNO [M+H]+, 
found 158.0380. 
 
5-(Benzyloxy)-2-chloro-4-methylaniline (1.14). Following General Procedure D using 
1 equiv NaH, 1 equiv BnBr, 2.4 mL DMF and 24 mL THF on a 2.41 mmol scale, the product 
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was obtained as a light tan solid (372 mg) in 62% yield. Rf = 0.40 (EtOAc:Hexanes = 1:5): 
1H NMR (500 MHz, CDCl3)  7.43-7.31 (m, 5H), 7.01 (s, 1H), 6.34 (s, 1H), 5.01 (s, 2H), 
3.88 (s, 2H), 2.15 (s, 3H); 13C NMR (125 MHz, CDCl3)  156.3, 141.2, 137.2, 130.6, 128.5, 
127.8, 127.0, 118.3, 110.4, 100.4, 70.1, 15.3; IR (neat) 3465, 3390, 2945, 1619, 1506, 
1454, 1413, 1380, 1282, 1265, 1215, 1201, 1169. 1079, 1045, 1028, 988, 875, 819, 801, 
734, 695, 651 cm-1; HRMS (ESI-TOF) m/z = 248.0842 calcd for C14H15ClNO [M+H]+, found 
248.0839. 
 
5-(Benzyloxy)-2-chloro-N-(4-methoxyphenyl)-4-methylaniline (1.16). Following 
General Procedure A, the product was obtained as red oil (316 mg) in 68% yield. Rf = 
0.80 (EtOAc:Hexanes = 1:5): 1H NMR (500 MHz, CDCl3)  7.38-7.31 (m, 5H), 7.09 (s, 1H), 
6.97 (dd, J = 6.7, 2.2 Hz, 2H), 6.84 (dd, J = 5.7, 3.5 Hz, 2H), 6.55 (s, 1H), 5.79 (s, 1H), 
4.92 (s, 2H), 3.82 (s, 3H), 2.18 (s, 3H); 13C NMR (125 MHz, acetone-d6)  157.3, 157.0, 
141.8, 138.8, 136.5, 132.1, 129.8, 129.0, 128.5, 124.0, 119.6, 115.9, 112.9, 101.4, 71.0, 
56.3, 16.1; IR (neat) 3400, 2940, 1611, 1578, 1508, 1489, 1454, 1416, 1399, 1375, 1287, 
1242, 1164, 1032, 1002, 841, 820, 775, 735, 696, 655, 600 cm-1; HRMS (ESI-TOF) m/z = 
354.1261 calcd for C21H21ClNO2 [M+H]+, found 354.1268. 
 
2-(Benzyloxy)-6-methoxy-3-methyl-9H-carbazole (1.17). Following General 
Procedure B, the product was obtained as a light tan solid (161 mg) in 80% yield. Rf = 
0.23 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  9.86 (br s, 1H), 7.83 (s, 
59 
 
1H), 7.55-7.53 (m, 3H), 7.41 (td, J = 5.8, 1.6 Hz, 2H), 7.34-7.31 (m, 2H), 7.07 (s, 1H), 6.91 
(dd, J = 8.7, 2.5 Hz, 1H), 5.19 (s, 2H), 3.86 (s, 3H), 2.38 (s, 3H); 13C NMR (125 MHz, 
acetone-d6)  157.3, 154.7, 141.5, 138.8, 135.7, 129.3, 128.5, 128.1, 124.7, 122.1, 119.0, 
117.3, 113.8, 111.9, 103.2, 95.0, 70.6, 56.1, 17.1; IR (neat) 3385, 2910, 1648, 1486, 1472, 
1450, 1429, 1298, 1276, 1217, 1203, 1179, 1170, 1135, 1113, 1026, 839, 837, 813, 743, 
699, 468 cm-1; HRMS (ESI-TOF) m/z = 317.1416 calcd for C21H19NO2 [M]+, found 
317.1430. 
 
9-Benzyl-2-(benzyloxy)-6-methoxy-3-methyl-9H-carbazole (1.18). Following General 
Procedure D using 1.1 equiv NaH, 1.1 equiv BnBr, 0.51 mL DMF and 5.1 mL THF on a 
0.51 mmol scale, the product was obtained as a light tan solid (129 mg) in 62% yield. Rf 
= 0.65 (EtOAc:Hexanes = 1:5): 1H NMR (500 MHz, acetone-d6)  7.88 (s, 1H), 7.60 (d, J 
= 2.5 Hz, 1H), 7.52 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.33-7.31 (m, 2H), 7.24-
7.20 (m, 4H), 7.16 (dd, J = 8.2 Hz, 1.5 Hz, 2H), 6.93 (dd, J = 8.8, 2.5 Hz, 1H), 5.86 (s, 2H), 
5.21 (s, 2H), 3.86 (s, 3H), 2.39 (s, 3H); 13C NMR (125 MHz, acetone-d6)  157.5, 155.0, 
142.0, 139.1, 138.7, 136.3, 129.4, 129.3, 128.5, 128.3, 128.0, 127.6, 124.5, 122.4, 119.2, 
116.8, 113.7, 110.5, 103.5, 93.7, 70.7, 56.1, 46.9, 17.0; IR (neat) 2910, 1645, 1494, 1474, 
1464, 1454, 1441, 1431, 1305, 1252, 1234, 1226, 1202, 1181, 1141, 1053, 1027, 807, 
793, 778, 732, 698 cm-1; HRMS (ESI-TOF) m/z = 408.1964 calcd for C28H26NO2 [M+H]+, 
found 408.1960.   
60 
 
 
2-(Benzyloxy)-6-methoxy-3,9-dimethyl-9H-carbazole (1.4o). Mono debenzylation of S-
5j following the procedure for 4h afforded a tan solid (39 mg) in 58% yield. Rf = 0.17 
(EtOAc:Hexanes = 1:5): 1H NMR (500 MHz, acetone-d6)  8.29 (s, 1H), 7.83 (s, 1H), 7.59 
(dd, J = 2.4 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 7.25-7.20 (m, 3H), 7.13 (d, J = 7.1 Hz, 2H), 
6.92 (dd, J = 8.8, 2.5 Hz, 1H), 6.86 (s, 1H), 5.44 (s, 2H), 3.86 (s, 3H), 2.35 (s, 3H); 13C 
NMR (125 MHz, acetone-d6)  156.0, 155.0, 142.3, 139.2, 136.5, 129.5, 128.1, 127.5, 
124.8, 122.7, 117.7, 116.8, 113.4, 110.2, 103.6, 95.8, 56.2, 47.0, 16.7; IR (neat) 3375, 
2910, 1633, 1474, 1453, 1433, 1298, 1275, 1253, 1233, 1219, 1202, 1182, 1170, 1140, 
1046, 1014, 823, 803, 732, 700, 632 cm-1; HRMS (ESI-TOF) m/z = 318.1494 calcd for 
C21H20NO2 [M+H]+, found 318.1492. 
 
N-(2-Chloro-5-methoxy-4-methylphenyl)-[1,1'-biphenyl]-4-amine (1.8p). Following 
General Procedure A, the product was obtained as a white solid (412 mg) in 73% yield. 
Rf = 0.75 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  7.60 (d, J = 8.0 Hz, 2H), 
7.57 (d, J = 9.0 Hz, 2H), 7.45 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 Hz, 1H), 7.21 (d, J = 8.5 
Hz, 2H), 7.15 (s, 1H), 6.89 (s, 1H), 6.03(br s, 1H), 3.76 (s, 3H), 2.17 (s, 3H); 13C NMR (125 
MHz, CDCl3)  157.0, 141.9, 140.8, 138.1, 134.8, 131.0, 128.9, 128.2, 126.9, 126.2, 120.2, 
119.1, 113.4, 100.4, 55.7, 15.4; IR (neat) 3400, 2921, 1589, 1523, 1486, 1450, 1412, 
1374, 1248, 1232, 992, 822 cm-1; HRMS (ESI-TOF) calcd for C20H19ClNO [M+H]+ m/z = 
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324.1155, found 324.1176. 
 
2-Methoxy-3-methyl-6-phenyl-9H-carbazole (1.9p). Following General Procedure B, 
the product was obtained as a brown solid (143 mg) in 83% yield. Rf = 0.25 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  8.20 (s, 1H), 7.86 (s, 1H), 7.74 (d, J 
= 7.0 Hz, 2H), 7.64 (br s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.50 (t, J = 7.5 Hz, 2H), 7.37 (t, J 
= 7.5 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 6.68 (s, 1H), 3.84 (s, 3H), 2.42 (s, 3H); 13C NMR 
(125 MHz, CDCl3)  157.7, 142.4, 139.9, 138.9, 132.9, 128.8, 127.4, 126.5, 124.1, 123.8, 
121.6, 119.5, 117.9, 116.3, 110.6, 92.7, 55.5, 16.8; IR (neat) 3390, 2925, 1621, 1481, 
1323, 1284, 1226, 1195, 1171, 1034, 881, 752 cm-1; HRMS (ESI-TOF) calcd for C20H18NO 
[M+H]+ m/z = 288.1388, found 288.1387. 
 
3-Methyl-6-phenyl-9H-carbazol-2-ol (1.10p), Following General Procedure C, the 
product was obtained as a dark brown solid (103 mg) in 76% yield. Rf = 0.21 
(EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CD3CN)  8.74 (br s, 1H), 7.88 (d, J = 1.5 Hz, 
1H), 7.52 (s, 1H), 7.39 (dd, J = 8.0, 1.0 Hz, 2H), 7.23 (dd, J = 8.0, 1.5 Hz, 1H), 7.15-7.12 
(m, 3H), 6.99 (td, J = 8.0, 1.0 Hz, 1H), 6.67 (br s, 1H), 6.59 (s, 1H), 2.00 (s, 3H); 13C NMR 
(125 MHz, CD3CN)  155.5, 143.1, 141.2, 140.3, 132.9, 129.8, 127.9, 127.3, 124.9, 124.2, 
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122.6, 118.4, 118.1, 117.2, 111.7, 97.3, 16.7; IR (neat) 3409, 2923, 1635, 1480, 1398, 
1264, 1175, 1122, 1009, 879, 764 cm-1; HRMS (ESI-TOF) calcd for C19H16NO [M+H]+ m/z 
= 274.1232, found 274.1245. 
 
9-Benzyl-3-methyl-6-phenyl-9H-carbazol-2-ol (1.4p). Following General Procedure D, 
the product was obtained as a white powder (71 mg) in 52% yield. Rf = 0.45 
(EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.22 (d, J = 1.5 Hz, 1H), 7.89 (s, 
1H), 7.70 (dd, J = 8.5, 1.5 Hz, 2H), 7.59 (dd, J = 8.5, 1.5 Hz, 1H), 7.47 (t, J = 8.0 Hz, 2H), 
7.36-7.32 (m, 2H), 7.30-7.24 (m, 3H), 7.16 (d, J = 8.0 Hz, 2H), 6.76 (s, 1H), 5.43 (s, 2H), 
4.81 (s, 1H), 2.43 (s, 3H); 13C NMR (125 MHz, CDCl3)  153.5, 142.3, 141.2, 140.3, 137.2, 
132.8, 128.9, 128.8, 127.6, 127.4, 126.5, 126.4, 124.0, 123.8, 122.1, 118.1, 117.1, 116.4, 
108.8, 95.3, 46.8, 16.2; IR (neat) 3305, 2920, 1634, 1607, 1482, 1466, 1454, 1368, 1348, 
1300, 1249, 1219, 1174, 1139, 998, 871 cm-1; HRMS (ESI-TOF) calcd for C26H22NO 
[M+H]+ m/z = 364.1701, found 364.1692. 
 
9-Benzyl-2-(benzyloxy)-9H-carbazole. To a stirring solution of DMF (20 mL) and NaH 
concentrated to a volume of 25 mL and EtOAc was added. The resultant precipitate was 
filtered and (784 mg, 32.7 mmol) was added a solution of 2-hydroxycarbazole (2.00 g, 
10.9 mmol) in THF (75 mL). After stirring 30 min at room temperature, BnBr (4.50 mL, 
38.5 mmol) was added to the solution. After stirring 3 h, the solution was quenched with 
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H2O (100 mL), extracted with CH2Cl2 (3 X 100 mL), washed with brine (100 mL), and dried 
with MgSO4. After filtration, the solution was washed with cold EtOAc to afford a white 
powder (3.85 g) in 97% yield. Rf = 0.5 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CD2Cl2) 
 8.02 (d, J = 7.6 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 7.1 Hz, 2H), 7.38 (td, J = 
8.6, 1.0 Hz, 2H), 7.36-7.31 (m, 3H), 7.24 (m, 4H), 7.13 (d, J = 6.7 Hz, 2H), 6.95-6.92 (m, 
2H), 5.45 (s, 2H) 5.12 (s, 2H); 13C NMR (125 MHz, CD2Cl2)  159.0 142.6, 141.4, 137.87, 
137.85, 129.3, 129.0, 128.5, 128.2, 128.0, 127.1, 125.2, 123.7, 121.6, 120.0, 119.9, 117.6, 
109.3, 108.9, 95.2, 71.0, 47.1; IR (neat) 3020, 1626, 1598, 1495, 1460, 1451, 1437, 1359, 
1328, 1246, 1179, 1120, 1009, 993, 944, 820, 804, 735, 726, 719, 695 cm-1; HRMS (ESI-
TOF) m/z = 363.1623 calcd for C26H21NO [M]+, found 363.1612.  
 
9-Benzyl-2-(benzyloxy)-3-bromo-9H-carbazole (1.13). To a stirring solution of 9-benzyl-
2-(benzyloxy)-9H-carbazole (1.45 g, 3.99 mmol) and CH2Cl2 (40 mL) was added N-
bromosuccinimide (729 mg, 4.11 mmol). After stirring 30 min at room temperature, the 
mixture was quenched with ice-cold water, extracted with EtOAc, washed (3 X 20 mL) with 
brine (30 mL), and dried with MgSO4. After filtration and concentration, trituration with 
acetone (3 X 10 mL) afforded a white solid (1.46 g) in 83% yield. Rf = 0.43 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  8.26 (s, 1H), 7.98 (d, J = 7.7 Hz, 
1H), 7.47 (d, J = 7.5 Hz, 2H), 7.35 (m, 5H), 7.24 (m, 4H), 7.08 (dd, J = 5.2, 1.7 Hz, 2H), 
6.87 (s, 1H), 5.42 (s, 2H), 5.16 (s, 2H); 13C NMR (125 MHz, CD2Cl2)  154.2, 141.31, 
141.29, 137.4, 137.2, 129.4, 129.1, 128.5, 128.1, 127.9, 127.0, 125.8, 125.1, 122.7, 120.3, 
120.2, 118.4, 109.5, 104.4, 95.2, 71.8, 47.1; IR (neat) 3015, 1597, 1469, 1445, 1433, 
1356, 1307, 1273, 1249, 1182, 1151, 1121, 1024, 996, 748, 736, 724, 715, 695, 673, 616 
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cm-1; HRMS (ESI-TOF) m/z = 363.1623 calcd for C26H20BrNO [M]+, found 363.1612.  
 
9-Benzyl-3-bromo-9H-carbazol-2-ol (1.4q). To a stirring solution of 9-benzyl-2-
(benzyloxy)-3-bromo-9H-carbazole (1.20 g, 2.72 mmol) in CH2Cl2 (30.0 mL) was added 
N,N-dimethylaniline (3.40 mL, 27.2 mmol) followed by the slow addition of AlCl3 (2.18 g, 
16.32 mmol). After stirring 10 min at room temperature, the solution was cooled to 0 0C 
and quenched with H2O (30 mL). The solution was extracted with EtOAc (3 X 30 mL), 
washed with brine (30 mL), and dried with MgSO4. Removal of solvent and 
chromatography (5:1 Hex/EtOAc) afforded a white solid (382 mg) in 40% yield. Rf = 0.27 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.72 (br s, 1H), 8.29 (s, 1H), 
8.08 (d, J = 8.5 Hz, 1H), 7.47 (d, J = 8.2 Hz, 1H), 7.36 (td, J = 8.3, 1.1 Hz, 1H), 7.28-7.18 
(m, 4H), 7.16(d, J = 7.1 Hz, 2H), 7.10 (s, 1H), 5.52 (s, 2H); 13C NMR (125 MHz, acetone-
d6)  153.4, 142.2, 142.0, 138.5, 129.6, 128.3, 127.5, 126.0, 125.1, 123.3, 120.53, 120.45, 
118.5, 110.0, 102.9, 97.3, 47.0; IR (neat) 3410 (w), 2925, 1601, 1475, 1451, 1380, 1360, 
1337, 1318, 1262, 1216, 1157, 1120, 1079, 1059, 1020, 946, 883, 824, 738, 717, 696 cm-
1; HRMS (ESI-TOF) m/z = 351.0259 calcd for C19H14BrNO [M]+, found 351.0283. 
 
3-Allyl-9-benzyl-2-(benzyloxy)-9H-carbazole. To a flask charged with 9-benzyl-2-
(benzyloxy)-3-bromo-9H-carbazole (300 mg, 0.680 mmol), Pd(OAc)2 (7.60 mg, 0.034 
mmol), and CPhos(24 mg, 0.068 mmol), was added THF (0.7 mL) followed by allyl zinc 
bromide27 (1.85 mL, 1.02 mmol). After stirring 18 h under Ar atmosphere, the solution was 
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quenched with H2O (10 mL), extracted with EtOAc (3 X 20 mL), washed with brine (20 
mL), and dried with MgSO4. Removal of solvent and chromatography (10:1 Hex/EtOAc) 
afforded a white solid (183 mg) in 67% yield. Rf = 0.6 (EtOAc:Hexanes = 1:5): 1H NMR 
(500 MHz, acetone-d6)  8.04 (dt, J = 7.9, 1.0 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.52 (dt, 
J = 7.5, 0.5 Hz, 2H), 7.46 (d, J = 8.5 Hz, 1H), 7.39 (td, J = 7.5, 1.5 Hz, 2H), 7.32-7.25 (m, 
6H), 7.19 (dd, J = 8.3, 1.5 Hz, 2H), 7.14 (td, J = 7.0, 0.5 Hz, 1H), 6.14-6.09 (m, 1H), 5.62 
(s, 2H), 5.23 (s, 2H), 5.10 (dd, J = 17.1, 3.8 Hz, 1H), 5.01 (dd, J = 11.3, 2.4 Hz, 1H), 3.57 
(d, J = 6.6 Hz, 2H); 13C NMR (125 MHz, acetone-d6)  157.1, 141.7, 141.5, 139.0, 138.9, 
138.6, 129.5, 129.4, 128.6, 128.4, 128.2, 127.7, 125.1, 124.1, 122.1, 121.9, 120.2, 120.0, 
117.03, 115.4, 110.0, 94.1, 71.0, 46.9, 35.7; IR (neat) 3010, 1602, 1495, 1480, 1462, 
1448, 1355, 1328, 1254, 1175, 1156, 1145, 1122, 1056, 1028, 910, 807, 740, 731, 719, 
694 cm-1; HRMS (ESI-TOF) m/z = 403.1936 calcd for C29H25NO [M]+, found 403.1939. 
 
3-Allyl-9-benzyl-9H-carbazol-2-ol (1.4r). Mono debenzylation of S-9 following the 
procedure for 1.4q afforded a white solid (22 mg) in 63% yield. Rf = 0.23 (EtOAc:Hexanes 
= 1:5): 1H NMR (500 MHz, acetone-d6)  8.35 (s, 1H), 8.01 (dd, J = 7.6, 0.7 Hz, 1H), 7.85 
(s, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.31-7.21 (m, 4H), 7.18-7.12 (m, 3H), 6.91 (s, 1H), 6.15-
6.07 (m, 1H), 5.51 (s, 2H), 5.11 (dd, J = 19.1, 2.1 Hz, 1H), 5.01 (dd, J = 10.1, 1.3 Hz, 1H), 
3.53 (d, J = 6.6 Hz, 2H); 13C NMR (125 MHz, acetone-d6)  155.4, 141.8, 141.6, 138.98, 
138.97, 129.5, 128.2, 127.5, 125.0, 124.3, 122.0, 120.6, 120.0, 119.9, 116.9, 115.2, 109.6, 
96.0, 46.9, 35.4; IR (neat) 3300 (w), 2995, 1636, 1604, 1495, 1467, 1450, 1441, 1348, 
1319, 1247, 1178, 1139, 1122, 959, 914, 823, 741, 729, 709, 697, 603 cm-1; HRMS (ESI-
TOF) m/z = 313.1467 calcd for C22H19NO [M]+, found 313.1466. 
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9-Benzyl-2-(benzyloxy)-3-phenyl-9H-carbazole. 9-Benzyl-2-(benzyloxy)-3-bromo-9H-
carbazole (300 mg, 0.680 mmol), potassium phenyl trifluoroborate (188 mg, 1.02 mmol), 
Pd(dppf)Cl2 (28 mg, 0.0340 mmol), and cesium carbonate (775 mg, 2.38 mmol) were 
treated with a 2:1 mixture of THF and H2O (30 mL). After stirring 18 h at 70 0C, the solution 
was cooled to room temperature and diluted with H2O (20 mL). The solution was then 
extracted with EtOAc (3 X 30 mL), washed with brine (30 mL), and dried with MgSO4. 
Removal of solvent and chromatography (5:1 = Hex/EtOAc) afforded a white solid (257 
mg) in 88% yield. Rf = 0.52 (EtOAc:Hexanes = 1:5): 1H NMR (500 MHz, CD2Cl2)  8.12 (s, 
1H), 8.10 (d, J = 7.5 Hz, 1H), 7.73 (d, J = 7.5 Hz, 2H), 7.50 (t, J = 7.5 Hz, 2H), 7.41-7.28 
(m, 12H), 7.19 (d, J = 6.0 Hz, 2H), 7.04 (s, 1H), 5.49 (s, 2H), 5.15 (s, 2H); 13C NMR (125 
MHz, CD2Cl2)  155.8, 141.7, 141.3, 140.1, 137.8, 137.7, 130.6, 129.3, 129.0, 128.5, 
128.3, 128.1, 127.7, 127.1, 127.0, 125.3, 124.8, 123.8, 123.0, 120.1, 120.0, 117.3, 109.4, 
94.2, 71.3, 47.1; IR (neat) 2940, 1601, 1456, 1448, 1430, 1351, 1314, 1262, 1225, 1210, 
1179, 1125, 1028, 1021, 809, 764, 737, 732, 701, 692, 662 cm-1; HRMS (ESI-TOF) m/z = 
440.2014 calcd for C32H26NO [M+H]+, found 440.2003. 
 
9-Benzyl-3-phenyl-9H-carbazol-2-ol (1.4s). Mono debenzylation of S-10 following the 
procedure for 1.4q afforded a white solid (25 mg) in 71% yield. Rf = 0.24 (EtOAc:Hexanes 
= 1:5): 1H NMR (500 MHz, acetone-d6)  8.39 (br s, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.06 (s, 
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1H), 7.66 (dd, J = 8.3, 1.3 Hz, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.42 (t, J = 5.8 Hz, 2H), 7.36-
7.30 (m, 4H), 7.29 (dd, J = 6.0, 1.7 Hz, 1H), 7.22 (dd, J = 8.5, 1.4 Hz, 2H), 7.18 (td, J =  
7.8, 0.8 Hz, 1H), 7.03 (s, 1H), 5.58, (s, 2H); 13C NMR (125 MHz, CDCl3)  152.0, 142.0, 
141.2, 138.0, 137.2, 129.8, 129.6, 129.0, 127.8, 127.7, 126.7, 125.0, 123.5, 121.9, 121.6, 
119.74, 119.65, 117.4, 109.0, 95.6, 46.9 cm-1; IR (neat) 3495 (w), 2910, 1633, 1603, 1490, 
1477, 1453, 1431, 1353, 1324, 1291, 1263, 1218, 1167, 1122, 950, 822, 744, 723, 700, 
660, 608 cm-1; HRMS (ESI-TOF) m/z = 350.1545 calcd for C25H20NO [M+H]+, found 
350.1556. 
 
9,9'-Dibenzyl-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5a). Following 
General Procedure E, the product was obtained as a yellow solid (109 mg) in 91% yield. 
Rf  = 0.65 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.06 (d, J = 8.0 Hz, 
2H), 7.94 (s, 2H), 7.23 (td, J = 8.2, 1.2 Hz, 2H), 7.17 (t, J = 7.2 Hz, 2H), 7.08 (d, J = 8.1 
Hz, 2H), 6.85-6.82 (m, 8H), 6.46-6.44 (m, 4H), 4.83 (d, J = 17.3 Hz, 2H), 4.61 (d, J = 17.3 
Hz, 2H), 2.21 (s, 6H); 13C NMR (125 MHz, acetone-d6)  153.6, 141.7, 139.0, 138.0, 127.5, 
126.0, 125.4, 123.9, 123.1, 122.0, 119.0, 118.6, 117.5, 116.8, 109.0, 101.0, 46.5, 16.2; IR 
(neat) 3513, 2923, 1603, 736, 706 cm-1; HRMS (ESI-TOF) calcd for C40H33N2O2 [M-H]  
C40H32N2O2  571.2386, found 571.2380; [α]D22 +164 (c 0.35, 87% ee, CH2Cl2); Chiral HPLC: 
Chiralpak IA column (10% i-PrOH/hexanes, 1 mL/min) tR(1) = 8.12 min, tR(2) = 11.8 min. 
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3,3',9,9'-Tetramethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5b). Following General 
Procedure E, the product was obtained as a yellow solid (9.0 mg) in 82% yield. Rf  = 0.63 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.03 (dd, J = 7.8, 0.8 Hz, 2H), 
8.00 (d, J = 1.0 Hz, 2H), 7.31-7.30 (m, 4H), 7.25 (s, 2H), 7.16 (ddd, J = 2.9, 5.2, 7.9 Hz, 
2H), 3.45 (s, 6H), 2.45 (s, 6H); 13C NMR (125 MHz, acetone-d6)  153.9, 141.7, 139.8, 
123.9, 122.9, 122.1, 118.8, 118.6, 117.0, 116.3, 108.4, 101.7, 29.3, 16.3; IR (neat) 3509, 
2924, 2854, 1626, 1603, 882, 768, 737 cm-1; HRMS (ESI-TOF) calcd for C28H25N2O2 
[M+H]+ 421.1916, found: 421.1928. [α]D22 +180 (c 0.43, 60% ee, CH2Cl2); CSP HPLC 
(Chiralpak AD, 1.0 mL/min, 90:10 hexanes:i-PrOH): tR(1) = 16.6 min, tR(2) = 20.9 min.  
 
9,9'-Diallyl-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5c). Following General 
Procedure E, the product was obtained as pale yellow oil (5.7 mg) in 71% yield. Rf  = 0.48 
(EtOAc:Hexanes = 1:9): 1H NMR (500 MHz, CDCl3)  8.05 (d, J = 7.7 Hz, 2H), 8.03 (s, 
2H), 7.36 (td, J = 8.2, 1.0 Hz, 2H), 7.25 (t, J = 7.6 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H),  5.40-
5.33 (m, 2H), 5.17 (br s, 2H), 4.74 (dd, J = 10.4, 1.2 Hz, 2H), 4.41 (dd, J = 17.2, 1.2 Hz, 
2H), 4.25-4.15 (m, 4H), 2.46 (s, 6H); 13C NMR (125 MHz, CDCl3)  152.4, 141.2, 138.2, 
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132.5, 124.8, 123.6, 122.9, 119.7, 119.2, 117.6, 117.4, 115.8, 109.3, 98.3, 46.0, 16.8; IR 
(neat) 3510, 2919, 1603, 1477, 1459, 1355, 1235, 1184, 1072, 737cm-1; HRMS (ESI-TOF) 
calcd for C32H29N2O2 [M+H]+ m/z = 473.2229; found 473.2236; [α]D22 +177 (c 0.28, 76% 
ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (10% i-PrOH/hexanes, 1 mL/min) tR(1) = 
11.5 min, tR(2) = 21.1 min. 
 
9,9'-Diisopropyl-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5d). Following 
General Procedure E, the product was obtained as pale yellow oil (3.5 mg) in 58%  yield. 
Rf  = 0.60 (EtOAc:Hexanes = 1:9): 1H NMR (500 MHz, CDCl3)  8.07 (d, J = 7.7 Hz, 2H), 
8.00 (s, 2H), 7.52 (d, J = 8.2 Hz, 2H), 7.33 (td, J = 8.3, 1.2 Hz, 2H), 7.23 (t, J = 7.7 Hz, 
2H),  5.16 (s, 2H), 4.62-4.54 (m, 2H), 2.45 (s, 6H), 1.38 (d, J = 7.0 Hz, 6H), 1.18 (d, J = 
7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  152.0, 139.1, 137.5, 124.2, 124.1, 123.2, 119.4, 
119.2, 117.5, 117.2, 112.6, 99.2, 46.8, 20.9, 20.7, 16.7; IR (neat) 3510, 2918, 2832, 1601, 
1459, 1395, 1183, 1133, 1066, 738 cm-1; HRMS (ESI-TOF) calcd for C32H33N2O2 [M+H]+ 
m/z = 477.2542; found 477.2522; [α]D22 +18 (c 0.15, 42% ee, CH2Cl2); Chiral HPLC: 
Chiralpak IA column (10% i-PrOH/hexanes, 1 mL/min) tR(1) = 7.46 min, tR(2) = 11.0 min. 
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3,3'-Dimethyl-9,9'-bis(2,4,6-trimethylbenzyl)-9H,9'H-[1,1'-bicarbazole]-2,2'-diol 
(1.5e). Following General Procedure E, the product was obtained as yellow oil (4.0 mg) 
in 37% yield. Rf  = 0.50 (EtOAc:Hexanes = 1:9): 1H NMR (500 MHz, CDCl3)  7.96 (d, J = 
7.7 Hz, 2H), 7.94 (s, 2H), 7.12 (t, J = 7.8 Hz, 2H), 7.03 (td, J = 8.4, 1.2 Hz, 2H),  6.70 (s, 
2H), 6.64 (s, 2H), 6.48 (d, J = 8.5 Hz, 2H), 5.30 (br s, 2H), 4.91 (d, J = 15.3 Hz, 2H), 4.75 
(d, J = 15.3 Hz, 2H), 2.37 (s, 6H), 2.19 (s, 6H), 1.82 (s, 6H), 1.64 (s, 6H); 13C NMR (125 
MHz, CDCl3)  152.3, 141.4, 139.4, 137.2, 136.7, 130.0, 129.8, 129.22, 129. 124.6, 123.6, 
123.4, 119.4, 119.0, 117.9, 117.5, 110.6, 100.2, 44.7, 20.9, 20.1, 19.6, 16.7; IR (neat) 
3509, 2920, 1603, 1456, 1180, 1135, 1076, 1041, 851, 743m-1; HRMS (EI-TOF) calcd for 
C46H43N2O2 [M-H]¯ m/z = 655.3325; found 655.3322; [α]D22 +182 (c 0.18, 37% ee, CH2Cl2); 
Chiral HPLC: Chiralpak IA column (5% i-PrOH/hexanes, 1 mL/min) tR(1) = 5.09 min, tR(2) 
= 14.9 min. 
 
9,9'-Dibenzyl-6,6'-difluoro-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5f). 
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Following General Procedure E, the product was obtained as a yellow solid (26 mg) in 
87% yield. Rf  = 0.58 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.94 (s, 
2H), 7.78 (dd, J = 9.0, 2.5 Hz, 2H), 7.06 -6.98 (m, 6H), 6.86-6.84 (m, 6H), 6.47-6.45 (m, 
4H), 4.82 (d, J = 17.3 Hz, 2H), 4.60 (d, J = 17.3 Hz, 2H), 2.21 (s, 6H); 13C NMR (125 MHz, 
acetone-d6)  158.5 (d, J = 233 Hz), 155.3, 140.9, 139.0, 138.8, 128.5, 127.1, 126.2, 124.6 
(d, J = 8.8 Hz), 123.4, 118.7, 117.4 (d, J = 3.8 Hz), 112.1 (d, J = 26.4 Hz), 110.7 (d, J = 
10.1 Hz), 105.2 (d, J = 23.9 Hz), 101.9, 47.7, 17.1; IR (neat) 3515, 2923, 1627, 856, 796, 
781, 703 cm-1; HRMS (ESI-TOF) calcd for C40H31F2N2O2 [M+H]+ 609.2354, found 
609.2368; [α]D22 +183 (c 0.40, 92% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (10% 
i-PrOH/hexanes, 1 mL/min) tR(1) = 9.52 min, tR(2) = 10.4 min. 
 
9,9'-Dibenzyl-7,7'-difluoro-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5g). 
Following General Procedure E, the product was obtained as a yellow solid (17.8 mg) in 
93% yield. Rf  = 0.60 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.95 (s, 
2H), 7.21 (td, J = 8.1, 5.5 Hz, 2H), 7.06 (s, 2H), 6.91 (d, J = 8.1 Hz, 2H), 6.89 (d, J = 8.1 
Hz, 2H), 6.84-6.82 (m, 6H), 6.45-6.43 (m, 4H), 4.85 (d, J = 17.9 Hz, 2H), 4.60 (d, J = 17.4 
Hz, 2H), 2.21 (s, 6H); 13C NMR (125 MHz, acetone-d6)  157.7 (d, J = 243 Hz), 153.9, 
144.1 (d, J = 10.6 Hz), 138.7, 137.5, 127.5, 126.1, 125.2, 124.6 (d, J = 20.1 Hz), 124.4 (d, 
J = 20.1 Hz), 118.4, 114.1, 110.8, 105.3, 104.7 (d, J = 18.7 Hz), 101.0, 47.0, 16.2; IR 
(neat) 3519, 2925, 1601, 965, 709 cm-1; HRMS (ESI-TOF) calcd for C40H29F2N2O2 [M-H]– 
607.2197, found 607.2191, [α]D22 +157 (c 0.35, 92% ee, CH2Cl2); Chiral HPLC: Chiralpak 
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IA column (5% i-PrOH/hexanes, 1 mL/min) tR(1) = 6.80 min, tR(2) = 7.61 min. 
 
9,9'-Dibenzyl-8,8'-difluoro-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5h). 
Following General Procedure E, the product was obtained as yellow oil (12 mg) in 80% 
yield. Rf  = 0.65 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.97 (s, 2H), 
7.90 (d, J = 5.0 Hz, 2H), 7.16-7.12 (m, 2H), 7.00-6.96 (m, 4H), 6.87-6.83 (m, 6H), 6.38 (d, 
J = 5.0 Hz, 4H), 4.95 (d, J = 15.0 Hz, 2H), 4.81 (d, J = 15.0 Hz, 2H), 2.19 (s, 6H); 13C NMR 
(125 MHz, acetone-d6)  155.2, 150.2 (d, J = 243 Hz), 140.2, 139.9, 129.5 (d, J = 7.5 Hz), 
128.3, 128.1 (d, J = 5.0 Hz), 126.8, 125.6, 123.1, 120.4 (d, J = 6.3 Hz), 119.5, 117.8, 115.6 
(d, J = 2.5 Hz), 111.1 (d, J = 18.9 Hz), 102.0, 49.5, 17.1; IR (neat) 3516, 2920, 1630, 1613, 
1579, 1497, 1450, 1414, 1380, 1348, 1239, 1216, 1192, 1178, 1160, 1141, 1124, 1062, 
987 cm-1; HRMS (ESI-TOF) calcd for C40H31F2N2O2 [M+H]+ m/z = 609.2354, found 
609.2370; [α]D22 +211 (c 0.25, 91% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (10% 
i-PrOH/hexanes, 1 mL/min) tR(1) = 8.29 min, tR(2) = 9.39 min. 
 
9,9'-Dibenzyl-3,3'-dimethyl-6,6'-bis(trifluoromethyl)-9H,9'H-[1,1'-bicarbazole]-2,2'-
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diol (1.5i). Following General Procedure E, the product was obtained as light yellow oil 
(12 mg) in 70% yield. Rf  = 0.53 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6) 
 8.43 (s, 2H), 8.12 (s, 2H), 7.54 (d, J = 8.5 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 7.23 (s, 2H), 
6.86-6.83 (m, 6H), 6.45-6.43 (m, 4H), 4.89 (d, J = 17.4 Hz, 2H), 4.68 (d, J = 17.4 Hz, 2H), 
2.23 (s, 6H); 13C NMR (125 MHz, acetone-d6)  155.6, 144.0, 140.7, 138.2, 128.5, 127.1, 
126.6 (q, J = 270 Hz), 126.0, 123.8, 123.5, 121.6 (q, J = 31.4 Hz), 121.5 (q, J = 2.5 Hz), 
119.0, 117.2, 117.0 (q, J = 3.8 Hz), 110.3, 102.2, 47.7, 17.1; IR (neat) 3525, 2925, 1609, 
1451, 1411, 1365, 1346, 1325, 1300, 1262, 1186, 1163, 1148, 1113, 1080, 1069, 1051, 
1034, 1005 cm-1; HRMS (ESI-TOF) calcd for C42H31F6N2O2 [M+H]+ m/z = 709.2292, found 
709.2290; [α]D22 +175 (c 0.6, 93% ee, CH2Cl2); Chiralpak IA column (10% i-PrOH/hexanes, 
1 mL/min) tR(1) = 8.61 min, tR(2) = 9.89 min. 
 
9,9'-Dibenzyl-3,3'-dimethyl-7,7'-bis(trifluoromethyl)-9H,9'H-[1,1'-bicarbazole]-2,2'-
diol (1.5j). Following General Procedure E, the product was obtained as yellow oil (15 
mg) in 60% yield. Rf  = 0.55 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  
8.25 (d, J = 8.2 Hz, 2H), 8.07 (s, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.42 (s, 2H), 7.29 (s, 2H), 
6.86-6.79 (m, 6H), 6.44 (d, J = 7.0 Hz, 4H), 4.93 (d, J = 17.5 Hz, 2H), 4.73 (d, J = 17.5 Hz, 
2H), 2.24 (s, 6H); 13C NMR (125 MHz, acetone-d6)  156.0, 141.6, 141.2, 138.3, 128.5, 
127.1, 126.9, 126.3 (q, J = 271.1 Hz), 126.1 (q, J = 31.2 Hz), 126.0, 123.7, 120.0, 119.8, 
116.8, 116.5 (q, J = 3.6 Hz), 107.0 (q, J = 4.1 Hz), 102.0, 47.7, 17.1; IR (neat) 3519, 2925, 
1629, 1574, 1451, 1351, 1321, 1294, 1280, 1264, 1232, 1164, 1135, 1118, 1061, 1005, 
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910 cm-1; HRMS (ESI-TOF) calcd for C42H31F6N2O2 [M+H]+ m/z = 709.2290, found 
709.2270; [α]D22 +254 (c 0.42, 94% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (5% i-
PrOH/hexanes, 1 mL/min) tR(1) = 6.42 min, tR(2) = 21.8 min. 
 
(9,9'-Dibenzyl-2,2'-dihydroxy-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-6,6'-
diyl)bis(phenylmethanone) (1.5k). Following General Procedure E with 
chlorobenzene/HFIP(1:1, 0.5 M) as a solvent, the product was obtained as an off-white 
solid (9.1 mg) in 76% yield based on recovered starting material. Rf  = 0.50 
(EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, acetone-d6)  8.56 (d, J = 1.0 Hz, 2H), 8.03 
(s, 2H), 7.85 (d, J = 8.0 Hz, 4H), 7.79 (dd, J = 8.5, 1.5 Hz, 2H), 7.67 (d, J = 7.5 Hz, 2H), 
7.60 (t, J = 7.5 Hz, 4H), 7.25 (br s, 2H), 7.22 (d, J = 8.5 Hz, 2H), 6.89-6.86 (m, 6H), 6.50-
6.48 (m, 4H), 4.94 (d, J = 15.0 Hz, 2H), 4.70 (d, J = 15.0 Hz, 2H), 2.23 (s, 6H); 13C NMR 
(125 MHz, acetone-d6)  196.2, 155.4, 145.0, 140.7, 140.1, 138.2, 132.4, 130.4, 129.8, 
129.1, 128.5, 127.4, 127.2, 126.1, 123.6, 123.4, 122.6, 119.7, 117.8, 109.6, 102.4, 47.8, 
17.1; IR (neat) 3500, 2923, 2853, 1645, 1596, 1569, 1494, 1449, 1412, 1365, 1346, 1318, 
1286, 1250, 1184, 1134, 1072, 1003, 948 cm-1; HRMS (ESI-TOF) calcd for C54H41N2O4 
[M+H]+ m/z = 781.3066, found 781.3054; [α]D22 +55 (c 0.15, 85% ee, CH2Cl2); Chiral HPLC: 
Chiralpak IA column (20% i-PrOH/hexanes, 1 mL/min) tR(1) = 29.8 min, tR(2) = 39.8 min. 
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Dibutyl 9,9'-dibenzyl-2,2'-dihydroxy-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-6,6'-
dicarboxylate (1.5l). Following General Procedure E, the product was obtained as light 
yellow oil (16 mg) in 67% yield based on recovered starting material. Rf  = 0.41 
(EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.75 (d, J = 1.5 Hz, 2H), 8.08 
(s, 2H), 7.95 (dd, J = 8.6, 1.7 Hz, 2H), 7.15 (d, J = 8.9 Hz, 2H), 7.14 (s, 2H), 6.84-6.82 (m, 
6H), 6.43-6.41 (m, 4H), 4.87 (d, J = 17.3 Hz, 2H), 4.65 (d, J = 17.3 Hz, 2H), 4.39-4.34 (m, 
4H), 2.23 (s, 6H), 1.84-1.78 (m, 4H), 1.59-1.51 (m, 4H), 1.02 (t, J = 7.4 Hz, 6H); 13C NMR 
(125 MHz, acetone-d6)  167.6, 155.3, 145.2, 140.6, 138.2, 128.5, 127.1, 126.4, 126.1, 
123.8, 123.3, 122.4, 121.5, 119.7, 117.7, 109.6, 102.4, 64.8, 47.8, 31.8, 20.0, 17.1, 14.1; 
IR (neat) 3395, 2958, 2926, 1697, 1603, 1577, 1495, 1451, 1412, 1382, 1364, 1348, 1287, 
1240, 1182, 1132, 1102, 1071, 1004, 972 cm-1; HRMS (ESI-TOF) calcd for C50H49N2O6 
[M+H]+ m/z = 773.3591, found 773.3585; [α]D22 +100 (c 0.30, 96% ee, CH2Cl2); Chiral 
HPLC: Chiralpak IA column (20% i-PrOH/hexanes, 1 mL/min) tR(1) = 9.80 min, tR(2) = 19.9 
min. 
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9,9'-Dibenzyl-6,6'-bis(diphenylamino)-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-
diol (1.5m). Following General Procedure E, the product was obtained as a colorless 
solid (8.0 mg) in 62% yield. Rf  = 0.58 (EtOAc:Hexanes = 1:9): 1H NMR (500 MHz, acetone-
d6)  7.85 (s, 2H),  7.83 (d, J = 2.0 Hz, 2H), 7.27 (t,  J = 8.6 Hz, 8H), 7.09-7.03 (m, 12H), 
7.00 (s, 2H), 6.96 (t,  J = 7.4 Hz, 4H), 6.91-6.88 (m, 6H), 6.54 d, (J = 6.6 Hz, 4H), 4.87 (d, 
J = 17.2 Hz, 2H), 4.61 (d, J = 17.2 Hz, 2H), 2.19 (s, 6H); 13C NMR (125 MHz, acetone-d6) 
 154.9, 149.7, 140.6, 140.5, 140.0, 138.9, 129.9, 128.5, 127.1, 126.3, 125.1, 124.7, 
123.2, 122.3, 121.8, 118.6, 118.2, 117.5, 110.9, 101.8, 47.8, 17.1; IR (neat) 3526, 3032, 
2919, 1635, 1585, 1490, 1454, 1326, 1285, 1257, 1217, 1164, 1132, 1028, 998, 804, 752 
cm-1; HRMS (EI-TOF) calcd for C64H50N4O2Na [M+Na]+ m/z 929.3831; found 929.3810; 
[α]D22 +31 (c 0.35, 37% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (5% i-
PrOH/hexanes, 1 mL/min) tR(1) = 6.95 min, tR(2) = 8.19 min. 
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9,9'-Dibenzyl-3,3',6,6'-tetramethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5n). Following 
General Procedure E, the product was obtained as a yellow solid (13 mg) in 93% yield. 
Rf  = 0.74 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  7.89 (s, 2H), 7.84 (s, 
2H), 7.06 (dd, J = 1.8, 7.5, 2H), 6.97 (d, J = 8.0, 2H), 6.86-6.82 (m, 6H), 6.71 (s, 2H), 6.45 
(s, 2H), 6.46-6.42 (m, 2H), 4.77 (d, J = 17.1, 2H), 4.58 (d, J = 17.1, 2H), 2.49 (s, 6H), 2.19 
(s, 6H); 13C NMR (125 MHz, acetone-d6)  140.0, 139.2, 138.3, 128.1, 127.3, 126.1, 125.4, 
125.2, 123.3, 121.9, 118.6, 117.2, 116.7, 108.9, 108.8, 100.9, 46.6, 20.5, 16.2; IR (neat) 
3503, 2920, 1608, 793, 733, 701 cm-1; HRMS(ESI-TOF) calcd for C42H37N2O2 [M+H]+ 
601.2855, found 601.2849 [α]D22 +180 (c 0.43, 60% ee, CH2Cl2); Chiral HPLC: Chiralpak 
IA column (10% i-PrOH/hexanes, 1 mL/min): tR(1) = 8.97 min, tR(2) = 13.3 min. 
 
9,9'-Dibenzyl-6,6'-dimethoxy-3,3'-dimethyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5o). 
Following General Procedure E for 26 h, the product was obtained as a light brown 
powder (10.6 mg) in 82% yield. Rf  = 0.33 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, 
acetone-d6)  7.91 (s, 2H), 7.63 (d, J = 2.5 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 6.88-6.83 (m, 
8H), 6.81 (s, 2H), 6.46 (d, J = 7.8 Hz, 4H), 4.78 (d, J = 17.2 Hz, 2H), 4.56 (d, J = 17.2 Hz, 
2H), 3.90 (s, 6H), 2.20 (s, 6H); 13C NMR (125 MHz, acetone-d6)  155.1, 154.5, 140.4, 
139.2, 137.4, 128.4, 126.9, 126.3, 124.4, 123.0, 117.9, 117.6, 113.5, 110.6, 102.9, 101,7, 
56.1, 47.5, 17.1; IR (neat) 3500, 2925, 1627, 1482, 1450, 1433, 1409, 1349, 1298, 1229, 
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1191, 1181, 1159, 1145, 1073, 1055, 1027, 1004 cm-1; HRMS (ESI-TOF) calcd for 
C42H37N2O4 [M+H]+ m/z = 633.2753, found 633.2766. [α]D22 +142 (c 0.45, 74% ee, CH2Cl2); 
Chiral HPLC: Chiralpak IA column (15% i-PrOH/hexanes, 1 mL/min) tR(1) = 12.6 min, tR(2) 
= 14.1 min. 
 
9,9'-Dibenzyl-3,3'-dimethyl-6,6'-diphenyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5p). 
Following General Procedure E, the product was obtained as a yellow solid (23 mg) in 
70% yield. Rf  = 0.64 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  8.32 (d, J = 
1.5 Hz, 2H), 8.04 (s, 2H), 7.77 (d, J = 7.0 Hz, 4H), 7.61 (dd, J = 8.5, 2.0 Hz, 2H), 7.52 (t, 
J = 7.5 Hz, 4H), 7.34 (t, J = 7.0 Hz, 2H), 7.18 (d, J = 8.5 Hz, 2H), 6.94 (t, J = 7.0 Hz, 2H), 
6.89 (t, J = 7.0 Hz, 4H), 6.31 (d, J = 7.0 Hz, 4H), 4.78 (s, 2H), 4.74 (d, J = 17.0 Hz, 2H), 
4.69 (d, J = 17.0 Hz, 2H), 2.22 (s, 6H); 13C NMR (125 MHz, CDCl3)  152.7, 142.2, 141.4, 
138.7, 137.3, 133.3, 128.9, 128.0, 127.4, 126.8, 126.6, 125.1, 124.4, 123.4, 123.3, 118.0, 
117.8, 117.7, 109.3, 99.2, 47.0, 16.6; IR (neat) 3502, 2921, 1603, 1468, 1450, 1406, 1361, 
1347, 1290, 1251, 1178, 1135, 1076, 1003, 964, 878 cm-1; HRMS (ESI-TOF) calcd for 
C52H41N2O2 [M+H]+ m/z = 725.3168, found 725.3168. [α]D22 +82 (c 0.25, 82% ee, CH2Cl2); 
Chiral HPLC: Chiralpak IA column (10% i-PrOH/hexanes, 1 mL/min) tR(1) = 14.6 min, tR(2) 
= 27.1 min. 
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9,9'-Dibenzyl-3,3'-dibromo-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5q). Following 
General Procedure E, the product was obtained as yellow oil (12.0 mg) in 30% yield 
based on recovered starting material. Rf  = 0.63 (EtOAc:Hexanes = 1:4): 1H NMR (500 
MHz, acetone-d6)  8.37 (s, 2H), 8.14 (d, J = 7.4 Hz, 2H), 7.56 (s, 2H), 7.31 (td, J = 8.3, 
1.2 Hz, 2H), 7.23 (td, J = 7.8, 0.8 Hz, 2H), 7.13 (d, J = 8.2 Hz, 2H), 6.87-6.82 (m, 6H), 6.48 
(dd, J = 8.1, 1.9 Hz, 4H), 4.90 (d, J = 17.3 Hz, 2H), 4.63 (d, J = 17.4 Hz, 2H); 13C NMR 
(125 MHz, acetone-d6)  152.1, 143.0, 140.6, 138.4, 128.6, 127.3, 126.2, 126.1, 125.1, 
123.1, 120.7, 120.1, 119.5, 110.3, 104.7, 103.6, 47.8; IR (neat) 3503, 2924, 2853, 1591, 
1473, 1446, 1412, 1340, 1319, 1259, 1205, 1184, 1123, 1027, 960, 777, 746, 730 cm-1; 
HRMS (ESI-TOF) calcd for C38H27Br2N2O2 [M+H]+ m/z = 701.0439, found 701.0462; [α]D22 
+58 (c 0.25, 72% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (20% i-PrOH/hexanes, 
1 mL/min) tR(1) = 12.0 min, tR(2) = 19.6 min. 
 
3,3'-Diallyl-9,9'-dibenzyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5r). Following General 
Procedure E, the product was obtained as a yellow powder (9.0 mg) in 75% yield. Rf  = 
0.72 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, acetone-d6)  8.07 (d, J = 7.5 Hz, 2H), 
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7.94 (s, 2H), 7.23 (dt, J = 8.3, 1.3 Hz, 2H), 7.18 (dt, J = 7.8, 1.0 Hz, 2H), 7.06 (d, J = 8.0 
Hz, 2H), 7.00 (br s, 2H), 6.83-6.81 (m, 6H), 6.48-6.46 (m, 4H), 6.00-5.93 (m, 2H), 5.11 
(dq, J = 17.1, 1.6 Hz, 2H), 4.98 (dq, J = 10.0, 1.2 Hz, 2H), 4.88 (d, J = 17.2 Hz, 2H), 4.58 
(d, J = 17.2 Hz, 2H), 3.42-3.33 (m, 4H); 13C NMR (125 MHz, acetone-d6)  154.1, 142.5, 
140.0, 138.8, 138.6, 128.4, 126.9, 126.2, 125.0, 124.1, 122.3, 120.8, 120.0, 119.5, 118.0, 
115.3, 110.1, 101.9, 47.4, 35.7; IR (neat) 3513, 2923, 1603, 1477, 1449, 1417, 1348, 
1244, 1180, 1124, 919 cm-1; HRMS (ESI-TOF) calcd for C44H36N2O2Na [M+Na]+ m/z = 
647.2674, found 647.2659; [α]D22 +268 (c 0.10, 83% ee, CH2Cl2); Chiral HPLC: Chiralpak 
IA column (10% i-PrOH/hexanes, 1 mL/min) tR(1) = 9.72 min, tR(2) = 11.0 min. 
 
9,9'-Dibenzyl-3,3'-diphenyl-9H,9'H-[1,1'-bicarbazole]-2,2'-diol (1.5s). Following 
General Procedure E, the product was obtained as orange oil (12 mg) in 43% based on 
recovery of starting material yield. Rf  = 0.62 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, 
acetone-d6)  8.16 (d, J = 10.0 Hz, 2H), 8.14 (s, 2H), 7.40 (d, J = 10.0 Hz, 4H), 7.35 (d, J 
= 10.0 Hz, 4H), 7.29-7.20 (m, 8H), 7.09 (d, J = 5.0 Hz, 2H), 6.88-6.86 (m, 6H), 6.63-6.61 
(m, 4H), 5.10 (d, J = 20.0 Hz, 2H), 4.74 (d, J = 20.0 Hz, 2H); 13C NMR (125 MHz, acetone-
d6)  153.3, 142.7, 140.7, 140.3, 138.8, 130.6, 128.69, 128.65, 127.1, 127.0, 126.3, 125.3, 
124.3, 123.4, 123.3, 120.3, 119.8, 118.5, 110.3, 102.8, 47.5; IR (neat) 3506, 2923, 1625, 
1603, 1495, 1474, 1448, 1434, 1411, 1347, 1320, 1264, 1228, 1203, 1182, 1152, 1125, 
958 cm-1; HRMS (ESI-TOF) calcd for C50H37N2O2 [M+H]+ m/z = 697.2855, found 697.2839. 
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[α]D22 +39 (c 0.25, 60% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column (10% i-
PrOH/hexanes, 1 mL/min) tR(1) = 10.4 min, tR(2) = 15.7 min. 
 
82 
 
CHAPTER 2: Total Synthesis of Chaetoglobin A1 
2.1. Introduction 
 Chaetoglobin A is one of the azaphilone dimers, which contains two identical 
oxygenated bicyclic cores incorporating quaternary stereocenters that are connected 
through an axial chiral bond (Figure 2.1). It is isolated from the endophytic fungus 
chaetomium globosum, which lives in the stem of Imperata cylindrical. In 2008, Tan et al. 
reported its inhibitory ability on the propagation of human breast cancer and colon cancer 
cell lines.2 Previous studies on the biosynthesis of azaphilone alkaloids indicate that its 
core backbone is polyketide in origin.3 However, the nature of the dimerization and 
generation of attendant axial chiral stereochemistry has not been delineated.  Specifically, 
it is unclear whether the stereochemistry of the chiral axis forms first and directs formation 
of the quaternary centers (via 2.3), if the quaternary centers form first and then direct 
formation of the chiral axis (via 2.4), or if these stereoelements are formed independently.  
                                                     
1 Adapted from Kang, H.; Pagan, C. T.; Liu, J.; Kozlowski, M. C. Org. Lett. 2018 submitted. 
Copyright 2018 American Chemical Society. 
2 Ming Ge, H.; Yun Zhang, W.; Ding, G.; Saparpakorn, P.; Chun Song, Y.; Hannongbua, S.; Xiang 
Tan, R. Chaetoglobins A and B, Two Unusual Alkaloids from Endophytic Chaetomium Globosum 
Culture. Chem. Commun. 2008, 5978-5980. 
3 (a) Colombo, L.; Gennari, C.; Ricca, G. S.; Scolastico, C.; Aragozzini, F. Detection of One 
Symmetrical Precursor during the Biosynthesis of the Fungal Metabolite Austdiol Using [1,2-
13C2]Acetate and [Me-13C]Methionine. J. Chem. Soc. Chem. Commun. 1981, 575-576. (b) 
Takahashi, M.; Koyama, K.; Natori, S. Four New Azaphilones from Chaetomium Globosum Var. 
Flavo-Viridae. Chem. Pharm. Bull. (Tokyo) 1990, 38, 625–628. (c) Seto, H.; Tanabe, M. Utilization 
of 13C-13C Coupling in Structural and Biosynthetic Studies. III. Ochrephilone - a New Fungal 
Metabolite. Tetrahedron Lett. 1974, 15, 651–654. (d) Duncan, S. J.; Williams, D. H.; Ainsworth, M.; 
Martin, S.; Ford, R.; Wrigley, S. K. On the Biosynthesis of an Inhibitor of the P53/MDM2 Interaction. 
Tetrahedron Lett. 2002, 43, 1075–1078. (e) Nakazawa, T.; Ishiuchi, K.; Sato, M.; Tsunematsu, Y.; 
Sugimoto, S.; Gotanda, Y.; Noguchi, H.; Hotta, K.; Watanabe, K. Targeted Disruption of 
Transcriptional Regulators in Chaetomium Globosum Activates Biosynthetic Pathways and 
Reveals Transcriptional Regulator-Like Behavior of Aureonitol. J. Am. Chem. Soc. 2013, 135, 
13446–13455. 
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Figure 2.1. Structure of Chaetoglobin A (2.1) and B (2.2)1 
 
 Due to their intriguing structures and biological activities, numerous attempts to 
synthesize the azaphilone alkaloids have been reported since the early 1970s.4  
Approaches to introducing the bicyclic core proceed from either a keto-formyl precursor or 
alkynyl-formyl precursor that generate benzopyrylium salts or pyronoquinones as key 
intermediates. Often, acid-catalyzed cycloisomerization, followed by oxidation, was used 
to construct the 2H-isoquinoline-2,6-dione backbone. However, no synthetic efforts have 
been reported toward azaphilone dimers to date. Recently, we reported an efficient 
                                                     
4 (a) Galbraith, M. N.; Whalley, W. B. The Chemistry of Fungi. Part LIX. The Synthesis of (±)-
Ascochitine. J Chem Soc C 1971, 3557–3559. (b) Chong, R.; Gray, R. W.; King, R. R.; Whalley, 
W. B. The Chemistry of Fungi. Part LXII. The Synthesis of (+/-)-Mitorubrin, a Metabolite of 
Penicillium Rubrum. J Chem Soc C 1971, 3571–3575. (c) Zhu, J.; Grigoriadis, N. P.; Lee, J. P.; 
Porco, J. A. Synthesis of the Azaphilones Using Copper-Mediated Enantioselective Oxidative 
Dearomatization. J. Am. Chem. Soc. 2005, 127, 9342–9343. (d) Marsini, M. A.; Gowin, K. M.; 
Pettus, T. R. R. Total Synthesis of (±)-Mitorubrinic Acid. Org. Lett. 2006, 8, 3481–3483. (e) Clark, 
R. C.; Yeul Lee, S.; Boger, D. L. Total Synthesis of Chlorofusin, Its Seven Chromophore 
Diastereomers, and Key Partial Structures. J. Am. Chem. Soc. 2008, 130, 12355–12369. (f) 
Germain, A. R.; Bruggemeyer, D. M.; Zhu, J.; Genet, C.; O’Brien, P.; Porco, J. A. Synthesis of the 
Azaphilones (+)-Sclerotiorin and (+)-8-O-Methylsclerotiorinamine Utilizing (+)-Sparteine 
Surrogates in Copper-Mediated Oxidative Dearomatization. J. Org. Chem. 2011, 76, 2577–2584. 
(g) Somoza, A. D.; Lee, K.-H.; Chiang, Y.-M.; Oakley, B. R.; Wang, C. C. C. Reengineering an 
Azaphilone Biosynthesis Pathway in Aspergillus Nidulans to Create Lipoxygenase Inhibitors. Org. 
Lett. 2012, 14, 972–975. (h) Gao, J.-M.; Yang, S.-X.; Qin, J.-C. Azaphilones: Chemistry and 
Biology. Chem. Rev. 2013, 113, 4755–4811. 
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method to construct a chiral biaryl axis by means of vanadium-catalyzed enantioselective 
oxidative phenol coupling.5 The oxidative coupling permits the formation of chiral axes 
effectively. Here, we describe the total synthesis of chaetoglobin A utilizing this 
asymmetric oxidative phenol coupling to generate an axial chiral bisphenol dimer 2.7 as a 
key intermediate. 
2.2. Retrosynthetic Analysis 
 
Scheme 2.1. Retrosynthetic Analysis of Chaetoglobin A (2.1)1 
 
 In our retrosynthetic analysis, the final isoquinoline moiety could be prepared by 
amination of 2.5 (Scheme 2.1). Lewis acid-catalyzed dearomatization followed by 
oxidation would allow the construction of the corresponding bicyclic core from formylated 
                                                     
5 Kang, H.; Lee, Y. E.; Reddy, P. V. G.; Dey, S.; Allen, S. E.; Niederer, K. A.; Sung, P.; Hewitt, K.; 
Torruellas, C.; Herling, M. R.; Kozlowski, M. C. Asymmetric Oxidative Coupling of Phenols and 
Hydroxycarbazoles. Org. Lett. 2017, 19, 5505–5508. 
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dimer 2.6. We hypothesized that the axial chirality of 2.6 could direct formation of the 
quaternary centers of 2.5. In doing so, we could determine the feasibility one of the 
possible biosynthetic pathways (i.e., via 2.3, Figure 2.1). Vilsmeier-Haack formylation 
could install the necessary formyl groups on tetraphenol 2.7. We envisioned the 
asymmetric oxidative phenol coupling of 2.8 to afford pure atropoisomer 2.7. It was 
anticipated that the acetoxy stereocenters of 2.8 would have little effect on stereochemical 
course of the phenol coupling with the chiral catalyst exerting control. Internal alkynyl 
monomer 2.8 would be prepared from the Sonogashira cross-coupling of bisphenol 2.9 
and alkyne 2.10.  
2.3. Preparation of Sonogashira Coupling Pair 
 Synthetic efforts commenced with preparation of phenol 2.9 and alkyne 2.10 as 
shown in Scheme 2.2. Iridium-catalyzed borylation of commercially available 2.11, 
followed by halogenation, allowed the formation of bromide 2.13.6 Due to need for a more 
reactive electrophile for Sonogashira cross-coupling, halogen exchange was undertaken 
to generate iodophenol 2.9 after demethylation. Surprisingly, stepwise iodination via 
halogen exchange7 from bromide 2.13 proved to be more efficient than direct iodination8 
from boronic ester 2.12. 
                                                     
6 Murphy, J. M.; Liao, X.; Hartwig, J. F. Meta Halogenation of 1,3-Disubstituted Arenes via Iridium-
Catalyzed Arene Borylation. J. Am. Chem. Soc. 2007, 129, 15434–15435. 
7 Klapars, A.; Buchwald, S. L. Copper-Catalyzed Halogen Exchange in Aryl Halides:  An Aromatic 
Finkelstein Reaction. J. Am. Chem. Soc. 2002, 124, 14844–14845. 
8 Partridge, B. M.; Hartwig, J. F. Sterically Controlled Iodination of Arenes via Iridium-Catalyzed C–
H Borylation. Org. Lett. 2013, 15, 140–143. 
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Scheme 2.2. Synthesis of 2,6-Dihydroxy-4-iodotoluene (2.9)1 
 
 Following a literature report9 to prepare enantiomerically pure hydroxyalkyne 2.17, 
a nucleophilic ring opening with commercially available propylene oxide 2.14 and butyne 
2.15 gave internal alkyne 2.16. Sequential alkyne isomerization was effected with a 
Li/KOt-Bu in 1,3-diaminopropane. Acetate protection of the free hydroxyl group provided 
the desired alkyne 2.10 in 74% yield over three steps (Scheme 2.3). 
 
Scheme 2.3. Synthesis of Terminal Alkyne (2.10)1 
 
2.4. Diastereoselective Oxidative Phenol Coupling to Generate Chiral Axis 
                                                     
9 Wu, Y.; Gao, J. Total Synthesis of (+)-Brefeldin A. Org. Lett. 2008, 10, 1533–1536. 
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Scheme 2.4. Asymmetric Oxidative Phenol Coupling and Determination of its Absolute 
Stereochemistry1 
 
 Optimization of Sonogashira coupling between iodide 2.9 and alkyne 2.10 led to 
the formation of oxidative phenol coupling precursor 2.8 in 98% yield (Scheme 2.4). Using 
our recently reported atroposelective oxidative coupling of phenols,5 vanadium catalyst 
2.18 was applied to this transformation. Notably, complete catalyst control over the 
diastereoselectivity was observed with the opposite enantiomer of the catalyst providing 
the diastereomeric product with comparable dr. The additives, LiCl and HOAc, which are 
theorized to activate the vanadium catalyst, result in significant improvements (Table 2.1). 
Treatment of 2.8 with LiCl as an additive gave high diastereoselectivity (Table 2.1, entry 
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2). Increased catalyst loading showed neither a significant improvement in yield nor 
selectivity (entry 3). Among alternative solvents, chlorobenzene seemed a promising 
candidate in terms of improving yield (entry 2 vs 4 and entry 5 vs 6). Improved yield and 
comparable selectivity of dimer was realized with HOAc as the additive and chlorobenzene 
as solvent (entry 6). Finally, further improved yield and diastereoselectivity was achieved 
under more concentrated reaction conditions (entry 7). Use of asymmetric vanadyl catalyst 
2.18 under the optimized conditions allowed access to the axially chiral dimer 2.7 in 67% 
yield with >15:1 dr. The absolute stereochemistry of product 2.7 was confirmed by X-ray 
crystallographic analysis of the para-bromobenzoyl substituted derivative 2.19.10  
 
entry v-cat 2.18 additivea solventb yield (%)c dr 
1 20 mol% – Chlorobenzened 34 (44) 79:21 
2 20 mol% LiCl Toluene 52 (59) 92:8 
3 40 mol% LiCl Toluene 49 (52) 93:7 
4 20 mol% LiCl Chlorobenzene 54 (60) 90:10 
5 20 mol% HOAc Toluene 49 (55) 87:13 
6 20 mol% HOAc Chlorobenzene 49 (64) 90:10 
7 20 mol% HOAc Chlorobenzened 58 (67) 94:6 
a20 mol% b0.3 M cIsolated yield based on recovery of substrate in parentheses d0.5 M 
Table 2.1. Diastereoselective Oxidative Coupling of 2.81 
 
2.5. Formylation 
                                                     
10 Opposite chiral axis compound (P)-19 crystallographic data included in Experimental Section. 
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Entry R condition T (C) Time Yield (%) 
1 TBDPS POCl3, DMF, CH2Cl2 25 20 min 16 
2 TBDPS POCl3, DMF, CH2Cl2 0 20 min 27 
3 TBDPS Cl2CHOMe, AgOTf, CH2Cl2 –78 3 h <10 
4 TBDPS MgCl2, (CH2O)n, Et3N, THF 70 3 h –a 
5b TBDPS ClCHN(CH3)2Cl, CH2Cl2 25 20 min  36 
6b TBDPS ClCHN(CH3)2Cl, CH2Cl2 0 20 min 42 
7 Ac ClCHN(CH3)2Cl, CH2Cl2 25 3 h 23c 
8 Ac ClCHN(CH3)2Cl, CH2Cl2 0 20 min 43 
9 Ac ClCHN(CH3)2Cl, CH2Cl2 –35 12 h 75 (86)d 
aSubstrates decomposition occured.bTBDPS deprotection detected in 1H NMR.cNo deprotection 
was observed. dBased on recovery of starting material yield in parentheses. TBDPS=tert-
butyldiphenyl silyl, Ac=acetyl 
Table 2.2. Formylation Optimization 
 
 With the coupled atropoisomer in hand, our attention turned to generating the 
formyl functional group adjacent to the alkyne chain. Attempts at formylation with various 
methods11 are shown in Table 2.2. Owing to inherent acidic conditions of the formylation 
                                                     
11 (a) Ramadas, S.; Krupadanam, G. L. D. Enantioselective Acylation of 2-Hydroxymethyl-2,3-
Dihydrobenzofurans Catalysed by Lipase from Pseudomonas Cepacia (Amano PS) and Total 
Stereoselective Synthesis of (−)-(R)-MEM-Protected Arthrographol. Tetrahedron Asymmetry 2000, 
11, 3375–3393. (b) Phan, D. H. T.; Kim, B.; Dong, V. M. Phthalides by Rhodium-Catalyzed Ketone 
Hydroacylation. J. Am. Chem. Soc. 2009, 131, 15608–15609. (c) Ohsawa, K.; Yoshida, M.; Doi, T. 
A Direct and Mild Formylation Method for Substituted Benzenes Utilizing Dichloromethyl Methyl 
Ether–Silver Trifluoromethanesulfonate. J. Org. Chem. 2013, 78, 3438–3444. 
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reaction, the tert–butyldiphenylsilyl (TBDPS) was used as an initial hydroxyl protecting 
group. The Vilsmeier–Haack formylation gave promising results (entry 1–2), compared to 
Lewis acid assisted conditions (entry 3–4). Interestingly, use of the preformed Vilsmeier 
reagent improved the reaction yield to 42% (entry 6). However, TBDPS deprotection was 
faster than the formylation under these conditions. Surprisingly, an acetyl group was 
tolerated under Vilsmeier–Haack conditions without the ester deprotection (entry 7). 
Finally, it was revealed that the Vilsmeier-Haack formylation with preformed 
(chloromethylene)dimethyliminium chloride at –35 ºC provided bisformylated product 2.6 
in 86% yield without acyl deprotection (entry 9). 
 
 
Scheme 2.5. Vilsmeier–Haack Formylation1 
 
2.6. Oxidative Dearomatization 
 Subsequently, an oxidative dearomatization reaction, which was developed by 
Porco and coworkers, was used to generate the bicyclic core featuring a quaternary 
stereocenter.12 Initially, we tested this transformation using monomeric formylated phenol 
2.20, which was easily prepared from monomer 2.8 in 85% yield (Scheme 2.6). Based on 
the literature, Au(OAc)3 was the optimal Lewis acid for this transformation. These 
                                                     
12 Zhu, J.; Germain, A. R.; Porco, J. A. Synthesis of Azaphilones and Related Molecules by 
Employing Cycloisomerization of O-Alkynylbenzaldehydes. Angew. Chem. Int. Ed. 2004, 43, 1239–
1243. 
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conditions efficiently provided the desired oxygenated core 2.21 upon IBX oxidation as 
gaining access to a monomer 2.22 after acetylation (72% yield over three steps). 
 
Scheme 2.6. Oxidative Dearomatization with Monomer 2.201 
 
 With dimer 2.6, however, Au(OAc)3-catalyzed dearomatization did not generate 
desired product 2.5. The use of Au catalyst to activate bisformyl 2.6 causing 
decomposition. After screening several Lewis acids, we found that AgOTf13 gave a similar 
result (63% overall yield from 2.20) as in the model system (Scheme 2.6). 
Cycloisomerization of 2.6 occured in the presence of AgOTf, and subsequent oxidation 
with hypervalent iodine, IBX, allowed access to bicyclic dimer 2.5 (Scheme 2.7). We had 
theorized that the chiral axis would influence the stereochemistry during formation of this 
quaternary center, with the bulk of the 2H-isoquinoline-2,6-dione backbone blocking one 
stereoface. That the reaction gave a 1:1:1 mixture of the three possible isomers (7S,7’S, 
7S,7’R, and 7R,7’R) indicates that such a stereocontrol scenario is most likely not active 
in the biosynthesis. Fortunately, sufficient amounts of each isomer were obtained to 
proceed with the synthesis. The following section describes the results  obtained with the 
                                                     
13 Feng, X.; Wang, H.; Yang, B.; Fan, R. One-Pot Synthesis of Highly Substituted 4-Acetonylindoles 
via Sequential Dearomatization and Silver-Catalyzed Domino Reaction. Org. Lett. 2014, 16, 3600–
3603. 
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faster eluting symmetric diastereomer, which could not be definitively assigned as 7S,7’S 
or 7R,7’R at this stage. 
 
Scheme 2.7. Oxidative Dearomatization with Dimer 2.61 
 
 At this juncture, selective acylation of the tertiary alcohol centers was needed, 
which was achieved either by deacylation of the secondary alcohols followed by selective 
acylation of the tertiary alcohols or by global acetylation followed by selection deacylation 
of the less hindered secondary alcohols.  The former possibility takes advantage of the 
greater reactivity of the alcohols adjacent to the ketone.14 Upon removal of the acetyl 
groups from 2.5, the resultant product was found to be prone to decomposition.  As such, 
the latter alternative became a focus.  Acetylation of 2.5 afforded product 2.23 in 22% over 
three steps from 2.6, which represent six sets of chemical transformations due to the 
dimeric nature of the material (Scheme 2.7). 
                                                     
14 Holton, R. A.; Zhang, Z.; Clarke, P. A.; Nadizadeh, H.; Procter, D. J. Selective Protection of the 
C(7) and C(10) Hydroxyl Groups in 10-Deacetyl Baccatin III. Tetrahedron Lett. 1998, 39, 2883–
2886. 
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2.7. Selective Acetyl Deprotection 
 Unexpectedly, selective deprotection of the secondary acetoxy group in the 
presence of the sterically congested quaternary acetoxy group was challenging. 
Attempted hydrolysis of 2.23 with acidic or basic conditions led to decomposition that was 
faster than deprotection. We explored a wide range of hydrolysis conditions,15 including 
enzymatic methods (see Experimental Section),16 and finally established that 10 equiv of 
                                                     
15 (a) Plattner, J. J.; Gless, R. D.; Rapoport, H. Synthesis of Some DE and CDE Ring Analogs of 
Camptothecin. J. Am. Chem. Soc. 1972, 94, 8613–8615. (b) Mori, K.; Tominaga, M.; Takigawa, T.; 
Matsui, M. A Mild Transesterification Method. Synthesis 1973, 790–791. (c) Askin, D.; Angst, C.; 
Danishefsky, S. An Approach to the Synthesis of Bactobolin and the Total Synthesis of N-
Acetylactinobolamine: Some Remarkably Stable Hemiacetals. J. Org. Chem. 1987, 52, 622–635. 
(d) Nudelman, A.; Herzig, J.; Gottlieb, H. E.; Keinan, E.; Sterling, J. Selective Deacetylation of 
Anomeric Sugar Acetates with Tin Alkoxides. Carbohydr. Res. 1987, 162, 145–152. (e) Baptistella, 
L. H. B.; Santos, J. F. D.; Ballabio, K. C.; Marsaioli, A. J. 1,8-Diazabicyclo[5.4.0]Undec-7-Ene as a 
Mild Deprotective Agent for Acetyl Groups. Synthesis 1989, 21, 436–439. (f) Roush, W. R.; Lin, X.-
F. Studies on the Synthesis of Aureolic Acid Antibiotics: Highly Stereoselective Synthesis of Aryl 2-
Deoxy-.Beta.-Glycosides via the Mitsunobu Reaction and Synthesis of the Olivomycin A-B 
Disaccharide. J. Am. Chem. Soc. 1995, 117, 2236–2250. (g) Yamamoto, N.; Nishikawa, T.; Isobe, 
M. Synthesis of Bicyclic Hydroxy Lactone Intermediates toward (-)-Tetrodotoxin. Synlett 1995, 505–
506. (h) Yanada, R.; Negoro, N.; Bessho, K.; Yanada, K. Metallic Samarium and Iodine in Alcohol. 
Deacylation and Dealkyloxycarbonylation of Protected Alcohols and Lactams. Synlett 1995, 1261–
1263. (i) Xu, Y.-C.; Bizuneh, A.; Walker, C. A Reagent for Selective Deprotection of Alkyl Acetates. 
J. Org. Chem. 1996, 61, 9086–9089. (j) Kajiro, H.; Mitamura, S.; Mori, A.; Hiyama, T. Scandium 
Trifluoromethanesulfonate-Catalyzed Mild, Efficient, and Selective Cleavage of Acetates Bearing 
a Coordinative Group. Tetrahedron Lett. 1999, 40, 1689–1692. (k) Sharma, G. V. M.; Ilangovan, A. 
Ytterbium Triflate Mediated Selective Deprotection of Acetates. Synlett 1999, 1963–1965. (l) 
Yoshimoto, K.; Kawabata, H.; Nakamichi, N.; Hayashi, M. Tris(2,4,6-Trimethoxyphenyl)Phosphine 
(TTMPP): A Novel Catalyst for Selective Deacetylation. Chem. Lett. 2001, 30, 934–935. (m) 
Ravindranathan Kartha, K. P.; Mukhopadhyay, B.; Field, R. A. Practical De-O-Acylation Reactions 
Promoted by Molecular Sieves. Carbohydr. Res. 2004, 339, 729–732. (n) Wang, S.-M.; Ge, W.-Z.; 
Liu, H.-M.; Zou, D.-P.; Yan, X.-B. Syntheses of Acetylated Steroid Glycosides and Selective 
Cleavage of O-Acetyl Groups in Sugar Moiety. Steroids 2004, 69, 599–604. (o) Ren, B.; Cai, L.; 
Zhang, L.-R.; Yang, Z.-J.; Zhang, L.-H. Selective Deacetylation Using Iodine–methanol Reagent in 
Fully Acetylated Nucleosides. Tetrahedron Lett. 2005, 46, 8083–8086. (p) Yeom, C.-E.; Lee, S. Y.; 
Kim, Y. J.; Kim, B. M. Mild and Chemoselective Deacetylation Method Using a Catalytic Amount of 
Acetyl Chloride in Methanol. Synlett 2005, 1527–1530. (q) B. C. Ranu, S. K. Guchhait, M. Saha, J. 
Indian Chem. Soc. 1999, 76, 547. 
16 (a) Sakaki, J.; Sakoda, H.; Sugita, Y.; Sato, M.; Kaneko, C. Lipase-Catalyzed Asymmetric 
Synthesis of 6-(3-Chloro-2-Hydroxypropyl)-1,3-Dioxin-4-Ones and Their Conversion to Chiral 5,6-
Epoxyhexanoates. Tetrahedron Asymmetry 1991, 2, 343–346. (b) Lopez, R.; Montero, E.; 
Sanchez, F.; Canada, J.; Fernandez-Mayoralas, A. Regioselective Acetylations of Alkyl .Beta.-D-
Xylopyranosides by Use of Lipase PS in Organic Solvents and Application to the Chemoenzymic 
Synthesis of Oligosaccharides. J. Org. Chem. 1994, 59, 7027–7032. (c) Houille, O.; Schmittberger, 
T.; Uguen, D. A Remarkably Simple Process for Monoprotecting Diols. Tetrahedron Lett. 1996, 37, 
625–628. 
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Ti(Oi-Pr)4 in CH2Cl2 at elevated temperature afforded free hydroxylated 2.24 in 52% yield 
(Scheme 2.8).15p Exposure of oxygenated bicycle 2.24 to excess NH4OAc furnished 
synthetic chaetoglobin A (2.1) in nearly quantitative yield. 
 
Scheme 2.8. Selective Acetyl Deprotection and Amination to make Chaetoglobin A (2.1)1 
 
2.8. Confirmation of Synthetic Product 2.1 
 The spectroscopic data from synthetic 2.1 was in accord with those reported in the 
literature for chaetoglobin A (Table 2.3).2 In particular, the 13C NMR gave rise to 17 
differentiable carbons supporting the symmetric structure, and the chemical shifts of those 
signals closely matched those from the natural product, securing evidence that the correct 
diastereomeric relationship between the quaternary carbons and the stereoaxis had been 
generated (Table 2.3). Importantly, circular dichroism data obtained from the synthetic 
material proved identical to that from the natural product (Figure 2.2), which indicates that 
both the correct absolute and relative stereochemistries are established. 
Natural Product Synthetic Product 
1H (ppm) IR (cm–1) 13C (ppm) 1H (ppm) IR (cm–1) 13C (ppm) 
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1.16 (d) 3384 20.4 1.12 (d) 3383 20.6 
1.45 (m) 2931 23.3 1.39–1.45 (m) 2928 23.4 
1.64 (s) 1732 23.4 1.60 (s) 1732 23.6 
1.72 (m) 1692 25.3 1.63–1.72 (m) 1692 25.5 
2.19 (s) 1644 33.9 2.15 (s) 1643 34.1 
2.49 (t) 1549 39.0 2.45 (t) 1547 39.2 
3.73 (m) 1471 67.8 3.67–3.73 (m) 1465 68.1 
6.42 (s) 1372 85.7 6.37 (s) 1373 86.0 
8.05 (s) 1247 103.7 8.00 (s) 1248 104.0 
 1204 116.0  1206 116.1 
 1128 116.7  1130 116.9 
 1080 139.6  1081 139.7 
  151.2   151.3 
  153.2   153.2 
  171.8   172.0 
  189.6   189.9 
  197.8   198.0 
a20 mol% b0.3 M cIsolated yield based on recovery of substrate in parentheses d0.5 M 
Table 2.3. Comparing Spectral Data between Natural Product vs Synthetic Product (2.1) 
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Figure 2.2. Comparing Circular Dichroism of Chaetoglobin A (2.1) (a) CD Spectrum of Natural 
Product Isolate. Adapted from reference 2 with permission of The Royal Society of Chemistry; (b) 
Synthetic 2.1 CD Spectrum.1 
 
2.9. Conclusions 
 In conclusion, we have accomplished the first total synthesis of chaetoglobin A in 
4.3% overall yield, with 12 steps in the longest linear sequence. A vanadium-catalyzed 
asymmetric oxidative phenol coupling serves as a key step in the formation of stereoaxis 
of chiral azaphilone dimer 1.  The stereochemical results from oxidative cyclization after 
formation of the stereoaxis raise interesting questions about the operating biosynthetic 
pathways; oxidative cyclization after dimerization appears unlikely.   
2.10. Experimental Section 
General Information  
 Unless otherwise noted, all non-aqueous reactions were carried out under an 
atmosphere of dry N2 in dried glassware. When necessary, solvents and reagents were 
dried prior to use. THF was distilled from sodium benzophenone ketyl. CH2Cl2, and toluene 
were distilled from CaH2. High throughput experiments were performed at the Penn/Merck 
97 
 
High Throughput Experimentation Laboratory at the University of Pennsylvania. The 
screens were analyzed by HPLC using an internal standard. 
Analytical thin layer chromatography (TLC) was performed on EM Reagents 0.25 mm 
silica-gel 254-F plates. Visualization was accomplished with UV light. Chromatography 
was performed using a forced flow of the indicated solvent system on EM Reagents Silica 
Gel 60 (230-400 mesh). When necessary, the column was pre-washed with 1% Et3N in 
the eluent system. 1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical 
shifts are reported in ppm from tetramethylsilane (0 ppm) or from the solvent resonance 
(CDCl3 7.26 ppm, acetone-d6 2.05 ppm, DMF-d7 2.50 ppm, CD3CN 1.94 ppm, CD2Cl2 5.32 
ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. 
Decoupled 13C NMR spectra were recorded at 125 MHz. IR spectra were taken on an FT-
IR spectrometer using a neat film. Accurate mass measurement analyses were conducted 
via time-of-flight mass analyzer GCMS with electron ionization (EI) or via time-of-flight 
mass analyzer LCMS with electrospray ionization (ESI). The signals were measured 
against an internal reference of perfluorotributylamine for EI-GCMS and leucine 
enkephalin for ESI-LCMS. The instrument was calibrated and measurements were made 
using neutral atomic masses; the mass of the electron removed or added to create the 
charged species is not taken into account. Low resolution LCMS data were obtained by 
use of a UPLC system with a SQD mass analyzer equipped with electrospray ionization. 
Melting points are corrected. Enantiomeric excesses were determined using analytical 
HPLC with UV detection at 254 nm. Analytical Chiralpak columns (4.6 mm x 250 mm, 5 
µm) from Daicel were used. Optical rotations were measured on a polarimeter with a 
sodium lamp. 
Experimental Procedures and Characterization Data 
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5-Bromo-1,3-dimethoxy-2-methylbenzene (2.13). In a glove box, [Ir(COD)(OMe)]2 (54 
mg, 0.08 mmol), 4,4’-di-tert-butyl-2,2’-dipyridyl (44 mg, 0.16 mmol), B2Pin2 (7.09 g, 27.9 
mmol), and 2,6-dimethoxytoluene (5.00 g, 32.9 mmol) were added to a Schlenk flask, 
which was then sealed with septum. The reactants were dissolved in distilled THF (41 mL) 
under an argon atmosphere and the resultant mixture was heated at 80 °C for 44 h. The 
mixture was cooled to ambient temperature and concentrated. After standing under 
vacuum for 3 h, the ester was subjected to MeOH (230 mL) and CuBr2 (22.0 g, 98.6 mmol) 
in distilled H2O (230 mL). The resultant mixture was heated at 80 °C for 48 h and then, 
cooled to ambient temperature. The mixture was extracted with EtOAc (150 mL X 3) and 
the combined organic layer were washed with brine, dried over Na2SO4, filtered, and 
concentrated. Column chromatography (Hex:EtOAc = 99:1) afforded a white powder (6.78 
g) in 89% overall yield17: Rf = 0.56 (Hexane:EtOAc = 40:1); 1H NMR (500 MHz, CDCl3)  
6.67 (s, 2H), 3.80 (s, 6H), 2.02 (s, 3H); 13C NMR (125 MHz, CDCl3)  158.9, 119.3, 113.7, 
107.4, 56.0, 8.2; IR (neat) 2938, 2834, 1586, 1464, 1402, 1310, 1283, 1253, 1227, 1181, 
1139, 1126, 1041, 843 cm–1; HRMS (EI-TOF) m/z calcd for C9H11BrO2 [M]+ 229.9942, 
found 229.9927 
 
5-Iodo-1,3-dimethoxy-2-methylbenzene (2.S1). A Schlenk flask was charged with CuI 
                                                     
17 Murphy, J. M.; Liao, X.; Hartwig, J. F. Meta Halogenation of 1,3-Disubstituted Arenes via Iridium-
Catalyzed Arene Borylation. J. Am. Chem. Soc. 2007, 129, 15434–15435. 
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(279 mg, 1.47 mmol), NaI (8.80 g, 58.7 mmol), and 2.13 (6.78 g, 29.3 mmol). The reactants 
were dissolved in 1,4-dioxane (29 mL) and N,N’-dimethylethylenediamine (0.32 mL, 2.93 
mmol) under an argon atmosphere. The resultant mixture was stirred at 110 °C for 48 h. 
The resulting suspension was allowed to cool to ambient temperature, diluted with satd 
NH4Cl, poured into water and extracted with CH2Cl2 (15 mL X 3). The combined organic 
phases were dried over Na2SO4 and filtered. Removal of solvent and chromatography 
(Hex:EtOAc = 99:1) afforded a white powder (7.75 g) in 95% yield. 1H NMR spectrum is 
in accord with that previously reported18: Rf  = 0.61 (Hexane:EtOAc = 40:1); 1H NMR (500 
MHz, CDCl3)  6.85 (s, 2H), 3.80 (s, 6H), 2.03 (s, 3H); 13C NMR (125 MHz, CDCl3)  158.9, 
114.8, 113.4, 89.7, 56.1, 8.2; IR (neat) 2996, 2911, 2852, 1575, 1485, 1448, 1435, 1396, 
1304, 1279, 1234, 1180, 1132, 841 cm–1; HRMS (EI-TOF) m/z calcd for C9H11IO2 [M]+ 
277.9804, found 277.9804 
 
5-Iodo-2-methylbenzene-1,3-diol (2.9). 2.S1 (6.94 g, 25.0 mmol) was dissolved in 
CH2Cl2 (50 mL). After cooling to –78 ºC, a solution of BBr3 (1 M in dichloromethane, 62 
mL) was added dropwise. The resultant mixture was allowed to warm to ambient 
temperature and stirred until completion as judged by TLC (24 h). The mixture was 
subsequently quenched with water (15 mL) in an ice bath. The solution was extracted with 
CH2Cl2 (20 mL X 3). The combined organic phases were washed with brine and dried over 
Na2SO4. Removal of solvent followed by chromatography (100 % CH2Cl2) afforded a white 
powder (5.62 g) in 90% yield: Rf  = 0.22 (100 % CH2Cl2); 1H NMR (500 MHz, (CD3)2CO)  
                                                     
18 Duggan, K. A. Compositions for the Treatment of Hypertension and/or Fibrosis. WO2015039172 
(A1), March 26, 2015. 
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8.37 (br s, 2H), 6.78 (s, 2H), 2.02 (s, 3H); 13C NMR (125 MHz, CD3CN)  157.6, 116.8, 
112.1, 89.6, 8.4; IR (neat) 3367, 2918, 2496, 1580, 1494, 1442, 1396, 1324, 1274, 1229, 
1055, 952, 845 cm–1; HRMS (EI-TOF) m/z calcd for C7H7IO2 [M]+ 249.9491, found 
249.9475 
 
(S)-Hept-6-yn-2-yl acetate (2.10). To a stirred solution of 2.17 (35.7 mmol), which was 
prepared over two steps without chromatography,9 in CH2Cl2 (71 mL) was added pyridine 
(5.8 mL, 71.4 mmol), at 0 ºC followed by the addition of 4-(dimethylamino)pyridine (1.09 
g, 8.93 mmol) and Ac2O (3.7 mL, 39.3 mmol). The resultant mixture was stirred for 30 min 
and then was quenched with 1N HCl (95 mL) in an ice bath. The resulting mixture was 
extracted with CH2Cl2 (20 mL X 3) and the combined organic phases were sequentially 
washed with H2O (50 mL) and satd NaHCO3 (50 mL). The organic layer was dried over 
Na2SO4 and filtered. Removal of the solvent followed by chromatography (Hex:EtOAc = 
10:1) gave the desired product as clear liquid (4.09 g) in 74% over three steps: Rf  = 0.75 
(Hexane:EtOAc = 4:1); [α]D22 = +4.1 (c 1.4, CH3OH); 1H NMR (500 MHz, CDCl3)  4.88-
4.94 (m, 1H), 2.20 (td, J = 7.0, 2.5 Hz, 2H), 2.02 (s, 3H), 1.95 (t, J = 2.5 Hz, 1H), 1.49-1.71 
(m, 4H), 1.22 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  170.9, 84.1, 70.6, 68.8, 
35.1, 24.5, 21.5, 20.1, 18.4; IR (neat) 3295, 2978, 2937, 2870, 1731, 1436, 1371, 1241, 
1133, 1073, 1049, 1018, 976 cm–1; HRMS (EI-TOF) m/z calcd for C9H14O2 [M]+ 154.0994, 
found 154.0982 
 
(S)-7-(3,5-Dihydroxy-4-methylphenyl)hept-6-yn-2-yl acetate (2-8). To an oven-dried 
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Schlenk flask was added 2.9 (2.67 g, 10.7 mmol), Pd(PPh3)2Cl2 (750 mg, 1.07 mmol), CuI 
(203 mg, 1.07 mmol) and 2.10 (1.81 g, 11.7 mmol). The flask was sealed with a septum 
and purged with argon. The resultant mixture was dissolved in DMF (36 mL) and Et2NH 
(3.9 mL, 37.4 mmol). The mixture was stirred at 65 ºC for 18 h. After cooling to ambient 
temperature, the reaction mixture was treated with satd NH4Cl (15 mL). The resultant 
mixture was poured into water and extracted with Et2O (40 mL X 3). The combined organic 
layers were washed thoroughly with satd LiCl (3 mL X 3) and brine. The organic layer was 
dried over Na2SO4 and filtered. Removal of the solvent followed by chromatography 
(Hex:EtOAc = 4:1) afforded a brown oil (2.88 g) in 98% yield: Rf = 0.36 (Hexane:EtOAc = 
2:1); [α]D22 = –4.5 (c 0.24, CH3OH); 1H NMR (500 MHz, CDCl3)  6.46 (s, 2H), 5.99 (br s, 
2H), 4.96-5.02 (m, 1H), 2.38 (t, J = 7.0 Hz, 2H), 2.11 (s, 3H), 2.06 (s, 3H), 1.53-1.77 (m, 
4H), 1.24 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  172.1, 154.8, 121.5, 111.6, 
110.9, 88.7, 80.9, 71.4, 35.0, 24.5, 21.5, 19.9, 19.2, 8.2; IR (neat) 3386, 2935, 1699, 1616, 
1583, 1413, 1375, 1341, 1323, 1265, 1165, 1133, 1078, 1023, 950 cm–1; HRMS (ESI-
TOF) m/z calcd for C16H20O4Na [M+Na]+ 299.1259, found 299.1273 
 
(2S,2'S)-((R)-4,4',6,6'-Tetrahydroxy-5,5'-dimethyl-[1,1'-biphenyl]-2,2'-diyl)bis(hept-6-
yne-7,2-diyl) diacetate (2.7). To a microwave vial was added phenol 2.8 (320 mg, 1.15 
mmol), vanadium catalyst 2.18 (103 mg, 0.23 mmol), and HOAc (13 mL, 0.23 mmol). The 
vial was sealed and chlorobenzene (2.3 mL) was added. Oxygen was added via an active 
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purge. The deep blue solution was stirred for 42 h at 0 °C. The reaction mixture was 
directly chromatographed (Hex:EtOAc = 4:1) to afford the mixture of coupled products 
(214 mg) in 67% yield with 94:6 dr (the diastereoselectivity varies depending on batch of 
the catalyst from 4:1 to >15:1). The combined mixture of products (1.497 g) was dissolved 
in methanol (10 mL). This solution was used as feeding solution (150 mg/mL) for 
Supercritical Fluid Chromatographic separation (SFC). The separation of the two isomers 
was performed using a Lux Celluiose-4 column (21 x 250 mm) with 30% MeOH / 70% CO2 
at 35 °C (flow rate 60 mL/min, BP 100 bar, detector 210 nm).  Five hundred L of feeding 
solution was injected at a time and two fractions (2.2-2.5 min,  and 3.1-3.7 min) were 
collected for each run. Concentration of the two fractions afforded 180 mg of the (P)-7 as 
light yellow powder and 1.05 g of 2.7 as light yellow powder: Rf = 0.23 (Hexane:EtOAc = 
2:1); [α]D22 = –33.5 (c 0.30, CH3OH); 1H NMR (500 MHz, CDCl3)  6.53 (s, 2H), 5.76 (br 
s, 2H), 5.03 (br s, 2H), 4.76-4.83 (m, 2H), 2.16-2.19 (m, 4H), 2.17 (s, 6H), 2.06 (s, 6H), 
1.20-1.43 (m, 8H), 1.15 (d, J = 6.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  171.7, 155.1, 
153.6, 123.1, 115.3, 112.0, 111.3, 92.1, 79.2, 71.1, 34.7, 24.6, 21.6, 20.0, 19.3, 8.8; IR 
(neat) 3540, 3375, 2950, 1708, 1683, 1604, 1585, 1431, 1404, 1377, 1345, 1323, 1288, 
1277, 1239, 1163, 1136, 1076, 1047, 1020, 839 cm–1; HRMS (ESI-TOF) m/z calcd for 
C32H39O8 [M+H]+ 551.2645, found 551.2650; HPLC (Chiralpak IA column) 20% i-
PrOH/Hexane (1 mL/min), t(7) = 10.5 min, t((P)-7) = 28.7 min 
 
103 
 
 
Racemic HPLC  
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(2S,2'S)-((S)-4,4',6,6'-Tetrahydroxy-5,5'-dimethyl-[1,1'-biphenyl]-2,2'-diyl)bis(hept-6-
yne-7,2-diyl) diacetate [(P)-2.7]: Rf = 0.23 (Hexane:EtOAc = 2:1); [α]D22 = +8.4 (c 0.39, 
CH3OH); 1H NMR (500 MHz, CDCl3)  6.76 (br s, 2H), 6.59 (s, 2H), 5.23 (br s, 2H), 4.75-
4.80 (m, 2H), 2.12-2.22 (m, 4H), 2.13 (s, 6H), 2.02 (s, 6H), 1.31-1.43 (m, 6H), 1.17 (d, J = 
6.5 Hz, 6H), 1.05-1.18 (m, 2H); 13C NMR (125 MHz, CDCl3)  171.9, 155.3, 153.7, 122.9, 
115.4, 112.1, 111.0, 92.0, 79.5, 71.6, 34.6, 24.5, 21.5, 20.0, 19.2, 8.8; IR (neat) 3406, 
HPLC of Compound 2.7 
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2944, 1709, 1604, 1582, 1398, 1374, 1348, 1322, 1267, 1164, 1132, 1077, 1032, 991, 
952 cm–1; HRMS (ESI-TOF) m/z calcd for C32H38O8Na [M+Na]+ 573.2464, found 573.2479 
 
6,6'-Bis((S)-6-acetoxyhept-1-yn-1-yl)-3,3'-dimethyl-[1,1'-biphenyl]-2,2',4,4'-tetrayl 
tetrakis(4-bromobenzoate) (2.19). To a stirred solution of 2.7 (50 mg, 0.09 mmol) in 
CH2Cl2 (0.91 mL) was added 4-bromobenzoyl chloride (90 mg, 0.41 mmol) and Et3N (40 
L, 0.27 mmol) at room temperature. The mixture was stirred for 14 h and the resultant 
solution was washed with 1 N HCl (2 mL X 2) and brine. The organic layer was dried over 
Na2SO4 and filtered. Removal of the solvent and chromatography (Hex:EtOAc = 10:1) 
afforded light yellow powder (105 mg) in 91% yield. Crystallization from EtOAc and 
pentane via the vapor diffusion method gave white crystals. The absolute axial 
configuration was determined as M from the X-Ray crystal structure: Rf = 0.44 
(Hexane:EtOAc = 4:1); [α]D22 = –13.1 (c 2.30, CH2Cl2); 1H NMR (500 MHz, CDCl3)  8.07 
(d, J = 8.5 Hz, 4H), 7.75 (d, J = 8.5 Hz, 4H), 7.67 (d, J = 8.5 Hz, 4H), 7.58 (d, J = 8.5 Hz, 
4H), 7.20 (s, 2H), 4.81-4.88 (m, 2H), 2.25 (t, J = 6.0 Hz, 4H), 1.98 (s, 12H), 1.33-1.53 (m, 
8H), 1.17 (d, J = 6.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  170.8, 163.6, 162.9, 149.4, 
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148.4, 132.3, 132.1, 131.8, 131.7, 130.1, 129.2, 128.8, 128.2, 128.1, 124.9, 123.8, 123.1, 
94.6, 78.2, 70.8, 34.8, 24.3, 21.5, 20.0, 19.4, 11.2; IR (neat) 2940, 1737, 1588, 1484, 
1398, 1371, 1246, 1173, 1154, 1132, 1110, 1084, 1068, 1009, 954 cm–1; HRMS (ESI-
TOF) m/z calcd for C60H51Br4O12 [M+H]+ 1279.0114, found 1279.0121 
 
(2S,2'S)-(3,3'-Diformyl-4,4',6,6'-tetrahydroxy-5,5'-dimethyl-[1,1'-biphenyl]-2,2'-
diyl)bis(hept-6-yne-7,2-diyl) diacetate (2.6). The bisphenol 2.7 (457 mg, 0.83 mmol) 
was dissolved in CH2Cl2 (41 mL). After cooling to –35 ºC, five portions of commercial 
(chloromethylene)dimethyliminium chloride (424 mg, 3.31 mmol) was added every 20 min. 
The reaction mixture was stirred for 12 h and the mixture was subsequently quenched 
with satd NaHCO3 (20 mL) in an ice bath. The solution was extracted with EtOAc (40 mL 
X 3), washed thoroughly with satd LiOH solution (2 mLX 5), and brine. The combined 
organic layers were dried over Na2SO4. Removal of the solvent followed by 
chromatography (Hex:EtOAc = 4:1) provided a yellow oil (433 mg) in 86 % yield: Rf = 0.32 
(Hexane:EtOAc = 2:1); [α]D22 = –138.1 (c 0.43, CH3OH); 1H NMR (500 MHz, CDCl3)  
12.32 (s, 2H), 10.21 (s, 2H), 5.92 (s, 2H), 4.76-4.82 (m, 2H), 2.27 (t, J = 6.5 Hz, 4H), 2.17 
(s, 6H), 2.01 (s, 6H), 1.28-1.44 (m, 8H), 1.12 (d, J = 6.5 Hz, 6H); 13C NMR (125 MHz, 
CDCl3)  195.5, 170.9, 163.5, 159.8, 128.4, 115.5, 114.8, 112.9, 101.4, 74.2, 70.2, 34.7, 
24.2, 21.5, 20.0, 19.4, 7.9; IR (neat) 3350, 2936, 1734, 1622, 1417, 1368, 1324, 1292, 
1248, 1177, 1142, 1104, 1021, 952 cm–1; HRMS (ESI-TOF) m/z calcd for C34H39O10 
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[M+H]+ 607.2543, found 607.2546 
 
(S)-7-(2-Formyl-3,5-dihydroxy-4-methylphenyl)hept-6-yn-2-yl acetate (2.20). 
Following the same procedure as 2.6 for 30 min using 2.8, the product was obtained as 
yellow oil (601 mg) in 85% yield after chromatography (CH2Cl2:EtOAc = 20:1): Rf = 0.68 
(CH2Cl2:EtOAc = 10:1); [α]D22 = +9.3 (c 1.85, CHCl3); 1H NMR (500 MHz, CDCl3)  12.25 
(s, 1H), 10.15 (s, 1H), 6.50 (s, 1H), 5.83 (s, 1H), 4.95-4.98 (m, 1H), 2.45 (t, J = 7.0 Hz, 
2H), 2.09 (s, 3H), 2.06 (s, 3H), 1.57-1.78 (m, 4H), 1.24 (d, J = 6.0 Hz, 3H); 13C NMR (125 
MHz, CDCl3)  195.1, 171.9, 163.1, 161.5, 127.0, 114.2, 112.5, 112.1, 96.2, 76.5, 71.0, 
35.1, 24.4, 21.5, 19.9, 19.4, 7.3; IR (neat) 3250, 2933, 1732, 1703, 1614, 1487, 1432, 
1368, 1305, 1248, 1174, 1139, 1107, 1080, 1046, 1023, 848 cm–1; HRMS (ESI-TOF) m/z 
calcd for C17H20O5Na [M+Na]+ 327.1208, found 327.1202 
 
(2S)-5-(7-Hydroxy-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-3-yl)pentan-2-yl 
acetate (2.21). An oven-dried round bottom flask was charged with 2.20 (445 mg, 1.46 
mmol) and Au(OAc)3 (27 mg, 0.07 mmol) or AgOTf (38 mg, 0.15 mmol). The mixture was 
dissolved in 1,2-dichloroethane (7.3 mL), followed by trifluoroacetic acid (0.73 mL). The 
resulting mixture was stirred for 15 min at rt and then, 2-iodoxybenzoic acid (1.23 g, 4.39 
mmol) and tetrabutylammonium iodide (27 mg, 0.07 mmol) were added. The mixture was 
stirred for 1.5 h and quenched with satd NaS2O3 (10 mL). The resultant mixture was 
extracted with EtOAc (10 mL X 3) and the combined organic layers were washed with 
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brine. The solution was dried over Na2SO4 and filtered. Removal of the solvent was 
followed by chromatography (Hex:EtOAc = 1:2) afforded red brown oil (379 mg) in 81 % 
yield: Rf = 0.44 (100 % EtOAc); 1H NMR (500 MHz, CDCl3)  7.85 (s, 1H), 6.10 (s, 1H), 
5.49 (s, 1H), 4.89-4.92 (m, 1H), 3.93 (br s, 1H), 2.39-2.43 (m, 2H), 2.01 (s, 3H), 1.54-1.68 
(m, 4H), 1.52 (s, 3H), 1.21 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  196.3, 195.8, 
170.7, 162.2, 152.9, 143.9, 115.9, 108.6, 105.3, 83.5, 70.1, 35.1, 32.9, 28.5, 22.5, 21.3, 
20.0; IR (neat) 3441, 2977, 2934, 1718, 1665, 1621, 1548, 1443, 1371, 1346, 1242, 1214, 
1169, 1133, 1077, 1047, 1020, 963, 907 cm–1; HRMS (ESI-TOF) m/z calcd for C17H21O6 
[M+H]+ 321.1338, found 321.1333 
 
(2S)-5-(7-Acetoxy-7-methyl-6,8-dioxo-7,8-dihydro-6H-isochromen-3-yl)pentan-2-yl 
acetate (2.22). Alcohol 2.21 was subject to the same procedure used for 2.10 for –78 ºC 
for 10 min with Et3N as the base. The product was obtained as a red brown oil (379 mg) 
in 89% yield after chromatography (Hex:EtOAc = 1:1): Rf = 0.43 (Hexane:EtOAc = 1:2); 
1H NMR (500 MHz, CDCl3)  7.82 (d, J = 1.0 Hz, 1H), 6.06 (s, 1H), 5.46 (d, J = 1.0 Hz, 
1H), 4.86-4.89 (m, 1H), 2.36-2.39 (m, 2H), 2.10 (s, 3H), 1.99 (s, 3H), 1.49-1.63 (m, 4H), 
1.47 (s, 3H), 1.18 (d, J = 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  193.2, 192.6, 170.6, 
169.9, 161.6, 153.8, 142.5, 115.2, 108.9, 106.9, 84.4, 70.0, 35.0, 32.7, 22.4, 22.2, 21.3, 
20.1, 19.9; IR (neat) 2940, 1716, 1669, 1634, 1592, 1553, 1446, 1370, 1343, 1308, 1243, 
1181, 1132, 1088, 1045, 1019, 975, 939 cm–1; HRMS (ESI-TOF) m/z calcd for C19H23O7 
[M+H]+ 363.1444, found 363.1463 
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(7S,7'S)-3,3'-Bis((S)-4-acetoxypentyl)-7,7'-dimethyl-6,6',8,8'-tetraoxo-7,7',8,8'-
tetrahydro-6H,6'H-[5,5'-biisochromene]-7,7'-diyl diacetate (2.23). To 2.6 (244 mg, 
0.40 mmol) and AgOTf (10 mg, 0.04 mmol) was added 1,2-dichloroethane (4 mL) and 
trifluoroacetic acid (0.2 mL) addition. The resulting mixture was stirred for 1.5 h at rt and 
then, 2-iodoxybenzoic acid (676 mg, 2.41 mmol) and tetrabutylammonium iodide (7.4 mg, 
0.02 mmol) were added. The mixture was stirred for additional 18 h, followed by quenching 
with satd NaS2O3 (8 mL). The resultant mixture was extracted with EtOAc (10 mL X 3) and 
the combined organic layers were washed with brine. The solution was dried over Na2SO4 
and filtered. Removal of the solvent followed by chromatography (Hex:EtOAc = 1:2 to 1:5) 
afforded one separable isomer and mixture of two isomers (1:1). Both fractions were 
contaminated with IBX waste. 
 Without further purification, the pure isomer (0.13 mmol) was dissolved in CH2Cl2 
(7 mL) and the mixture was cooled to –78 ºC. To the solution was added Ac2O (76 L, 
0.80 mmol), 4-(dimethylamino)pyridine (33 mg, 0.27 mmol), and Et3N (75 L, 0.54 mmol). 
After stirring 15 min, the solution was quenched with 1N HCl (2 mL) in an ice bath. The 
resulting mixture was extracted with CH2Cl2 (10 mL X 3) and the combined organic phases 
were washed with brine. The organic layer was dried over Na2SO4 and filtered. Removal 
of the solvent followed by chromatography (Hex:EtOAc = 1:1) gave the product as orange 
oil (64 mg) in 22% yield over three steps: Rf = 0.52 (Hexane:EtOAc = 1:2); [α]D22 = –11.5 
(c 0.24, CH2Cl2); 1H NMR (500 MHz, CDCl3)  7.92 (s, 2H), 5.95 (s, 2H), 4.84-4.90 (m, 
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2H), 2.35 (t, J = 7.0 Hz, 4H), 2.16 (s, 6H), 2.01 (s, 6H), 1.48-1.66 (m, 14H), 1.20 (d, J = 
6.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  193.5, 190.7, 170.8, 170.5, 162.4, 153.7, 141.9, 
115.6, 110.6, 107.8, 84.9, 70.4, 35.2, 33.2, 22.4, 22.3, 21.5, 20.4, 20.0; IR (neat) 2936, 
1730, 1715, 1631, 1582, 1528, 1431, 1371, 1335, 1244, 1131, 1087, 1022, 985, 936 cm–
1; HRMS (ESI-TOF) m/z calcd for C38H43O14 [M+H]+ 723.2653, found 723.2661 
 
(7S,7'S)-3,3'-bis((S)-4-hydroxypentyl)-7,7'-dimethyl-6,6',8,8'-tetraoxo-7,7',8,8'-
tetrahydro-6H,6'H-[5,5'-biisochromene]-7,7'-diyl diacetate (2.24). Compound 2.23 (24 
mg, 0.03 mmol) was dissolved in THF (0.66 mL) In a microwave vial under an argon 
atmosphere. Freshly distilled Ti(Oi-Pr)4 (0.10 mL, 0.33 mmol) added to the mixture and 
the vial was sealed. The resultant mixture was stirred at 50 ºC for 24 h. After cooling to 
ambient temperature, the reaction mixture was diluted with EtOAc (50 mL) and washed 
with satd Na2SO4 until the organic phase became clear. The combined aqueous layers 
were back-extracted with EtOAc (5 mL) and the organic layer was washed with brine. The 
solution was dried over MgSO4 and filtered. Removal of the solvent followed by 
chromatography (Hex:EtOAc = 1:5 to 100 % EtOAc) afforded yellow oil (11 mg) in 52% 
yield: Rf = 0.13 (Hexane:EtOAc = 1:2); [α]D22 = +14.3 (c 0.22, CH3OH); 1H NMR (500 MHz, 
CDCl3)  7.93 (s, 2H), 5.97 (s, 2H), 3.75-3.81 (m, 2H), 2.39 (t, J = 7.5 Hz, 4H), 2.17 (s, 
6H), 1.68-1.77 (m, 2H), 1.54-1.62 (m, 10H), 1.42-1.47 (m, 4H), 1.17 (d, J = 6.2 Hz, 6H); 
13C NMR (125 MHz, CDCl3)  193.4, 190.6, 170.9, 162.9, 153.9, 142.1, 115.6, 110.4, 
107.7, 85.2, 67.6, 38.2, 33.0, 23.5, 22.49, 22.47, 20.5; IR (neat) 3463, 2924, 1713, 1663, 
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1629, 1582, 1525, 1432, 1372, 1247, 1183, 1132, 1086, 986, 937, 875 cm–1; HRMS (ESI-
TOF) m/z calcd for C34H39O12 [M+H]+ 639.2442, found 639.2450 
 
Chaetoglobin A (2.1). Compound 2.24 (9.0 mg, 0.01 mmol) in CH2Cl2 (0.28 mL) was 
treated with NH4OAc (22 mg, 0.28 mmol) and stirred for 20 h at room temperature. 
Removal of the solvent followed by chromatography (CH2Cl2:MeOH = 9:1) afforded an 
orange red gum (8.6 mg) in 96% yield: Rf = 0.10 (CH2Cl2:CH3OH = 10:1); [α]D22 = +478.4 
(c 0.10, CH3OH); 1H NMR (500 MHz, CD3OD)  8.00 (s, 2H), 6.37 (s, 2H), 3.67-3.73 (m, 
2H), 2.45 (t, J = 7.5 Hz, 4H), 2.15 (s, 6H), 1.63-1.72 (m, 4H), 1.60 (s, 6H), 1.39-1.45 (m, 
4H), 1.12 (d, J = 6.2 Hz, 6H); 13C NMR (125 MHz, CD3OD)  198.0, 189.9, 172.0, 153.2, 
151.3, 139.7, 116.9, 116.1, 104.0, 86.0, 68.1, 39.2, 34.1, 25.5, 23.6, 23.4, 20.6; IR (neat) 
3383, 2928, 1732, 1692, 1643, 1547, 1465, 1373, 1248, 1206, 1130, 1081, 994 cm–1; 
HRMS (ESI-TOF) m/z calcd for C34H41N2O10 [M+H]+ 637.2761, found 637.2775 
 
X-ray Crystallographic Data for compound 2.19 
Table 1. Summary of Structure Determination of Compound 2.19 
Empirical formula  C60H50Br4O12  
Formula weight  1282.64  
Temperature/K  100  
Crystal system  orthorhombic  
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Space group  P21212  
a  25.002(2)Å  
b  7.8642(7)Å  
c  16.1018(14)Å  
Volume  3165.9(5)Å3  
Z  2  
dcalc  1.346 g/cm3  
μ  2.597 mm-1  
F(000)  1292.0  
Crystal size, mm  0.15 × 0.08 × 0.02  
2θ range for data collection      2.53 - 55.14°  
Index ranges  -18 ≤ h ≤ 32, -10 ≤ k ≤ 10, -20 ≤ l ≤ 20  
Reflections collected  47673  
Independent reflections  7260[R(int) = 0.0853]  
Data/restraints/parameters  7260/0/346  
Goodness-of-fit on F2  1.028  
Final R indexes [I>=2σ (I)]  R1 = 0.0835, wR2 = 0.2093  
Final R indexes [all data]  R1 = 0.1317, wR2 = 0.2316  
Largest diff. peak/hole  1.84/-0.62 eÅ-3  
Flack parameter 0.028(7) 
 
Table 2 . Refined Positional Parameters for Compound 2.19 
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Atom x y z U(eq) 
Br1 0.81867(5) 1.58691(16) 0.30710(9) 0.0682(5) 
Br2 0.57919(10) -0.16032(17) -0.11975(9) 0.1081(8) 
O1 0.3861(3) 0.3655(8) 0.6913(5) 0.0442(17) 
O2 0.4023(4) 0.6339(10) 0.7322(5) 0.058(2) 
O3 0.6287(3) 0.9713(7) 0.2937(4) 0.0348(15) 
O4 0.6625(3) 0.9073(12) 0.4189(5) 0.062(2) 
O5 0.5706(3) 0.4322(7) 0.1879(4) 0.0405(15) 
O6 0.5555(4) 0.6027(8) 0.0787(4) 0.057(2) 
C1 0.5190(4) 0.5739(10) 0.2920(5) 0.031(2) 
C2 0.5130(4) 0.7071(9) 0.3486(5) 0.0232(18) 
C3 0.5500(4) 0.8382(11) 0.3503(5) 0.030(2) 
C4 0.5927(4) 0.8329(10) 0.2981(6) 0.032(2) 
C5 0.6027(4) 0.7018(11) 0.2414(6) 0.033(2) 
C6 0.5631(4) 0.5749(10) 0.2413(5) 0.037(2) 
C7 0.4702(4) 0.7072(10) 0.4072(6) 0.0276(19) 
C8 0.4355(4) 0.7054(10) 0.4587(6) 0.033(2) 
C9 0.3936(4) 0.6984(13) 0.5244(6) 0.041(2) 
C10 0.3661(5) 0.5168(14) 0.5266(6) 0.045(3) 
C11 0.4043(4) 0.3754(11) 0.5446(6) 0.042(3) 
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C12 0.4293(4) 0.3709(11) 0.6279(7) 0.041(2) 
C13 0.4634(6) 0.2167(16) 0.6427(9) 0.067(4) 
C14 0.3772(5) 0.5022(16) 0.7372(7) 0.050(3) 
C15 0.3297(5) 0.4807(18) 0.7916(7) 0.061(3) 
C16 0.6627(4) 0.9970(11) 0.3604(6) 0.034(2) 
C17 0.6967(4) 1.1442(11) 0.3461(6) 0.034(2) 
C18 0.6988(5) 1.2367(13) 0.2741(7) 0.048(3) 
C19 0.7348(5) 1.3659(16) 0.2626(8) 0.058(3) 
C20 0.7689(5) 1.4088(15) 0.3253(8) 0.056(3) 
C21 0.7677(4) 1.3176(15) 0.3992(6) 0.046(3) 
C22 0.7337(4) 1.1902(14) 0.4102(6) 0.041(2) 
C23 0.6512(5) 0.7016(15) 0.1865(8) 0.060(3) 
C24 0.5636(5) 0.4653(10) 0.1066(6) 0.041(2) 
C25 0.5686(5) 0.3080(11) 0.0551(6) 0.045(3) 
C26 0.5706(6) 0.3281(13) -0.0313(7) 0.061(4) 
C27 0.5759(6) 0.1930(15) -0.0812(7) 0.070(4) 
C28 0.5745(7) 0.0300(15) -0.0465(7) 0.070(4) 
C29 0.5712(6) 0.0079(13) 0.0360(7) 0.057(3) 
C30 0.5691(6) 0.1438(13) 0.0875(6) 0.057(3) 
 
Table 3 . Positional Parameters for Hydrogens in Compound 2.19 
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Atom x y z U(eq) 
H3 0.545484 0.930904 0.387447 0.036 
H9a 0.366152 0.786339 0.513315 0.049 
H9b 0.409893 0.722789 0.579112 0.049 
H10a 0.337757 0.517092 0.56947 0.054 
H10b 0.348829 0.495295 0.472245 0.054 
H11a 0.385195 0.266543 0.53619 0.051 
H11b 0.433377 0.380336 0.502877 0.051 
H12 0.451255 0.475749 0.636085 0.049 
H13a 0.481798 0.227962 0.696168 0.101 
H13b 0.489972 0.206778 0.598138 0.101 
H13c 0.440845 0.114924 0.64338 0.101 
H15a 0.297994 0.526779 0.763677 0.091 
H15b 0.335448 0.541577 0.843949 0.091 
H15c 0.324196 0.359561 0.803082 0.091 
H18 0.674553 1.210241 0.230599 0.058 
H19 0.735914 1.425392 0.211309 0.07 
H21 0.791679 1.347056 0.442637 0.055 
H22 0.733787 1.129 0.461108 0.049 
H23a 0.654621 0.590391 0.159599 0.09 
H23b 0.683081 0.724149 0.220077 0.09 
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H23c 0.647431 0.790084 0.14407 0.09 
H26 0.568263 0.438737 -0.054676 0.073 
H27 0.58045 0.20766 -0.139347 0.085 
H29 0.570353 -0.103838 0.058458 0.069 
H30 0.567885 0.127161 0.145867 0.069 
 
Table 4 . Refined Thermal Parameters (U's) for Compound 2.19 
 
Atom U11 U22 U33 U23 U13 U12 
Br1 0.0683(8) 0.0432(6) 0.0932(10) -0.0002(7) -0.0194(7) -0.0234(6) 
Br2 0.226(2) 0.0378(7) 0.0607(9) -0.0248(6) 0.0131(12) 0.0185(10) 
O1 0.058(4) 0.026(3) 0.049(4) -0.005(3) 0.012(4) 0.003(3) 
O2 0.074(6) 0.039(5) 0.061(5) -0.013(4) 0.011(4) -0.003(4) 
O3 0.050(4) 0.020(3) 0.034(4) -0.001(3) -0.006(3) -0.012(3) 
O4 0.060(5) 0.070(5) 0.057(5) 0.026(5) -0.020(4) -0.017(4) 
O5 0.078(5) 0.011(3) 0.032(3) -0.003(2) 0.006(3) -0.003(3) 
O6 0.114(7) 0.017(3) 0.041(4) 0.005(3) 0.007(4) 0.006(4) 
C1 0.055(6) 0.006(3) 0.032(5) 0.000(3) 0.003(4) -0.003(4) 
C2 0.039(5) 0.009(3) 0.021(4) 0.008(3) -0.007(4) 0.002(3) 
C3 0.045(6) 0.016(4) 0.029(5) 0.000(3) -0.006(4) -0.003(4) 
C4 0.049(6) 0.015(4) 0.033(5) 0.005(4) -0.005(5) -0.011(4) 
C5 0.050(6) 0.019(4) 0.031(5) 0.001(3) 0.014(4) -0.002(4) 
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C6 0.074(7) 0.007(4) 0.029(5) -0.004(3) 0.003(5) -0.001(4) 
C7 0.038(5) 0.015(4) 0.030(5) 0.001(3) -0.004(4) -0.004(4) 
C8 0.056(6) 0.015(4) 0.029(5) 0.001(3) 0.008(5) -0.005(4) 
C9 0.041(6) 0.036(6) 0.045(6) 0.005(4) 0.002(5) -0.002(4) 
C10 0.050(7) 0.054(7) 0.032(5) 0.003(5) 0.007(5) -0.014(5) 
C11 0.061(7) 0.016(4) 0.050(6) -0.004(4) 0.015(5) -0.016(4) 
C12 0.043(6) 0.022(5) 0.057(6) -0.001(4) 0.014(5) -0.002(4) 
C13 0.079(9) 0.043(7) 0.079(9) -0.001(6) 0.016(7) 0.008(6) 
C14 0.054(7) 0.061(8) 0.035(6) 0.010(5) -0.007(5) 0.019(6) 
C15 0.063(8) 0.072(8) 0.047(7) 0.006(6) 0.026(6) 0.007(6) 
C16 0.048(6) 0.026(5) 0.029(5) 0.004(4) 0.000(4) 0.002(4) 
C17 0.032(5) 0.022(4) 0.049(6) -0.004(4) 0.001(4) 0.007(4) 
C18 0.068(8) 0.031(5) 0.046(6) 0.009(4) -0.018(5) -0.016(5) 
C19 0.071(8) 0.052(7) 0.051(7) 0.009(5) -0.019(6) -0.021(6) 
C20 0.051(7) 0.038(6) 0.078(9) -0.010(6) 0.001(6) 0.002(5) 
C21 0.048(7) 0.060(7) 0.029(5) -0.004(5) -0.009(5) -0.004(5) 
C22 0.033(6) 0.051(7) 0.038(5) -0.005(5) 0.002(5) 0.006(5) 
C23 0.079(9) 0.040(6) 0.060(7) -0.004(6) 0.030(7) -0.005(6) 
C24 0.069(7) 0.012(4) 0.041(6) 0.004(4) 0.002(5) -0.006(4) 
C25 0.073(8) 0.014(4) 0.047(6) -0.007(4) 0.012(5) 0.008(5) 
C26 0.110(11) 0.032(6) 0.042(6) 0.013(5) 0.019(7) 0.020(6) 
C27 0.130(12) 0.042(7) 0.040(6) 0.005(5) 0.020(7) -0.007(7) 
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C28 0.130(13) 0.038(6) 0.043(6) -0.019(5) 0.017(7) 0.025(7) 
C29 0.102(10) 0.019(5) 0.051(7) 0.002(4) 0.016(7) 0.005(6) 
C30 0.109(10) 0.037(6) 0.025(5) 0.004(4) 0.026(6) -0.007(6) 
 
Table 5 . Bond Distances in Compound 2.19, Å 
          
Br1-C20 1.896(12)   Br2-C28 1.909(10)   O1-C12 1.487(12) 
O1-C14 1.324(13)   O2-C14 1.213(14)   O3-C4 1.414(10) 
O3-C16 1.384(11)   O4-C16 1.177(11)   O5-C6 1.426(10) 
O5-C24 1.345(11)   O6-C24 1.188(11)   C1-C1 1.502(16) 
C1-C2 1.397(11)   C1-C6 1.371(13)   C2-C3 1.385(12) 
C2-C7 1.428(13)   C3-C4 1.360(13)   C4-C5 1.399(12) 
C5-C6 1.405(13)   C5-C23 1.500(15)   C7-C8 1.199(13) 
C8-C9 1.490(14)   C9-C10 1.585(14)   C10-C11 1.495(15) 
C11-C12 1.479(16)   C12-C13 1.502(15)   C14-C15 1.487(16) 
C16-C17 1.454(13)   C17-C18 1.369(14)   C17-C22 1.433(14) 
C18-C19 1.369(15)   C19-C20 1.364(17)   C20-C21 1.390(16) 
C21-C22 1.326(15)   C24-C25 1.495(12)   C25-C26 1.400(15) 
C25-C30 1.393(14)   C26-C27 1.338(16)   C27-C28 1.400(17) 
C28-C29 1.342(16)   C29-C30 1.353(14)       
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Table 6 . Bond Angles in Compound 2.19, ° 
          
C14-O1-C12 118.8(8)   C16-O3-C4 117.6(7)   C24-O5-C6 114.7(7) 
C2-C1-C1 120.8(8)   C6-C1-C1 120.9(8)   C6-C1-C2 118.1(8) 
C1-C2-C7 120.9(7)   C3-C2-C1 119.9(8)   C3-C2-C7 119.2(8) 
C4-C3-C2 119.4(8)   C3-C4-O3 120.5(8)   C3-C4-C5 124.4(8) 
C5-C4-O3 114.9(8)   C4-C5-C6 113.6(8)   C4-C5-C23 121.9(9) 
C6-C5-C23 124.5(9)   C1-C6-O5 117.4(8)   C1-C6-C5 124.7(8) 
C5-C6-O5 117.9(8)   C8-C7-C2 177.5(10)   C7-C8-C9 177.9(10) 
C8-C9-C10 110.7(8)   C11-C10-C9 113.4(9)   C12-C11-C10 117.6(8) 
O1-C12-C13 106.3(8)   C11-C12-O1 108.5(9)   C11-C12-C13 113.8(9) 
O1-C14-C15 111.7(11)   O2-C14-O1 124.8(10)   O2-C14-C15 123.3(12) 
O3-C16-C17 110.6(8)   O4-C16-O3 122.0(9)   O4-C16-C17 127.4(9) 
C18-C17-C16 125.5(9)   C18-C17-C22 116.8(9)   C22-C17-C16 117.6(9) 
C19-C18-C17 122.3(10)   C20-C19-C18 119.6(11)   C19-C20-Br1 118.6(10) 
C19-C20-C21 119.5(11)   C21-C20-Br1 121.9(9)   C22-C21-C20 121.2(10) 
C21-C22-C17 120.5(10)   O5-C24-C25 111.7(7)   O6-C24-O5 124.5(8) 
O6-C24-C25 123.8(9)   C26-C25-C24 117.5(8)   C30-C25-C24 124.0(9) 
C30-C25-C26 118.4(9)   C27-C26-C25 120.7(10)   C26-C27-C28 119.0(10) 
C27-C28-Br2 118.0(9)   C29-C28-Br2 120.9(9)   C29-C28-C27 121.0(10) 
C28-C29-C30 120.4(10)   C29-C30-C25 120.2(9)       
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X-ray Crystallographic Data for compound (P)-2.19 
 
Table 1. Summary of Structure Determination of Compound (P)-2.19 
 
Empirical formula  C60H50O12Br4  
Formula weight  1282.64  
Temperature/K  100  
Crystal system  orthorhombic  
Space group  P212121  
a  7.9305(4)Å  
b  24.3507(11)Å  
c  28.5067(13)Å  
Volume  5505.0(4)Å3  
Z  4  
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dcalc  1.548 g/cm3  
μ  2.987 mm-1  
F(000)  2584.0  
Crystal size, mm  0.49 × 0.13 × 0.13  
2θ range for data collection      2.2 - 55.132°  
Index ranges  -10 ≤ h ≤ 10, -31 ≤ k ≤ 31, -37 ≤ l ≤ 37  
Reflections collected  136749  
Independent reflections  12717[R(int) = 0.0454]  
Data/restraints/parameters  12717/0/691  
Goodness-of-fit on F2  1.112  
Final R indexes [I>=2σ (I)]  R1 = 0.0464, wR2 = 0.1120  
Final R indexes [all data]  R1 = 0.0511, wR2 = 0.1140  
Largest diff. peak/hole  1.56/-0.96 eÅ-3  
Flack parameter 0.012(3) 
 
Table 2 . Refined Positional Parameters for Compound (P)-2.19 
 
Atom x y z U(eq) 
Br1 1.23685(8) 0.44568(3) 0.05928(2) 0.02343(14) 
Br2 -0.52858(8) 0.21531(3) 0.38159(2) 0.02642(15) 
Br3 -0.19236(10) 0.61127(3) 0.06765(3) 0.03514(19) 
Br4 1.49398(8) 0.83407(3) 0.40537(2) 0.02286(14) 
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O1 0.7559(6) 0.6684(2) 0.47351(15) 0.0236(9) 
O2 1.0083(6) 0.69479(19) 0.44614(17) 0.0275(10) 
O3 0.6209(5) 0.44265(18) 0.22661(15) 0.0186(9) 
O4 0.4624(6) 0.4637(2) 0.16369(16) 0.0233(10) 
O5 0.0827(6) 0.3682(2) 0.27720(18) 0.0256(10) 
O6 0.2430(7) 0.3146(2) 0.3227(2) 0.0468(16) 
O7 0.2761(6) 0.34866(19) 0.47353(16) 0.0252(10) 
O8 0.0348(8) 0.3127(2) 0.4469(2) 0.0467(15) 
O9 0.4156(7) 0.5887(2) 0.23501(18) 0.0319(12) 
O10 0.5757(7) 0.5769(2) 0.1715(2) 0.0360(13) 
O11 0.9358(6) 0.66063(19) 0.30152(16) 0.0222(10) 
O12 0.7542(6) 0.7132(2) 0.3418(2) 0.0324(12) 
C1 0.4553(8) 0.4895(3) 0.2839(2) 0.0169(12) 
C2 0.4733(7) 0.4450(3) 0.2537(2) 0.0174(11) 
C3 0.3556(8) 0.4022(3) 0.2505(2) 0.0229(14) 
C4 0.2138(8) 0.4077(3) 0.2787(2) 0.0241(14) 
C5 0.1892(8) 0.4508(3) 0.3096(2) 0.0238(14) 
C6 0.3129(8) 0.4917(3) 0.3131(2) 0.0193(12) 
C7 0.2945(8) 0.5350(3) 0.3463(2) 0.0205(13) 
C8 0.2898(8) 0.5699(3) 0.3756(2) 0.0205(13) 
C9 0.2977(8) 0.6151(3) 0.4097(2) 0.0218(13) 
C10 0.4781(8) 0.6371(3) 0.4145(2) 0.0214(13) 
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C11 0.5912(8) 0.5969(3) 0.4412(2) 0.0225(13) 
C12 0.7689(8) 0.6171(3) 0.4476(2) 0.0220(13) 
C13 0.8804(9) 0.5774(3) 0.4734(3) 0.0337(17) 
C14 0.8835(8) 0.7049(3) 0.4681(2) 0.0205(13) 
C15 0.8453(9) 0.7583(3) 0.4922(3) 0.0284(15) 
C16 0.5984(8) 0.4551(2) 0.1804(2) 0.0192(13) 
C17 0.7592(8) 0.4549(2) 0.1532(2) 0.0172(12) 
C18 0.7500(8) 0.4657(3) 0.1061(2) 0.0193(12) 
C19 0.8918(8) 0.4648(3) 0.0783(2) 0.0199(13) 
C20 1.0451(7) 0.4518(2) 0.0991(2) 0.0168(11) 
C21 1.0615(8) 0.4424(3) 0.1464(2) 0.0214(13) 
C22 0.9162(8) 0.4440(3) 0.1739(2) 0.0203(13) 
C23 0.384(1) 0.3530(3) 0.2194(3) 0.0285(16) 
C24 0.1104(9) 0.3261(3) 0.3063(3) 0.0300(16) 
C25 -0.0518(9) 0.2953(3) 0.3173(3) 0.0297(16) 
C26 -0.0376(9) 0.2551(3) 0.3501(3) 0.0312(16) 
C27 -0.1800(9) 0.2301(3) 0.3683(3) 0.0290(15) 
C28 -0.3351(8) 0.2464(3) 0.3526(2) 0.0207(13) 
C29 -0.3529(9) 0.2860(3) 0.3186(3) 0.0304(16) 
C30 -0.2073(10) 0.3108(3) 0.3012(3) 0.0330(17) 
C31 0.5844(8) 0.5335(3) 0.2868(2) 0.0173(12) 
C32 0.5645(9) 0.5831(3) 0.2621(2) 0.0239(14) 
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C33 0.6759(9) 0.6267(3) 0.2661(2) 0.0243(14) 
C34 0.8112(8) 0.6194(3) 0.2963(2) 0.0190(12) 
C35 0.8382(8) 0.5718(3) 0.3216(2) 0.0182(12) 
C36 0.7215(7) 0.5289(2) 0.3176(2) 0.0164(12) 
C37 0.7384(8) 0.4810(2) 0.3469(2) 0.0192(12) 
C38 0.7415(8) 0.4425(3) 0.3725(2) 0.0250(13) 
C39 0.7325(10) 0.3945(3) 0.4047(3) 0.0340(16) 
C40 0.5511(10) 0.3744(3) 0.4111(3) 0.0320(16) 
C41 0.4366(9) 0.4168(3) 0.4342(3) 0.0302(15) 
C42 0.2621(9) 0.3960(3) 0.4420(2) 0.0265(14) 
C43 0.1462(10) 0.4383(3) 0.4629(3) 0.0344(17) 
C44 0.1594(9) 0.3094(3) 0.4703(2) 0.0267(15) 
C45 0.204(1) 0.2602(3) 0.5006(3) 0.0350(17) 
C46 0.4387(9) 0.5836(3) 0.1894(3) 0.0311(16) 
C47 0.2771(8) 0.5875(3) 0.1606(3) 0.0297(16) 
C48 0.2919(9) 0.5867(3) 0.1133(3) 0.0290(15) 
C49 0.1511(9) 0.5927(3) 0.0868(3) 0.0309(16) 
C50 -0.0045(8) 0.5998(3) 0.1081(2) 0.0206(12) 
C51 -0.0257(9) 0.5998(3) 0.1554(2) 0.0291(15) 
C52 0.1214(11) 0.5930(3) 0.1832(3) 0.0342(17) 
C53 0.6477(12) 0.6799(3) 0.2397(3) 0.041(2) 
C54 0.8936(8) 0.7046(3) 0.3286(2) 0.0223(14) 
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C55 1.0431(8) 0.7387(2) 0.3408(2) 0.0183(12) 
C56 1.0144(8) 0.7848(3) 0.3682(2) 0.0229(13) 
C57 1.1492(8) 0.8140(3) 0.3869(2) 0.0216(13) 
C58 1.3116(7) 0.7965(2) 0.3765(2) 0.0175(12) 
C59 1.3440(8) 0.7528(3) 0.3478(2) 0.0205(13) 
C60 1.2074(8) 0.7230(3) 0.3293(2) 0.0210(13) 
 
Table 3 . Positional Parameters for Hydrogens in Compound (P)-2.19 
  
Atom x y z U(eq) 
H5 0.092 0.4525 0.3278 0.032 
H9a 0.2585 0.6022 0.44 0.029 
H9b 0.2238 0.6446 0.3996 0.029 
H10a 0.5248 0.6435 0.3835 0.028 
H10b 0.4757 0.6719 0.431 0.028 
H11a 0.5422 0.59 0.4718 0.03 
H11b 0.594 0.5623 0.4243 0.03 
H12 0.8182 0.6246 0.4167 0.029 
H13a 0.8849 0.5433 0.4565 0.051 
H13b 0.8356 0.5711 0.5042 0.051 
H13c 0.9919 0.5925 0.4759 0.051 
H15a 0.9488 0.7773 0.4986 0.043 
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H15b 0.7873 0.7512 0.5211 0.043 
H15c 0.7755 0.7805 0.4722 0.043 
H18 0.6461 0.4738 0.0926 0.026 
H19 0.8852 0.4726 0.0464 0.026 
H21 1.1663 0.4352 0.1596 0.028 
H22 0.9233 0.4378 0.206 0.027 
H23a 0.3345 0.3597 0.1892 0.043 
H23b 0.3326 0.3213 0.2333 0.043 
H23c 0.5029 0.3468 0.2158 0.043 
H26 0.0686 0.2442 0.3604 0.041 
H27 -0.1704 0.2027 0.3909 0.039 
H29 -0.4589 0.2959 0.3075 0.04 
H30 -0.2159 0.3381 0.2785 0.044 
H35 0.9322 0.5683 0.3408 0.024 
H39a 0.7788 0.4046 0.4349 0.045 
H39b 0.8006 0.3648 0.3921 0.045 
H40a 0.505 0.3648 0.3807 0.043 
H40b 0.5521 0.3414 0.4301 0.043 
H41a 0.4849 0.4274 0.4641 0.04 
H41b 0.4317 0.4492 0.4145 0.04 
H42 0.2154 0.3837 0.412 0.035 
H43a 0.1287 0.4674 0.4406 0.052 
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H43b 0.1961 0.4531 0.4908 0.052 
H43c 0.04 0.4216 0.4704 0.052 
H45a 0.1781 0.227 0.4839 0.052 
H45b 0.1399 0.2614 0.5291 0.052 
H45c 0.3222 0.261 0.5078 0.052 
H48 0.3968 0.5822 0.0993 0.039 
H49 0.1589 0.592 0.0543 0.041 
H51 -0.1315 0.604 0.169 0.039 
H52 0.1145 0.5921 0.2158 0.045 
H53a 0.7364 0.685 0.2172 0.062 
H53b 0.6477 0.71 0.2615 0.062 
H53c 0.5412 0.6785 0.2238 0.062 
H56 0.9045 0.7962 0.374 0.03 
H57 1.1311 0.8445 0.4058 0.029 
H59 1.4544 0.7431 0.3406 0.027 
H60 1.2263 0.6931 0.3097 0.028 
 
Table 4 . Refined Thermal Parameters (U's) for Compound (P)-2.19 
 
Atom U11 U22 U33 U23 U13 U12 
Br1 0.0168(3) 0.0284(3) 0.0251(3) 0.0014(3) 0.0061(2) 0.0030(2) 
Br2 0.0226(3) 0.0298(3) 0.0269(3) -0.0007(3) 0.0052(3) -0.0114(3) 
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Br3 0.0371(4) 0.0336(4) 0.0347(4) -0.0031(3) -0.0171(3) 0.0107(3) 
Br4 0.0183(3) 0.0248(3) 0.0255(3) -0.0002(2) -0.0047(3) -0.0078(3) 
O1 0.018(2) 0.031(2) 0.022(2) -0.0094(19) 0.0004(18) 0.000(2) 
O2 0.020(2) 0.031(2) 0.032(2) -0.006(2) 0.006(2) 0.001(2) 
O3 0.014(2) 0.021(2) 0.021(2) -0.0017(18) 0.0015(17) -0.0018(17) 
O4 0.014(2) 0.034(3) 0.021(2) -0.0053(19) -0.0039(18) 0.0028(19) 
O5 0.017(2) 0.027(2) 0.032(3) 0.000(2) -0.0011(19) -0.0073(19) 
O6 0.019(3) 0.041(3) 0.080(4) 0.018(3) -0.005(3) -0.005(2) 
O7 0.027(3) 0.026(2) 0.024(2) 0.0030(18) -0.004(2) -0.002(2) 
O8 0.037(3) 0.043(3) 0.060(4) 0.015(3) -0.019(3) -0.015(3) 
O9 0.035(3) 0.032(3) 0.028(3) 0.007(2) -0.010(2) -0.012(2) 
O10 0.026(3) 0.044(3) 0.038(3) -0.005(3) -0.001(2) 0.001(2) 
O11 0.019(2) 0.022(2) 0.026(2) -0.0016(19) 0.0010(18) -0.0117(18) 
O12 0.014(2) 0.023(2) 0.060(3) -0.009(2) -0.002(2) -0.007(2) 
C1 0.013(3) 0.021(3) 0.016(3) 0.002(2) 0.000(2) -0.001(2) 
C2 0.011(2) 0.024(3) 0.018(3) 0.001(2) 0.003(2) -0.005(2) 
C3 0.023(3) 0.017(3) 0.028(3) -0.007(3) 0.004(3) -0.009(3) 
C4 0.018(3) 0.026(3) 0.029(3) -0.002(3) -0.001(3) -0.012(3) 
C5 0.015(3) 0.036(4) 0.020(3) -0.007(3) 0.004(2) -0.005(3) 
C6 0.015(3) 0.023(3) 0.020(3) -0.003(2) 0.003(2) -0.005(2) 
C7 0.014(3) 0.023(3) 0.025(3) 0.001(3) 0.002(2) -0.004(2) 
C8 0.014(3) 0.026(3) 0.022(3) -0.001(3) 0.004(2) 0.002(2) 
129 
 
C9 0.018(3) 0.024(3) 0.024(3) -0.011(3) 0.002(2) 0.003(2) 
C10 0.021(3) 0.022(3) 0.022(3) -0.009(2) -0.002(3) 0.000(3) 
C11 0.021(3) 0.026(3) 0.020(3) -0.002(3) 0.001(3) -0.004(3) 
C12 0.022(3) 0.024(3) 0.020(3) -0.001(2) 0.002(2) 0.002(3) 
C13 0.025(4) 0.037(4) 0.039(4) 0.008(3) 0.004(3) 0.005(3) 
C14 0.015(3) 0.029(3) 0.018(3) -0.003(3) -0.005(2) 0.003(2) 
C15 0.023(3) 0.032(4) 0.031(4) -0.013(3) -0.002(3) 0.004(3) 
C16 0.017(3) 0.013(3) 0.028(3) -0.005(2) -0.002(2) -0.003(2) 
C17 0.014(3) 0.016(3) 0.022(3) -0.007(2) 0.003(2) -0.002(2) 
C18 0.011(3) 0.023(3) 0.024(3) -0.003(2) -0.003(2) 0.000(2) 
C19 0.018(3) 0.020(3) 0.021(3) 0.003(2) -0.004(2) -0.003(2) 
C20 0.013(3) 0.016(3) 0.022(3) 0.000(2) 0.002(2) -0.001(2) 
C21 0.016(3) 0.023(3) 0.024(3) 0.000(3) -0.004(2) 0.001(2) 
C22 0.014(3) 0.031(3) 0.016(3) 0.001(3) -0.001(2) -0.004(3) 
C23 0.032(4) 0.021(3) 0.033(4) -0.012(3) 0.011(3) -0.012(3) 
C24 0.027(4) 0.027(4) 0.036(4) -0.008(3) -0.006(3) 0.009(3) 
C25 0.025(4) 0.018(3) 0.046(4) -0.008(3) 0.009(3) -0.008(3) 
C26 0.016(3) 0.027(4) 0.051(5) -0.006(3) 0.002(3) -0.001(3) 
C27 0.026(3) 0.024(3) 0.037(4) 0.002(3) 0.005(3) -0.002(3) 
C28 0.013(3) 0.018(3) 0.031(3) -0.002(3) 0.005(2) -0.009(2) 
C29 0.016(3) 0.039(4) 0.037(4) 0.013(3) -0.002(3) -0.004(3) 
C30 0.026(4) 0.034(4) 0.039(4) 0.012(3) 0.007(3) -0.005(3) 
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C31 0.017(3) 0.017(3) 0.018(3) -0.005(2) 0.001(2) -0.006(2) 
C32 0.025(3) 0.025(3) 0.022(3) 0.003(3) -0.007(3) -0.008(3) 
C33 0.030(4) 0.023(3) 0.020(3) 0.005(2) -0.010(3) -0.007(3) 
C34 0.015(3) 0.019(3) 0.023(3) -0.003(2) 0.002(2) -0.008(2) 
C35 0.013(3) 0.017(3) 0.024(3) -0.002(2) 0.000(2) 0.001(2) 
C36 0.011(3) 0.018(3) 0.021(3) -0.003(2) -0.002(2) 0.000(2) 
C37 0.011(3) 0.015(3) 0.031(3) 0.000(2) 0.001(3) -0.005(2) 
C38 0.012(3) 0.025(3) 0.038(4) 0.002(3) -0.006(3) 0.002(3) 
C39 0.030(4) 0.024(3) 0.048(4) 0.013(3) -0.008(3) 0.005(3) 
C40 0.032(4) 0.019(3) 0.044(4) 0.011(3) 0.002(3) 0.000(3) 
C41 0.035(4) 0.025(3) 0.031(4) 0.007(3) -0.005(3) -0.002(3) 
C42 0.027(3) 0.022(3) 0.031(3) -0.004(3) -0.008(3) 0.001(3) 
C43 0.032(4) 0.035(4) 0.037(4) -0.007(3) -0.007(3) 0.006(3) 
C44 0.027(4) 0.027(4) 0.026(3) 0.001(3) 0.006(3) 0.003(3) 
C45 0.034(4) 0.027(4) 0.044(4) 0.006(3) 0.003(4) -0.002(3) 
C46 0.026(4) 0.023(3) 0.044(4) -0.004(3) 0.005(3) 0.000(3) 
C47 0.016(3) 0.019(3) 0.054(5) 0.005(3) -0.005(3) -0.001(3) 
C48 0.021(3) 0.026(3) 0.040(4) -0.003(3) 0.002(3) -0.002(3) 
C49 0.027(4) 0.024(3) 0.042(4) -0.006(3) 0.003(3) -0.002(3) 
C50 0.012(3) 0.024(3) 0.026(3) 0.004(2) -0.009(2) 0.002(2) 
C51 0.020(3) 0.041(4) 0.026(3) 0.001(3) -0.002(3) -0.009(3) 
C52 0.046(5) 0.033(4) 0.023(4) 0.006(3) -0.003(3) -0.005(3) 
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C53 0.050(5) 0.031(4) 0.043(5) 0.016(3) -0.025(4) -0.020(4) 
C54 0.018(3) 0.018(3) 0.030(4) 0.003(3) -0.004(3) -0.006(2) 
C55 0.016(3) 0.015(3) 0.024(3) 0.005(2) -0.005(2) -0.003(2) 
C56 0.015(3) 0.019(3) 0.035(3) -0.002(3) -0.002(3) -0.001(3) 
C57 0.019(3) 0.012(3) 0.033(4) -0.003(3) 0.002(3) 0.000(2) 
C58 0.013(3) 0.019(3) 0.021(3) 0.003(2) -0.002(2) -0.007(2) 
C59 0.011(3) 0.023(3) 0.028(3) 0.003(3) 0.002(2) -0.006(2) 
C60 0.021(3) 0.019(3) 0.023(3) -0.001(2) -0.001(2) -0.006(3) 
 
Table 5 . Bond Distances in Compound (P)-2.19, Å 
          
Br1-C20 1.904(6)   Br2-C28 1.900(6)   Br3-C50 1.904(6) 
Br4-C58 1.900(6)   O1-C12 1.456(8)   O1-C14 1.354(8) 
O2-C14 1.196(8)   O3-C2 1.404(7)   O3-C16 1.363(8) 
O4-C16 1.198(8)   O5-C4 1.418(7)   O5-C24 1.337(9) 
O6-C24 1.184(9)   O7-C42 1.465(8)   O7-C44 1.334(9) 
O8-C44 1.195(9)   O9-C32 1.417(8)   O9-C46 1.318(10) 
O10-C46 1.212(9)   O11-C34 1.417(7)   O11-C54 1.360(8) 
O12-C54 1.187(9)   C1-C2 1.389(9)   C1-C6 1.405(8) 
C1-C31 1.484(8)   C2-C3 1.403(8)   C3-C4 1.390(9) 
C3-C23 1.506(9)   C4-C5 1.382(9)   C5-C6 1.402(9) 
C6-C7 1.426(9)   C7-C8 1.190(9)   C8-C9 1.471(8) 
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C9-C10 1.533(9)   C10-C11 1.530(9)   C11-C12 1.504(9) 
C12-C13 1.501(9)   C14-C15 1.502(9)   C16-C17 1.492(8) 
C17-C18 1.371(9)   C17-C22 1.403(8)   C18-C19 1.375(9) 
C19-C20 1.389(8)   C20-C21 1.373(9)   C21-C22 1.395(9) 
C24-C25 1.522(10)   C25-C26 1.358(11)   C25-C30 1.369(11) 
C26-C27 1.383(10)   C27-C28 1.367(10)   C28-C29 1.373(10) 
C29-C30 1.395(10)   C31-C32 1.408(9)   C31-C36 1.402(9) 
C32-C33 1.386(9)   C33-C34 1.389(9)   C33-C53 1.513(10) 
C34-C35 1.380(9)   C35-C36 1.401(8)   C36-C37 1.440(9) 
C37-C38 1.188(9)   C38-C39 1.488(9)   C39-C40 1.530(10) 
C40-C41 1.524(10)   C41-C42 1.491(10)   C42-C43 1.504(10) 
C44-C45 1.518(10)   C46-C47 1.525(10)   C47-C48 1.353(11) 
C47-C52 1.399(11)   C48-C49 1.357(10)   C49-C50 1.386(10) 
C50-C51 1.360(9)   C51-C52 1.420(11)   C54-C55 1.490(8) 
C55-C56 1.384(9)   C55-C60 1.398(9)   C56-C57 1.391(9) 
C57-C58 1.388(9)   C58-C59 1.365(9)   C59-C60 1.408(9) 
 
Table 6 . Bond Angles in Compound (P)-2.19, ° 
          
C14-O1-C12 116.8(5)   C16-O3-C2 114.4(5)   C24-O5-C4 112.5(5) 
C44-O7-C42 118.0(5)   C46-O9-C32 114.3(6)   C54-O11-C34 116.4(5) 
C2-C1-C6 118.6(6)   C2-C1-C31 121.8(5)   C6-C1-C31 119.6(6) 
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C1-C2-O3 117.3(5)   C1-C2-C3 123.5(6)   C3-C2-O3 119.1(5) 
C2-C3-C23 122.1(6)   C4-C3-C2 115.3(6)   C4-C3-C23 122.6(6) 
C3-C4-O5 120.7(6)   C5-C4-O5 115.5(6)   C5-C4-C3 123.8(6) 
C4-C5-C6 119.1(6)   C1-C6-C7 120.3(6)   C5-C6-C1 119.6(6) 
C5-C6-C7 120.1(6)   C8-C7-C6 175.2(7)   C7-C8-C9 174.7(7) 
C8-C9-C10 111.1(5)   C11-C10-C9 111.6(5)   C12-C11-C10 113.7(5) 
O1-C12-C11 106.0(5)   O1-C12-C13 110.2(6)   C13-C12-C11 113.7(6) 
O1-C14-C15 111.4(5)   O2-C14-O1 122.9(6)   O2-C14-C15 125.7(6) 
O3-C16-C17 112.9(5)   O4-C16-O3 122.8(6)   O4-C16-C17 124.3(6) 
C18-C17-C16 117.6(6)   C18-C17-C22 119.7(6)   C22-C17-C16 122.7(5) 
C17-C18-C19 121.2(6)   C18-C19-C20 118.2(6)   C19-C20-Br1 117.5(5) 
C21-C20-Br1 119.8(5)   C21-C20-C19 122.7(6)   C20-C21-C22 118.0(6) 
C21-C22-C17 120.1(6)   O5-C24-C25 111.6(6)   O6-C24-O5 124.8(7) 
O6-C24-C25 123.6(7)   C26-C25-C24 115.3(7)   C26-C25-C30 120.3(7) 
C30-C25-C24 123.8(7)   C25-C26-C27 120.5(7)   C28-C27-C26 119.0(7) 
C27-C28-Br2 117.9(5)   C27-C28-C29 121.8(6)   C29-C28-Br2 120.2(5) 
C28-C29-C30 118.0(6)   C25-C30-C29 120.4(7)   C32-C31-C1 120.9(6) 
C36-C31-C1 120.8(6)   C36-C31-C32 118.0(6)   C31-C32-O9 116.6(6) 
C33-C32-O9 120.2(6)   C33-C32-C31 123.0(6)   C32-C33-C34 116.4(6) 
C32-C33-C53 121.4(6)   C34-C33-C53 122.1(6)   C33-C34-O11 120.8(6) 
C35-C34-O11 115.6(6)   C35-C34-C33 123.5(6)   C34-C35-C36 118.9(6) 
C31-C36-C37 120.0(5)   C35-C36-C31 120.1(6)   C35-C36-C37 119.8(5) 
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C38-C37-C36 175.2(7)   C37-C38-C39 176.1(7)   C38-C39-C40 111.7(6) 
C41-C40-C39 113.3(6)   C42-C41-C40 112.8(6)   O7-C42-C41 106.8(5) 
O7-C42-C43 110.1(6)   C41-C42-C43 113.1(6)   O7-C44-C45 111.4(6) 
O8-C44-O7 124.3(7)   O8-C44-C45 124.3(7)   O9-C46-C47 114.1(6) 
O10-C46-O9 123.6(7)   O10-C46-C47 122.3(7)   C48-C47-C46 117.6(7) 
C48-C47-C52 122.5(7)   C52-C47-C46 120.0(7)   C47-C48-C49 118.8(7) 
C48-C49-C50 120.1(7)   C49-C50-Br3 116.7(5)   C51-C50-Br3 120.3(5) 
C51-C50-C49 123.0(6)   C50-C51-C52 116.9(7)   C47-C52-C51 118.6(7) 
O11-C54-C55 112.1(5)   O12-C54-O11 123.2(6)   O12-C54-C55 124.6(6) 
C56-C55-C54 117.0(6)   C56-C55-C60 120.5(6)   C60-C55-C54 122.2(6) 
C55-C56-C57 120.3(6)   C58-C57-C56 118.3(6)   C57-C58-Br4 117.8(5) 
C59-C58-Br4 119.4(5)   C59-C58-C57 122.8(6)   C58-C59-C60 118.8(6) 
C55-C60-C59 119.2(6)            
 
Table 2.S1. Selective Acetyl Deprotection 
 
entry substrate condition yield (%) 
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1 2.22 KCN, EtOH, rt, 1.5 h decomposition 
2 2.22 I2, MeOH, 20 min 2.S3 
3 2.22 BF3•Et2O, CH3CN, 50 ºC, 2 d decomposition 
4 2.22 Sc(OTf)3, MeOH/H2O, 50 ºC, 2 d decomposition
 
5 2.22 AcCl, MeOH, rt, 1 h 17 
6 2.22 K2CO3, MeOH, rt, 19 h 29 
7 2.22 Lipase PS, toluene, n-BuOH, 80 ºC, 5 d 34 
8 2.22 Bu4NOH, MeOH, rt, 10 h 54 
9 2.22 Ti(Oi-Pr)4, THF, 50 ºC, 1 d 44 
10 2.23 AcCl, MeOH, rt, 2 d 18 
11 2.23 K2CO3, MeOH, rt, 12 h 8~44
a 
12 2.23 Sm, I2, MeOH, rt, 3.5 h 19 
13 2.23 Lipase PS, toluene, n-BuOH, 100 ºC, 5 d N/Rb 
14 2.23 Bu4NOH, MeOH, rt, 2.5 h 30 
15 2.23 Ti(Oi-Pr)4, THF, 50 ºC, 1 d 52 
aReproducibility issue bSubstrate decomposition occurred. 
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CHAPTER 3: LIGAND EVOLUTION TO DRIVE REACTION DISCOVERY 
3.1. Introduction 
 Addressing unsolved challenges in organometallic chemistry, such as selective 
Heck coupling of complex substrates,1 selective cross coupling of dihalides,2 and hindered 
C–N bond formation,3 is an important aspect of academic research and industrial 
development. Promoting these types of reactivity requires the design and rapid synthesis 
of ligand scaffolds possessing diverse physical properties. The goal of this research is to 
develop a platform for the synthesis, characterization, and purification of novel phosphine 
ligands in parallel, thus creating large ligand libraries to expand the current ligand 
landscape. Microscale parallel ligand synthesis, paired with High–Throughput 
Experimentation, will be valuable in expediting reaction discovery or resolving challenging 
issues via exploring new chemical reactivity. 
                                                     
1 Beletskaya, I. P.; Cheprakov, A. V. The Heck Reaction as a Sharpening Stone of Palladium 
Catalysis. Chem. Rev. 2000, 100 (8), 3009–3066. 
2 (a) Strotman, N. A.; Chobanian, H. R.; He, J.; Guo, Y.; Dormer, P. G.; Jones, C. M.; Steves, J. E. 
Catalyst-Controlled Regioselective Suzuki Couplings at Both Positions of Dihaloimidazoles, 
Dihalooxazoles, and Dihalothiazoles. J. Org. Chem. 2010, 75 (5), 1733–1739. (b) Rossi, R.; Bellina, 
F.; Lessi, M. Highly Selective Palladium-Catalyzed Suzuki–Miyaura Monocoupling Reactions of 
Ethene and Arene Derivatives Bearing Two or More Electrophilic Sites. Tetrahedron 2011, 67 (37), 
6969–7025. (c) Dai, X.; Chen, Y.; Garrell, S.; Liu, H.; Zhang, L.-K.; Palani, A.; Hughes, G.; Nargund, 
R. Ligand-Dependent Site-Selective Suzuki Cross-Coupling of 3,5-Dichloropyridazines. J. Org. 
Chem. 2013, 78 (15), 7758–7763. (d) Manabe, K.; Yamaguchi, M. ChemInform Abstract: Catalyst-
Controlled Site-Selectivity Switching in Pd-Catalyzed Cross-Coupling of Dihaloarenes. Catalysts 
2014, 4, 307–320. 
3 Qiao, J. X.; Lam, P. Y. S. Copper-Promoted Carbon-Heteroatom Bond Cross-Coupling with 
Boronic Acids and Derivatives. Synthesis 2011, 2011 (6), 829–856. 
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Figure 3.1. Ligand Evolution to Drive Reaction Discovery 
 
3.2. Significance of Triazole-based Monophosphine Ligand 
 
Scheme 3.1. Utility of ClickPhos Ligands in Suzuki-Miyaura Coupling and Amination Reaction 
 
 One of the most widely-employed methods for C-C bond formation is the Suzuki-
Miyaura coupling reaction.4 Utilizing aryl chlorides in this reaction is especially 
advantageous due to the reduced cost and greater diversity of available compounds.5 Fu6 
and Buchwald7 reported that electron–rich and sterically hindered phosphine ligands, such 
                                                     
4 Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron 
Compounds. Chem. Rev. 1995, 95, 2457–2483. 
5 Littke, A. F.; Fu, G. C. Palladium-Catalyzed Coupling Reactions of Aryl Chlorides. Angew. Chem. 
Int. Ed. 2002, 41, 4176–4211. 
6 Littke, A. F.; Dai, C.; Fu, G. C. Versatile Catalysts for the Suzuki Cross-Coupling of Arylboronic 
Acids with Aryl and Vinyl Halides and Triflates under Mild Conditions. J. Am. Chem. Soc. 2000, 
122, 4020–4028. 
7 Yin, J.; Rainka, M. P.; Zhang, X.-X.; Buchwald, S. L. A Highly Active Suzuki Catalyst for the 
Synthesis of Sterically Hindered Biaryls: Novel Ligand Coordination. J. Am. Chem. Soc. 2002, 124, 
1162–1163. 
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as t-Bu3P and dialkylbisphenylphosphine, are effective for this type of transformation. 
Recently, Zhang demonstrated that triazole-based monophosphines are promising 
candidates for palladium-catalyzed C(sp2)–C(sp2) bond formation and the amination with 
aryl chlorides (Scheme 3.1).8 The triazole moiety not only supports the production of 
numerous analogs but also features diverse physical properties (Figure 3.2). For 
example, triazole contains an acidic site (pKa of triazole ~9.2)9 and supports a diverse 
array of steric, electronic, and hemilabile environments. Inspired by the untapped 
structural diversity possible with the triazole scaffolds, we decided to develop a triazole-
based monophosphine ligand library through [3+2]-cycloaddition between 
alkynylphosphine oxides and azides. Subsequent reduction of the resultant phosphine 
oxides in the same reaction flask provides a protocol that can be implemented in a parallel 
manner. 
 
Figure 3.2. Diversity of ClickPhos Ligand Physical Properties 
 
3.3. Previous Approaches to Prepare Triazole Moiety and ClickPhos Ligand 
                                                     
8 (a) Liu, D.; Gao, W.; Dai, Q.; Zhang, X. Triazole-Based Monophosphines for Suzuki−Miyaura 
Coupling and Amination Reactions of Aryl Chlorides. Org. Lett. 2005, 7, 4907–4910. (b) Dai, Q.; 
Gao, W.; Liu, D.; Kapes, L. M.; Zhang, X. Triazole-Based Monophosphine Ligands for Palladium-
Catalyzed Cross-Coupling Reactions of Aryl Chlorides. J. Org. Chem. 2006, 71, 3928–3934. (c) 
Spinella, S.; Guan, Z.-H.; Chen, J.; Zhang, X. Suzuki Coupling of Heteroaromatic Chlorides Using 
Highly Electron-Donating ClickPhos Ligands. Synthesis 2009, 2009 (18), 3094–3098. 
9 Tanaka, Y.; Velen, S. R.; Miller, S. I. Syntheses and Properties of H-1,2,3-Triazoles. Tetrahedron 
1973, 29, 3271–3283. 
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Scheme 3.2. Regioselective [3+2]-Cycloaddition 
 
 Over the last two decades, the 1,3-dipolar cycloaddition reaction between organic 
azides and alkynes, known as Huisgen’s dipolar cycloaddition,10 has been explored 
extensively with and without metal catalysts.11 Thermal Huisgen cycloaddition reactions 
afford a mixture of 1,4- and 1,5-disubstituted 1,2,3-triazole products (1:1). In 2002, 
Sharpless and coworkers reported that a Cu-catalyzed azide-alkyne cycloaddition 
(CuAAC) with terminal alkynes permits access to 1,4-disubstituted-1,2,3-triazole 
selectively (Scheme 3.2.A).12 Alternatively, the Sharpless group also utilized Mg-acetylide 
to form 1,4,5-trisubstituted-1,2,3-triazoles preferentially by quenching with a variety of 
electrophiles (Scheme 3.3.A).13 On the other hand, Fokin and Jia achieved inverted 
                                                     
10 Huisgen, R. 1.3-Dipolare Cycloadditionen Rückschau und Ausblick. Angew. Chem. 1963, 75, 
604–637. 
11 (a) Spiteri, C.; Moses, J. E. Copper-Catalyzed Azide–Alkyne Cycloaddition: Regioselective 
Synthesis of 1,4,5-Trisubstituted 1,2,3-Triazoles. Angew. Chem. Int. Ed. 2010, 49, 31–33. (b) 
Schulze, B.; Schubert, U. S. Beyond Click Chemistry – Supramolecular Interactions of 1,2,3-
Triazoles. Chem. Soc. Rev. 2014, 43, 2522. (c) Johansson, J. R.; Beke-Somfai, T.; Said 
Stålsmeden, A.; Kann, N. Ruthenium-Catalyzed Azide Alkyne Cycloaddition Reaction: Scope, 
Mechanism, and Applications. Chem. Rev. 2016, 116, 14726–14768. 
12 Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise Huisgen Cycloaddition 
Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes. Angew. 
Chem. Int. Ed. 2002, 41, 2596–2599. 
13 Krasiński, A.; Fokin, V. V.; Sharpless, K. B. Direct Synthesis of 1,5-Disubstituted-4-Magnesio-
1,2,3-Triazoles, Revisited. Org. Lett. 2004, 6, 1237–1240. 
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regioselectivity compared to CuAAC with terminal alkynes by means of a Ru-catalyzed 
azide-alkyne cycloaddition (RuAAC) to produce another regioisomer, 1,5-disubstituted-
1,2,3-triazole (Scheme 3.2.B).14 Furthermore, RuAAC afforded the cycloaddition product 
not only with terminal alkynes, but also with internal alkynes to generate the 1,4,5-
trisubstituted-1,2,3-triazole moiety (Scheme 3.3.B).14,15 
 
Scheme 3.3. Syntheses of 1,4,5-Trisubstituted-1,2,3-triazole 
 
 Owing to their ease of purification,16 Zhang’s ClickPhos ligands were synthesized 
in a two-step sequence; (1) [3+2]-cycloaddition between azide and Mg-acetylide to yield 
1,5-disubstituted triazole after quenching with NH4Cl, then (2) treatment with LDA followed 
by addition of chlorophosphine to generate the triazole-based monophosphine ligand 
(Scheme 3.4).8 
                                                     
14 Zhang, L.; Chen, X.; Xue, P.; Sun, H. H. Y.; Williams, I. D.; Sharpless, K. B.; Fokin, V. V.; Jia, G. 
Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides. J. Am. Chem. Soc. 2005, 127, 
15998–15999. 
15 (a) Majireck, M. M.; Weinreb, S. M. A Study of the Scope and Regioselectivity of the 
Ruthenium-Catalyzed [3 + 2]-Cycloaddition of Azides with Internal Alkynes. J. Org. Chem. 2006, 
71 (22), 8680–8683. (b) Boren, B. C.; Narayan, S.; Rasmussen, L. K.; Zhang, L.; Zhao, H.; Lin, 
Z.; Jia, G.; Fokin, V. V. Ruthenium-Catalyzed Azide−Alkyne Cycloaddition: Scope and 
Mechanism. J. Am. Chem. Soc. 2008, 130 (28), 8923–8930. 
16 One pot synthesis was capable by means of directly quenching with chlorophosphine. 
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Scheme 3.4. Zhang’s Approach to the Synthesis of ClickPhos 
 
3.4. Preparation of Alkynylphosphine Oxides and Azides 
 To build the 1,2,3-triazole monophosphine scaffold, we designed a route that 
utilizes alkynylphosphine oxides and azides. The advantages of this route include the 
ability to generate both isomeric adducts and to synthesize many triazole phosphines 
easily by simply combining different substrates. Both substrates are simple to prepare 
from commericial sources– the alkynylphosphine oxides were synthesized in a linear 
sequence of 3–5 steps from commercially available aldehydes or alkynes (Scheme 3.5.A) 
and azides were prepared in ≤2 steps from either corresponding bromides or anilines 
(Scheme 3.5.B).  
 
Scheme 3.5. Preparation of Alkynylphosphine Oxides and Azides 
 
 The Corey-Fuchs alkyne synthesis has been utilized to generate terminal alkynes 
from aldehydes. In the presence of PPh3 and CBr4, a one-carbon homolyzed dibromide 
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alkene intermediate was generated. Subsequent treatment of the dibromide with two 
equivalents of n-butyllithium afforded the corresoponding terminal alkyne. To prepare the 
phosphine oxide, a substitution reaction was conducted by alkyne deprotonation with n-
butyllihium, followed by treatment with chloro dialkyl phosphines to make 
alkynylphosphine oxides in one-pot after quenching with H2O2 (Scheme 3.5.A).  
 Various organic azides were synthesized within 2 steps. Benzyl (3.4a)17 and octyl 
azides (3.4b)18 were prepared directly from their corresponding bromides by means of an 
SN2 reaction. Aromatic azides (3.4c–d) were prepared via diazotization and sequential 
nucleophilic aromatic substitution reaction in one pot (Scheme 3.5.B).19 
                                                     
17 Daskalaki, E.; Le Droumaguet, B.; Gérard, D.; Velonia, K. Multifunctional Giant Amphiphiles via 
Simultaneous Copper(I)-Catalyzed Azide–Alkynecycloaddition and Living Radical Polymerization. 
Chem Commun 2012, 48 (10), 1586–1588. 
18 Ngai, M. H.; Yang, P.-Y.; Liu, K.; Shen, Y.; Wenk, M. R.; Yao, S. Q.; Lear, M. J. Click-Based 
Synthesis and Proteomic Profiling of Lipstatin Analogues. Chem. Commun. 2010, 46 (44), 8335. 
19 Hu, M.; Li, J.; Q. Yao, S. In Situ “Click” Assembly of Small Molecule Matrix Metalloprotease 
Inhibitors Containing Zinc-Chelating Groups. Org. Lett. 2008, 10 (24), 5529–5531. 
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3.5. [3+2]-Cycloaddition Reaction 
 
Entry R R’ Solvent T (C) Time Conversiona 
1 i-Pr (3.3a) Bn (3.4a) toluene 110 3 d 94% 
2 i-Pr (3.3a) Bn (3.4a) toluene 150 3 d 100% 
3b i-Pr (3.3a) 4-OMeC6H4 (3.4c) toluene 110 5 d 50% 
4b i-Pr (3.3a) 4-FC6H4 (3.4d) toluene 110 5 d 75% 
5c i-Pr (3.3a) 4-OMeC6H4 (3.4c) toluene 110 10 min N/R 
6b,c i-Pr (3.3a) 4-OMeC6H4 (3.4c) toluene 150 30 min trace 
7b,c i-Pr (3.3a) 4-OMeC6H4 (3.4c) DMF 110 30 min N/R 
8b,c i-Pr (3.3a) 4-OMeC6H4 (3.4c) NMP 110 30 min N/R 
9d i-Pr (3.3a) 4-OMeC6H4 (3.4c) toluene 110 3 d 95% 
aDetermined by 1H NMR.bAzide decomposition was observed.cReaction was carried out in 
microwave reactor.dAdditional 2 equiv of azide added after 1 d. 
 
Table 3.1. [3+2]-Cycloaddition Optimization 
 
 To obtain as many triazole phosphine ligands as possible, the cycloaddition 
reaction was conducted under thermal conditions, which yields both isomeric 
cycloadducts. Attempts to optimize the thermal [3+2]-cycloaddition are shown in Table 
3.1. Increased temperature was necessary to achieve full conversion with benzyl azide 
3.4a (entry 1 vs 2). Thermal cycloaddition with aryl azides, however, gave lower 
conversion even after the prolonged reaction time (entry 3,4). In addition, thermal 
decomposition of both azides was detected during the course of the reaction. Use of a 
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microwave reactor neither improved the reactivity nor resolved the observed 
decomposition (entry 5–8). Addition of a second portion of azide after one day eventually 
enabled access to triazole phosphine oxides in good conversion and yield (entry 9). 
 
Figure 3.3. Regioisomer Characterization by X-ray Crystal Structures20 
 
 To verify the structure of both regioisomers, Dr. Rosaura Padilla–Salinas 
performed crystallographic analysis on several triazole phosphine oxides (Figure 3.3). 
Based on this analysis, the less polar compound (on TLC) was found to be the phosphine 
oxide at the C-5 position (Figure 3.3.A). In terms of the phosphine NMR shifts, the 
relationship between the regioisomers varies, depending on the azide source. With a C-1 
benzyl substituent, the shift in the 31P NMR of isomer A is more downfield than that of the 
other isomer B. With an octyl substituent at C-1, however, the opposite relationship is 
observed in the phosphine NMR shifts (Figure 3.3). 
3.6. Scope of Triazole Phosphine Oxides 
 With optimized conditions in hand for the synthesis of triazole phosphine oxides, 
                                                     
20 Dr. Rosaura Padilla–Salinas conducted X-ray crystallographic structure determinations. 
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the substrate scope of the cycloaddition was investigated first with alkyl azides (Table 
3.2). Use of phenylalkynylphosphine oxide (3.3a) with benzyl azide (3.4a) produced 
triazole-based phosphine oxides in good yield (Table 3.2, 87%). ortho-Substituted 
arylalkynylphosphine oxides (3.3b–c) were also used to produce the cyclized products in 
good yield. In addition, 2,6-dimethoxyphenylalkynylphosphine oxide (3.3d) generated the 
corresponding electron-rich heterocycles in excellent yield (91%). The expected product 
ratio between regioisomers was observed in most cases (~1:1). Interestingly, 2,6-
dimethoxyphenyl–substituted alkynylphosphine oxide (3.3d) resulted in some preferential 
formation of phosphine oxide substituted at the C-4 position (3.6i). Compared to benzyl 
azide (3.4a), the reaction with octyl azide (3.4b) required prolonged reaction times (5 days).  
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               aReaction conducted for 5 d. 
Table 3.2. Scope of [3+2]-Cycloaddition with Alkyl Azides 
 
 Given success in the cycloaddition with alkyl azides, triazole synthesis using aryl 
azides was explored (Table 3.3). 4-Methoxyphenyl azide (3.4c) afforded 1,4,5-
trisubstituted triazoles in good yield (58–84%). Notably, significant regioselectivity was 
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detected when an electron-donating aryl azide (3.4c) was employed, implicating that the 
azide electronics play a key role to induce the regioselectivity (3.5k–o:3.6k–o = ~1:10). 
Electron-withdrawing aryl azides (3.4d) were also treated with a variety of 
alkynylphosphine oxides to yield the corresponding triazole phosphine oxides in yields of 
42–77% (Table 3.3). Slightly lower regioselectivity was observed across the series of 
electron-deficient aryl azide substrates (3.5p–t:3.6p–t = ~1:6). 
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Table 3.3. Scope of [3+2]-Cycloaddition with Aryl Azides 
 
 To produce more active phosphine ligands, other electron-rich phosphine sources 
(n-Bu, t-Bu) were used to make triazole phosphine oxides (Table 3.4). The click reaction 
afforded the corresponding triazole phosphine oxides, incorporating electron-rich 
substituents, in good to excellent yields and similar regioselectivity. 
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Table 3.4. Scope of [3+2]-Cycloaddition with Other Phosphine Sources 
 
3.7. Reduction of Triazole Phosphine Oxides 
 Upon successful transformation to triazole phosphine oxides, the reduction of 
phosphine oxide was performed to generate heterocyclic phosphines. In 2012, the Beller 
group reported that the acid-catalyzed reduction of phosphine oxides in the presence of 
silane enables efficient transformation to phosphines.21 Initial attempts at reduction were 
carried out with the more sterically hindered isomer of triazole phosphine oxide (3.5a) with 
the reported phosphoric acid and silane (Table 3.5). However, Beller’s representative 
conditions did not convert the phosphine oxide (3.5a) into the corresponding phosphine, 
even after 2 days (entry 1). Increasing the amount of phosphoric acid catalyst and silane 
gave a promising result (entry 2). Unfortunately, no further improvement was achieved, 
even with elevated temperature (entry 3). A Cu-catalyzed tertiary phosphine oxide 
                                                     
21 Li, Y.; Lu, L.-Q.; Das, S.; Pisiewicz, S.; Junge, K.; Beller, M. Highly Chemoselective Metal-Free 
Reduction of Phosphine Oxides to Phosphines. J. Am. Chem. Soc. 2012, 134 (44), 18325–18329. 
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reduction method was also developed by Beller and coworkers.22 However, the Cu-
catalyzed condition failed to produce triazole phosphine ligand (3.7a), even after 3 days 
(entry 4). Next, Ti(Oi-Pr)4-assisted phosphine oxide reduction, reported by the 
Nishibayashi group in 2005,23 was examined with various silane sources (entry 5–9). This 
mild method allowed access to the reduced phosphine product (3.7a). Use of Ti(Oi-Pr)4 
and triethoxysilane in benzene was found to be one of the most effective conditions (entry 
9). At a later time, use of trichlorosilane was found to convert phosphine oxide to its 
corresponding ClickPhos ligand in excellent yield, without additional additives (entry 10).24 
                                                     
22 Li, Y.; Das, S.; Zhou, S.; Junge, K.; Beller, M. General and Selective Copper-Catalyzed 
Reduction of Tertiary and Secondary Phosphine Oxides: Convenient Synthesis of Phosphines. J. 
Am. Chem. Soc. 2012, 134 (23), 9727–9732. 
23 Onodera, G.; Matsumoto, H.; Milton, M. D.; Nishibayashi, Y.; Uemura, S. Ruthenium-Catalyzed 
Formation of Aryl(Diphenyl)Phosphine Oxides by Reactions of Propargylic Alcohols with 
Diphenylphosphine Oxide. Org. Lett. 2005, 7 (18), 4029–4032. 
24 Gray, M.; Chapell, B. J.; Felding, J.; Taylor, N. J.; Snieckus, V. The Di- t -Butylphosphinyl Directed 
Ortho Metalation Group. Synthesis of Hindered Dialkylarylphosphines. Synlett 1998, 1998 (4), 422–
424. 
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Entry conditions solvent Time Conversiona 
1 cat (7.5 mol%), (EtO)2MeSiH (4 equiv), 110 C toluene 2 d N/R 
2 cat (30 mol%), (EtO)2MeSiH (8 equiv), 110 C toluene 3 d 33% 
3 cat (30 mol%), (EtO)2MeSiH (8 equiv), 150 C mesitylene 2 d 22% 
4 Cu(OTf)2 (10 mol%), TMDS (3 equiv), 100 C toluene 3 d N/R 
5 Ti(Oi-Pr)4 (30 mol%), (EtO)2MeSiH (3 equiv), 80 C benzene 16 h  66% 
6 Ti(Oi-Pr)4 (30 mol%), (MeO)3SiH (3 equiv), 80 C benzene 16 h 68% 
7 Ti(Oi-Pr)4 (30 mol%), Ph2SiH2 (3 equiv), 80 C benzene 16 h 49% 
8 Ti(Oi-Pr)4 (30 mol%), TMDS (3 equiv), 80 C benzene 16 h 70% 
9 Ti(Oi-Pr)4 (30 mol%), (EtO)3SiH (3 equiv), 80 C benzene 16 h 92% 
10 Cl3SiH, 80 C toluene 20 h 95%b 
aDetermined by 1H NMR.bIsolated yield. 
Table 3.5. Phosphine Oxide Reduction Optimization 
 
 To explore the validity of this synthetic approach in rapidly generating a large 
ligand library, High Throughput Experimentation (HTE) was employed. Using the 
optimized reduction protocol, a one-pot synthesis was tested using 
phenylalkynylphosphine oxide (3.3a) and benzyl azide (3.4a). The click reaction and 
subsequent reduction in benzene gave the corresponding triazole phosphines in good 
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yield (Scheme 3.6). In addition, mass-directed liquid chromatography (MDLC) allowed 
efficient separation of the regioisomeric mixture of phosphine ligands. 
 
Scheme 3.6. One-pot Synthesis of ClickPhos Ligand 
 
3.8. Preliminary Studies toward Suzuki Coupling of 3,5-Dichloropyridazine 
 With a small array of ClickPhos ligands, we began to investigate ligand effects in 
selective Suzuki-Miyaura cross-coupling. Based on the literature by Dai and coworkers,2c 
variable chemoselectivity was achieved by utilizing different ligands. An electron-deficient 
bidentate ligand, DPPF, gave 3.11 as a major and an electron-rich monodentate ligand, 
Q-Phos, showed inverted selectivity. Inspired by this site-selective cross-coupling 
precedent,2c Suzuki coupling of 3,5-dichloropyridazine with 13 pairs of ClickPhos ligands25 
was screened under the reported condition (Scheme 3.7).  
 As shown in Figure 3.4, screening results support the reported hypothesis of Dai 
and coworkers. Due to the electron-rich nature of the triazole-based phosphine ligands, 
we anticipated formation of the challenging C-5 substituted pyridazine (3.12) as the major 
product. Across the plate, most of the ClickPhos ligands generated the 5-substituted 
product (3.12) preferentially over the 3-substituted (3.11) or 3,5-disubstituted products 
(3.13). Notably, the most electron-rich ClickPhos ligand (3.7d-Cy) produced the highest 
C-5:C-3 ratio of 4.9:1. Interestingly, the least electron-rich triazole phosphine (3.8e) gave 
                                                     
25 Sobia Jabeen, visiting student, assisted to synthesize ClickPhos ligands. 
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C-3 substituted pyridazine (3.11) as the major product. 
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 Reaction condition:1.0 equiv 3.9, 1.1 equiv 3.10, 10 mol% Pd(OAc)2, 10 or 20 mol% ligands, 3.0 
equiv Cs2CO3, 0.1 M 1,4-dioxane. aLigands were synthesized by Sobia Jabeen. 
Scheme 3.7. Preliminary Screening of Suzuki-Miyaura Coupling with Diverse ClickPhos Ligands 
 
 
Figure 3.4. Screening Results of 13 ClickPhos Ligands 
 
3.9. Conclusion 
 In conclusion, a variety of triazole-based phosphine ligands have been synthesized 
via thermal [3+2]-cycloaddition, followed by phosphine oxide reduction. A one-pot protocol 
has also been developed, which will allow rapid expansion of the ligand library through 
the use of High–Throughput Experimentation. Although a small array of phosphine ligands 
was tested, the preliminary reaction screen gave promising results that seem to indicate 
selective substitution of chemically challenging substrates. To expand the ligand library, it 
is necessary to develop a more efficient phosphine oxide reduction method. The current 
conditions cannot reduce sterically hindered phosphine oxides, such as the di-tert-butyl 
phosphine oxides (3.5a-tBu), which will be more active ligands based on the preliminary 
data. Furthermore, additional data, obtained from a larger collection of ligands, need to be 
collected to disclose novel ligand effects.  
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3.10. Experimental Section 
General Considerations 
 Unless otherwise noted, all non-aqueous reactions were carried out under an 
atmosphere of dry N2 in dried glassware. When necessary, solvents and reagents were 
dried prior to use. THF was distilled from sodium benzophenone ketyl. CH2Cl2, 
ClCH2CH2Cl, and toluene were distilled from CaH2. High throughput experiments were 
performed at the Penn/Merck High Throughput Experimentation Laboratory at the 
University of Pennsylvania. The screens were analyzed by HPLC by addition of an internal 
standard. 
 Analytical thin layer chromatography (TLC) was performed on EM Reagents 0.25 
mm silica-gel 254-F plates. Visualization was accomplished with UV light. 
Chromatography was performed using a forced flow of the indicated solvent system on 
EM Reagents Silica Gel 60 (230-400 mesh). When necessary, the column was pre-
washed with 1% Et3N in the eluent system. 1H NMR spectra were recorded on a 500 MHz 
spectrometer. Chemical shifts are reported in ppm from tetramethylsilane (0 ppm) or from 
the solvent resonance (CDCl3 7.26 ppm, DMSO-d6 3.58 ppm, acetone-d6 2.05 ppm, DMF-
d7 2.50 ppm, CD3CN 1.94 ppm, CD2Cl2 5.32 ppm). Data are reported as follows: chemical 
shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), 
coupling constants, and number of protons. Decoupled 13C NMR spectra were recorded 
at 125 MHz. IR spectra were taken on an FT-IR spectrometer. Accurate mass 
measurement analyses were conducted via time-of-flight mass analyzer GCMS with 
electron ionization (EI) or via time-of-flight mass analyzer LCMS with electrospray 
ionization (ESI). The signals were measured against an internal reference of 
perfluorotributylamine for EI-GCMS and leucine enkephalin for ESI-LCMS. The instrument 
was calibrated and measurements were made using neutral atomic masses; the mass of 
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the electron removed or added to create the charged species is not taken into account. 
Low resolution LCMS data were obtained by use of a UPLC system with a SQD mass 
analyzer equipped with electrospray ionization. Circular dichroism and UV-vis 
spectroscopy measurements carried out at ambient temperature (23 C). Enantiomeric 
excesses were determined using analytical HPLC with UV detection at 254 nm. Analytical 
Chiralpak columns (4.6 mm x 250 mm, 5 µm) from Daicel were used.  
General procedure A: preparation of alkynylphosphine oxide. A solution of n-BuLi 
(1.6 M in hexane) (9.4 mL, 15.0 mmol) was added dropwise to the solution of the acetylene 
(13.7 mmol) in THF (45 mL) at –78 °C. The reaction was allowed to warm to 0 C, stirred 
for 20 min, and then again cooled to –78 C. Chlorodiisopropylphosphine (2.2 mL, 13.7 
mmol), or di-tert-butylchlorophosphine (2.6 mL, 13.7 mmol), or chlorodibutylphosphine 
(2.6 mL, 13.7 mmol) was added dropwise. The solution was allowed to warm to room 
temperature and was stirred for a further 2.5 h. The reaction was then cooled to 0 C and 
hydrogen peroxide (30% aq solution, 2.0 mL, 6.7 M) was added dropwise. The solution 
was warmed to room temperature. After stirring 30 min at room temperature, the reaction 
mixture was dried over Na2SO4, filtered, and concentrated. Chromatography afforded the 
desired product. 
 
Diisopropyl(phenylethynyl)phosphine oxide (3.3a). Following General procedure A, 
the product was obtained as a colorless oil (3.16 g) in 98% yield. Rf  = 0.21 (100% EtOAc): 
1H NMR (500 MHz, CDCl3)  7.54 (d, J = 7.0 Hz, 2H), 7.43 (t, J = 7.5 Hz, 1H), 7.37 (t, J = 
7.5 Hz, 2H), 2.18–2.10 (m, 2H), 1.35–1.24 (m, 12H); 13C NMR (125 MHz, CDCl3)  132.3, 
130.2, 128.4, 120.2, 103.1 (d, J = 21.9 Hz), 80.6 (d, J = 135.9 Hz), 27.1 (d, J = 78.5 Hz), 
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16.1 (d, J = 1.8 Hz), 14.9 (d, J = 1.8 Hz); 31P NMR  40.8; IR (neat) 2964, 2933, 2873, 
2173, 1489, 1463, 1443, 1263, 1223, 1188, 1156, 1025 cm–1; HRMS (ESI-TOF) calcd for 
C14H19OPNa [M+Na]+ 257.1071, found 257.1075. 
 
Diisopropyl(o-tolylethynyl)phosphine oxide (3.3b). Following General procedure A, 
the product was obtained as a white solid (0.90 g) in 82% yield. Rf  = 0.17 (100% EtOAc): 
1H NMR (500 MHz, CDCl3)  7.45 (d, J = 7.5 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 
7.5 Hz, 1H), 7.12 (t, J = 7.5 Hz, 1H), 2.41 (s, 3H), 2.13–2.03 (m, 2H), 1.30–1.24 (m, 12H); 
13C NMR (125 MHz, CDCl3)  141.3, 132.9, 130.2, 129.7, 125.8, 120.2 (d, J = 3.3 Hz), 
102.1 (d, J = 21.8 Hz), 84.5 (d, J = 136.3 Hz), 27.2 (d, J = 78.4 Hz), 20.7, 16.2 (d, J = 2.5 
Hz), 15.0 (d, J = 3.3 Hz); 31P NMR  41.7; IR (neat) 2968, 2171, 1457, 1177, 1144, 1114, 
1032, 884 cm–1; HRMS (ESI-TOF) calcd for C15H22OP [M+H]+ 249.1408, found 249.1423. 
 
Diisopropyl((2-methoxyphenyl)ethynyl)phosphine oxide (3.3c). Following General 
Procedure A, the product was obtained as a off-white oil (1.01 g) in 74% yield. Rf  = 0.20 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.42 (dd, J = 7.5, 1.5 Hz, 1H), 7.33 (td, J = 
7.5, 1.5 Hz, 1H), 6.88 (t, J = 7.5 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 3.81 (s, 3H), 2.14–2.03 
(m, 2H), 1.28 (dd, J = 16.5, 7.0 Hz, 6H), 1.27 (dd, J = 17.0, 7.0 Hz, 6H); 13C NMR (125 
MHz, CDCl3)  161.4, 134.1, 131.8, 120.5, 110.8, 109.8 (d, J = 3.4 Hz), 100.0 (d, J = 22.6 
Hz), 84.6 (d, J = 139.2 Hz), 55.8, 27.2 (d, J = 78.6 Hz), 16.2 (d, J = 2.4 Hz), 15.0 (d, J = 
3.1 Hz); 31P NMR  42.0; IR (neat) 2964, 2172, 1595, 1490, 1462, 1435, 1290, 1258, 1185, 
158 
 
1157, 1114, 1045, 1022 cm–1; HRMS (ESI-TOF) calcd for C15H22O2P [M+H]+ 265.1357, 
found 265.1345. 
 
((2,6-Dimethoxyphenyl)ethynyl)diisopropylphosphine oxide (3.3d). Following 
General procedure A, the product was obtained as a white solid (1.08 g) in 74% yield. Rf  
= 0.13 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.24 (t, J = 8.5 Hz, 1H), 6.45 (d, J = 
8.5 Hz, 2H), 3.79 (s, 6H), 2.10–2.05 (m, 2H), 1.27 (dd, J = 17.0, 7.0 Hz, 12H); 13C NMR 
(125 MHz, CDCl3)  162.7, 131.9, 103.4, 99.2 (d, J = 3.6 Hz), 96.7 (d, J = 24.4 Hz), 88.6 
(d, J = 143.0 Hz), 56.0, 27.2 (d, J = 78.8 Hz), 16.1 (d, J = 2.5 Hz), 15.0 (d, J = 3.4 Hz); 31P 
NMR  41.0; IR (neat) 2955, 2872, 2174, 1593, 1579, 1474, 1447, 1438, 1258, 1176, 
1149, 1108, 1025, 884 cm–1; HRMS (ESI-TOF) calcd for C16H24O3P [M+H]+ 295.1463, 
found 295.1443. 
 
Ethynyldiisopropylphosphine oxide (3.3e). Following General Procedure A, the 
product was obtained as a white solid (1.59 g) in 94% yield. Rf  = 0.21 (100% EtOAc): 1H 
NMR (500 MHz, CDCl3)  3.00 (d, J = 8.5 Hz, 1H), 2.05–1.97 (m, 2H), 1.24–1.17 (m, 12H); 
13C NMR (125 MHz, CDCl3)  91.9 (d, J = 19.4 Hz), 76.6 (d, J = 127.5 Hz), 26.9 (d, J = 
77.9 Hz), 16.0 (d, J = 2.6 Hz), 14.8 (d, J = 3.0 Hz); 31P NMR  42.2; IR (neat) 3129, 2966, 
2934, 2907, 2874, 2044, 1464, 1448, 1387, 1251, 1176, 1154, 1025 cm–1; HRMS (ESI-
TOF) calcd for C8H15OP [M]+ 158.0861, found 158.0864.  
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Di-tert-butyl(phenylethynyl)phosphine oxide (3.3a-tBu). Following General 
Procedure A, the product was obtained as a white solid (1.38 g) in 82% yield. Rf  = 0.15 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.46 (d, J = 7.0 Hz, 2H), 7.35 (td, J = 7.0, 1.0 
Hz, 1H), 7.29 (t, J = 7.0 Hz, 2H), 1.32 (d, J = 15.0 Hz, 18H); 13C NMR (125 MHz, CDCl3) 
 132.2 (d, J = 1.3 Hz), 130.1, 128.5, 120.5 (d, J = 3.4 Hz), 102.9 (d, J = 18.8 Hz), 81.7 (d, 
J = 127.4 Hz), 36.1 (d, J = 72.4 Hz), 26.4; 31P NMR  48.3. Spectral data were in 
agreement with those reported.26 
 
Dibutyl(phenylethynyl)phosphine oxide (3.3a-nBu). Following General Procedure A, 
the product was obtained as a white solid (0.94 g) in 98% yield. Rf  = 0.23 (100% EtOAc): 
1H NMR (500 MHz, CDCl3)  7.53 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.0 Hz, 1H), 7.36 (t, J = 
7.5 Hz, 2H), 1.96–1.89 (m, 4H), 1.79–1.66 (m, 4H), 1.52–1.44 (m, 4H), 0.96 (t, J = 7.5 Hz, 
6H); 13C NMR (125 MHz, CDCl3)  132.3, 130.3, 128.5, 120.2, 102.4 (d, J = 25.4 Hz), 82.9 
(d, J = 144.5 Hz), 31.1 (d, J = 79.9 Hz), 24.0 (d, J = 4.0 Hz), 23.9 (d, J = 16.1 Hz), 13.6; 
31P NMR  26.2. Spectral data were in agreement with those reported.27 
                                                     
26 Kondoh, A.; Yorimitsu, H.; Oshima, K. Synthesis of 2-Indolylphosphines by Palladium-Catalyzed 
Annulation of 1-Alkynylphosphine Sulfides with 2-Iodoanilines. Org. Lett. 2010, 12 (7), 1476–1479. 
27 Yang, J.; Chen, T.; Zhou, Y.; Yin, S.; Han, L.-B. Palladium-Catalyzed Dehydrogenative Coupling 
of Terminal Alkynes with Secondary Phosphine Oxides. Chem. Commun. 2015, 51 (17), 3549–
3551. 
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Dibutyl((2,6-dimethoxyphenyl)ethynyl)phosphine oxide (3.3d-nBu). Following 
General Procedure A, the product was obtained as an off-white solid (1.04 g) in 87% 
yield. Rf  = 0.26 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.29 (t, J = 8.5 Hz, 1H), 6.50 
(d, J = 8.5 Hz, 2H), 3.84 (s, 6H), 1.96–1.87 (m, 4H), 1.81–1.71 (m, 4H), 1.48 (sext, J = 7.5 
Hz, 4H), 0.96 (t, J = 7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  162.8, 132.0, 103.5, 99.5, 
96.3 (d, J = 27.4 Hz), 91.2 (d, J = 150.0 Hz), 56.1, 31.4 (d, J = 80.1 Hz), 24.2 (d, J = 4.3 
Hz), 24.1 (d, J = 15.8 Hz), 13.8; 31P NMR  26.0; IR (neat) 2957, 2934, 2871, 2169, 1593, 
1581, 1475, 1433, 1403, 1298, 1258, 1223, 1173, 1109, 1029 cm–1; HRMS (EI-TOF) calcd 
for C18H27O3P [M]+ 322.1698, found 322.1701. 
 
Dibutyl(ethynyl)phosphine oxide (3.3e-nBu). Following General procedure A, the 
product was obtained as a white solid (0.25 g) in 81% yield. Rf  = 0.30 (100% EtOAc): 1H 
NMR (500 MHz, CDCl3)  3.00 (d, J = 9.0 Hz, 1H), 1.89–1.78 (m, 4H), 1.71–1.60 (m, 4H), 
1.45 (sext, J = 7.5 Hz, 4H), 0.94 (t, J = 7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  91.0 (d, 
J = 23.0 Hz), 79.0 (d, J = 135.6 Hz), 31.0 (d, J = 79.5 Hz), 24.0 (d, J = 13.9 Hz), 23.9 (d, 
J = 2.8 Hz), 13.7; 31P NMR  27.1; IR (neat) 3109, 2959, 2929, 2873, 2043, 1465, 1379, 
1222, 1202, 1163, 1088, 1053, 967 cm–1; HRMS (ESI-TOF) calcd for C10H20OP [M+H]+ 
187.1252, found 187.1256. 
General procedure B: [3+2]-cycloaddition with alkyl azides. Azide (0.70 mmol) was 
added in the solution of the corresponding alkynylphosphine oxide (0.63 mmol) in toluene 
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(1.3 mL) under argon and sealed with a cap. The reaction mixture was stirred for 3–5 d at 
150 °C. The resultant mixture was cooled to room temperature and removal of solvent 
was followed by chromatography.  
General procedure C: [3+2]-cycloaddition with aryl azides. Azide (0.88 mmol) was 
added in the solution of the corresponding alkynylphosphine oxide (0.44 mmol) in toluene 
(0.88 mL) under argon and sealed with a cap. The reaction mixture was stirred for 1 d at 
110 °C. Subsequent addition of the second portion of azide (0.88 mmol) added into the 
reaction mixture and stirred for 2 d. The resultant mixture was cooled to room temperature 
and removal of solvent was followed by chromatography.  
 
(1-Benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)diisopropylphosphine oxide (3.5a). 
Following General procedure B, the product was obtained as an off-white solid (0.32 g) 
in 41% yield. Rf  = 0.58 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.55 (d, J = 7.0 Hz, 
2H), 7.45–7.43 (m, 3H), 7.35 (dd, J = 8.0, 1.5 Hz, 2H), 7.33–7.29 (m, 3H), 6.14 (s, 2H), 
1.81–1.75 (m, 2H), 1.11 (dd, J = 16.0, 7.0 Hz, 6H), 0.78 (dd, J = 17.0, 7.5 Hz, 6H); 13C 
NMR (125 MHz, CDCl3)  150.4 (d, J = 14.3 Hz), 136.3, 131.6, 129.5, 129.4, 129.0, 128.6, 
128.5, 128.2, 124.2 (d, J = 83.9 Hz), 54.0, 29.1 (d, J = 69.9 Hz), 16.5 (d, J = 3.8 Hz), 15.4 
(d, J = 2.8 Hz); 31P NMR  49.7; IR (neat) 2967, 2932, 1496, 1464, 1445, 1190, 1151, 
1073, 1029 cm–1; HRMS (ESI-TOF) calcd for C21H27N3OP [M+H]+ 368.1892, found 
368.1886. 
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(1-Benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide (3.6a). 
Following General procedure B, the product was obtained as an off-white solid (0.37 g) 
in 47% yield. Rf  = 0.21 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.44 (t, J = 7.5 Hz, 
1H), 7.39 (t, J = 7.5 Hz, 2H), 7.31–7.26 (m, 5H), 7.01–6.99 (m, 2H), 5.44 (s, 2H), 2.46–
2.38 (m, 2H), 1.14 (dd, J = 16.5, 7.0 Hz, 6H), 1.10 (dd, J = 15.5, 7.0 Hz, 6H); 13C NMR 
(125 MHz, CDCl3)  145.6 (d, J = 18.2 Hz), 136.2 (d, J = 110.3 Hz), 135.1, 130.5, 130.0, 
128.9, 128.4, 128.3, 127.4, 125.9, 51.9, 26.4 (d, J = 70.6 Hz), 16.0 (d, J = 2.5 Hz), 14.9 
(d, J = 2.9 Hz); 31P NMR  46.4; IR (neat) 2963, 2932, 2872, 1454, 1407, 1278, 1243, 
1202, 1181, 1154, 1027 cm–1; HRMS (ESI-TOF) calcd for C21H27N3OP [M+H]+ 368.1892, 
found 368.1864. 
 
(1-Benzyl-4-(o-tolyl)-1H-1,2,3-triazol-5-yl)diisopropylphosphine oxide (3.5b). 
Following General procedure B, the product was obtained as a white solid (40 mg) in 
26% yield. Rf  = 0.60 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.53 (d, J = 7.0 Hz, 2H), 
7.35–7.27 (m, 5H), 7.20 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 6.14 (s, 2H), 2.16 (s, 
3H), 1.75–1.67 (m, 2H), 1.06 (dd, J = 16.5, 7.0 Hz, 6H), 0.79 (dd, J = 16.5, 7.0 Hz, 6H); 
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13C NMR (125 MHz, CDCl3)  149.4 (d, J = 14.4 Hz), 138.7, 136.4, 130.9, 130.6, 129.7, 
129.6, 128.9, 128.5, 128.2, 125.6, 124.9 (d, J = 83.7 Hz), 54.0, 29.2 (d, J = 69.9 Hz), 20.2, 
16.5 (d, J = 3.8 Hz), 15.4 (d, J = 2.8 Hz); 31P NMR  50.5; IR (neat) 2964, 2929, 1456, 
1191, 1151, 1019, 880, 769 cm–1; HRMS (ESI-TOF) calcd for C22H29N3OP [M+H]+ 
382.2048, found 382.2063. 
 
(1-Benzyl-5-(o-tolyl)-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide (3.6b). 
Following General procedure B, the product was obtained a white solid (71 mg) in 46% 
yield. Rf  = 0.23 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.32 (t, J = 7.5 Hz, 1H), 7.23–
7.15 (m, 5H), 6.94 (d, J = 7.0 Hz, 1H), 6.89 (d, J = 7.0 Hz, 2H), 5.27 (d, J = 14.5 Hz, 1H), 
5.22 (d, J = 14.5 Hz, 1H), 2.53–2.46 (m, 1H), 2.24–2.16 (m, 1H), 1.80 (s, 3H), 1.19–1.13 
(m, 6H), 1.10–1.01 (m, 6H); 13C NMR (125 MHz, CDCl3)  144.6 (d, J = 18.2 Hz), 138.6, 
136.9 (d, J = 110.9 Hz), 134.3, 130.3, 130.2, 130.1, 128.7, 128.4, 128.2, 125.8, 125.5, 
52.0, 26.9 (d, J = 70.3 Hz), 26.0 (d, J = 70.5 Hz), 19.8, 16.0 (d, J = 3.1 Hz), 15.9 (d, J = 
1.4 Hz), 15.2 (d, J = 3.1 Hz), 14.6 (d, J = 1.5 Hz); 31P NMR  46.9; IR (neat) 2962, 2933, 
1456, 1406, 1364, 1197, 1178, 1154, 1025, 880 cm–1; HRMS (ESI-TOF) calcd for 
C22H29N3OP [M+H]+ 382.2048, found 382.2056. 
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(1-Benzyl-4-(2-methoxyphenyl)-1H-1,2,3-triazol-5-yl)diisopropylphosphine oxide 
(3.5c). Following General procedure B, the product was obtained as a light yellow solid 
(67 mg) in 43% yield. Rf  = 0.64 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.56 (d, J = 
7.0 Hz, 2H), 7.43 (td, J = 8.5, 1.5 Hz, 1H), 7.33 (t, J = 7.5 Hz, 2H), 7.29 (d, J = 7.0 Hz, 
1H), 7.16 (dd, J = 7.5, 1.5 Hz, 1H), 6.99 (td, J = 7.5, 1.0 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 
6.13 (s, 2H), 3.70 (s, 3H), 1.73–1.66 (m, 2H), 1.09 (dd, J = 16.0, 7.0 Hz, 6H), 0.81 (dd, J 
= 17.0, 7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  158.0, 146.7 (d, J = 14.0 Hz), 136.3, 
131.6, 131.3, 129.0, 128.4, 128.1, 125.5 (d, J = 84.8 Hz), 120.4, 120.3, 111.1, 55.2, 53.8, 
28.7 (d, J = 70.1 Hz), 16.4 (d, J = 3.6 Hz), 15.3 (d, J = 2.8 Hz); 31P NMR  50.1; IR (neat) 
2965, 2934, 1496, 1471, 1435, 1281, 1245, 1188, 1151, 1112, 1049, 1023 cm–1; HRMS 
(ESI-TOF) calcd for C22H29N3O2P [M+H]+ 398.1997, found 398.1994. 
 
(1-Benzyl-5-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide 
(3.6c). Following General procedure B, the product was obtained as a light yellow solid 
(74 mg) in 47% yield. Rf  = 0.23 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.39 (td, J = 
8.5, 1.5 Hz, 1H), 7.20–7.17 (m, 3H), 7.14 (dd, J = 7.5, 1.5 Hz, 1H), 6.95–6.92 (m, 3H), 
6.89 (d, J = 8.0 Hz, 1H), 5.42 (d, J = 15.0 Hz, 1H), 5.20 (d, J = 15.0 Hz, 1H), 3.61 (s, 3H), 
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2.56–2.45 (m, 1H), 2.25–2.17 (m, 1H), 1.24–1.18 (m, 6H), 1.05–0.94 (m, 6H); 13C NMR 
(125 MHz, CDCl3)  156.8, 142.5 (d, J = 18.1 Hz), 136.6 (d, J = 111.9 Hz), 134.9, 133.0, 
131.8, 128.6, 128.1, 127.9, 120.6, 114.9, 110.6, 55.2, 52.2, 26.9 (d, J = 70.8 Hz), 25.8 (d, 
J = 71.0 Hz), 16.0 (d, J = 2.3 Hz), 15.8 (d, J = 2.0 Hz), 14.8 (d, J = 3.1 Hz), 14.5 (d, J = 
4.0 Hz); 31P NMR  46.7; IR (neat) 2963, 2933, 1477, 1456, 1411, 1293, 1274, 1245, 1199, 
1182, 1155, 1115, 1024 cm–1; HRMS (EI-TOF) calcd for C22H29N3O2P [M+H]+ 398.1997, 
found 398.2017. 
 
(1-Benzyl-4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-5-yl)diisopropylphosphine 
oxide (3.5d). Following General procedure B, the product was obtained as an off-white 
solid (65 mg) in 39% yield. Rf  = 0.47 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.53 
(d, J = 7.5 Hz, 2H), 7.33 (t, J = 8.5 Hz, 1H), 7.30–7.22 (m, 3H), 6.55 (d, J = 8.5 Hz, 2H), 
6.09 (s, 2H), 3.61 (s, 6H), 1.68–1.61 (m, 2H), 1.04 (dd, J = 16.5, 7.0 Hz, 6H), 0.78 (dd, J 
= 16.5, 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  159.3, 143.2 (d, J = 13.8 Hz), 136.5, 
131.6, 128.9, 128.3, 127.9, 126.5 (d, J = 85.5 Hz), 108.4, 103.6, 55.3, 53.7, 28.8 (d, J = 
70.4 Hz), 16.3 (d, J = 3.8 Hz), 15.4 (d, J = 2.6 Hz); 31P NMR  50.5; IR (neat) 2960, 2942, 
1603, 1587, 1473, 1458, 1433, 1289, 1252, 1183, 1149, 1109, 1031, 994 cm–1; HRMS 
(ESI-TOF) calcd for C23H31N3O3P [M+H]+ 428.2103, found 428.2110. 
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(1-Benzyl-5-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)diisopropylphosphine 
oxide (3.6d). Following General procedure B, the product was obtained as an off-white 
solid (88 mg) in 53% yield. Rf  = 0.08 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.33 (t, 
J = 8.5 Hz, 1H), 7.20–7.19 (m, 3H), 6.99–6.98 (m, 2H), 6.49 (d, J = 8.5 Hz, 2H), 5.25 (s, 
2H), 3.52 (s, 6H), 2.33–2.28 (m, 2H), 1.12 (dd, J = 16.0, 7.0 Hz, 12H); 13C NMR (125 MHz, 
CDCl3)  158.6, 139.4 (d, J = 18.9 Hz), 137.3 (d, J = 114.4 Hz), 134.9, 132.1, 128.3, 128.1, 
127.9, 103.8, 103.5, 55.4, 52.1, 26.8 (d, J = 70.4 Hz), 15.8 (d, J = 1.3 Hz), 14.7 (d, J = 2.5 
Hz); 31P NMR  47.5; IR (neat) 2964, 2936, 2874, 1607, 1589, 1476, 1434, 1292, 1254, 
1201, 1176, 1151, 1111, 1028, 779 cm–1; HRMS (ESI-TOF) calcd for C23H31N3O3P [M+H]+ 
428.2103, found 428.2103. 
 
(1-Benzyl-1H-1,2,3-triazol-5-yl)diisopropylphosphine oxide (3.5e). Following General 
procedure B, the product was obtained as a white solid (78 mg) in 42% yield. Rf  = 0.37 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.67 (s, 1H), 7.47 (d, J = 8.0 Hz, 2H), 7.30–
7.23 (m, 3H), 6.01 (s, 2H), 2.14–2.08 (m, 2H), 1.05 (dd, J = 16.5, 7.0 Hz, 6H), 1.02 (dd, J 
= 17.0, 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  137.7 (d, J = 14.3 Hz), 136.0, 128.9, 
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128.7, 128.5, 125.5 (d, J = 85.3 Hz), 53.6, 27.7 (d, J = 70.9 Hz), 15.8 (d, J = 2.6 Hz), 14.7 
(d, J = 3.1 Hz); 31P NMR  47.1; IR (neat) 2966, 2933, 2874, 1496, 1457, 1388, 1367, 
1271, 1182, 1150, 1028 cm–1; HRMS (ESI-TOF) calcd for C15H23N3OP [M+H]+ 292.1579, 
found 292.1572. 
 
(1-Benzyl-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide (3.6e). Following General 
procedure B, the product was obtained as a white solid (81 mg) in 44% yield. Rf  = 0.11 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.98 (s, 1H), 7.34–7.32 (m, 3H), 7.23–7.22 
(m, 2H), 5.53 (s, 2H), 2.40–2.30 (m, 2H), 1.15 (dd, J = 16.0, 7.5 Hz, 6H), 1.07 (dd, J = 
16.5, 7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  139.7 (d, J = 112.0 Hz), 133.9, 131.6 (d, 
J = 18.5 Hz), 129.3, 129.1, 128.3, 54.3, 25.8 (d, J = 70.1 Hz), 15.6 (d, J = 2.4 Hz), 14.7 
(d, J = 3.3 Hz); 31P NMR  48.2; IR (neat) 2963, 2933, 2874, 1498, 1457, 1367, 1267, 
1212, 1176, 1148, 1104, 1048, 1024 cm–1; HRMS (ESI-TOF) calcd for C15H23N3OP [M+H]+ 
292.1579, found 292.1572. 
 
Diisopropyl(1-octyl-4-phenyl-1H-1,2,3-triazol-5-yl)phosphine oxide (3.5f). Following 
General procedure B, the product was obtained as a white solid (56 mg) in 30% yield. Rf  
= 0.67 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.45–7.40 (m, 3H), 7.35 (dd, J = 7.5, 
1.5 Hz, 2H), 4.86 (t, J = 7.5 Hz, 2H), 2.02 (quint, J = 7.5 Hz, 2H), 1.89–1.82 (m, 2H), 1.42–
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1.24 (m, 10H), 1.18 (dd, J = 16.0, 7.0 Hz, 6H), 0.97 (dd, J = 17.0, 7.5 Hz, 6H), 0.86 (t, J = 
7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3)  150.1 (d, J = 14.5 Hz), 131.9, 129.7, 129.5, 
128.6, 124.2 (d, J = 84.3 Hz), 51.6, 31.9, 31.8, 29.3, 29.0 (d, J = 70.6 Hz), 26.8, 22.79 (2), 
16.8 (d, J = 3.8 Hz), 15.4 (d, J = 2.9 Hz), 14.2; 31P NMR  49.2; IR (neat) 2925, 2855, 
1525, 1464, 1405, 1330, 1265, 1188, 1149, 1073, 1016, 919 cm–1; HRMS (ESI-TOF) calcd 
for C22H37N3OP [M+H]+ 390.2674, found 390.2654. 
 
Diisopropyl(1-octyl-5-phenyl-1H-1,2,3-triazol-4-yl)phosphine oxide (3.6f). Following 
General procedure B, the product was obtained as a colorless oil (74 mg) in 40% yield. 
Rf  = 0.25 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.44–7.39 (m, 5H), 4.21 (t, J = 7.5 
Hz, 2H), 2.42–2.34 (m, 2H), 1.74 (quint, J = 7.0 Hz, 2H), 1.22–1.05 (m, 22H), 0.81 (t, J = 
7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  145.2 (d, J = 18.2 Hz), 135.8 (d, J = 110.9 Hz), 
130.3, 129.8, 128.4, 126.3, 48.4, 31.7, 29.9, 29.0, 28.8, 26.34 (d, J = 70.4 Hz), 26.31, 
22.6, 16.0 (d, J = 2.5 Hz), 14.9 (d, J = 3.8 Hz), 14.1; 31P NMR  47.2; IR (neat) 2959, 2927, 
2872, 2856, 1461, 1409, 1385, 1264, 1204, 1180, 1153, 1025, 1006, 883 cm–1; HRMS 
(ESI-TOF) calcd for C22H37N3OP [M+H]+ 390.2674, found 390.2658. 
 
Diisopropyl(1-octyl-4-(o-tolyl)-1H-1,2,3-triazol-5-yl)phosphine oxide (3.5g). Following 
General procedure B, the product was obtained as a brown oil (61 mg) in 23% yield. Rf  
= 0.64 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.31 (td, J = 7.5, 1.0 Hz, 1H), 7.26 (d, 
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J = 7.5 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 4.85 (t, J = 7.5 Hz, 2H), 
2.14 (s, 3H), 2.00 (quint, J = 7.5 Hz, 2H), 1.80–1.73 (m, 2H), 1.39–1.20 (m, 10H), 1.13 
(dd, J = 16.0, 7.0 Hz, 6H), 0.96 (dd, J = 17.0, 7.5 Hz, 6H), 0.83 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz, CDCl3)  149.0 (d, J = 14.3 Hz), 138.6, 130.9, 130.7, 129.64, 129.63, 
125.5, 124.8 (d, J = 84.4 Hz), 51.5, 31.8, 31.7, 29.24, 29.23, 29.1 (d, J = 70.0 Hz), 26.7, 
22.7, 20.2, 16.7 (d, J = 3.8 Hz), 15.4 (d, J = 2.9 Hz), 14.2; 31P NMR  48.5; IR (neat) 2957, 
2925, 2856, 1463, 1382, 1187, 1151, 1037, 1016, 996, 878 cm–1; HRMS (ESI-TOF) calcd 
for C23H39N3OP [M+H]+ 404.2831, found 404.2829. 
 
Diisopropyl(1-octyl-5-(o-tolyl)-1H-1,2,3-triazol-4-yl)phosphine oxide (3.6g). Following 
General procedure B, the product was obtained as a yellow oil (92 mg) in 35% yield. Rf  
= 0.31 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.32 (t, J = 7.5 Hz, 1H), 7.24 (d, J = 
7.5 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.08 (d, J = 7.5 Hz, 1H), 4.11–4.05 (m, 1H), 3.93–
3.87 (m, 1H), 2.47–2.39 (m, 1H), 2.27–2.19 (m, 1H), 2.07 (s, 3H), 1.72–1.64 (m, 2H), 1.19–
1.02 (m, 22H), 0.79 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  144.5 (d, J = 18.3 
Hz), 137.8, 136.0 (d, J = 112.0 Hz), 130.5, 130.3, 130.0, 126.0, 125.6, 48.0, 31.6, 29.6, 
28.9, 28.7, 26.7 (d, J = 81.5 Hz), 26.3, 26.1 (d, J = 81.7 Hz), 22.5, 20.0, 15.9 (d, J = 3.5 
Hz), 15.8 (d, J = 2.0 Hz), 15.1 (d, J = 2.9 Hz), 14.5 (d, J = 2.6 Hz), 14.0; 31P NMR  45.9; 
IR (neat) 2958, 2926, 2872, 2856, 1461, 1410, 1384, 1264, 1183, 1154, 1024, 1003, 883 
cm–1; HRMS (ESI-TOF) calcd for C23H39N3OP [M+H]+ 404.2831, found 404.2829. 
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Diisopropyl(4-(2-methoxyphenyl)-1-octyl-1H-1,2,3-triazol-5-yl)phosphine oxide 
(3.5h). Following General procedure B, the product was obtained as an off-white solid 
(58 mg) in 31% yield. Rf  = 0.64 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.38 (t, J = 
7.5 Hz, 1H), 7.14 (dd, J = 7.5, 1.5 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.90 (d, J = 8.5 Hz, 
1H), 4.81 (t, J = 7.5 Hz, 2H), 3.66 (s, 3H), 1.99 (quint, J = 7.5 Hz, 2H), 1.76–1.69 (m, 2H), 
1.39–1.22 (m, 10H), 1.12 (dd, J = 16.0, 7.0 Hz, 6H), 0.95 (dd, J = 16.5, 7.0 Hz, 6H), 0.82 
(t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  157.9, 146.3 (d, J = 15.1 Hz), 131.5, 
131.2, 125.3 (d, J = 85.5 Hz), 120.42, 120.35, 111.0, 55.2, 51.3, 31.8, 31.67 (2), 29.2, 
28.6 (d, J = 70.4 Hz), 26.7, 22.7, 16.5 (d, J = 3.5 Hz), 15.4 (d, J = 2.8 Hz), 14.1; 31P NMR 
 50.0; IR (neat) 2957, 2928, 1473, 1435, 1282, 1242, 1183, 1163, 1147, 1029, 879 cm–
1; HRMS (ESI-TOF) calcd for C23H39N3O2P [M+H]+ 420.2780, found 420.2791. 
 
Diisopropyl(5-(2-methoxyphenyl)-1-octyl-1H-1,2,3-triazol-4-yl)phosphine oxide 
(3.6h). Following General procedure B, the product was obtained as a yellow solid (83 
mg) in 44% yield. Rf  = 0.19 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.39 (td, J = 8.5, 
1.5 Hz, 1H), 7.31 (dd, J = 7.5, 1.5 Hz, 1H), 7.00 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 8.5 Hz, 
1H), 4.18–4.13 (m, 1H), 3.99–3.91 (m, 1H), 3.70 (s, 3H), 2.54–2.44 (m, 1H), 2.20–2.12 
(m, 1H), 1.76–1.66 (m, 2H), 1.21–1.08 (m, 16H), 0.96 (dd, J = 16.5, 7.0 Hz, 3H), 0.90 (dd, 
J = 15.5, 7.0 Hz, 3H), 0.79 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3)  156.8, 142.2 
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(d, J = 18.2 Hz), 135.9 (d, J = 112.6 Hz), 133.0, 131.7, 120.5, 115.0, 110.6, 55.3, 48.3, 
31.6, 29.5, 28.9, 28.8, 26.8 (d, J = 70.6 Hz), 26.3, 25.6 (d, J = 70.6 Hz), 22.6, 15.9 (d, J = 
2.9 Hz), 15.7 (d, J = 1.5 Hz), 14.7 (d, J = 2.4 Hz), 14.4 (d, J = 3.0 Hz), 14.0; 31P NMR  
45.8; IR (neat) 2958, 2927, 2872, 2856, 1464, 1415, 1293, 1243, 1179, 1152, 1122, 1047, 
1023, 1001, 883 cm–1; HRMS (ESI-TOF) calcd for C23H39N3O2P [M+H]+ 420.2780, found 
420.2786. 
 
(4-(2,6-Dimethoxyphenyl)-1-octyl-1H-1,2,3-triazol-5-yl)diisopropylphosphine oxide 
(3.5i). Following General procedure B, the product was obtained as a light yellow solid 
(25 mg) in 18% yield. Rf  = 0.69 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.33 (t, J = 
8.5 Hz, 1H), 6.55 (d, J = 8.5 Hz, 2H), 4.83 (t, J = 7.5 Hz, 2H), 3.64 (s, 6H), 2.00 (quint, J 
= 7.5 Hz, 2H), 1.74–1.68 (m, 2H), 1.40–1.23 (m, 10H), 1.13 (dd, J = 16.0, 7.0 Hz, 6H), 
0.97 (dd, J = 16.5, 7.0 Hz, 6H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3)  
159.3, 142.8 (d, J = 14.2 Hz), 131.5, 126.5 (d, J = 87.1 Hz), 108.8, 103.7, 55.4, 51.3, 31.8, 
31.7, 29.3, 29.2, 28.8 (d, J = 70.5 Hz), 26.7, 22.7, 16.6 (d, J = 3.8 Hz), 15.5 (d, J = 2.6 
Hz), 14.1; 31P NMR  50.3; IR (neat) 2923, 1605, 1588, 1472, 1433, 1253, 1185, 1146, 
1107, 992, 880 cm–1; HRMS (ESI-TOF) calcd for C24H41N3O3P [M+H]+ 450.2886, found 
450.2886. 
 
(5-(2,6-dimethoxyphenyl)-1-octyl-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide 
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(3.6i). Following General procedure B, the product was obtained as an off-white solid (69 
mg) in 50% yield. Rf  = 0.08 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.35 (t, J = 8.5 
Hz, 1H), 6.57 (d, J = 8.5 Hz, 2H), 4.03 (t, J = 7.0 Hz, 2H), 3.68 (s, 6H), 2.32–2.28 (m, 2H), 
1.73 (quint, J = 7.0 Hz, 2H), 1.24–1.16 (m, 10H), 1.11 (dd, J = 16.0, 7.0 Hz, 6H), 1.10 (dd, 
J = 15.5, 7.0 Hz, 6H), 0.83 (t, J = 7.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  158.8, 139.0 
(d, J = 18.9 Hz), 136.5 (d, J = 113.2 Hz), 132.0, 104.1, 103.7, 55.6, 48.2, 31.8, 29.5, 29.1, 
29.0, 26.7 (d, J = 71.7 Hz), 26.4, 22.7, 15.8 (d, J = 2.5 Hz), 14.6 (d, J = 2.5 Hz), 14.1; 31P 
NMR  47.3; IR (neat) 2958, 2925, 1607, 1590, 1475, 1463, 1434, 1254, 1173, 1146, 
1108, 1025, 883 cm–1; HRMS (ESI-TOF) calcd for C24H41N3O3P [M+H]+ 450.2886, found 
450.2893. 
 
Diisopropyl(1-octyl-1H-1,2,3-triazol-5-yl)phosphine oxide (3.5j). Following General 
procedure B, the product was obtained as a white solid (68 mg) in 34% yield. Rf  = 0.37 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.63 (s, 1H), 4.75 (t, J = 7.5 Hz, 2H), 2.23–
2.16 (m, 2H), 1.96 (quint, J = 7.5 Hz, 2H), 1.34–1.20 (m, 10H), 1.19 (dd, J = 16.5, 7.5 Hz, 
6H), 1.07 (dd, J = 17.0, 7.5 Hz, 6H), 0.83 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) 
 137.3 (d, J = 14.2 Hz), 125.3 (d, J = 86.1 Hz), 50.8, 31.8, 31.3, 29.2, 29.1, 27.5 (d, J = 
71.5 Hz), 26.6, 22.7, 15.7 (d, J = 2.5 Hz), 14.7 (d, J = 3.3 Hz), 14.1; 31P NMR  48.1; IR 
(neat) 3093, 2959, 2923, 2872, 2855, 1487, 1459, 1369, 1278, 1255, 1179, 1154, 1129, 
1031, 976 cm–1; HRMS (ESI-TOF) calcd for C16H33N3OP [M+H]+ 314.2361, found 
314.2369. 
173 
 
 
Diisopropyl(1-octyl-1H-1,2,3-triazol-4-yl)phosphine oxide (3.6j). Following General 
procedure B, the product was obtained as a white solid (109 mg) in 55% yield. Rf  = 0.12 
(100% EtOAc): 1H NMR (500 MHz, CDCl3)  8.09 (s, 1H), 4.35 (t, J = 7.5 Hz, 2H), 2.36–
2.31 (m, 2H), 1.86 (quint, J = 7.0 Hz, 2H), 1.23–1.12 (m, 16H), 1.05 (dd, J = 16.5, 7.0 Hz, 
6H), 0.78 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3)  138.8 (d, J = 113.2 Hz), 131.6 
(d, J = 17.6 Hz), 50.5, 31.6, 30.1, 29.0, 28.8, 26.3, 25.7 (d, J = 70.2 Hz), 22.6, 15.5 (d, J 
= 1.9 Hz), 14.6 (d, J = 2.9 Hz), 14.0; 31P NMR  48.3; IR (neat) 3102, 2959, 2927, 2872, 
2857, 1498, 1464, 1213, 1176, 1148, 1124, 1098, 1045, 1025, 998, 883 cm–1; HRMS (ESI-
TOF) calcd for C16H33N3OP [M+H]+ 314.2361, found 314.2365. 
 
Diisopropyl(1-(4-methoxyphenyl)-5-phenyl-1H-1,2,3-triazol-4-yl)phosphine oxide 
(3.6k). Following General procedure C, the product was obtained as a dark brown solid 
(128 mg) in 74% yield. Rf  = 0.22 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.42 (dd, J 
= 7.5, 1.0 Hz, 2H) 7.38–7.30 (m, 3H), 7.21 (d, J = 9.0 Hz, 2H), 6.87 (d, J = 9.0 Hz, 2H), 
3.82 (s, 3H), 2.54–2.46 (m, 2H), 1.19 (dd, J = 16.5, 7.0 Hz, 6H), 1.13 (dd, J = 15.5, 7.0 
Hz, 6H); 13C NMR (125 MHz, CDCl3)  160.2, 145.2 (d, J = 18.1 Hz), 136.4 (d, J = 108.9 
Hz), 131.0, 129.8, 129.3, 128.3, 126.8, 126.1, 114.6, 55.7, 26.6 (d, J = 70.6 Hz), 16.2 (d, 
J = 2.5 Hz), 15.1 (d, J = 2.8 Hz); 31P NMR  48.0; IR (neat) 2966, 1513, 1464, 1303 1251, 
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1181, 1155, 1110, 1028 cm–1; HRMS (EI-TOF) calcd for C21H26N3O2P [M]+ 383.1763, 
found 383.1748. 
 
Diisopropyl(1-(4-methoxyphenyl)-5-(o-tolyl)-1H-1,2,3-triazol-4-yl)phosphine oxide 
(3.6l). Following General procedure C, the product was obtained as a dark brown oil (147 
mg) in 84% yield. Rf  = 0.20 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.28 (t, J = 7.5 
Hz, 2H) 7.22–7.16 (m, 3H), 7.11 (d, J = 7.5 Hz, 1H), 6.80 (d, J = 9.0 Hz, 2H), 3.76 (s, 3H), 
2.47–2.38 (m, 2H), 1.92 (s, 3H), 1.25–1.09 (m, 12H); 13C NMR (125 MHz, CDCl3)  159.9, 
144.6 (d, J = 18.0 Hz), 137.5, 136.9 (d, J = 110.0 Hz), 131.5, 130.2, 130.1, 129.3, 126.0, 
125.6, 125.5, 114.4, 55.5, 26.62 (d, J = 70.6 Hz), 26.56 (d, J = 70.3 Hz), 20.1, 16.10 (d, J 
= 2.0 Hz), 16.06 (d, J = 2.6 Hz), 15.2 (d, J = 2.9 Hz), 14.7 (d, J = 2.8 Hz); 31P NMR  47.5; 
IR (neat) 2965, 1608, 1514, 1463, 1303, 1252, 1181, 1029, 883 cm–1; HRMS (ESI-TOF) 
calcd for C22H29N3O2P [M+H]+ 398.1997, found 398.2016. 
 
Diisopropyl(5-(2-methoxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-
yl)phosphine oxide (3.6m). Following General procedure C, the product was obtained 
as a dark brown oil (100 mg) in 60% yield. Rf  = 0.11 (100% EtOAc): 1H NMR (500 MHz, 
CDCl3)  7.47 (d, J = 7.5 Hz, 1H) 7.31 (t, J = 7.5 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 6.97 (t, 
J = 7.5 Hz, 1H), 6.78 (d, J = 8.5 Hz, 2H), 6.70 (d, J = 8.0 Hz, 1H), 3.73 (s, 3H), 3.37 (s, 
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3H), 2.62–2.56 (m, 1H), 2.26–2.21 (m, 1H), 1.30–1.22 (m, 6H), 1.03 (dd, J = 16.0, 7.0 Hz, 
3H), 0.94 (dd, J = 15.0, 6.5 Hz, 3H); 13C NMR (125 MHz, CDCl3)  159.7, 156.6, 142.4 (d, 
J = 17.7 Hz), 136.4 (d, J = 110.5 Hz), 132.9, 131.6, 129.9, 125.4, 120.4, 115.2, 113.9, 
110.7, 55.5, 55.0, 27.0 (d, J = 69.3 Hz), 25.6 (d, J = 71.2 Hz), 16.0 ,15.8, 14.7, 14.5; 31P 
NMR  47.7; IR (neat) 2964, 1608, 1513, 1463, 1301, 1281, 1247, 1177, 1152, 1118, 
1048, 1024, 993, 882 cm–1; HRMS (ESI-TOF) calcd for C22H29N3O3P [M+H]+ 414.1947, 
found 414.1935. 
 
(5-(2,6-Dimethoxyphenyl)-1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-
yl)diisopropylphosphine oxide (3.6n). Following General procedure C, the product 
was obtained as a dark brown solid (106 mg) in 70% yield. Rf  = 0.09 (100% EtOAc): 1H 
NMR (500 MHz, CDCl3)  7.31–7.27 (m, 3H), 6.82 (d, J = 8.5 Hz, 2H), 6.48 (d, J = 8.0 Hz, 
2H), 3.77 (s, 3H), 3.63 (s, 6H), 2.41–2.34 (m, 2H), 1.26–1.15 (m, 12H); 13C NMR (125 
MHz, CDCl3)  159.9, 158.7, 139.5 (d, J = 17.9 Hz), 137.2 (d, J = 113.0 Hz), 131.9, 129.7, 
125.7, 113.9, 104.6, 103.7, 55.6, 55.5, 26.8 (d, J = 70.7 Hz), 15.8 (d, J = 2.5 Hz), 14.7 (d, 
J = 2.8 Hz); 31P NMR  46.5; IR (neat) 2959, 1609, 1588, 1516, 1474, 1306, 1253, 1201, 
1182, 1146, 1107, 1019, 991, 833 cm–1; HRMS (ESI-TOF) calcd for C23H31N3O4P [M+H]+ 
444.2052, found 444.2057. 
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Diisopropyl(1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)phosphine oxide (3.6o). 
Following General procedure C, the product was obtained as a dark brown solid (125 
mg) in 58% yield. Rf  = 0.07 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  8.47 (s, 1H), 
7.66 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.0 Hz, 2H), 3.86 (s, 3H), 2.49–2.42 (m, 2H), 1.25 
(dd, J = 16.0, 7.0 Hz, 6H), 1.17 (dd, J = 16.5, 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  
160.2, 140.1 (d, J = 110.7 Hz), 130.0, 129.8 (d, J = 18.9 Hz), 122.2, 115.1, 55.8, 26.0 (d, 
J = 70.4 Hz), 15.8 (d, J = 2.5 Hz), 14.8 (d, J = 3.8 Hz); 31P NMR  46.5; IR (neat) 3052, 
2964, 1519, 1469, 1253, 1228, 1203, 1181, 1149, 1042, 1026, 982, 884 cm–1; HRMS (ESI-
TOF) calcd for C15H23N3O2P [M+H]+ 308.1528, found 308.1533. 
 
(1-(4-Fluorophenyl)-5-phenyl-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide 
(3.6p). Following General procedure C, the product was obtained as an off-white solid 
(108 mg) in 67% yield. Rf  = 0.20 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.38 (d, J 
= 8.5 Hz, 2H) 7.35–7.30 (m, 3H), 7.28–7.25 (m, 2H), 7.05 (t, J = 8.5 Hz, 2H), 2.52–2.44 
(m, 2H), 1.17 (dd, J = 16.0, 7.0 Hz, 6H), 1.11 (dd, J = 15.5, 7.0 Hz, 6H); 13C NMR (125 
MHz, CDCl3)  162.7 (d, J = 250.5 Hz), 145.2 (d, J = 17.9 Hz), 136.6 (d, J = 108.9 Hz), 
132.3, 130.9, 129.9, 128.3, 127.2 (d, J = 8.9 Hz), 125.6, 116.4 (d, J = 23.3 Hz), 26.5 (d, J 
= 70.3 Hz), 16.1 (d, J = 2.5 Hz), 14.9 (d, J = 3.1 Hz); 31P NMR  48.1; IR (neat) 3050, 
2955, 1510, 1469, 1219, 1202, 1177, 1166, 1157, 1140, 1105, 881 cm–1; HRMS (ESI-
TOF) calcd for C20H24FN3OP [M+H]+ 372.1641, found 372.1638. 
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(1-(4-Fluorophenyl)-5-(o-tolyl)-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide 
(3.6q). Following General procedure C, the product was obtained as a brown solid (115 
mg) in 70% yield. Rf  = 0.19 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.30–7.24 (m, 
4H), 7.21 (t, J = 7.0 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 7.00 (t, J = 8.0 Hz, 2H), 2.45–2.40 
(m, 2H), 1.92 (s, 3H), 1.25–1.08 (m, 12H); 13C NMR (125 MHz, CDCl3)  162.6 (d, J = 
249.9 Hz), 144.8 (d, J = 18.2 Hz), 137.4, 137.3 (d, J = 108.3 Hz), 132.4, 131.4, 130.4 (d, 
J = 8.2 Hz), 126.04, 125.97, 125.8, 125.7, 116.4 (d, J = 23.3 Hz), 26.64 (d, J = 70.2 Hz), 
26.57 (d, J =70.7 Hz), 20.0, 16.1 (d, J = 2.9 Hz), 16.0 (d, J = 3.6 Hz), 15.1 (d, J = 2.8 Hz), 
14.7 (d, J = 2.8 Hz); 31P NMR  47.0; IR (neat) 3048, 2953, 1510, 1475, 1221, 1199, 1180, 
1159, 1141, 1114, 1025, 875 cm–1; HRMS (ESI-TOF) calcd for C21H26FN3OP [M+H]+ 
386.1798, found 386.1802. 
 
(1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1H-1,2,3-triazol-4-
yl)diisopropylphosphine oxide (3.6r). Following General procedure C, the product was 
obtained as a brown solid (64 mg) in 39% yield. Rf  = 0.15 (100% EtOAc): 1H NMR (500 
MHz, CDCl3)  7.53 (dd, J = 7.5, 1.0 Hz, 1H), 7.35 (t, J = 7.5 Hz, 1H), 7.28–7.25 (m, 2H), 
7.02–6.99 (m, 3H), 6.71 (d, J = 8.0 Hz, 1H), 3.37 (s, 3H), 2.64–2.59 (m, 1H), 2.27–2.21 
(m, 1H), 1.31–1.22 (m, 6H), 1.03 (dd, J = 16.5, 6.5 Hz, 3H), 0.94 (dd, J = 15.0, 6.5 Hz, 
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3H); 13C NMR (125 MHz, CDCl3)  162.5 (d, J = 249.0 Hz), 156.5, 142.5 (d, J = 17.6 Hz), 
136.9 (d, J = 110.7 Hz), 133.1, 132.0, 126.0, 125.9, 120.7, 115.9 (d, J = 22.6 Hz), 114.9, 
110.7, 55.0, 27.1 (d, J = 70.4 Hz), 25.6 (d, J =70.4 Hz), 16.1 (d, J = 1.8 Hz), 15.9 (d, J = 
3.5 Hz), 14.8 (d, J = 1.8 Hz), 14.6 (d, J = 2.9 Hz); 31P NMR  46.1; IR (neat) 2958, 2928, 
1505, 1475, 1241, 1223, 1196, 1178, 1151, 1122, 1098, 1027, 996, 844 cm–1; HRMS (ESI-
TOF) calcd for C21H26FN3O2P [M+H]+ 402.1747, found 402.1725. 
 
(5-(2,6-Dimethoxyphenyl)-1-(4-fluorophenyl)-1H-1,2,3-triazol-4-
yl)diisopropylphosphine oxide (3.6s). Following General procedure C, the product 
was obtained as a brown solid (104 mg) in 68% yield. Rf  = 0.05 (100% EtOAc): 1H NMR 
(500 MHz, CDCl3)  7.34–7.31 (m, 2H), 7.26 (t, J = 8.5 Hz, 1H), 6.99 (t, J = 8.5 Hz, 2H), 
6.46 (d, J = 8.5 Hz, 2H), 3.60 (s, 6H), 2.37–2.32 (m, 2H), 1.23–1.12 (m, 12H); 13C NMR 
(125 MHz, CDCl3)  162.6 (d, J = 249.1 Hz), 158.6, 139.6 (d, J = 17.7 Hz), 137.5 (d, J = 
112.2 Hz), 132.7 (d, J = 2.9 Hz), 132.1, 115.8 (d, J = 23.2 Hz), 104.1, 103.7, 55.6, 26.8 
(d, J = 70.3 Hz), 15.8 (d, J = 2.5 Hz), 14.7 (d, J = 2.6 Hz); 31P NMR  46.6; IR (neat) 2926, 
1590, 1509, 1476, 1435, 1256, 1227, 1199, 1181, 1143, 1106, 1081, 1026, 853 cm–1; 
HRMS (ESI-TOF) calcd for C22H28FN3O3P [M+H]+ 432.1852, found 432.1855. 
 
(1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)diisopropylphosphine oxide (3.6t). 
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Following General procedure C, the product was obtained as a brown solid (65 mg) in 
35% yield. Rf  = 0.08 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  8.59 (s, 1H), 7.78–7.76 
(m, 2H), 7.22 (t, J = 8.5 Hz, 2H), 2.46–2.42 (m, 2H), 1.24 (dd, J = 16.0, 7.0 Hz, 6H), 1.15 
(dd, J = 16.5, 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  162.7 (d, J = 249.7 Hz), 140.6 (d, 
J = 109.6 Hz), 132.9 (d, J = 2.4 Hz), 130.0 (d, J = 18.7 Hz), 122.6 (d, J = 8.4 Hz), 117.0 
(d, J = 23.4 Hz), 25.9 (d, J = 70.2 Hz), 15.7 (d, J = 2.5 Hz), 14.8 (d, J = 2.9 Hz); 31P NMR 
 48.3; IR (neat) 3071, 2965, 1519, 1466, 1229, 1202, 1179, 1150, 1041, 1032, 1022, 981, 
883 cm–1; HRMS (ESI-TOF) calcd for C14H20FN3OP [M+H]+ 296.1328, found 296.1325. 
 
(1-Benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)di-tert-butylphosphine oxide (3.5a-tBu). 
Following General procedure B, the product was obtained as a light yellow powder (0.11 
g) in 59% yield. Rf  = 0.65 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.46 (d, J = 7.0 
Hz, 2H), 7.41–7.36 (m, 5H), 7.28 (t, J = 7.5 Hz, 2H), 7.23 (t, J = 7.0 Hz, 1H), 6.28 (s, 2H), 
1.03 (d, J = 15.5 Hz, 18H); 13C NMR (125 MHz, CDCl3)  150.0 (d, J = 12.4 Hz), 137.0, 
132.9, 131.5, 129.4, 128.7, 128.4, 128.0, 127.9, 124.2 (d, J = 69.9 Hz), 54.9, 37.5 (d, J = 
62.3 Hz), 26.5; 31P NMR  59.5; IR (neat) 2951, 2870, 1475, 1457, 1428, 1199, 1165, 
1149, 992, 811 cm–1; HRMS (ESI-TOF) calcd for C23H31N3OP [M+H]+ 396.2205, found 
396.2229. 
180 
 
 
(1-Benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)di-tert-butylphosphine oxide (3.6a-tBu). 
Following General procedure B, the product was obtained as a yellow solid (63 mg) in 
35% yield. Rf  = 0.35 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.32 (t, J = 7.0 Hz, 1H), 
7.26 (t, J = 7.5 Hz, 2H), 7.18–7.17 (m, 3H), 7.11 (d, J = 7.0 Hz, 2H), 6.91–6.90 (m, 2H), 
5.30 (s, 2H), 1.20 (d, J = 14.5 Hz, 18H); 13C NMR (125 MHz, CDCl3)  145.6 (d, J = 16.6 
Hz), 137.0 (d, J = 103.2 Hz), 135.0, 130.1, 129.5, 128.6, 128.1, 127.8, 127.3, 126.2, 51.6, 
36.1 (d, J = 63.5 Hz), 26.3; 31P NMR  48.4; IR (neat) 2950, 1474, 1455, 1398, 1390, 1368, 
1198, 1153, 814 cm–1; HRMS (ESI-TOF) calcd for C23H31N3OP [M+H]+ 396.2205, found 
396.2209. 
 
(1-Benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)dibutylphosphine oxide (3.5a-nBu). 
Following General procedure B, the product was obtained as an off-white solid (33 mg) 
in 22% yield. Rf  = 0.70 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.46–7.40 (m, 5H), 
7.35–7.30 (m, 5H), 6.11 (s, 2H), 1.60–1.52 (m, 2H), 1.40–1.28 (m, 4H), 1.14–1.03 (m, 6H), 
0.69 (t, J = 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  151.2 (d, J = 16.3 Hz), 136.2, 131.3, 
129.62, 129.56, 128.71, 128.69, 128.67, 128.4, 124.9 (d, J = 90.5 Hz), 54.1, 30.9 (d, J = 
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72.9 Hz), 23.8 (d, J = 15.1 Hz), 23.1 (d, J = 5.0 Hz), 13.5; 31P NMR  35.8; IR (neat) 2957, 
2928, 1466, 1455, 1448, 1403, 1178, 1160, 1132, 1073, 905 cm–1; HRMS (ESI-TOF) calcd 
for C23H31N3OP [M+H]+ 396.2205, found 396.2175. 
 
(1-Benzyl-5-phenyl-1H-1,2,3-triazol-4-yl)dibutylphosphine oxide (3.6a-nBu). 
Following General procedure B, the product was obtained as a white solid (74 mg) in 
49% yield. Rf  = 0.33 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.47–7.39 (m, 3H), 
7.32–7.30 (m, 2H), 7.26–7.23 (m, 3H), 7.00–6.98 (m, 2H), 5.43 (s, 2H), 2.05–1.96 (m, 2H), 
1.92–1.84 (m, 2H), 1.50–1.42 (m, 4H), 1.34–1.27 (m, 4H), 0.82 (t, J = 7.5 Hz, 6H); 13C 
NMR (125 MHz, CDCl3)  143.5 (d, J = 21.4 Hz), 139.1 (d, J = 119.5 Hz), 134.8, 130.3, 
130.2, 128.9, 128.8, 128.4, 127.6, 125.7, 52.0, 29.0 (d, J = 72.9 Hz), 24.1 (d, J = 16.3 Hz), 
23.6 (d, J = 3.8 Hz), 13.6; 31P NMR  35.4; IR (neat) 2956, 2931, 2870, 1454, 1407, 1279, 
1221, 1207, 1166, 1118, 1092, 1075, 1049, 1008, 902 cm–1; HRMS (ESI-TOF) calcd for 
C23H31N3OP [M+H]+ 396.2205, found 396.2212. 
 
(1-Benzyl-4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-5-yl)dibutylphosphine oxide 
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(3.5d-nBu). Following General procedure B, the product was obtained as a white solid 
(47 mg) in 28% yield. Rf  = 0.57 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.47 (d, J = 
7.0 Hz, 2H), 7.37 (t, J = 8.5 Hz, 1H), 7.35–7.27 (m, 3H), 6.60 (d, J =8.5 Hz, 2H), 6.10 (s, 
2H), 3.67 (s, 6H), 1.53–1.45 (m, 2H), 1.39–1.31 (m, 2H), 1.24–1.08 (m, 8H), 0.72 (t, J = 
7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  159.2, 143.9 (d, J = 14.6 Hz), 136.5, 131.7, 
128.7, 128.6, 128.2, 127.0 (d, J = 94.2 Hz), 108.6, 103.9, 55.7, 53.9, 30.1 (d, J = 73.0 Hz), 
24.2 (d, J = 16.3 Hz), 23.0 (d, J = 4.6 Hz), 13.7; 31P NMR  37.0; IR (neat) 2960, 2931, 
1605, 1589, 1474, 1433, 1289, 1253, 1218, 1175, 1159, 1113, 1035, 996 cm–1; HRMS 
(ESI-TOF) calcd for C25H35N3O3P [M+H]+ 456.2416, found 456.2410. 
 
(1-Benzyl-5-(2,6-dimethoxyphenyl)-1H-1,2,3-triazol-4-yl)dibutylphosphine oxide 
(3.6d-nBu). Following General procedure B, the product was obtained as a light yellow 
solid (99 mg) in 59% yield. Rf  = 0.12 (100% EtOAc): 1H NMR (500 MHz, CDCl3)  7.32 (t, 
J = 8.5 Hz, 1H), 7.17–7.12 (m, 3H), 6.92–6.90 (m, 2H), 6.47 (d, J = 8.5 Hz, 2H), 5.22 (s, 
2H), 3.49 (s, 6H), 1.89–1.84 (m, 4H), 1.53–1.39 (m, 4H), 1.26 (sext, J = 7.5 Hz, 4H), 0.81 
(t, J = 7.5 Hz, 6H); 13C NMR (125 MHz, CDCl3)  158.3, 139.7 (d, J = 123.2 Hz), 136.6 (d, 
J = 21.4 Hz), 134.6, 132.4, 128.2, 127.9, 127.8, 103.6, 103.3, 55.4, 52.1, 29.2 (d, J = 71.7 
Hz), 24.1 (d, J = 15.1 Hz), 23.3 (d, J = 2.5 Hz), 13.6; 31P NMR  35.7; IR (neat) 2956, 
2932, 2871, 1605, 1587, 1475, 1456, 1434, 1413, 1292, 1254, 1220, 1205, 1169, 1109, 
1030, 1002 cm–1; HRMS (ESI-TOF) calcd for C25H35N3O3P [M+H]+ 456.2416, found 
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456.2391. 
General procedure D: reduction of triazole phosphine oxide. To the stirring solution 
of the triazole phosphine oxide (0.20 mmol,) in toluene (0.20 M), was added trichlorosilane 
(4.00 mmol) under argon. After stirring for 20 h at 80 oC, the reaction mixture was diluted 
with CH2Cl2 (10 mL) and cooled in an ice bath. Aqueous NaOH (20%) was added dropwise 
at 0oC with continuous stirring until gas evolution ceased. The resulting organic and 
aqueous phases were separated.  The organic layer was dried by Na2SO4, filtered, and 
removal of solvent was followed by chromatography. 
 
1-Benzyl-5-(diisopropylphosphaneyl)-4-phenyl-1H-1,2,3-triazole (3.7a). Following 
General procedure D, the product was obtained as a white solid (67 mg) in 95% yield. Rf  
= 0.68 (EtOAc:Hexane=1:2): 1H NMR (500 MHz, CDCl3)  7.50 (dd, J = 7.5, 2.0 Hz, 2H), 
7.42–7.40 (m, 3H), 7.37 (d, J = 8.0 Hz, 2H), 7.34–7.29 (m, 3H), 5.84 (s, 2H), 2.08–2.01 
(m, 2H), 1.04 (dd, J = 14.0, 7.0 Hz, 6H), 0.54 (dd, J = 14.0, 7.0 Hz, 6H); 13C NMR (125 
MHz, CDCl3)  152.5 (d, J = 4.5 Hz), 136.2, 132.9, 130.5 (d, J = 29.6 Hz), 129.5, 128.8, 
128.7, 128.45, 128.42, 128.3, 53.1 (d, J = 12.7 Hz), 25.0 (d, J = 8.0 Hz), 21.7 (d, J = 26.3 
Hz), 20.9 (d, J = 10.4 Hz); 31P NMR  –17.8; IR (neat) 2953, 2924, 2865, 1464, 1384, 
1260, 1223, 1153, 1132, 1073, 1028 cm–1; HRMS (ESI-TOF) calcd for C21H27N3P [M+H]+ 
352.1943, found 352.1940. 
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1-Benzyl-4-(diisopropylphosphaneyl)-5-phenyl-1H-1,2,3-triazole (3.8a). Following 
General procedure D, the product was obtained as an off-white solid (65 mg) in 92% 
yield. Rf  = 0.69 (EtOAc:Hexane=1:2): 1H NMR (500 MHz, CDCl3)  7.44–7.37 (m, 3H), 
7.25 (d, J = 6.5 Hz, 2H), 7.14 (dd, J = 8.0, 1.5 Hz, 2H), 7.00–6.98 (m, 3H), 5.44 (s, 2H), 
2.42–2.37 (m, 2H), 1.04–1.00 (m, 12H); 13C NMR (125 MHz, CDCl3)  135.8, 130.5 (d, J 
= 42.7 Hz), 129.6, 129.0, 128.9, 128.8, 128.5, 128.4, 128.3, 127.4, 52.1, 23.7 (d, J = 6.4 
Hz), 20.3 (d, J = 17.6 Hz), 19.7 (d, J = 8.2 Hz); 31P NMR  –18.7; IR (neat) 2955, 2865, 
1496, 1455, 1410, 1382, 1363, 1240, 1183, 1155, 1114, 1028, 1007 cm–1; HRMS (ESI-
TOF) calcd for C21H27N3P [M+H]+ 352.1943, found 352.1951. 
 
1-Benzyl-4-(diisopropylphosphaneyl)-5-(o-tolyl)-1H-1,2,3-triazole (3.8b). Following 
General procedure D, the product was obtained as a white solid (28 mg) in 99% yield. Rf  
= 0.49 (EtOAc:Hex=1:4): 1H NMR (500 MHz, CDCl3)  7.34 (td, J = 7.5, 1.0 Hz, 1H), 7.24–
7.17 (m, 5H), 6.91–6.89 (m, 3H), 5.31 (d, J = 15.0 Hz, 1H), 5.25 (d, J = 15.0 Hz, 1H), 2.67–
2.60 (m, 1H), 2.11–2.05 (m, 1H), 1.75 (s, 3H), 1.08 (dd, J = 15.5, 7.0 Hz, 3H), 1.05–0.99 
(m, 6H), 0.91 (dd, J = 16.0, 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3)  144.2 (d, J = 39.0 
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Hz), 140.9 (d, J = 21.4 Hz), 137.9, 135.0, 130.9, 130.5, 130.0, 128.7, 128.3, 128.1, 127.0, 
125.8, 52.2, 24.2 (d, J = 8.8 Hz), 22.5 (d, J = 5.0 Hz), 20.42 (d, J = 30.2 Hz), 20.40, 19.9 
(d, J = 18.9 Hz), 19.7 (d, J = 3.8 Hz), 18.9 (d, J = 3.8 Hz); 31P NMR  46.9; IR (neat) 2950, 
2923, 2864, 1637, 1455, 1410, 1381, 1363, 1236, 1181 cm–1; HRMS (ESI-TOF) calcd for 
C22H29N3P [M+H]+ 366.2099, found 366.2085. 
 
1-Benzyl-5-(diisopropylphosphaneyl)-4-(2-methoxyphenyl)-1H-1,2,3-triazole (3.7c). 
Following General procedure D, the product was obtained as an off-white solid (73 mg) 
in 96% yield. Rf  = 0.48 (EtOAc:Hex=1:2): 1H NMR (500 MHz, CDCl3)  7.41–7.37 (m, 3H), 
7.33 (t, J = 7.0 Hz, 2H), 7.29 (d, J = 7.5 Hz, 1H), 7.18 (dd, J = 7.5, 1.5 Hz, 1H), 6.96 (t, J 
= 8.0 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 5.82 (s, 2H), 3.71 (s, 3H), 1.93–1.86 (m, 2H), 0.96 
(dd, J = 17.0, 7.0 Hz, 6H), 0.60 (dd, J= 14.0, 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  
158.2, 136.1, 131.74, 131.67 (d, J = 26.5 Hz), 130.4, 128.7 (d, J = 65.3 Hz), 128.6, 128.3, 
128.1, 121.7, 120.0, 110.8, 55.2, 52.8 (d, J = 12.4 Hz), 24.5 (d, J = 7.2 Hz), 21.3 (d, J = 
23.7 Hz), 20.8 (d, J = 11.6 Hz); 31P NMR  –15.4; IR (neat) 2925, 2865, 1607, 1526, 1496, 
1470, 1434, 1384, 1331, 1281, 1248, 1182, 1160, 1113, 1049, 1026 cm–1; HRMS (ESI-
TOF) calcd for C22H29N3OP [M+H]+ 382.2048, found 382.2034. 
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1-Benzyl-4-(diisopropylphosphaneyl)-5-(2-methoxyphenyl)-1H-1,2,3-triazole (3.8c). 
Following General procedure D, the product was obtained as a light yellow solid (72 mg) 
in 94% yield. Rf  = 0.65 (EtOAc:Hex=1:2): 1H NMR (500 MHz, CDCl3)  7.42–7.38 (m, 1H), 
7.22–7.18 (m, 3H), 6.97–6.90 (m, 5H), 5.43 (d, J = 14.5 Hz, 1H), 5.24 (d, J = 14.5 Hz, 1H), 
3.59 (s, 3H), 2.53–2.44 (m, 1H), 2.25–2.13 (m, 1H), 1.08–0.88 (m, 12H); 13C NMR (125 
MHz, CDCl3)  157.2, 142.0 (d, J = 41.0 Hz), 141.1 (d, J = 19.5 Hz), 135.6, 132.5, 131.4, 
128.5, 127.8, 127.7, 120.7, 116.5, 110.9, 55.2, 52.2, 23.7 (d, J = 7.8 Hz), 23.0 (d, J = 7.0 
Hz), 20.1 (d, J = 19.1 Hz), 19.9 (d, J = 8.2 Hz), 19.8 (d, J = 18.6 Hz), 19.1 (d, J = 5.6 Hz); 
31P NMR  –20.7; IR (neat) 2951, 2925, 2864, 1607, 1476, 1455, 1414, 1289, 1266, 1244, 
1181, 1162, 1114, 1046, 1025, 1001 cm–1; HRMS (ESI-TOF) calcd for C22H29N3OP [M+H]+ 
382.2048, found 382.2055. 
 
1-Benzyl-5-(diisopropylphosphaneyl)-4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazole 
(3.7d). Following General procedure D, the product was obtained as a white solid (22 
mg) in 41% yield. Rf  = 0.14 (EtOAc:Hex=1:4): 1H NMR (500 MHz, CDCl3)  7.36 (t, J = 
8.0 Hz, 2H), 7.33–7.25 (m, 4H), 6.56 (d, J = 8.5 Hz, 2H), 5.83 (s, 2H), 3.64 (s, 6H), 1.93–
1.85 (m, 2H), 0.94 (dd, J = 16.0, 6.5 Hz, 6H), 0.61 (dd, J = 15.0, 7.0 Hz, 6H); 13C NMR 
(125 MHz, CDCl3)  159.5, 144.9 (d, J = 5.5 Hz), 136.3, 132.8 (d, J = 25.7 Hz), 130.8, 
128.5, 128.3, 128.0, 110.0, 103.4, 55.3, 52.9 (d, J = 12.4 Hz), 24.3 (d, J = 7.0 Hz), 21.2 
(d, J = 22.1 Hz), 21.0 (d, J = 13.6 Hz); 31P NMR  –15.1; IR (neat) 2947, 2865, 1603, 1587, 
1472, 1456, 1432, 1328, 1287, 1251, 1215, 1109, 1031, 992 cm–1; HRMS (ESI-TOF) calcd 
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for C23H31N3O2P [M+H]+ 412.2154, found 412.2151. 
 
1-Benzyl-5-(dibutylphosphaneyl)-4-(2,6-dimethoxyphenyl)-1H-1,2,3-triazole (3.7d-
nBu). Following General procedure D, the product was obtained as an off-white solid (82 
mg) in 93% yield. Rf  = 0.45 (EtOAc:Hex=1:2): 1H NMR (500 MHz, CDCl3)  7.32 (t, J = 
8.5 Hz, 1H), 7.19–7.14 (m, 3H), 6.94 (dd, J = 6.5, 2.0 Hz, 2H), 6.49 (d, J = 8.5 Hz, 2H), 
5.24 (s, 2H), 3.51 (s, 6H), 1.96–1.87 (m, 2H), 1.64–1.59 (m, 2H), 1.31–1.25 (m, 8H), 0.81 
(t, J = 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  158.6, 144.5 (d, J = 14.8 Hz), 136.7 (d, 
J = 35.2 Hz), 135.6, 131.9, 128.2, 128.0, 127.7, 104.9, 103.7, 55.4, 52.3, 28.5 (d, J = 13.8 
Hz), 26.8 (d, J = 6.5 Hz), 24.5 (d, J = 4.7 Hz), 14.0; 31P NMR  –-49.8; IR (neat) 2956, 
2929, 2871, 1605, 1589 1497, 1475, 1456, 1434, 1292, 1253, 1185, 1111, 1031. 1001 
cm–1; HRMS (ESI-TOF) calcd for C25H35N3O2P [M+H]+ 440.2467, found 440.2458. 
 
1-Benzyl-4-(diisopropylphosphaneyl)-1H-1,2,3-triazole (3.8e). Following General 
procedure D, the product was obtained as an off-white solid (52 mg) in 94% yield. Rf  = 
0.80 (EtOAc:Hex=1:2): 1H NMR (500 MHz, CDCl3)  7.71 (s, 1H) 7.29–7.23 (m, 5H), 5.71 
(s, 2H), 2.03–1.94 (m, 2H), 0.92 (dd, J = 16.0, 7.0 Hz, 6H), 0.84 (dd, J = 12.5, 7.0 Hz, 6H); 
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13C NMR (125 MHz, CDCl3)  138.8 (d, J = 5.5 Hz), 136.0, 132.8 (d, J = 26.4 Hz), 128.7, 
128.3, 128.1, 52.6 (d, J = 9.8 Hz), 24.0 (d, J = 8.4 Hz), 19.7 (d, J = 17.6 Hz), 19.0 (d, J = 
8.3 Hz); 31P NMR  –23.4; IR (neat) 2954, 2928, 2867, 1456, 1433, 1384, 1270, 1211, 
1187, 1153, 1121, 1028 cm–1; HRMS (ESI-TOF) calcd for C15H23N3P [M+H]+ 276.1630, 
found 276.1639. 
 
4-(Diisopropylphosphaneyl)-1-(4-methoxyphenyl)-5-phenyl-1H-1,2,3-triazole (3.8k). 
Following General procedure D, the product was obtained as a white solid (65 mg) in 
89% yield. Rf  = 0.70 (EtOAc:Hex=1:2): 1H NMR (500 MHz, CDCl3)  7.36–7.33 (m, 3H), 
7.25 (dd, J = 7.5, 2.0 Hz, 2H), 7.21 (dd, J = 7.0, 2.0 Hz, 2H), 6.86 (dd, J = 7.0, 2.0 Hz, 2H), 
3.81 (s, 3H), 2.53–2.47 (m, 2H), 1.11–1.05 (m, 12H); 13C NMR (125 MHz, CDCl3)  159.8, 
144.2 (d, J = 33.7 Hz), 140.6 (d, J = 23.6 Hz), 130.5 (d, J = 3.1 Hz), 129.9, 129.1, 128.6, 
127.7, 126.4, 114.3, 55.6, 23.6 (d, J = 7.8 Hz), 20.1 (d, J = 18.1 Hz), 19.7 (d, J = 8.5 Hz); 
31P NMR  –18.8; IR (neat) 2951, 2924, 2864, 1609, 1513, 1463, 1301, 1251, 1181, 1171, 
1108, 1067, 1030 cm–1; HRMS (ESI-TOF) calcd for C21H27N3OP [M+H]+ 368.1892, found 
368.1879. 
 
4-(Diisopropylphosphaneyl)-1-(4-fluorophenyl)-5-phenyl-1H-1,2,3-triazole (3.8p). 
Following General procedure D, the product was obtained as an off-white solid (10 mg) 
189 
 
in 83% yield. Rf  = 0.68 (EtOAc:Hex=1:4): 1H NMR (500 MHz, CDCl3)  7.38–7.34 (m, 3H) 
7.31–7.28 (m, 2H), 7.23 (dd, J = 7.5, 2.0 Hz, 2H), 7.06 (t, J = 8.5 Hz, 2H), 2.48–2.39 (m, 
2H), 1.09–1.03 (m, 12H); 13C NMR (125 MHz, CDCl3)  162.5 (d, J = 249.0 Hz), 144.3 (d, 
J = 33.5 Hz), 141.1 (d, J = 24.5 Hz), 130.9, 130.5 (d, J = 2.8 Hz), 129.4, 128.8, 127.4, 
126.9 (d, J = 8.6 Hz), 116.3 (d, J = 23.1 Hz), 23.6 (d, J = 7.7 Hz), 20.2 (d, J = 18.0 Hz), 
19.7 (d, J = 8.6 Hz); 31P NMR  –19.6; IR (neat) 2956, 2924, 2865, 1509, 1466, 1449, 
1265, 1234, 1221, 1180, 1157, 1140, 1067, 839 cm–1; HRMS (ESI-TOF) calcd for 
C20H24FN3P [M+H]+ 356.1692, found 356.1685. 
 
Parallel Microscale Experimentation Data 
 The solutions of clickphos ligands (0.1 M), Pd(OAc)2 (0.05 M), and Cs2CO3 (0.086 
M) in THF were prepared. First, each ligand (20 L, 2 mol) was dosed into the 24-well 
plate vials and removed the solvent by Genevac. The Pd(OAc)2 (20 L, 1 mol) was 
introduced across the plate and stripped off the solvent by Genevac. Next, the base (350 
L, 30 mol) was added as a slurry, followed by removal of solvent by Genevac. Finally, 
0.2 M concentration of both a solution of 3,5-dichloropyridazine (50 L, 10 mol) and 
phenylboronic acid (50 L, 10 mol) in 1,4-dioxane were dosed into each vial. After 
purging with the micro stirbar to each vial, the reaction plate was sealed and stirred for 1 
h at 75 C. Upon cooling to room temperature, the reaction mixture vials were diluted with 
500 L of the 4,4’-di-tert-butylbiphenyl in MeCN solution (10 mol). The plate was stirred 
vigorously for 2 min after sealing the plate. To a 96-well plate LC block were added 700 
L of MeCN, followed by 25 L of the mixture from the reaction well-plate addition. The 
diluted mixture was then analyzed using Agilent Technologies UPLC with a 96-well plate 
auto-sampler. 
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HTE Results of Suzuki-Miyaura Coupling with 3,5-Dichloropyridazine (Scheme 3.7) 
 
Ligand 3.11/IS 3.12/IS 3.13/IS 3.12/3.11 
3.7a 0.072 0.205 0.017 2.847 
3.8a 0.118 0.264 0.028 2.242 
3.7c 0.064 0.253 0.023 3.959 
3.8c 0.096 0.246 0.033 2.553 
3.7c-Cy 0.050 0.207 0.018 4.123 
3.8c-Cy 0.081 0.290 0.022 3.589 
3.7d-nBu 0.057 0.279 0.015 4.912 
3.8k 0.085 0.181 0.016 2.140 
3.8b 0.046 0.214 0.017 4.661 
3.8e 0.093 0.023 0.012 0.250 
3.7d 0.063 0.256 0.013 4.08 
3.7d-nBu 0.096 0.047 0.019 0.486 
3.8p 0.094 0.207 0.029 2.207 
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CHAPTER 4: OXIDATIVE COUPLING OF 3-OXINDOLE TO CONSTRUCT 
QUATERNARY CENTERS 
4.1. Introduction 
 
Figure 4.1. Representative Natural Prodcuts Containing 2,2-Disubstituted Indolin-3-one 
 
 Many natural products featuring the 2,2-disubstituted-3-oxindole backbone are 
found in indole alkaloids such as isatisine A, cephalinone, austimide, and halichrome A 
etc (Figure 4.1).1 Moreover, C-2 quaternary indolin-3-one scaffolds have been utilized as 
useful synthetic intermediates in numerous natural product syntheses (Scheme 4.1).2 In 
                                                     
1 (a) Wu, P.-L.; Hsu, Y.-L.; Jao, C.-W. Indole Alkaloids from Cephalanceropsis Gracilis. J. Nat. Prod. 
2006, 69 (10), 1467–1470. (b) Liu, J.-F.; Jiang, Z.-Y.; Wang, R.-R.; Zheng, Y.-T.; Chen, J.-J.; Zhang, 
X.-M.; Ma, Y.-B. Isatisine A, a Novel Alkaloid with an Unprecedented Skeleton from Leaves of Isatis 
Indigotica. Org. Lett. 2007, 9 (21), 4127–4129. (c) Tsukamoto, S.; Umaoka, H.; Yoshikawa, K.; 
Ikeda, T.; Hirota, H. Notoamide O, a Structurally Unprecedented Prenylated Indole Alkaloid, and 
Notoamides P−R from a Marine-Derived Fungus, Aspergillus Sp. J. Nat. Prod. 2010, 73 (8), 1438–
1440. (d) Liu, R.-R.; Ye, S.-C.; Lu, C.-J.; Zhuang, G.-L.; Gao, J.-R.; Jia, Y.-X. Dual Catalysis for the 
Redox Annulation of Nitroalkynes with Indoles: Enantioselective Construction of Indolin-3-Ones 
Bearing Quaternary Stereocenters. Angew. Chem. Int. Ed. 2015, 54 (38), 11205–11208. (e) Baran, 
P. S.; Corey, E. J. A Short Synthetic Route to (+)-Austamide, (+)-Deoxyisoaustamide, and (+)-
Hydratoaustamide from a Common Precursor by a Novel Palladium-Mediated Indole → 
Dihydroindoloazocine Cyclization. J. Am. Chem. Soc. 2002, 124 (27), 7904–7905. 
2 (a) Pearson, W. H.; Mi, Y.; Lee, I. Y.; Stoy, P. Total Synthesis of the Kopsia Lapidilecta Alkaloid 
(±)-Lapidilectine B. J. Am. Chem. Soc. 2001, 123 (27), 6724–6725. (b) Wang, C.; Wang, Z.; Xie, 
X.; Yao, X.; Li, G.; Zu, L. Total Synthesis of (±)-Grandilodine B. Org. Lett. 2017, 19 (7), 1828–1830. 
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2001, the Pearson group demonstrated that the treatment of ortho-azidoaryl ketones with 
KOH, referred to as the Smalley cyclization,3 was able to construct key 1,2-dihydro-3H-
indol-3-one successfully during the synthesis of lapidilectine B.2a The 2-spirocyclic indolin-
3-one backbone was employed via a Diels-Alder reaction in grandilodine B synthesis by 
Zhu and coworkers.2b The Kawasaki group disclosed that the Mannich-type nucleophilic 
addition reaction enabled generating a key intermediate, the C-2 quaternary indolin-3-one, 
from 2-hydroxyindolin-3-one in the presence of acid to accomplish the first total synthesis 
of hinckdentine A.2c Stepwise 2,2-disubstituted-3-oxindole moiety was obtained from 2-
hydroxyindolin-3-one via a Grignard reaction followed by a pinacol-like rearrangement 
under acidic conditions.2d In 2011, the Tamber and Movassaghi groups individually 
reported that the efficient strategy of oxindole preparation could be achieved by means of 
oxidation and Wagner–Meerwein [1,2]-rearrangement in the synthesis of (–)-trigonoliimine 
C.2e,f Recently, simple Michael addition afforded 2,2-dialkylated indolin-3-one as a 
synthetic building block for lundurine A by Nishida and coworkers.2g 
                                                     
(c) Higuchi, K.; Sato, Y.; Tsuchimochi, M.; Sugiura, K.; Hatori, M.; Kawasaki, T. First Total Synthesis 
of Hinckdentine A. Org. Lett. 2009, 11 (1), 197–199. (d) Liu, Y.; McWhorter, W. W. Synthesis of 8-
Desbromohinckdentine A1. J. Am. Chem. Soc. 2003, 125 (14), 4240–4252. (e) Han, S.; 
Movassaghi, M. Concise Total Synthesis and Stereochemical Revision of All (−)-Trigonoliimines. 
J. Am. Chem. Soc. 2011, 133 (28), 10768–10771. (f) Qi, X.; Bao, H.; Tambar, U. K. Total Synthesis 
of (±)-Trigonoliimine C via Oxidative Rearrangement of an Unsymmetrical Bis-Tryptamine. J. Am. 
Chem. Soc. 2011, 133 (26), 10050–10053. (g) Arai, S.; Nakajima, M.; Nishida, A. A Concise and 
Versatile Synthesis of Alkaloids from Kopsia Tenuis: Total Synthesis of (±)‐Lundurine A and B. 
Angew. Chem. Int. Ed. 2014, 53 (22), 5569–5572. 
3 Ardakani, M. A.; Smalley, R. K. Base-Induced Intramolecular Cyclisation of o-Azidophenyl sec-
Alkyl Ketones. A New Synthesis of 2,2-Dialkylindoxyls. Tetrahedron Lett. 1979, 20 (49), 4769–
4772. 
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Scheme 4.1. Examples of 2,2-Disubstituted Indolin-3-ones as Efficient Intermediates for Natural 
Product Syntheses  
 
4.2. Approaches to Construct 2,2-Disubstituted Indolin-3-one 
 Due to the versatile use of 3-oxindoles bearing C-2 quaternary centers in bioactive 
molecule syntheses,2 diverse synthetic methods have been developed for several 
decades.4 In the early 1950s, acid-catalyzed rearrangement with 
                                                     
4 (a) Witkop, B. The Structure of the So-Called 11-Hydroxytetrahydrocarbazolenine. J. Am. Chem. 
Soc. 1950, 72 (1), 614–620. (b) Witkop, B.; Patrick, J. B. The Course and Kinetics of the Acid-
Base-Catalyzed Rearrangements of 11-Hydroxytetrahydrocarbazolenine 1. J. Am. Chem. Soc. 
1951, 73 (5), 2188–2195. (c) Liu, Y.; McWhorter, W. W. Study of the Addition of Grignard Reagents 
to 2-Aryl-3 H -Indol-3-Ones 1. J. Org. Chem. 2003, 68 (7), 2618–2622. (d) Altinis Kiraz, C. I.; Emge, 
T. J.; Jimenez, L. S. Oxidation of Indole Substrates by Oxodiperoxomolybdenum·Trialkyl(Aryl)- 
Phosphine Oxide Complexes. J. Org. Chem. 2004, 69 (6), 2200–2202. (e) S. Baran, P.; Jessing, 
M. Oxidative Coupling of Indoles with 3-Oxindoles. HETEROCYCLES 2010, 82 (2), 1739. (f) Wetzel, 
A.; Gagosz, F. Gold‐Catalyzed Transformation of 2‐Alkynyl Arylazides: Efficient Access to the 
Valuable Pseudoindoxyl and Indolyl Frameworks. Angew. Chem. Int. Ed. 2011, 50 (32), 7354–7358. 
(g) Goriya, Y.; Ramana, C. V. Synthesis of Pseudo-Indoxyl Derivatives via Sequential Cu-
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hydroxytetrahydrocarbazole afforded a simple 2-spirocycloindolin-3-one (Scheme 4.2).4a,b 
This Wagner–Meerwein rearrangement strategy is still utilized in natural product synthesis 
as mentioned above (Scheme 4.1).2e,f 
 
Scheme 4.2. Wagner–Meerwein Rearrangement to Construct 2,2-Disubstituted Indolin-3-one 
 
 Base-induced intramolecular cyclization enabled easy access to 2,2-dialkylated 
indolin-3-one from ortho-azidoaryl ketones by Smalley in 1979.3 Later, the Ramana group 
modified the process via Cu-catalyzed SNAr and Smalley reaction in one pot.4g Instead of 
conventional multi-step synthesis of ortho-azidoaryl ketones, the modified procedure 
generated the corresponding cyclized C-2 quaternary indolin-3-one in the presence of 
catalytic Cu(I) salt, sodium ascorbate, NaN3 and K2CO3 from ortho-bromoaryl ketone 
(Scheme 4.3). 
                                                     
Catalyzed SNAr and Smalley Cyclization. Chem. Commun. 2013, 49 (57), 6376. (h) Dhara, K.; 
Mandal, T.; Das, J.; Dash, J. Synthesis of Carbazole Alkaloids by Ring‐Closing Metathesis and 
Ring Rearrangement–Aromatization. Angew. Chem. Int. Ed. 2015, 54 (52), 15831–15835. (i) 
Guchhait, S. K.; Chaudhary, V.; Rana, V. A.; Priyadarshani, G.; Kandekar, S.; Kashyap, M. 
Oxidative Dearomatization of Indoles via Pd-Catalyzed C–H Oxygenation: An Entry to C2-
Quaternary Indolin-3-Ones. Org. Lett. 2016, 18 (7), 1534–1537. (j) Zhang, C.; Li, S.; Bureš, F.; Lee, 
R.; Ye, X.; Jiang, Z. Visible Light Photocatalytic Aerobic Oxygenation of Indoles and pH as a 
Chemoselective Switch. ACS Catal. 2016, 6 (10), 6853–6860. (k) Li, Y.-J.; Yan, N.; Liu, C.-H.; Yu, 
Y.; Zhao, Y.-L. Gold/Copper-Co-Catalyzed Tandem Reactions of 2-Alkynylanilines: A Synthetic 
Strategy for the C2-Quaternary Indolin-3-Ones. Org. Lett. 2017, 19 (5), 1160–1163. (l) Xia, Z.; Hu, 
J.; Gao, Y.-Q.; Yao, Q.; Xie, W. Facile Access to 2,2-Disubstituted Indolin-3-Ones via a Cascade 
Fischer Indolization/Claisen Rearrangement Reaction. Chem. Commun. 2017, 53 (54), 7485–7488. 
(m) Fu, W.; Song, Q. Copper-Catalyzed Radical Difluoroalkylation and Redox Annulation of 
Nitroalkynes for the Construction of C2-Tetrasubstituted Indolin-3-Ones. Org. Lett. 2018, 20 (2), 
393–396. (n) Zhou, X.-Y.; Chen, X.; Wang, L.-G.; Yang, D.; Li, J.-H. Ruthenium-Catalyzed 
Oxidative Dearomatization of Indoles for the Construction of C2-Quaternary Indolin-3-Ones. Synlett 
2018, 29 (06), 835–839. 
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Scheme 4.3. Approaches to C-2 Quaternary Indolin-3-one via Smalley Cyclization 
 
 In 2003, McWhorter and Liu reported that Grignard addition to 2-aryl-3H-indol-3-
one followed by acid-induced rearrangement provided 2,2-disubstituted-3-oxindole 
(Scheme 4.4).4c This protocol was used as one of the key steps to synthesize the indoxyl 
natural product analog, 8-desbromohinckdentine A.2d 
 
Scheme 4.4. Grignard Addition and Pinacol-type Rearrangement to Access 2,2-Disubstituted-3-
oxindole 
 
 The Gagosz group developed a Au-catalyzed cylcoisomerization with 2-alkynyl 
aryl azides followed by Claisen rearrangement to generate various C-2 allyl–functionalized 
quaternary indolin-3-ones (Scheme 4.5.a).4f In 2017, Xie and coworkers demonstrated 
that readily accessible hydrazines and allyloxy ketones enabled access to similar 3-
allyloxy indole intermediates by means of a Fischer-Indole reaction (Scheme 4.5.b).4l After 
Claisen rearrangement, this protocol gave rise to 2,2-disubstituted-3-oxindoles, especially 
C-2 allyl–substituted indolin-3-ones, in good yield. 
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Scheme 4.5. Access to 2,2-Disubstituted Indolin-3-one via Au-catalyzed Cycloisomerization or 
Fischer Indolization and Claisen Rearrangement 
 
 Recently, owing to the efficiency of oxidation chemistry, a number of different types 
of oxidative routes have been employed to construct 2,2-disubstituted-3-oxindole. 
Oxidative coupling between 3-oxindoles, which can be prepared in two steps from 
commercial methyl anthranilate, and amino heterocycles was achieved by treatment with 
excess oxidant, CAN, in the presence of NaHCO3 (Scheme 4.6.a).4e The oxidative 
dearomatization of indole under Pd-catalyzed C-H oxygenation conditions achieved the 
construction of 2-tetrasubstituted indolin-3-one (Scheme 4.6.b).4i Moreover, Zhou and 
coworkers revealed that RuCl3 and NaIO4 were able to generate C-2 quaternary-3-
oxindole via oxidative indole dearomatization in 2018 (Scheme 4.6.c).4n 
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Scheme 4.6. Oxidative Approaches to Build C-2 Quaternary Indolin-3-one 
 
 Along with a variety of synthetic methods shown above, asymmetric approaches 
have also been developed over the past 10 years.5 In 2007, the Kawasaki group 
demonstrated that N-benzylated cinchonidine salt, a phase transfer catalyst, induced 
asymmetric prenylation at the C-2 position with moderate selectivity (Scheme 4.7.a).5a An 
asymmetric Friedel-Crafts reaction was accomplished to generate 2,2-disubstituted 
                                                     
5 (a) Kawasaki, T.; Higuchi, K.; Masuda, K.; Koseki, T.; Hatori, M.; Sakamoto, M. Asymmetric 
Alkylation of 2-Monosubstituted Indolin-3-Ones. HETEROCYCLES 2007, 73 (1), 641. (b) Rueping, 
M.; Raja, S.; Núñez, A. Asymmetric Brønsted Acid-Catalyzed Friedel-Crafts Reactions of Indoles 
with Cyclic Imines - Efficient Generation of Nitrogen-Substituted Quaternary Carbon Centers. Adv. 
Synth. Catal. 2011, 353 (4), 563–568. (c) Jin, C.-Y.; Wang, Y.; Liu, Y.-Z.; Shen, C.; Xu, P.-F. 
Organocatalytic Asymmetric Michael Addition of Oxindoles to Nitroolefins for the Synthesis of 2,2-
Disubstituted Oxindoles Bearing Adjacent Quaternary and Tertiary Stereocenters. J. Org. Chem. 
2012, 77 (24), 11307–11312. (d) Parra, A.; Alfaro, R.; Marzo, L.; Moreno-Carrasco, A.; García 
Ruano, J. L.; Alemán, J. Enantioselective Aza-Henry Reactions of Cyclic α-Carbonyl Ketimines 
under Bifunctional Catalysis. Chem. Commun. 2012, 48 (78), 9759. (e) Guo, C.; Schedler, M.; 
Daniliuc, C. G.; Glorius, F. N‐ Heterocyclic Carbene Catalyzed Formal [3+2] Annulation Reaction 
of Enals: An Efficient Enantioselective Access to Spiro‐ Heterocycles. Angew. Chem. Int. Ed. 2014, 
53 (38), 10232–10236. (f) Zhao, Y.-L.; Wang, Y.; Cao, J.; Liang, Y.-M.; Xu, P.-F. Organocatalytic 
Asymmetric Michael–Michael Cascade for the Construction of Highly Functionalized N-Fused 
Piperidinoindoline Derivatives. Org. Lett. 2014, 16 (9), 2438–2441. 
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indolin-3-one in high selectivity by using chiral phosphoric acid (Scheme 4.7.b).5b 
 
Scheme 4.7. Asymmetric Organocatalyzed Installation of Optically Active C-2 Quaternary Indolin-
3-one  
 
 Notably, bifunctionalized thioureas have been known for efficient asymmetric 
transformation of 2-tetrasubstituted indolin-3-one derivatives via either Michael addition 
(Scheme 4.8.a)5c,f or aza-Henry reaction (Scheme 4.8.b).5d According to the proposed 
transition state model, facial selectivity could be explained by means of hydrogen bonding 
between the thiourea and both substrates (Scheme 4.8). 
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Scheme 4.8. Chiral Thiourea-catalyzed Asymmetric Formation of 2,2-Disubstituted-3-oxindole  
 
4.3. Initial Screening to Optimize Oxidative Coupling of 3-Oxindole 
 Because of the structural importance of 3-oxindoles bearing a C-2 quaternary 
center in many natural products (Figure 4.1), the Kozlowski group began to develop an 
efficient strategy for constructing the corresponding 2,2-disubstituted indolin-3-one via 
transition metal-catalyzed aerobic oxidative coupling pathway. Due to the easy access of 
2-substituted-3-oxindoles (Scheme 4.9),4e as well as its favorable oxidation potential and 
possible transformations of the 2-ester group into versatile synthetic moieties,2c,6 2-
carboxymethyl-3-oxindole (4.1) was adopted as our initial substrate. 
                                                     
6 Karadeolian, A.; Kerr, M. A. Total Synthesis of (+)‐Isatisine A. Angew. Chem. Int. Ed. 2010, 49 
(6), 1133–1135. 
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Scheme 4.9. Preparation of 2-Carboxymethyl-3-oxindole (4.1) 
 
 Additional transition metals with salan/salen ligand complexes have proven to be 
effective for aerobic oxidative coupling of phenols.7 To find the optimal catalyst, a previous 
student, Erin Nigro, conducted HTE screening with 24 different combinations of 7 metals 
(Co,Cu, Cr, Ru, Mn, Fe, V) and 5 Schiff base ligands (Figure 4.2). Copper was found to 
be the most effective transition metal for the transformation, with the diphenyl salan 
(Figure 4.2, D) being the most efficient complex. 
                                                     
7 Lee, Y. E.; Cao, T.; Torruellas, C.; Kozlowski, M. C. Selective Oxidative Homo- and Cross-
Coupling of Phenols with Aerobic Catalysts. J. Am. Chem. Soc. 2014, 136 (19), 6782–6785. 
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Figure 4.2. HTE Screening with Metal-Schiff Base Complexes 
 
 With the optimal conditions, Erin Nigro tested the reaction with selected indoles 
and pyrroles from a previous report4e to prove the concept of the oxidative cross-coupling 
of 3-oxindole (Table 4.1). The 3-oxindole oxidative cross-coupling reaction was catalyzed 
by Cu-Salan-Ph (Table 4.1) with molecular oxygen as an oxidant. Across the table, 
coupling efficiency was shown to be similar to that of Baran or even better. For example, 
coupling with 4.2n yielded 65% coupled product instead of 18% yield according to the 
Baran’s protocol.4e 
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Table 4.1. Scope of 3-Oxindole Oxidative Cross-coupling by Erin Nigro 
 
4.4. Scope of 3-Oxindole Oxidative Cross-coupling 
 Success with Erin’s preliminary results enabled expansion of the substrate scope 
with a diverse array of substituted indoles and other heterocycles, including electron-rich 
arenes and is shown in Table 4.2–3. The Cu-catalyzed oxidative coupling condition 
tolerated both electron-rich and electron-deficient indoles (Table 4.2). Indoles with 
aromatic groups at the C-2 position afforded facile quaternary formation of 3-oxindoles in 
good to excellent yield (4.2f–h). Notably, our method shows much higher efficiency with 
electron-rich substrate (4.2k, 84%) compared to the previously reported protocol (17%).4e 
Furthermore, other improved results were able to be obtained such as 4.2i (62% vs 48%4e) 
and 4.2j (94% vs 66%4e).  
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Table 4.2. Expanded Substrate Scope of Indoles 
 
 Beyond the indoles, our attention moved onto other heterocycles to construct C-2 
quaternary 3-oxindoles (Table 4.3). Pyrrole smoothly converted to form a C-2 quaternary 
center. However, electronics plays a key role in pyrroles and furans that affect the 
transformation. In the case of pyrroles, a dramatic decrease in reactivity was observed in 
electron-poor substrate 4.2o. Interestingly, N-substituted pyrroles (4.2p, 4.2q) were able 
to couple with 3-oxindole in moderate yields (37–60%). The electron-donor substituted 
furan (4.2r) also produced 2,2-disubstituted indolin-3-one in 68% yield. Based on the 
observations in Table 4.3, we hypothesized that the oxidative coupling with 3-oxindole 
could be applied to the electron-rich aryl substrates, such as aniline or anisole. 
Representative electron-rich substrates, N,N-dialkylated aniline (4.2s, 4.2t) and 1,3,5-
trimethoxybenzene (4.2u), allowed extension of the reaction scope into simple arene 
moieties in good yields (52–66%).  
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Table 4.3. Other Heterocycles and Electron-rich Aryl Scope of 3-Oxindole Coupling  
 
4.5. Attempts to Develop Asymmetric Oxidative Coupling 
 After thorough studies on substrate scope, our attention turned to formation of the 
quaternary carbon in asymmetric fashion. Due to easy access to the asymmetric salan 
ligand, initial attempts examined the optimized catalyst, which was copper metal 
incorporated with an enantiomerically pure salan-Ph ligand (Table 4.4). Unfortunately, no 
asymmetric induction occurred with the chiral Cu-salan complex (entry 1). In addition, the 
bis(oxazoline) scaffold produced racemic C-2 quaternary indolin-3-one, and slowing the 
reaction did not improve the outcome (entries 2–3). Using a vanadium catalyst, which had 
been shown to be effective in asymmetric oxidative phenol coupling,8 however, gave a 
promising result (entry 5, 26% ee). 
                                                     
8 Kang, H.; Lee, Y. E.; Reddy, P. V. G.; Dey, S.; Allen, S. E.; Niederer, K. A.; Sung, P.; Hewitt, K.; 
Torruellas, C.; Herling, M. R.; et al. Asymmetric Oxidative Coupling of Phenols and 
Hydroxycarbazoles. Org. Lett. 2017, 19 (20), 5505–5508. 
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Entry Indole Catalyst Temperature (C) ee (%) 
1 4.2f Cu-salan-Ph 50 0 
2 4.2f CuCl2(indanolBox) 50 0 
3 4.2f CuCl2(indanolBox) 25 0 
4 4.2d CuCl2(indanolBox) 25 0 
5 4.2f V6 0 26 
Table 4.4. Initial Attempts at Asymmetric Oxidative Coupling of 3-Oxindole 
 
 To improve the selectivity, further investigation was conducted concerning the 
steric environment around the reaction center by changing to larger ester groups at the C-
2 position of the 3-oxindole. 2-tert-Butylcarboxyl-3-oxindole (4.4) was synthesized by 
means of Cossy’s Ir-catalyzed hydrogen transfer protocol (Scheme 4.10).9 
 
Scheme 4.10. Preparation of 2-tert-Butylcarboxylated-3-oxindole (4.4) 
 
                                                     
9 Anxionnat, B.; Gomez Pardo, D.; Ricci, G.; Rossen, K.; Cossy, J. Iridium-Catalyzed Hydrogen 
Transfer: Synthesis of Substituted Benzofurans, Benzothiophenes, and Indoles from Benzyl 
Alcohols. Org. Lett. 2013, 15 (15), 3876–3879. 
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 With 2-tert-buylcarboxylated 3-oxindole (4.4) and 2-phenylindole (4.2f), the same 
levels of selectivity were produced in the presence of V6 at room temperature (Table 4.5, 
entry 1). Improved enantiomeric excess was observed at lower temperatures (entry 2). 
Next, we utilized other amino acids and vanadium sources to study the effect of catalyst 
scaffold. Introducing smaller groups than tert-butyl at the amino acid branch resulted in 
slightly decreased selectivity (entry 5,6). Notably, varying enantioselectivity was detected 
depending on the vanadium source. A larger alkoxy–substituted vanadium catalyst 
engendered slightly higher selectivity (entry 3). Vanadium fluoride turned out to be the 
optimal group, and use of LiCl as an additive futher increased the selectivity (entry 4). 
Based on the improved results, we speculated that the sterics around the reaction center 
would be the key to induce a highly enantioselctive transformation. 
 
Entry R X Temperature (C) ee (%) 
1 t-Bu OMe (V6) 25 26 
2 t-Bu OMe (V6) 0 40 
3 t-Bu Oi-Pr (V7) 25 44 
4 t-Bu F (V8) 25 48(52)a 
5 Bn OMe (V6) 25 30 
6 CH2(2-naphthyl) F (V8) 25 20 
a0.5 equiv LiCl added as an additive 
Table 4.5. Optimization with 2-tert-Butylcarboxylated Indolin-3-one 
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 An adamantyl ester at C-2 was next chosen (4.6) according this hypothesis. In 
accordance with our hypothesis, it promoted the enantioselectivity in 68% ee (Table 4.6, 
entry 1). Additional modification was undertaken with a number of solvents, revealing that 
halogenated solvents are more effective with respect to both reactivity and selectivity 
(entry 2–5). The highest selectivity was obtained in chloroform (entry 5, 74% ee). 
 
Entry Solvent Yield (%) ee (%) 
1 1,2-dichloroethane 77 68 
2 toluene 47 46 
3 CH2Cl2 75 60 
4 1,2-dichlorobenzene 72 54 
5 CHCl3 66 74 
Table 4.6. Optimization with 2-Adamantylcarboxylated Indolin-3-one 
 
4.6. Conclusions and Future Directions 
  In summary, Cu-catalyzed oxidative cross-coupling of 3-oxindole has been 
accomplished under aerobic conditions, and the protocol allowed access to a larger scope 
of 2,2-disubstituted indolin-3-ones bearing synthetically useful heterocycles such as 
indoles, pyrroles and furan. In addition, promising levels of the asymmetric transformation 
also has been developed with an asymmetric vanadium catalyst.  
 Future work is required to tackle further selectivity improvement on the asymmetric 
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transformation and to perform the mechanistic investigation of this oxidative cross-
coupling reaction. We plan to explore additives to enhance enantioselectivity. Inspired by 
previous asymmetric methods to synthesize C-2 quaternary indolin-3-ones,5 an array of 
bifunctionalized thioureas bearing enantio-enriched cinchonidine moieties would be the 
initial additive candidates.  
4.4 Experimental Section 
General Considerations 
 Unless otherwise noted, all non-aqueous reactions were carried out under an 
atmosphere of dry N2 in dried glassware. When necessary, solvents and reagents were 
dried prior to use. THF was distilled from sodium benzophenone ketyl. CH2Cl2, 
ClCH2CH2Cl, and toluene were distilled from CaH2. High throughput experiments were 
performed at the Penn/Merck High Throughput Experimentation Laboratory at the 
University of Pennsylvania. The screens were analyzed by HPLC by addition of an internal 
standard. 
Analytical thin layer chromatography (TLC) was performed on EM Reagents 0.25 mm 
silica-gel 254-F plates. Visualization was accomplished with UV light. Chromatography 
was performed using a forced flow of the indicated solvent system on EM Reagents Silica 
Gel 60 (230-400 mesh). When necessary, the column was pre-washed with 1% Et3N in 
the eluent system. 1H NMR spectra were recorded on a 500 MHz spectrometer. Chemical 
shifts are reported in ppm from tetramethylsilane (0 ppm) or from the solvent resonance 
(CDCl3 7.26 ppm, DMSO-d6 3.58 ppm, acetone-d6 2.05 ppm, DMF-d7 2.50 ppm, CD3CN 
1.94 ppm, CD2Cl2 5.32 ppm). Data are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, 
and number of protons. Decoupled 13C NMR spectra were recorded at 125 MHz. IR 
spectra were taken on an FT-IR spectrometer. Accurate mass measurement analyses 
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were conducted via time-of-flight mass analyzer GCMS with electron ionization (EI) or via 
time-of-flight mass analyzer LCMS with electrospray ionization (ESI). The signals were 
measured against an internal reference of perfluorotributylamine for EI-GCMS and leucine 
enkephalin for ESI-LCMS. The instrument was calibrated and measurements were made 
using neutral atomic masses; the mass of the electron removed or added to create the 
charged species is not taken into account. Low resolution LCMS data were obtained by 
use of a UPLC system with a SQD mass analyzer equipped with electrospray ionization. 
Circular dichroism and UV-vis spectroscopy measurements carried out at ambient 
temperature (23 C). Enantiomeric excesses were determined using analytical HPLC with 
UV detection at 254 nm. Analytical Chiralpak columns (4.6 mm x 250 mm, 5 µm) from 
Daicel were used. Optical rotations were measured on a polarimeter with a sodium lamp. 
General procedure: oxidative 3-oxindole coupling. To a microwave vial was added 3-
oxindole (0.13 mmol), indole (0.13 mmol) and Cu-salan-Ph catalyst (9.3 mg, 0.01 mmol). 
The vial was sealed with a septum and the 1,2-dichloroethane (1.3 mL) was added. After 
degassing and purging with O2 three times, the vial was sealed with a microwave vial cap 
and was stirred at 50 oC for 20 h. Upon completion, the reaction mixture was then directly 
chromatographed using silica gel. 
 
Methyl 3-hydroxy-1H-indole-2-carboxylate (4.1). Following the literature protocol, the 
product was obtained as a yellow solid (1.74 g). Spectral data were in agreement with 
those reported.4e 
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Methyl 2-(1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2a). Following the General 
Procedure for 22 h, the product was obtained as a yellow solid in 90% NMR yield (50 mg, 
82% isolated yield). Spectral data were in agreement with those reported.4e 
 
Methyl 2-(5-cyano-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2b). Following the 
General Procedure for 16 h, the product was obtained as a yellow solid (39 mg) in 88% 
yield. Spectral data were in agreement with those reported.4e 
 
Methyl 2-(7-iodo-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2c). Following the 
General Procedure for 16 h, the product was obtained as a yellow solid (58 mg) in 95% 
yield. Rf  = 0.27 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.35 (br s, 1H), 7.68 
(d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.55–7.50 (m, 2H), 7.48 (d, J = 2.0 Hz, 1H), 
7.00 (d, J = 8.5 Hz, 1H), 6.93 (t, J = 7.5 Hz, 1H), 6.86 (t, J = 8.0 Hz, 1H), 5.76 (br s, 1H), 
3.80 (s, 3H); 13C NMR (125 MHz, CDCl3)  194.4, 168.8, 161.1, 138.3, 138.0, 131.4, 125.6, 
124.0, 122.0, 120.6, 120.0, 119.8, 113.6, 113.2, 77.0, 72.6, 53.9, 29.8; IR (neat) 3348, 
2920, 2850, 1731, 1693, 1611, 1485, 1466, 1428, 1323, 1291, 1230, 1150, 1101, 1083, 
1050, 971 cm–1; HRMS (ESI-TOF) calcd for C18H14IN2O3 [M+H]+ 433.0049, found 
433.0045. 
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Methyl 2-(1-methyl-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2d). Following the 
General Procedure for 19 h, the product was obtained as a yellow solid (45 mg) in 88% 
yield. Spectral data were in agreement with those reported.4e 
 
Methyl 2-(2-methyl-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2e). Following the 
General Procedure for 19 h, the product was obtained as a yellow solid (58 mg) in 77% 
yield. Spectral data were in agreement with those reported.4e 
 
Methyl 3-oxo-2-(2-phenyl-1H-indol-3-yl)indoline-2-carboxylate (4.2f). Following the 
General Procedure for 19 h, the product was obtained as a yellow solid (47 mg) in 94% 
yield. Rf  = 0.27 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.31 (br s, 1H), 7.62 
(d, J = 7.5 Hz, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.42 (d, J = 7.5 Hz, 2H), 7.37–7.34 (m, 3H), 
7.30 (d, J = 8.0 Hz, 1H), 7.19–7.14 (m, 2H), 7.01 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.5 Hz, 
1H), 6.93 (t, J = 7.5 Hz, 1H), 5.61 (br s, 1H), 3.18 (s, 3H); 13C NMR (125 MHz, CDCl3)  
195.2, 168.8, 160.9, 138.1, 138.0, 135.5, 132.5, 129.6, 128.8, 128.4, 126.8, 125.3, 122.7, 
120.6, 120.4, 120.2, 119.7, 113.4, 111.2, 108.2, 73.3, 53.2; IR (neat) 3345, 3052, 2950, 
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2920, 1697, 1613, 1485, 1457, 1431, 1323, 1292, 1233, 1196, 1150, 1099, 1072, 1013, 
972, 896 cm–1; HRMS (ESI-TOF) calcd for C24H19N2O3 [M+H]+ m/z = 383.1396; found 
383.1414. 
 
Methyl 2-(2-(4-fluorophenyl)-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2g). 
Following the General Procedure for 21 h, the product was obtained as a yellow solid (50 
mg) in 96% yield. Rf  = 0.4 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.35 (br 
s, 1H), 7.57 (d, J = 8.0 Hz, 1H), 7.54 (td, J = 8.0, 1.0 Hz, 1H), 7.38-7.35 (m, 2H), 7.29 (d, 
J = 8.0 Hz, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.16 (td, J = 8.0, 1.0 Hz, 1H), 7.03 (td, J = 8.0, 
1.0 Hz, 1H), 6.99–6.95 (m, 3H), 6.93 (t, J = 7.5 Hz, 1H), 5.62 (br s, 1H), 3.30 (s, 3H); 13C 
NMR (125 MHz, CDCl3)  195.2, 168.9, 163.0 (d, J = 249 Hz), 160.7, 138.1, 136.8, 135.5, 
131.6 (d, J = 8.3 Hz), 128.7, 126.9, 125.3, 122.8, 120.7, 120.5, 120.3, 119.5, 115.4 (d J = 
21.5 Hz), 113.4, 111.4, 108.5, 73.1, 53.4; IR (neat) 3354, 2951, 1704, 1613, 1498, 1457, 
1434, 1325, 1294, 1225, 1197, 1157, 1094, 1015, 974, 894 cm-1; HRMS (ESI-TOF) calcd 
for C24H18FN2O3 [M+H]+ 401.1301, found 401.1306. 
 
Methyl 2-(2-(4-chlorophenyl)-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2h). 
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Following the General Procedure for 22 h, the product was obtained as a yellow solid (40 
mg) in 73% yield. Rf  = 0.40 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  8.27 (br 
s, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.55 (td, J = 8.5, 1.5 Hz, 1H), 7.35 (d, J = 8.5 Hz, 2H), 
7.32 (d, J = 8.0 Hz, 1H), 7.28 (d, J =8.0 Hz, 2H), 7.22 (d, J = 8.5 Hz, 1H), 7.18 (td, J = 8.0, 
1.0 Hz, 1H), 7.03 (td, J = 8.0, 1.0 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 7.5 Hz, 
1H), 5.59 (br s, 1H), 3.32 (s, 3H); 13C NMR (125 MHz, CDCl3)  195.0, 168.9, 160.6, 138.1, 
136.6, 135.6, 135.0, 131.1, 130.9, 128.6, 126.9, 125.3, 123.0, 120.8, 120.6, 120.3, 119.6, 
113.4, 111.3, 108.8, 73.1, 53.4; IR (neat) 3341, 3052, 2950, 1698, 1610, 1483, 1467, 
1456, 1432, 1324, 1293, 1234, 1196, 1150, 1089, 1014, 973, 893, cm-1; HRMS (ESI-TOF) 
calcd for C24H18ClN2O3 [M+H]+ 417.1006, Found 417.1012. 
 
Methyl 2-(3-methyl-1H-indol-2-yl)-3-oxoindoline-2-carboxylate (4.2i). Following the 
General Procedure for 19 h, the product was obtained as a yellow solid (26 mg) in 62% 
yield. Spectral data were in agreement with those reported.4e 
 
Methyl 2-(7-bromo-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2j). Following the 
General Procedure for 22 h, the product was obtained as a brown solid (47 mg) in 94% 
yield. Spectral data were in agreement with those reported.4e 
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Methyl 2-(6-methoxy-1H-indol-3-yl)-3-oxoindoline-2-carboxylate (4.2k). Following the 
General Procedure for 21 h, the product was obtained as a yellow solid (37 mg) in 84% 
yield. Spectral data were in agreement with those reported.4e 
 
Methyl 3-(2-(methoxycarbonyl)-3-oxoindolin-2-yl)-1H-indole-4-carboxylate (4.2l). 
Following the General Procedure for 22 h at 80 C, the product was obtained as a yellow 
solid (37 mg) in 77% yield. Spectral data were in agreement with those reported.4e 
 
Methyl 3-oxo-2-(1H-pyrrol-2-yl)indoline-2-carboxylate (4.2m). Following the General 
Procedure for 15 h, the product was obtained as a brown oil (16 mg) in 49% yield. Rf  = 
0.50 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  9.38 (br s, 1H), 7.59 (d, J = 7.5 
Hz, 1H), 7.52 (td, J = 8.5, 1.0 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.91 (t, J = 7.5 Hz, 1H), 
6.83–6.82 (m, 1H), 6.30–6.28 (m, 1H), 6.15–6.14 (m, 1H), 5.61 (br s, 1H), 3.81 (s, 3H); 
13C NMR (125 MHz, CDCl3)  193.2, 167.7, 161.7, 138.1, 125.8, 124.9, 120.8, 119.3, 
118.9, 113.6, 108.3, 106.3, 71.9, 54.0; IR (neat) 3364, 2951, 1733, 1693, 1613, 1486, 
1467, 1433, 1324, 1233, 1197, 1153, 1139, 1101, 1028, 1008, 950 cm-1; HRMS (ESI-TOF) 
calcd for C14H12N2O3Na [M+Na]+ m/z = 279.0746; found 279.0756. 
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Methyl 2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-oxoindoline-2-carboxylate (4.2n). Following 
the General Procedure for 16 h, the product was obtained as a yellow solid (25 mg) in 
65% yield. Spectral data were in agreement with those reported.4e 
 
Methyl 2-(1-(2-cyanoethyl)-1H-pyrrol-2-yl)-3-oxoindoline-2-carboxylate (4.2p). 
Following the General Procedure for 24 h at 80 C , the product was obtained as a brown 
oil (24 mg) in 60% yield. Rf  = 0.25 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  
7.67 (dd, J = 8.0, 1.0 Hz, 1H), 7.57 (td, J = 8.0, 1.0 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 7.00 
(t, J = 7.5 Hz, 1H), 6.80 (t, J = 2.0 Hz, 1H), 6.16 (d, J = 2.0 Hz, 2H), 5.55 (s, 1H), 3.98–
3.89 (m, 2H), 3.88 (s, 3H), 2.73 (t, J = 7.0 Hz, 2H); 13C NMR (125 MHz, CDCl3)  193.8, 
168.1, 160.4, 138.4, 125.7, 125.6, 124.0, 121.5, 119.6, 117.4, 113.8, 111.7, 109.0, 73.1, 
54.3, 43.3, 20.0; IR (neat) 3347, 2952, 2250, 1737, 1704, 1613, 1483, 1468, 1434, 1323, 
1292, 1234, 1198, 1151, 1085, 1045, 979, 894 cm–1; HRMS (ESI-TOF) calcd for 
C17H16N3O3 [M+H]+ m/z = 310.1192; found 310.1180. 
 
Methyl 2-(1-methyl-1H-pyrrol-3-yl)-3-oxoindoline-2-carboxylate (4.2q). Following the 
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General Procedure for 18 h, the product was obtained as a yellow solid (13 mg) in 37% 
yield. Rf  = 0.5 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  7.67 (d, J = 7.5 Hz, 
1H), 7.53 (td, J = 7.5, 1.2 Hz, 1H), 7.00 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.61–
6.60 (m, 1H), 6.13–6.12 (m, 1H), 6.07–6.06 (m, 1H), 5.50 (br s, 1H), 3.87 (s, 3H), 3.42 (s, 
3H); 13C NMR (125 MHz, CDCl3)  193.8, 168.4, 160.6, 138.1, 126.2, 125.5, 125.4, 120.9, 
119.9, 113.8, 110.8, 107.2, 73.1, 54.2, 35.0; IR (neat) 3352, 2950, 1737, 1703, 1613, 
1484, 1467, 1434, 1322, 1306, 1291, 1246, 1230, 1196, 1150, 1092, 1027 cm–1; HRMS 
(ESI-TOF) calcd for C15H15N2O3 [M+H]+ 271.1083, found 271.1095. 
 
Methyl 2-(5-methoxyfuran-2-yl)-3-oxoindoline-2-carboxylate (4.2r). Following the 
General Procedure for 21 h, the product was obtained as a brown oil (26 mg) in 68% 
yield. Rf  = 0.33 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  7.64 (d, J = 8.0 Hz, 
1H), 7.51 (td, J = 8.0, 1.0 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 6.91 (t, J = 8.0 Hz, 1H), 6.37 
(d, J = 3.5 Hz, 1H), 5.56 (br s, 1H), 5.12 (d, J = 3.5 Hz, 1H), 3.81 (s, 6H); 13C NMR (125 
MHz, CDCl3)  191.8, 167.1, 162.0, 161.2, 138.4, 138.2, 125.7, 120.7, 119.4, 113.7, 110.7, 
80.5, 71.6, 58.0, 54.2; IR (neat) 3358, 2920, 1744, 1705, 1613, 1576, 1486, 1467, 1435, 
1367, 1324, 1295, 1258, 1199, 1152, 1099, 1027, 962 cm–1; HRMS (ESI-TOF) calcd for 
C15H14NO5 [M+H]+ 288.0872, found 288.0860. 
 
Methyl 2-(4-(dimethylamino)phenyl)-3-oxoindoline-2-carboxylate (4.2s). Following 
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the General Procedure for 19 h at 80 C, the product was obtained as a yellow solid (21 
mg) in 52% yield. Rf  = 0.4 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  7.60 (d, 
J = 8.0 Hz, 1H), 7.57 (d, J = 9.0 Hz, 2H), 7.49 (td, J = 7.0, 1.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 
1H), 6.88 (t, J = 7.5 Hz, 1H), 6.70 (d, J = 9.0 Hz, 2H), 5.61 (br s, 1H), 3.80 (s, 3H), 2.93 
(s, 6H); 13C NMR (125 MHz, CDCl3)  194.5, 169.0, 160.8, 150.8, 137.6, 127.2, 125.6, 
123.4, 120.3, 120.0, 113.3, 112.5, 74.8, 53.8, 40.6; IR (neat) 3352, 2950, 2922, 1740, 
1698, 1608, 1519, 1485, 1468, 1434, 1355, 1322, 1291, 1233, 1195, 1166, 1152, 1096, 
1061, 984 cm-1; HRMS (ESI-TOF) calcd for C18H19N2O3 [M+H]+ 311.1396, Found 
311.1408. 
 
Methyl 2-(4-(diethylamino)phenyl)-3-oxoindoline-2-carboxylate (4.2t). Following the 
General Procedure for 18 h at 80 C, the product was obtained as a yellow solid (29 mg) 
in 66% yield. Rf  = 0.50 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  7.60 (d, J = 
7.5 Hz, 1H), 7.51 (d, J = 9.0 Hz, 2H), 7.48 (td, J = 7.5, 1.0 Hz, 1H), 7.00 (d, J = 8.0 Hz, 
1H), 6.87 (t, J = 7.5 Hz, 1H), 6.63 (d, J = 9.0 Hz, 2H), 5.60 (br s, 1H), 3.80 (s, 3H), 3.33 
(q, J = 7.0 Hz, 4H), 1.13 (t, J = 7.0 Hz, 6H); 13C NMR (125 MHz, CDCl3)  194.7, 169.1, 
160.8, 148.0, 137.6, 127.4, 125.6, 124.3, 120.2, 120.0, 113.3, 111.6, 74.9, 53.7, 44.5, 
12.7; IR (neat) 3355, 2970, 1738, 1697, 1607, 1589, 1517, 1486, 1468, 1452, 1434, 1355, 
1321, 1291, 1264, 1231, 1194, 1153, 1089 cm-1; HRMS (ESI-TOF) calcd for C20H23N2O3 
[M+H]+ 339.1709, Found 339.1719. 
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Methyl 3-oxo-2-(2,4,6-trimethoxyphenyl)indoline-2-carboxylate (4.2u). Following the 
General Procedure for 24 h at 80 C, the product was obtained as a yellow solid (29 mg) 
in 62% yield. Rf  = 0.13 (EtOAc:Hexanes = 1:2): 1H NMR (500 MHz, CDCl3)  7.66 (d, J = 
8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.89 (t, J = 7.5 Hz, 1H), 6.13 
(s, 2H), 5.47 (br s, 1H), 3.77 (s, 6H), 3.65 (s, 6H); 13C NMR (125 MHz, CDCl3)  195.1, 
169.8, 161.7, 160.2, 159.4, 136.7, 124.7, 120.9, 120.0, 113.5, 108.5, 92.5, 72.3, 56.0, 
55.6, 53.6; IR (neat) 3353, 2948, 1716, 1605, 1587, 1484, 1468, 1435, 1417, 1322, 1226, 
1204, 1152, 1126, 1093, 1057, 1029, 993 cm-1; HRMS (ESI-TOF) calcd for C19H20NO6 
[M+H]+ 358.1291 Found: 358.1281. 
Asymmetric oxidative 3-oxindole coupling 
 
Methyl 3-oxo-2-(2-phenyl-1H-indol-3-yl)indoline-2-carboxylate (4.2f). Following the 
General Procedure using V6 (5.8 mg, 0.01 mmol) as a catalyst for 18 h at 0 C, the 
product was obtained as a yellow solid in 26% ee. [α]D22 = –14.3 (c 0.15, 26% ee, CH2Cl2); 
Chiral HPLC: Chiralpak IA column (20% i-PrOH/hexanes, 1 mL/min) tR(1) = 29.3 min, 
tR(2) = 34.5 min. 
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Methyl 3-hydroxy-1H-indole-2-carboxylate (4.4). Following a literature protocol, the 
product was obtained as a light yellow oil (335 mg). Spectral data were in agreement with 
those reported.9 
 
tert-Butyl 3-oxo-2-(2-phenyl-1H-indol-3-yl)indoline-2-carboxylate (4.5f). Following the 
General Procedure using V8 (4.7 mg, 0.01 mmol, 0.1 equiv) as a catalyst for 20 h at room 
temperature, the product was obtained as a yellow solid (41 mg) in 87% yield (48% ee). 
Rf  = 0.21 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, CDCl3)  8.13 (br s, 1H), 7.62 (d, J 
= 7.5 Hz, 1H), 7.51 (td, J = 8.5, 1.5 Hz, 1H), 7.47–7.45 (m, 2H), 7.40–7.36 (m, 4H), 7.33 
(d, J = 8.0 Hz, 1H), 7.16 (td, J = 8.0, 1.0 Hz, 1H), 7.03 (td, J = 8.0, 1.0 Hz, 1H), 6.92 (td, J 
= 8.0, 0.5 Hz, 1H), 6.89 (d, J = 8.0 Hz, 1H), 5.40 (br s, 1H), 1.10 (s, 9H); 13C NMR (125 
MHz, CDCl3)  195.6, 167.2, 160.7, 137.63, 137.57, 135.8, 133.6, 129.5, 128.8, 128.7, 
127.2, 125.3, 122.7, 120.7, 120.5, 120.4, 120.2, 113.2, 111.1, 108.2, 83.6, 74.2, 27.4; IR 
(neat) 3350, 2925, 1703, 1614, 1485, 1458, 1393, 1368, 1322, 1251, 1149, 1099, 1073, 
1013, 893 cm–1; HRMS (ESI-TOF) calcd for C27H25N2O3 [M+H]+ 425.1865, found 
425.1855.; [α]D22 = +23.7 (c 0.35, 48% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column 
(25% i-PrOH/hexanes, 1 mL/min) tR(1) = 10.7 min, tR(2) = 11.7 min. 
Synthesis of 2-Adamantyl carboxylated 3-oxindole (4.6) 
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Adamantan-1-yl N-(2-(hydroxymethyl)phenyl)-N-tosylglycinate (4.S1). Following 
literature procedure using BrCH2CO2Ad (2.96 g, 10.8 mmol, 1.5 equiv)10 for 23 h,9 the 
product was obtained as a pale yellow oil (3.35 g) in 99% yield. Rf  = 0.22 (EtOAc:Hexanes 
= 1:4): 1H NMR (500 MHz, CDCl3)  7.52 (dd, J = 7.5, 1.5 Hz, 1H), 7.46 (d, J = 8.5 Hz, 
2H), 7.29 (td, J = 7.5, 1.0 Hz, 1H), 7.24 (d, J = 8.5 Hz, 2H), 7.08 (td, J = 7.5, 1.5 Hz, 1H), 
6.49 (d, J = 7.5 Hz, 1H), 4.97 (d, J = 10.0 Hz, 1H), 4.73 (d, J = 10.0 Hz, 1H), 4.35 (d, J = 
17.0 Hz, 1H), 3.91 (d, J =16.5 Hz, 1H), 3.69 (br s, 1H), 2.40 (s, 3H), 2.09 (br s, 3H), 1.98 
(br s, 6H), 1.58 (br s, 6H); 13C NMR (125 MHz, CDCl3)  167.5, 144.3, 142.7, 138.3, 134.2, 
131.4, 129.6, 129.3, 128.4, 128.3, 127.5, 83.0, 61.7, 54.2, 41.1, 36.0, 30.9, 21.6; IR (neat) 
3450, 2911, 1728, 1454, 1351, 1275, 1205, 1186, 1159, 1125, 1090, 1049, 1015, 865 cm-
1; HRMS (ESI-TOF) calcd for C26H32NO5S [M+H]+ 470.2001 Found: 470.2009. 
 
Adamantan-1-yl 3-hydroxy-1H-indole-2-carboxylate (4.6). Following the literature 
procedure for 18 h,9 the product was obtained as a light yellow powder (397 mg) in 52% 
yield. Rf  = 0.75 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, (CD3)2CO)  9.89 (br s, 1H), 
                                                     
10 Dang, H.-S.; Elsegood, M. R. J.; Kim, K.-M.; Roberts, B. P. Radical-Chain Reductive Alkylation 
of Electron-Rich Alkenes Mediated by Silanes in the Presence of Thiols as Polarity-Reversal 
Catalysts. J. Chem. Soc. [Perkin 1] 1999, No. 15, 2061–2068. 
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8.18 (br s, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.28 (td, J = 8.0, 1.0 Hz, 
1H), 7.03 (td, J = 7.5, 1.0 Hz, 1H), 2.29 (br s, 6H), 2.21 (br s, 3H), 1.73 (br s, 6H); 13C NMR 
(125 MHz, (CD3)2CO)  163.8, 146.8, 136.1, 127.2, 120.2, 119.8, 118.4, 113.2, 110.2, 
82.4, 42.4 (3), 36.8 (3), 31.9 (3); IR (neat) 3475, 3320, 2906, 2850, 1682, 1581, 1547, 
1508, 1493, 1337, 1250, 1230, 1196, 1183, 1125, 1096, 1040, 922 cm-1; HRMS (ESI-TOF) 
calcd for C19H22NO3 [M+H]+ 312.1600 Found: 312.1591. 
 
Adamantan-1-yl 3-oxo-2-(2-phenyl-1H-indol-3-yl)indoline-2-carboxylate (4.7f). 
Following the General Procedure using V8 (2.7 mg, 6.4 mol, 0.1 equiv) as a catalyst in 
CHCl3 (0.64 mL) for 21 h at room temperature, the product was obtained as a yellow solid 
(21 mg) in 66% yield (74% ee). Rf  = 0.20 (EtOAc:Hexanes = 1:4): 1H NMR (500 MHz, 
CDCl3)  8.24 (br s, 1H), 7.59 (d, J = 7.5 Hz, 1H), 7.49 (td, J = 7.5, 1.0 Hz, 1H), 7.42–7.40 
(m, 3H), 7.36–7.28 (m, 4H), 7.14 (td, J = 7.5, 1.0 Hz, 1H), 7.04 (td, J = 7.5, 1.0 Hz, 1H), 
6.90 (t, J = 7.5 Hz, 1H), 6.86 (d, J = 8.5 Hz, 1H), 5.42 (br s, 1H), 1.99 (br s, 3H), 1.76 (d, 
J = 11.5 Hz, 3H), 1.69 (d, J = 11.0 Hz, 3H), 1.53–1.46 (m, 6H) ; 13C NMR (125 MHz, CDCl3) 
 195.7, 166.9, 160.6, 137.6, 137.5, 135.7, 133.5, 129.5, 128.7, 128.6, 127.2, 125.2, 
122.5, 120.6, 120.4, 120.3, 120.1, 113.2, 111.2, 108.1, 83.6, 74.2, 40.5, 36.0, 30.9; IR 
(neat) 3348, 2910, 1703, 1614, 1484, 1457, 1320, 1291, 1233, 1196, 1150, 1101, 1046, 
1013, 963 cm-1; HRMS (ESI-TOF) calcd for C33H31N2O3 [M+H]+ 503.2335 Found: 
503.2344; [α]D22 = +33.7 (c 0.18, 74% ee, CH2Cl2); Chiral HPLC: Chiralpak IA column 
(20% i-PrOH/hexanes, 1 mL/min) tR(1) = 17.9 min, tR(2) = 25.4 min. 
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APPENDIX A: SPECTROSCOPIC DATA 
 
Figure A.1. 1H NMR Spectrum of Compound 1.8a (500 MHz, acetone-d6) 
 
 
Figure A.2. 13C NMR Spectrum of Compound 1.8a (125 MHz, acetone-d6) 
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Figure A.3. 1H NMR Spectrum of Compound 1.4b (500 MHz, acetone-d6) 
오류! 책갈피가 정의되어 있지 않습니다. 
 
Figure A.4. 13C NMR Spectrum of Compound 1.4b (125 MHz, acetone-d6) 
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Figure A.5. 1H NMR Spectrum of Compound 1.4c (500 MHz, CDCl3) 
  
  
Figure A.6. 13C NMR Spectrum of Compound 1.4c (125 MHz, CDCl3) 
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Figure A.7. 1H NMR Spectrum of Compound 1.4d (500 MHz, CDCl3) 
 
 
Figure A.8. 13C NMR Spectrum of Compound 1.4d (125 MHz, CDCl3) 
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Figure A.9. 1H NMR Spectrum of Compound 1.4e (500 MHz, CDCl3) 
 
 
Figure A.10. 13C NMR Spectrum of Compound 1.4e (125 MHz, CDCl3) 
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Figure A.11. 1H NMR Spectrum of Compound 1.8f (500 MHz, acetone-d6) 
 
 
Figure A.12. 13C NMR Spectrum of Compound 1.8f (125 MHz, acetone-d6) 
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Figure A.13. 1H NMR Spectrum of Compound 1.9f (500 MHz, acetone-d6) 
 
 
Figure A.14. 13C NMR Spectrum of Compound 1.9f (125 MHz, acetone-d6) 
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Figure A.15. 1H NMR Spectrum of Compound 1.10f (500 MHz, acetone-d6) 
 
 
Figure A.16. 13C NMR Spectrum of Compound 1.10f (125 MHz, acetone-d6)  
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Figure A.17. 1H NMR Spectrum of Compound 1.4f (500 MHz, acetone-d6) 
 
 
Figure A.18. 13C NMR Spectrum of Compound 1.4f (125 MHz, acetone-d6) 
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Figure A.19. 1H NMR Spectrum of Compound 1.8g (500 MHz, acetone-d6) 
 
 
Figure A.20. 13C NMR Spectrum of Compound 1.8g (125 MHz, acetone-d6) 
232 
 
 
Figure A.21. 1H NMR Spectrum of Compound 1.9g (500 MHz, acetone-d6) 
 
 
Figure A.22. 13C NMR Spectrum of Compound 1.9g (125 MHz, acetone-d6) 
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Figure A.23. 1H NMR Spectrum of Compound 1.10g (500 MHz, acetone-d6) 
 
 
Figure A.24. 13C NMR Spectrum of Compound 1.10g (125 MHz, acetone-d6) 
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Figure A.25. 1H NMR Spectrum of Compound 1.4g (500 MHz, acetone-d6) 
 
 
Figure A.26. 13C NMR Spectrum of Compound 1.4g (125 MHz, acetone-d6) 
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Figure A.27. 1H NMR Spectrum of Compound 1.10h (500 MHz, acetone-d6) 
 
 
Figure A.28. 13C NMR Spectrum of Compound 1.10h (125 MHz, acetone-d6) 
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Figure A.29. 1H NMR Spectrum of Compound 1.4h (500 MHz, acetone-d6) 
 
 
Figure A.30. 13C NMR Spectrum of Compound 1.4h (125 MHz, acetone-d6) 
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Figure A.31. 1H NMR Spectrum of Compound 1.8i (500 MHz, CDCl3) 
 
 
Figure A.32. 13C NMR Spectrum of Compound 1.8i (125 MHz, CDCl3) 
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Figure A.33. 1H NMR Spectrum of Compound 1.9i (500 MHz, CDCl3) 
 
 
Figure A.34. 13C NMR Spectrum of Compound 1.9i (125 MHz, CDCl3) 
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Figure A.35. 1H NMR Spectrum of Compound 1.10i (500 MHz, acetone-d6) 
 
 
Figure A.36. 13C NMR Spectrum of Compound 1.10i (125 MHz, acetone-d6) 
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Figure A.37. 1H NMR Spectrum of Compound 1.4i (500 MHz, acetone-d6) 
 
 
Figure A.38. 13C NMR Spectrum of Compound 1.4i (125 MHz, acetone-d6) 
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Figure A.39. 1H NMR Spectrum of Compound 1.8j (500 MHz, CDCl3) 
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Figure A.40. 1H NMR Spectrum of Compound 1.9j (500 MHz, acetone-d6) 
 
 
Figure A.41. 13C NMR Spectrum of Compound 1.9j (125 MHz, acetone-d6) 
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Figure A.42. 1H NMR Spectrum of Compound 1.10j (500 MHz, acetone-d6) 
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Figure A.43. 1H NMR Spectrum of Compound 1.4j (500 MHz, acetone-d6) 
 
 
Figure A.44. 13C NMR Spectrum of Compound 1.4j (125 MHz, acetone-d6) 
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Figure A.45. 1H NMR Spectrum of Compound 1.8k (500 MHz, CDCl3) 
 
 
Figure A.46. 13C NMR Spectrum of Compound 1.8k (125 MHz, CDCl3) 
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Figure A.47. 1H NMR Spectrum of Compound 1.9k (500 MHz, DMF-d7) 
 
 
Figure A.48. 13C NMR Spectrum of Compound 1.9k (125 MHz, DMF-d7) 
247 
 
 
Figure A.49. 1H NMR Spectrum of Compound 1.11k (500 MHz, acetone-d6) 
 
 
Figure A.50. 13C NMR Spectrum of Compound 1.11k (125 MHz, acetone-d6) 
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Figure A.51. 1H NMR Spectrum of Compound 1.4k (500 MHz, acetone-d6) 
 
 
Figure A.52. 13C NMR Spectrum of Compound 1.4k (125 MHz, acetone-d6) 
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Figure A.53. 1H NMR Spectrum of Compound 1.8l (500 MHz, CDCl3) 
 
 
Figure A.54. 13C NMR Spectrum of Compound 1.8l (125 MHz, CDCl3) 
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Figure A.55. 1H NMR Spectrum of Compound 1.9l (500 MHz, acetone-d6) 
 
 
Figure A.56. 13C NMR Spectrum of Compound 1.9l (125 MHz, acetone-d6) 
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Figure A.57. 1H NMR Spectrum of Compound 1.11l (500 MHz, acetone-d6) 
 
 
Figure A.58. 13C NMR Spectrum of Compound 1.11l (125 MHz, acetone-d6) 
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Figure A.59. 1H NMR Spectrum of Compound 1.19 (500 MHz, DMSO-d6) 
 
 
Figure A.60. 13C NMR Spectrum of Compound 1.19 (125 MHz, DMSO-d6) 
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Figure A.61. 1H NMR Spectrum of Compound 1.4l (500 MHz, acetone-d6) 
 
 
Figure A.62. 13C NMR Spectrum of Compound 1.4l (125 MHz, acetone-d6) 
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Figure A.63. 1H NMR Spectrum of Compound 1.8m (500 MHz, acetone-d6) 
 
 
Figure A.64. 13C NMR Spectrum of Compound 1.8m (125 MHz, acetone-d6) 
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Figure A.65. 1H NMR Spectrum of Compound 1.9m (500 MHz, acetone-d6) 
 
 
Figure A.66. 13C NMR Spectrum of Compound 1.9m (125 MHz, acetone-d6) 
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Figure A.67. 1H NMR Spectrum of Compound 1.11m (500 MHz, acetone-d6) 
 
 
Figure A.68. 13C NMR Spectrum of Compound 1.11m (125 MHz, acetone-d6) 
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Figure A.69. 1H NMR Spectrum of Compound 1.4m (500 MHz, CDCl3) 
 
 
Figure A.70. 13C NMR Spectrum of Compound 1.4m (125 MHz, acetone-d6) 
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Figure A.71. 1H NMR Spectrum of Compound 1.8n (500 MHz, CDCl3) 
 
 
Figure A.72. 13C NMR Spectrum of Compound 1.9n (125 MHz, acetone-d6) 
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Figure A.73. 1H NMR Spectrum of Compound 1.10n (500 MHz, acetone-d6) 
 
 
Figure A.74. 13C NMR Spectrum of Compound 1.10n (125 MHz, acetone-d6) 
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Figure A.75. 1H NMR Spectrum of Compound 1.4n (500 MHz, acetone-d6) 
 
 
Figure A.76. 13C NMR Spectrum of Compound 1.4n (125 MHz, acetone-d6) 
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Figure A.77. 1H NMR Spectrum of Compound 1.S1 (500 MHz, CD3CN) 
 
 
Figure A.78. 13C NMR Spectrum of Compound 1.S1 (125 MHz, CD3CN) 
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Figure A.79. 1H NMR Spectrum of Compound 1.14 (500 MHz, CDCl3) 
 
 
Figure A.80. 13C NMR Spectrum of Compound 1.14 (125 MHz, CDCl3) 
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Figure A.81. 1H NMR Spectrum of Compound 1.16 (500 MHz, CDCl3) 
 
 
Figure A.82. 13C NMR Spectrum of Compound 1.16 (125 MHz, acetone-d6) 
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Figure A.83. 1H NMR Spectrum of Compound 1.17 (500 MHz, acetone-d6) 
 
 
Figure A.84. 13C NMR Spectrum of Compound 1.17 (125 MHz, acetone-d6) 
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Figure A.85. 1H NMR Spectrum of Compound 1.18 (500 MHz, acetone-d6) 
 
 
Figure A.86. 13C NMR Spectrum of Compound 1.18 (125 MHz, acetone-d6) 
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Figure A.87. 1H NMR Spectrum of Compound 1.4o (500 MHz, acetone-d6) 
 
 
Figure A.88. 13C NMR Spectrum of Compound 1.4o (125 MHz, acetone-d6) 
267 
 
 
Figure A.89. 1H NMR Spectrum of Compound 1.8p (500 MHz, CDCl3) 
 
 
Figure A.90. 13C NMR Spectrum of Compound 1.8p (125 MHz, CDCl3) 
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Figure A.91. 1H NMR Spectrum of Compound 1.9p (500 MHz, CDCl3) 
 
 
Figure A.92. 13C NMR Spectrum of Compound 1.9p (125 MHz, CDCl3) 
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Figure A.93. 1H NMR Spectrum of Compound 1.10p (500 MHz, CD3CN) 
 
 
Figure A.94. 13C NMR Spectrum of Compound 1.10p (125 MHz, CD3CN) 
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Figure A.95. 1H NMR Spectrum of Compound 1.4p (500 MHz, CDCl3) 
 
 
Figure A.96. 13C NMR Spectrum of Compound 1.4p (125 MHz, CDCl3) 
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Figure A.97. 1H NMR Spectrum of Compound 1.S2 (500 MHz, CD2Cl2) 
 
 
Figure A.98. 13C NMR Spectrum of Compound 1.S2 (125 MHz, CD2Cl2) 
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Figure A.99. 1H NMR Spectrum of Compound 1.13 (500 MHz, CDCl3) 
 
 
Figure A.100. 13C NMR Spectrum of Compound 1.13 (125 MHz, CD2Cl2) 
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Figure A.101. 1H NMR Spectrum of Compound 1.4q (500 MHz, acetone-d6) 
 
 
Figure A.102. 13C NMR Spectrum of Compound 1.4q (125 MHz, acetone-d6) 
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Figure A.103. 1H NMR Spectrum of Compound 1.S3 (500 MHz, acetone-d6) 
 
 
Figure A.104. 13C NMR Spectrum of Compound 1.S3 (125 MHz, acetone-d6) 
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Figure A.105. 1H NMR Spectrum of Compound 1.4r (500 MHz, acetone-d6) 
 
 
Figure A.106. 13C NMR Spectrum of Compound 1.4r (125 MHz, acetone-d6) 
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Figure A.107. 1H NMR Spectrum of Compound 1.S4 (500 MHz, CD2Cl2) 
 
 
Figure A.108. 13C NMR Spectrum of Compound 1.S4 (125 MHz, CD2Cl2) 
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Figure A.109. 1H NMR Spectrum of Compound 1.4s (500 MHz, acetone-d6) 
 
 
Figure A.110. 13C NMR Spectrum of Compound 1.4s (125 MHz, CDCl3) 
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Figure A.111. 1H NMR Spectrum of Compound 1.5a (500 MHz, acetone-d6) 
 
 
Figure A.112. 13C NMR Spectrum of Compound 1.5a (125 MHz, acetone-d6) 
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Figure A.113. 1H NMR Spectrum of Compound 1.5b (500 MHz, acetone-d6) 
 
 
Figure A.114. 13C NMR Spectrum of Compound 1.5b (125 MHz, acetone-d6) 
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Figure A.115. 1H NMR Spectrum of Compound 1.5c (500 MHz, CDCl3) 
 
 
Figure A.116. 13C NMR Spectrum of Compound 1.5c (125 MHz, CDCl3) 
281 
 
 
Figure A.117. 1H NMR Spectrum of Compound 1.5d (500 MHz, CDCl3) 
 
 
Figure A.118. 13C NMR Spectrum of Compound 1.5d (125 MHz, CDCl3) 
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Figure A.119. 1H NMR Spectrum of Compound 1.5e (500 MHz, CDCl3) 
 
 
Figure A.120. 13C NMR Spectrum of Compound 1.5e (125 MHz, CDCl3) 
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Figure A.121. 1H NMR Spectrum of Compound 1.5f (500 MHz, acetone-d6) 
 
 
Figure A.122. 13C NMR Spectrum of Compound 1.5f (125 MHz, acetone-d6) 
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Figure A.123. 1H NMR Spectrum of Compound 1.5g (500 MHz, acetone-d6) 
 
 
Figure A.124. 13C NMR Spectrum of Compound 1.5g (125 MHz, acetone-d6) 
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Figure A.125. 1H NMR Spectrum of Compound 1.5h (500 MHz, acetone-d6) 
 
 
Figure A.126. 13C NMR Spectrum of Compound 1.5h (125 MHz, acetone-d6) 
286 
 
 
Figure A.127. 1H NMR Spectrum of Compound 1.5i (500 MHz, acetone-d6) 
 
 
Figure A.128. 13C NMR Spectrum of Compound 1.5i (125 MHz, acetone-d6)  
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Figure A.129. 1H NMR Spectrum of Compound 1.5j (500 MHz, acetone-d6) 
 
 
Figure A.130. 13C NMR Spectrum of Compound 1.5j (125 MHz, acetone-d6) 
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Figure A.131. 1H NMR Spectrum of Compound 1.5k (500 MHz, acetone-d6) 
 
 
Figure A.132. 13C NMR Spectrum of Compound 1.5k (125 MHz, acetone-d6) 
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Figure A.133. 1H NMR Spectrum of Compound 1.5l (500 MHz, acetone-d6) 
 
 
Figure A.134. 13C NMR Spectrum of Compound 1.5l (125 MHz, acetone-d6) 
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Figure A.135. 1H NMR Spectrum of Compound 1.5m (500 MHz, acetone-d6) 
 
 
Figure A.136. 13C NMR Spectrum of Compound 1.5m (125 MHz, acetone-d6) 
291 
 
  
Figure A.137. 1H NMR Spectrum of Compound 1.5n (500 MHz, acetone-d6) 
 
 
Figure A.138. 13C NMR Spectrum of Compound 1.5n (125 MHz, acetone-d6) 
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Figure A.139. 1H NMR Spectrum of Compound 1.5o (500 MHz, acetone-d6) 
 
 
Figure A.140. 13C NMR Spectrum of Compound 1.5o (125 MHz, acetone-d6) 
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Figure A.141. 1H NMR Spectrum of Compound 1.5p (500 MHz, CDCl3) 
 
 
Figure A.142. 13C NMR Spectrum of Compound 1.5p (125 MHz, CDCl3) 
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Figure A.143. 1H NMR Spectrum of Compound 1.5q (500 MHz, acetone-d6) 
 
 
Figure A.144. 13C NMR Spectrum of Compound 1.5q (125 MHz, acetone-d6) 
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Figure A.145. 1H NMR Spectrum of Compound 1.5r (500 MHz, acetone-d6) 
 
 
Figure A.146. 13C NMR Spectrum of Compound 1.5r (125 MHz, acetone-d6) 
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Figure A.147. 1H NMR Spectrum of Compound 1.5s (500 MHz, acetone-d6) 
 
 
Figure A.148. 13C NMR Spectrum of Compound 1.5s (125 MHz, acetone-d6) 
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Figure A.149. 1H NMR Spectrum of Compound 2.13 (500 MHz, CDCl3) 
 
 
Figure A.150. 13C NMR Spectrum of Compound 2.13 (125 MHz, CDCl3) 
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Figure A.151. 1H NMR Spectrum of Compound 2.S1 (500 MHz, CDCl3) 
 
 
Figure A.152. 13C NMR Spectrum of Compound 2.S1 (125 MHz, CDCl3) 
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Figure A.153. 1H NMR Spectrum of Compound 2.9 (500 MHz, acetone-d6) 
 
 
Figure A.154. 13C NMR Spectrum of Compound 2.9 (125 MHz, CD3CN) 
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Figure A.155. 1H NMR Spectrum of Compound 2.10 (500 MHz, CDCl3) 
 
 
Figure A.156. 13C NMR Spectrum of Compound 2.10 (125 MHz, CDCl3) 
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Figure A.157. 1H NMR Spectrum of Compound 2.8 (500 MHz, CDCl3) 
 
 
Figure A.158. 13C NMR Spectrum of Compound 2.8 (125 MHz, CDCl3) 
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Figure A.159. 1H NMR Spectrum of Compound 2.7 (500 MHz, CDCl3) 
 
 
Figure A.160. 13C NMR Spectrum of Compound 2.7 (125 MHz, CDCl3) 
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Figure A.161. 1H NMR Spectrum of Compound (P)-2.7 (500 MHz, CDCl3) 
 
 
Figure A.162. 13C NMR Spectrum of Compound (P)-2.7 (125 MHz, CDCl3) 
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Figure A.163. 1H NMR Spectrum of Compound 2.19 (500 MHz, CDCl3) 
 
 
Figure A.164. 13C NMR Spectrum of Compound 2.19 (125 MHz, CDCl3) 
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Figure A.165. 1H NMR Spectrum of Compound 2.6 (500 MHz, CDCl3) 
 
 
Figure A.166. 13C NMR Spectrum of Compound 2.6 (125 MHz, CDCl3) 
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Figure A.167. 1H NMR Spectrum of Compound 2.20 (500 MHz, CDCl3) 
 
 
Figure A.168. 13C NMR Spectrum of Compound 2.20 (125 MHz, CDCl3) 
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Figure A.169. 1H NMR Spectrum of Compound 2.21 (500 MHz, CDCl3) 
 
 
Figure A.170. 13C NMR Spectrum of Compound 2.21 (125 MHz, CDCl3) 
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Figure A.171. 1H NMR Spectrum of Compound 2.22 (500 MHz, CDCl3) 
 
 
Figure A.172. 13C NMR Spectrum of Compound 2.22 (125 MHz, CDCl3) 
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Figure A.173. 1H NMR Spectrum of Compound 2.23 (500 MHz, CDCl3) 
 
 
Figure A.174. 13C NMR Spectrum of Compound 2.23 (125 MHz, CDCl3) 
 
310 
 
  
Figure A.175. 1H NMR Spectrum of Compound 2.24 (500 MHz, CDCl3) 
 
 
Figure A.176. 13C NMR Spectrum of Compound 2.24 (125 MHz, CDCl3) 
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Figure A.177. 1H NMR Spectrum of Compound 2.1 (500 MHz, CD3OD) 
 
 
Figure A.178. 13C NMR Spectrum of Compound 2.1 (125 MHz, CD3OD) 
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Figure A.179. 1H NMR Spectrum of Compound 3.3a (500 MHz, CDCl3) 
 
 
Figure A.180. 13C NMR Spectrum of Compound 3.3a (125 MHz, CDCl3) 
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Figure A.181. 31P NMR Spectrum of Compound 3.3a 
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Figure A.182. 1H NMR Spectrum of Compound 3.3b (500 MHz, CDCl3) 
 
 
Figure A.183. 13C NMR Spectrum of Compound 3.3b (125 MHz, CDCl3) 
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Figure A.184. 31P NMR Spectrum of Compound 3.3b 
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Figure A.185. 1H NMR Spectrum of Compound 3.3c (500 MHz, CDCl3) 
 
 
Figure A.186. 13C NMR Spectrum of Compound 3.3c (125 MHz, CDCl3) 
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Figure A.187. 31P NMR Spectrum of Compound 3.3c 
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Figure A.188. 1H NMR Spectrum of Compound 3.3d (500 MHz, CDCl3) 
 
 
Figure A.189. 13C NMR Spectrum of Compound 3.3d (125 MHz, CDCl3) 
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Figure A.190. 31P NMR Spectrum of Compound 3.3d 
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Figure A.191. 1H NMR Spectrum of Compound 3.3e (500 MHz, CDCl3) 
 
 
Figure A.192. 13C NMR Spectrum of Compound 3.3e (125 MHz, CDCl3) 
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Figure A.193. 31P NMR Spectrum of Compound 3.3e 
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Figure A.194. 1H NMR Spectrum of Compound 3.3d_nBu (500 MHz, CDCl3) 
 
 
Figure A.195. 13C NMR Spectrum of Compound 3.3d_nBu (125 MHz, CDCl3) 
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Figure A.196. 31P NMR Spectrum of Compound 3.3d_nBu 
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Figure A.197. 1H NMR Spectrum of Compound 3.3e_nBu (500 MHz, CDCl3) 
 
 
Figure A.198. 13C NMR Spectrum of Compound 3.3e_nBu (125 MHz, CDCl3) 
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Figure A.199. 31P NMR Spectrum of Compound 3.3e_nBu 
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Figure A.200. 1H NMR Spectrum of Compound 3.5a (500 MHz, CDCl3) 
 
 
Figure A.201. 13C NMR Spectrum of Compound 3.5a (125 MHz, CDCl3) 
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Figure A.202. 31P NMR Spectrum of Compound 3.5a 
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Figure A.203. 1H NMR Spectrum of Compound 3.6a (500 MHz, CDCl3) 
 
 
Figure A.204. 13C NMR Spectrum of Compound 3.6a (125 MHz, CDCl3) 
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Figure A.205. 31P NMR Spectrum of Compound 3.6a 
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Figure A.206. 1H NMR Spectrum of Compound 3.5b (500 MHz, CDCl3) 
 
 
Figure A.207. 13C NMR Spectrum of Compound 3.5b (125 MHz, CDCl3) 
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Figure A.208. 31P NMR Spectrum of Compound 3.5b 
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Figure A.209. 1H NMR Spectrum of Compound 3.6b (500 MHz, CDCl3) 
 
 
Figure A.210. 13C NMR Spectrum of Compound 3.6b (125 MHz, CDCl3) 
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Figure A.211. 31P NMR Spectrum of Compound 3.6b 
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Figure A.212. 1H NMR Spectrum of Compound 3.5c (500 MHz, CDCl3) 
 
 
Figure A.213. 13C NMR Spectrum of Compound 3.5c (125 MHz, CDCl3) 
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Figure A.214. 31P NMR Spectrum of Compound 3.5c 
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Figure A.215. 1H NMR Spectrum of Compound 3.6c (500 MHz, CDCl3) 
 
 
Figure A.216. 13C NMR Spectrum of Compound 3.6c (125 MHz, CDCl3) 
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Figure A.217. 31P NMR Spectrum of Compound 3.6c 
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Figure A.218. 1H NMR Spectrum of Compound 3.5d (500 MHz, CDCl3) 
 
 
Figure A.219. 13C NMR Spectrum of Compound 3.5d (125 MHz, CDCl3) 
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Figure A.220. 31P NMR Spectrum of Compound 3.5d 
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Figure A.221. 1H NMR Spectrum of Compound 3.6d (500 MHz, CDCl3) 
 
 
Figure A.222. 13C NMR Spectrum of Compound 3.6d (125 MHz, CDCl3) 
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Figure A.223. 31P NMR Spectrum of Compound 3.6d 
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Figure A.224. 1H NMR Spectrum of Compound 3.5e (500 MHz, CDCl3) 
 
 
Figure A.225. 13C NMR Spectrum of Compound 3.5e (125 MHz, CDCl3) 
 
343 
 
  
Figure A.226. 31P NMR Spectrum of Compound 3.5e 
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Figure A.227. 1H NMR Spectrum of Compound 3.6e (500 MHz, CDCl3) 
 
 
Figure A.228. 13C NMR Spectrum of Compound 3.6e (125 MHz, CDCl3) 
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Figure A.229. 31P NMR Spectrum of Compound 3.6e 
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Figure A.230. 1H NMR Spectrum of Compound 3.5f (500 MHz, CDCl3) 
 
 
Figure A.231. 13C NMR Spectrum of Compound 3.5f (125 MHz, CDCl3) 
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Figure A.232. 31P NMR Spectrum of Compound 3.5f 
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Figure A.233. 1H NMR Spectrum of Compound 3.6f (500 MHz, CDCl3) 
 
 
Figure A.234. 13C NMR Spectrum of Compound 3.6f (125 MHz, CDCl3) 
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Figure A.235. 31P NMR Spectrum of Compound 3.6f 
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Figure A.236. 1H NMR Spectrum of Compound 3.5g (500 MHz, CDCl3) 
 
 
Figure A.237. 13C NMR Spectrum of Compound 3.5g (125 MHz, CDCl3) 
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Figure A.238. 31P NMR Spectrum of Compound 3.5g 
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Figure A.239. 1H NMR Spectrum of Compound 3.6g (500 MHz, CDCl3) 
 
 
Figure A.240. 13C NMR Spectrum of Compound 3.6g (125 MHz, CDCl3) 
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Figure A.241. 31P NMR Spectrum of Compound 3.6g 
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Figure A.242. 1H NMR Spectrum of Compound 3.5h (500 MHz, CDCl3) 
 
 
Figure A.243. 13C NMR Spectrum of Compound 3.5h (125 MHz, CDCl3) 
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Figure A.244. 31P NMR Spectrum of Compound 3.5h 
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Figure A.245. 1H NMR Spectrum of Compound 3.6h (500 MHz, CDCl3) 
 
 
Figure A.246. 13C NMR Spectrum of Compound 3.6h (125 MHz, CDCl3) 
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Figure A.247. 31P NMR Spectrum of Compound 3.6h 
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Figure A.248. 1H NMR Spectrum of Compound 3.5i (500 MHz, CDCl3) 
 
 
Figure A.249. 13C NMR Spectrum of Compound 3.5i (125 MHz, CDCl3) 
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Figure A.250. 31P NMR Spectrum of Compound 3.5i 
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Figure A.251. 1H NMR Spectrum of Compound 3.6i (500 MHz, CDCl3) 
 
 
Figure A.252. 13C NMR Spectrum of Compound 3.6i (125 MHz, CDCl3) 
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Figure A.253. 31P NMR Spectrum of Compound 3.6i 
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Figure A.254. 1H NMR Spectrum of Compound 3.5j (500 MHz, CDCl3) 
 
 
Figure A.255. 13C NMR Spectrum of Compound 3.5j (125 MHz, CDCl3) 
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Figure A.256. 31P NMR Spectrum of Compound 3.5j 
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Figure A.257. 1H NMR Spectrum of Compound 3.6j (500 MHz, CDCl3) 
 
 
Figure A.258. 13C NMR Spectrum of Compound 3.6j (125 MHz, CDCl3) 
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Figure A.259. 31P NMR Spectrum of Compound 3.6j 
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Figure A.260. 1H NMR Spectrum of Compound 3.6k (500 MHz, CDCl3) 
 
 
Figure A.261. 13C NMR Spectrum of Compound 3.6k (125 MHz, CDCl3) 
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Figure A.262. 31P NMR Spectrum of Compound 3.6k 
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Figure A.263. 1H NMR Spectrum of Compound 3.6l (500 MHz, CDCl3) 
 
 
Figure A.264. 13C NMR Spectrum of Compound 3.6l (125 MHz, CDCl3) 
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Figure A.265. 31P NMR Spectrum of Compound 3.6l 
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Figure A.266. 1H NMR Spectrum of Compound 3.6m (500 MHz, CDCl3) 
 
 
Figure A.267. 13C NMR Spectrum of Compound 3.6m (125 MHz, CDCl3) 
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Figure A.268. 31P NMR Spectrum of Compound 3.6m 
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Figure A.269. 1H NMR Spectrum of Compound 3.6n (500 MHz, CDCl3) 
 
 
Figure A.270. 13C NMR Spectrum of Compound 3.6n (125 MHz, CDCl3) 
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Figure A.271. 31P NMR Spectrum of Compound 3.6n 
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Figure A.272. 1H NMR Spectrum of Compound 3.6o (500 MHz, CDCl3) 
 
 
Figure A.273. 13C NMR Spectrum of Compound 3.6o (125 MHz, CDCl3) 
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Figure A.274. 31P NMR Spectrum of Compound 3.6o 
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Figure A.275. 1H NMR Spectrum of Compound 3.6p (500 MHz, CDCl3) 
 
 
Figure A.276. 13C NMR Spectrum of Compound 3.6p (125 MHz, CDCl3) 
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Figure A.277. 31P NMR Spectrum of Compound 3.6p 
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Figure A.278. 1H NMR Spectrum of Compound 3.6q (500 MHz, CDCl3) 
 
 
Figure A.279. 13C NMR Spectrum of Compound 3.6q (125 MHz, CDCl3) 
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Figure A.280. 31P NMR Spectrum of Compound 3.6q 
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Figure A.281. 1H NMR Spectrum of Compound 3.6r (500 MHz, CDCl3) 
 
 
Figure A.282. 13C NMR Spectrum of Compound 3.6r (125 MHz, CDCl3) 
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Figure A.283. 31P NMR Spectrum of Compound 3.6r 
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Figure A.284. 1H NMR Spectrum of Compound 3.6s (500 MHz, CDCl3) 
 
 
Figure A.285. 13C NMR Spectrum of Compound 3.6s (125 MHz, CDCl3) 
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Figure A.286. 31P NMR Spectrum of Compound 3.6s 
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Figure A.287. 1H NMR Spectrum of Compound 3.6t (500 MHz, CDCl3) 
 
 
Figure A.288. 13C NMR Spectrum of Compound 3.6t (125 MHz, CDCl3) 
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Figure A.289. 31P NMR Spectrum of Compound 3.6t 
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Figure A.290. 1H NMR Spectrum of Compound 3.5a_tBu (500 MHz, CDCl3) 
 
 
Figure A.291. 13C NMR Spectrum of Compound 3.5a_tBu (125 MHz, CDCl3) 
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Figure A.292. 31P NMR Spectrum of Compound 3.5a_tBu 
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Figure A.293. 1H NMR Spectrum of Compound 3.6a_tBu (500 MHz, CDCl3) 
 
 
Figure A.294. 13C NMR Spectrum of Compound 3.6a_tBu (125 MHz, CDCl3) 
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Figure A.295. 31P NMR Spectrum of Compound 3.6a_tBu 
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Figure A.296. 1H NMR Spectrum of Compound 3.5a-nBu (500 MHz, CDCl3) 
 
 
Figure A.297. 13C NMR Spectrum of Compound 3.5a-nBu (125 MHz, CDCl3) 
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Figure A.298. 31P NMR Spectrum of Compound 3.5a-nBu 
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Figure A.299. 1H NMR Spectrum of Compound 3.6a-nBu (500 MHz, CDCl3) 
 
 
Figure A.300. 13C NMR Spectrum of Compound 3.6a-nBu (125 MHz, CDCl3) 
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Figure A.301. 31P NMR Spectrum of Compound 3.6a-nBu 
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Figure A.302. 1H NMR Spectrum of Compound 3.5d-nBu (500 MHz, CDCl3) 
 
 
Figure A.303. 13C NMR Spectrum of Compound 3.5d-nBu (125 MHz, CDCl3) 
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Figure A.304. 31P NMR Spectrum of Compound 3.5d-nBu 
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Figure A.305. 1H NMR Spectrum of Compound 3.6d-nBu (500 MHz, CDCl3) 
 
 
Figure A.306. 13C NMR Spectrum of Compound 3.6d-nBu (125 MHz, CDCl3) 
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Figure A.307. 31P NMR Spectrum of Compound 3.6d-nBu 
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Figure A.308. 1H NMR Spectrum of Compound 3.7a (500 MHz, CDCl3) 
 
 
Figure A.309. 13C NMR Spectrum of Compound 3.7a (125 MHz, CDCl3) 
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Figure A.310. 31P NMR Spectrum of Compound 3.7a 
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Figure A.311. 1H NMR Spectrum of Compound 3.8a (500 MHz, CDCl3) 
 
 
Figure A.312. 13C NMR Spectrum of Compound 3.8a (125 MHz, CDCl3) 
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Figure A.313. 31P NMR Spectrum of Compound 3.8a 
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Figure A.314. 1H NMR Spectrum of Compound 3.8b (500 MHz, CDCl3) 
 
 
Figure A.315. 13C NMR Spectrum of Compound 3.8b (125 MHz, CDCl3) 
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Figure A.316. 31P NMR Spectrum of Compound 3.8b 
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Figure A.317. 1H NMR Spectrum of Compound 3.7c (500 MHz, CDCl3) 
 
 
Figure A.318. 13C NMR Spectrum of Compound 3.7c (125 MHz, CDCl3) 
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Figure A.319. 31P NMR Spectrum of Compound 3.7c 
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Figure A.320. 1H NMR Spectrum of Compound 3.8c (500 MHz, CDCl3) 
 
 
Figure A.321. 13C NMR Spectrum of Compound 3.8c (125 MHz, CDCl3) 
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Figure A.322. 31P NMR Spectrum of Compound 3.8c 
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Figure A.323. 1H NMR Spectrum of Compound 3.7d (500 MHz, CDCl3) 
 
 
Figure A.324. 13C NMR Spectrum of Compound 3.7d (125 MHz, CDCl3) 
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Figure A.325. 31P NMR Spectrum of Compound 3.7d 
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Figure A.326. 1H NMR Spectrum of Compound 3.7d-nBu (500 MHz, CDCl3) 
 
 
Figure A.327. 13C NMR Spectrum of Compound 3.7d-nBu (125 MHz, CDCl3) 
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Figure A.328. 31P NMR Spectrum of Compound 3.7d-nBu 
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Figure A.329. 1H NMR Spectrum of Compound 3.8e (500 MHz, CDCl3) 
 
 
Figure A.330. 13C NMR Spectrum of Compound 3.8e (125 MHz, CDCl3) 
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Figure A.331. 31P NMR Spectrum of Compound 3.8e 
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Figure A.332. 1H NMR Spectrum of Compound 3.8k (500 MHz, CDCl3) 
 
 
Figure A.333. 13C NMR Spectrum of Compound 3.8k (125 MHz, CDCl3) 
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Figure A.334. 31P NMR Spectrum of Compound 3.8k 
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Figure A.335. 1H NMR Spectrum of Compound 3.8p (500 MHz, CDCl3) 
 
 
Figure A.336. 13C NMR Spectrum of Compound 3.8p (125 MHz, CDCl3) 
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Figure A.337. 31P NMR Spectrum of Compound 3.8p 
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Figure A.338. 1H NMR Spectrum of Compound 4.2c (500 MHz, CDCl3) 
 
 
Figure A.339. 13C NMR Spectrum of Compound 4.2c (125 MHz, CDCl3) 
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Figure A.340. 1H NMR Spectrum of Compound 4.2f (500 MHz, CDCl3) 
 
 
Figure A.341. 13C NMR Spectrum of Compound 4.2f (125 MHz, CDCl3) 
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Figure A.342. 1H NMR Spectrum of Compound 4.2g (500 MHz, CDCl3) 
 
 
Figure A.343. 13C NMR Spectrum of Compound 4.2g (125 MHz, CDCl3) 
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Figure A.344. 1H NMR Spectrum of Compound 4.2h (500 MHz, CDCl3) 
 
 
Figure A.345. 13C NMR Spectrum of Compound 4.2h (125 MHz, CDCl3) 
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Figure A.346. 1H NMR Spectrum of Compound 4.2m (500 MHz, CDCl3) 
 
 
Figure A.347. 13C NMR Spectrum of Compound 4.2m (125 MHz, CDCl3) 
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Figure A.348. 1H NMR Spectrum of Compound 4.2p (500 MHz, CDCl3) 
 
 
Figure A.349. 13C NMR Spectrum of Compound 4.2p (125 MHz, CDCl3) 
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Figure A.350. 1H NMR Spectrum of Compound 4.2q (500 MHz, CDCl3) 
 
 
Figure A.351. 13C NMR Spectrum of Compound 4.2q (125 MHz, CDCl3) 
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Figure A.352. 1H NMR Spectrum of Compound 4.2r (500 MHz, CDCl3) 
 
 
Figure A.353. 13C NMR Spectrum of Compound 4.2r (125 MHz, CDCl3) 
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Figure A.354. 1H NMR Spectrum of Compound 4.2s (500 MHz, CDCl3) 
 
 
Figure A.355. 13C NMR Spectrum of Compound 4.2s (125 MHz, CDCl3) 
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Figure A.356. 1H NMR Spectrum of Compound 4.2t (500 MHz, CDCl3) 
 
 
Figure A.357. 13C NMR Spectrum of Compound 4.2t (125 MHz, CDCl3) 
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Figure A.358. 1H NMR Spectrum of Compound 4.2u (500 MHz, CDCl3) 
 
 
Figure A.359. 13C NMR Spectrum of Compound 4.2u (125 MHz, CDCl3) 
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Figure A.360. 1H NMR Spectrum of Compound 4.5f (500 MHz, CDCl3) 
 
 
Figure A.361. 13C NMR Spectrum of Compound 4.5f (125 MHz, CDCl3) 
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Figure A.362. 1H NMR Spectrum of Compound 4.S1 (500 MHz, CDCl3) 
 
 
Figure A.363. 13C NMR Spectrum of Compound 4.S1 (125 MHz, CDCl3) 
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Figure A.364. 1H NMR Spectrum of Compound 4.6 (500 MHz, acetone-d6) 
 
 
Figure A.365. 13C NMR Spectrum of Compound 4.6 (125 MHz, acetone-d6) 
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Figure A.366. 1H NMR Spectrum of Compound 4.7f (500 MHz, CDCl3) 
 
 
Figure A.367. 13C NMR Spectrum of Compound 4.7f (125 MHz, CDCl3) 
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